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Attaching and effacing Escherichia coli are significant diarrhoeal pathogens that can spread between 
humans or via animal reservoirs. An important virulence factor produced by these bacteria is the large 
multifunctional protein lymphostatin (LifA), which has been reported to inhibit the mitogen- and 
antigen-stimulated proliferation of lymphocytes as well as mediate adherence to epithelial cells. Shiga 
toxin-producing E. coli lacking lifA are significantly impaired in their ability to colonise cattle. Little 
is known about the mode of action of LifA, however, in silico analysis has identified a putative 
glycosyltransferase domain homologous to that of large clostridial toxins and a putative cysteine 
protease domain homologous to that of C58 family proteases. LifA has recently been reported to bind 
uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc) and mutation of a DXD motif within the 
predicted glycosyltransferase domain abolished this binding and lymphostatin activity. In this study, I 
sought to identify domains of LifA required for cell binding and lymphostatin activity, probe the role 
of the cysteine protease motif in intracellular processing and LifA activity, and to identify potential 
targets and interacting partners of the protein. Domains of LifA predicted by limited proteolysis were 
cloned, expressed and affinity purified. Robust assays for detecting interactions between LifA, or 
fragments thereof, and T lymphocytes were developed but none of the domains possessed 
lymphostatin activity alone or in combination. LifA was found to be cleaved within T cells, which by 
analogy with large clostridial toxins was hypothesised to be the result of autoproteolysis mediated by 
the cysteine protease domain. A C1480A substitution mutant of full-length LifA was constructed by 
site-directed mutagenesis to disrupt the predicted catalytic triad of the cysteine protease domain. The 
C1480A substitution resulted in a lack of intracellular processing of LifA and impaired the ability of 
the protein to inhibit mitogen-stimulated proliferation of bovine T cells, without obvious changes to 
the biophysical properties of the protein. LifA processing was also found to require endosomal 
acidification using the inhibitors bafilomycin A1 and chloroquine. Shotgun mass spectrometry and 
protein pull-downs were used to identify potential targets of LifA activity and interacting partners. 
Relatively few candidate proteins were identified and these were generally not consistently observed 
between repeated experiments. Based on analysis of signal transduction pathways perturbed by LifA, 
I explored if the cellular kinase Akt may be targeted by LifA directly or indirectly. Akt is known to 
control T cell proliferation and to be regulated by phosphorylation and GlcNAcylation. S473 
phosphorylation of Akt in mitogen-stimulated T cells was inhibited by LifA in a manner dependent on 
the DXD and cysteine protease motifs, but O-GlcNAcylation of Akt was not detected. This inhibition 
only occurred in cells treated with LifA before mitogenic stimulation. Infection of T cells with an 
enteropathogenic E. coli strain inhibited Akt phosphorylation in a manner dependent on the Type III 
secretion system but not LifA or a homologous LifA-like protein. Taken together, this study advances 
our understanding of the mode of action of a key virulence factor of pathogenic E. coli and, in 
particular, identifies a key role for a cysteine protease motif in intracellular processing of the protein 





Lymphostatin (LifA) is a protein that is produced by certain strains of the bacterium 
Escherichia coli that can cause severe diarrhoea. The protein is required by the bacteria to 
colonise the intestines of their host and is known to interfere with the replication and activity 
of key cells of the immune system termed T cells in response to chemical triggers. The mode 
of action of LifA is not fully understood, however, it is known to bind a sugar molecule 
(uridine diphosphate-N-acetylglucosamine; UDP-GlcNAc) and is thought to transfer the 
sugar onto an unidentified target in host cells. LifA is also predicted to contain a region that 
may be involved in self-cleavage of the protein in a way that may be required for it to reach 
its target within cells. In this study, I developed robust assays to detect binding of LifA to T 
cells and inhibitory activity. I generated various fragments of the protein, but none of these 
possessed lymphostatin activity alone or in combination. I found that LifA was processed 
into two pieces inside host cells, which required a decrease in the pH of a compartment 
within host cells involved in the uptake of extracellular material called the endosome. A 
region predicted to be involved in self-cleavage of LifA was mutated by changing a specific 
amino acid in the protein. This change prevented LifA from being processed inside T cells 
and its ability to inhibit T cell replication, but without obvious effects on the structure of the 
mutated protein. I attempted to identify host cell proteins onto which LifA transfers the 
GlcNAc sugar and proteins that may interact with LifA, however, the results were 
inconsistent between repeated experiments. A cellular protein called Akt was investigated as 
a possible target of LifA based on evidence from independent studies. LifA was found to 
block the activation of Akt in T cells that had been chemically stimulated to replicate and 
required both the ability to bind UDP-GlcNAc and be processed in order to do this. This 
block of Akt activation only occurred when T cells were treated with LifA before stimulation 
and not after. LifA did not appear to transfer sugar onto Akt. Infecting T cells with live E. 
coli before stimulating them blocked Akt activation in a manner dependent on the 
syringe-like bacterial secretion system but not LifA or a similar protein termed LifA-like. 
Taken together, the research presented in this thesis represents a significant and original 
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1.1 Escherichia coli 
 
Escherichia coli are Gram-negative facultative anaerobes that are commonly found 
living in the environment (reviewed in Jang et al., 2017). They also exist primarily as 
commensals in the lower intestines of warm-blooded animals and reptiles (reviewed 
in Leimbach et al., 2013). Although. E. coli are the most abundant 
Enterobacteriaceae species in the human gut microbiota (Martinson et al., 2019), 
they account for less than 1 % of the total gut microbiota in healthy adults (Eckburg 
et al., 2005). The proportion of E. coli in the gut microbiota varies depending on 
multiple factors however, including age, species and host health. Their presence is 
usually beneficial to the host as E. coli are capable of synthesising vitamin K2 
(Bentley and Meganathan, 1982) and, along with the rest of the gut microbiota, exert 
a protective effect against pathogenic bacteria (Hudault et al., 2001). E. coli strains 
can be classified into serotypes based on the serological detection of distinct 
lipopolysaccharide (O), flagellar (H) and capsular (K) antigens (reviewed in 
Fratamico et al., 2016). 
 Although normally harmless to their host, E. coli are opportunistic pathogens 
that, through the acquisition of mobile genetic elements, can become serious 
pathogens (reviewed in Gomes et al., 2016). Pathogenic E. coli strains can be 
divided into two subgroups depending on the site of infection, with diarrhoeagenic E. 
coli infecting the intestines and extraintestinal E. coli (ExPEC) infecting sites beyond 
the intestines (Section 1.1.1). 
 
1.1.1 E. coli pathotypes 
 
 The diarrhoeagenic E. coli and ExPEC subgroups can be further divided into 
distinct pathotypes based on their characteristics, including the possession of specific 
virulence factors. ExPEC consists primarily of uropathogenic E. coli, which infect 
the urinary tract, and neonatal meningitis E. coli, which can cross and inflame the 
blood-brain barrier (reviewed in Sarowska et al., 2019). Other pathotypes of ExPEC 
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exist such as septicaemia-associated E. coli and avian pathogenic E. coli although 
these are less well defined beyond their association with clinical outcome (reviewed 
in Sarowska et al., 2019). The main diarrhoeagenic E. coli pathotypes are 
enterotoxigenic E. coli (ETEC), enteroaggregative E. coli (EAEC), enteroinvasive E. 
coli (EIEC), diffusely-adherent E. coli (DAEC), enteropathogenic E. coli (EPEC) 
and enterohaemorrhagic E. coli (EHEC; reviewed in Gomes et al., 2016). 
 ETEC are the most common cause of traveller’s diarrhoea and are also 
important in the farming industry, particularly as a cause of acute enteritis and 
colibacillosis in young pigs and calves (reviewed in Gomes et al., 2016; reviewed in 
Luppi, 2018). They are characterised by their adherence to enterocytes via 
colonisation factors and the secretion of heat-labile and heat-stable toxins, which 
cause diarrhoea (reviewed in Mirhoseini et al., 2018). EAEC are the second most 
common cause of traveller’s diarrhoea and are characterised by the formation of 
biofilms on enterocytes using aggregative adherence fimbriae (Tzipori et al., 1992; 
Nataro et al., 1992). EIEC, which include bacteria of the genus Shigella, are 
characterised by their facultative intracellular lifestyle. They achieve this by passing 
through microfold (M) cells via transcytosis, replicating inside macrophages in the 
intestinal submucosa, then invading enterocytes from their basolateral side (Wassef 
et al., 1989; Sansonetti et al., 1996; Zychlinsky et al., 1992; Mounier et al., 1992). 
DAEC are characterised by forming diffuse attachments to enterocytes using fimbrial 
and afimbrial adhesins (Scaletsky et al., 1984; reviewed in Servin, 2014). 
 EPEC and EHEC are collectively known as attaching and effacing (A/E) E. 
coli and are described in greater detail below. 
 
1.1.2 Attaching and effacing E. coli 
 
 A/E lesions are characterised by intimate bacterial attachment to the surface 
of enterocytes on actin-rich ‘pedestals’ and the destruction of microvilli, thereby 
disrupting the absorption of nutrients by the gut, contributing to diarrhoea 
(Figure 1.1; Moon et al., 1983; Tzipori et al., 1986; Knutton et al., 1987). The 
pedestals are also assembled with other cytoskeletal proteins besides actin, such as 
α-actinin, talin, ezrin and myosin light-chain (Finlay et al., 1992; 
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Manjarrez-Hernandez et al., 1992). Law et al. (2015) identified more than 
90 proteins present in the pedestals formed by EPEC, 17 of which were in 
significantly higher abundance than in uninfected cells. Actin-associated proteins 
such as cyclophilin A may only be present due to their interactions with actin, but 
non-actin-associated proteins such as transgelin may have other as yet undefined 
roles (Law et al., 2015). A/E lesion formation in E. coli is mediated by virulence 




















Figure 1.1. Transmission electron micrograph of EHEC O111:H- E45035N 
forming attaching and effacing lesions on a bovine calf colonocyte. Actin rich 
pedestals can be seen as electron dense regions beneath the EHEC cells. An 
uninfected cell to the right gives a comparison of a healthy cell surface and 
microvilli. Scale bar = 1 μm (from Stevens et al., 2002). 
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 EPEC are a major cause of infantile diarrhoea in the developing world and 
cause both acute and chronic diarrhoea (reviewed in Gomes et al., 2016). EPEC 
infect the proximal small intestine (Rothbaum et al., 1982; Sherman et al., 1989) and 
once attached to enterocytes, they disrupt the ion balance and water absorption in the 
intestine by inhibiting the sodium-D-glucose co-transporter and the Na+/H+ 
exchanger NHE3, resulting in diarrhoea (Dean et al., 2006; Hecht et al., 2004). 
Sanger et al. (1996) also found that EPEC are able to use A/E pedestals as a form of 
motility to travel across the surface of host cells at speeds of up to 0.07 μm/second. 
 EPEC strains can be further divided into typical EPEC, which possess 
bundle-forming pili (BFP) that mediate inter-bacterial interactions and micro-colony 
formation on epithelial cells, and atypical EPEC, which do not (Section 1.1.3.8; 
reviewed in Gomes et al., 2016). Prevalent EPEC serotypes include O55:H6, 
O127:H6, O128:H2 and O142:H34 among others (Gomes et al., 1989; reviewed in 
Trabulsi et al., 2002; Kozub-Witkowski et al., 2008). The prototype EPEC strain 
E2348/69 was isolated in 1969 from an outbreak at a residential nursery in Taunton, 
UK (Taylor, 1970). It was used in this study as it can be handled at biosafety level 2 
and it is the source of the lifA gene used to produce purified LifA, which is near 
identical to that from EHEC strains (Section 1.3). The genome of this prototype 
strain consists of an ~5 Mb circular chromosome, an ~97 kb EPEC adherence factor 
(EAF) plasmid, a small ~6 kb drug-resistant plasmid and a third ~5 kb plasmid 
encoding mobilization genes (Iguchi et al., 2009; Hanford et al., 2009; Nisa et al., 
2013). The core genome of E2348/69 is highly conserved with laboratory strains, 
commensal E. coli and other pathotypes of E. coli, but is broken up by 13 prophages 
and eight integrative elements (Iguchi et al., 2009). Iguchi et al., (2009) also 
identified 424 genes that were specific to EPEC E2348/69. A nalidixic acid 
derivative of EPEC E2348/69 that is commonly used in laboratories was found to 
have several differences in its genome compared to the original strain, including 
three unique nonsynonymous changes (Nisa et al., 2013). An S83L substitution in 
gyrA confers nalidixic acid resistance (Bagel et al., 1999) and a nonsynonymous 
substitution in ftsK has no effect on phenotype (Nisa et al., 2013). The conversion of 
a stop codon to a tryptophan results in the fusion of the λ lysogenisation regulator 
hflD and purB, which compromises the growth rate and ability to invade epithelial 
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cells in this clone due to deficient purine biosynthesis (Kihara et al., 2001; Jung et 
al., 2010; Nisa et al., 2013). Additionally, this clone has lost the ~6 kb plasmid and is 
therefore no longer resistant to streptomycin (Nisa et al., 2013). 
 EHEC causes acute enteritis, that may involve haemorrhagic colitis and 
severe systemic sequelae, and ruminants are a key reservoir (Riley et al., 1983; 
Beutin et al., 1993). Outbreaks in both the developing and developed world have 
been caused by cattle due to faecally contaminated food or water (reviewed in Ho et 
al., 2013). EHEC primarily infect the lymphoid follicle-dense mucosa at the terminal 
rectum of cattle (Naylor et al., 2003). EHEC infection is the leading antecedent to 
haemolytic uraemic syndrome (HUS) in humans in many countries (reviewed in Ho 
et al., 2013). HUS is characterised by damage to vascular endothelial cells in kidney 
glomeruli and haemolytic anaemia and is caused by the production of one or more 
Shiga toxins (Stx; Karmali et al., 1983b; O'Brien et al., 1983; Johnson et al., 1983; 
Karmali et al., 1983a). The pathogenesis of EHEC is similar to that of EPEC with the 
exception of the production of Stx, which acts as a cytotoxin by depurinating 28S 
ribosomal RNA to arrest translation in a manner similar to ricin (Section 1.1.3.9; 
Endo et al., 1988). The dominant serotype associated with human infections in many 
countries is O157:H7, however, infection with non-O157 EHEC (in particular of 
serogroups O26, O45, O103, O111 and O121) is a significant problem that is often 
under-estimated by national surveillance and diagnostic laboratories (Brooks et al., 
2005; Kozub-Witkowski et al., 2008). EHEC O157:H7 infection in cattle is widely 
reported to be asymptomatic, but Nart et al. (2008b) found that infection with this 
strain does in fact cause histopathological changes in the terminal rectal tissue of 
cattle and a slight but significant neutrophilic response. The chromosome of the 
prototype EHEC O157:H7 strain EDL933 has a similar backbone sequence to E. coli 
K-12 except for a 422 kb inversion, which spans the replication terminus (Perna et 
al., 2001). This backbone sequence is interrupted by 177 O-islands found in E. coli 
O157:H7 but not laboratory-adapted E. coli K-12, many of which encode known 
virulence proteins (Perna et al., 2001). There are also 18 prophages throughout the 
chromosome and various single nucleotide polymorphisms create proteins that are 
identical in size and function to E. coli K-12 homologues but overall only 25 % of 
proteins are identical (Perna et al., 2001). EHEC O157:H7 also contains the pO157 
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plasmid, which encodes various virulence factors (Burland et al., 1998; Makino et 
al., 1998). Numerous studies have suggested that EHEC O157:H7 has evolved from 
EPEC O55:H7 in a stepwise manner (Whittam et al., 1993; Wick et al., 2005; Zhou 
et al., 2010; Kyle et al., 2012). 
 
1.1.3 Major virulence factors in A/E E. coli 
 
 EPEC and EHEC produce several key virulence factors that aid their 
colonisation of human and animal hosts, many of which are required for the 
formation of A/E lesions. Effector proteins from EPEC and EHEC were discovered 
before and after the genomes of prototype strains were sequenced. A variety of 
methods have been used to identify ‘effector’ proteins from A/E E. coli including 
mutagenesis, loss/gain of function mutants, sequencing and homology with known 
effector proteins from other bacteria. 
 
1.1.3.1 The locus of enterocyte effacement (LEE) 
 
 The LEE is a pathogenicity island comprising over 40 contiguous genes, 
which encode virulence factors that aid colonisation of a host, many of which are 
required for attachment and effacement (reviewed in Stevens and Frankel, 2014). It 
is a ≥ 35 kb locus that is conserved amongst EPEC and EHEC as well as other A/E 
pathogens including certain strains of rabbit diarrhoeagenic E. coli (RDEC), E. 
albertii (previously thought to be Hafnia alvei) and the mouse pathogen Citrobacter 
rodentium (McDaniel et al., 1995; Deng et al., 2001; Huys et al., 2003). The GC 
content of the LEE of EPEC E2348/69 is only 38.36 % (Elliott et al., 1998) 
compared with 50.8 % across the E. coli K-12 genome (Blattner et al., 1997), which 
is typical of pathogenicity islands (Hacker et al., 1997). The LEE of E2348/69 was 
the first to be characterised and consists of 41 open reading frames arranged into five 
polycistronic operons (Figure 1.2; Elliott et al., 1998), three of which are involved in 
the production of proteins required for the assembly of a Type III secretion system 
(T3SS; reviewed in Gaytán et al., 2016) that functions in a manner akin to a 
molecular syringe (Section 1.1.3.2). 
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 The LEE contains the E. coli secretion (esc)/secretion of E. coli proteins (sep) 
genes and genes that encode intimin, E. coli secreted proteins (Esps), translocated 
intimin receptor (Tir), as well as chaperones and regulatory genes (Elliott et al., 
1998). The 3 end of the LEE in EPEC is homologous to genes from Shigella sonnei 
(Donnenberg et al., 1997), however, the DNA sequences surrounding the LEE vary 
since it is inserted into different positions depending on the serotype and strain of 
bacteria (Ogura et al., 2009). These variable flanking sequences along with the low 
GC content suggests that E. coli and other A/E pathogens acquired the LEE from 
other species (e.g. by Hfr transfer during conjugation), or that it once existed as a 
mobile genetic element (Donnenberg et al., 1997). The LEE from EHEC O157:H7 
contains 54 open reading frames, 13 of which belong to a prophage located at the 
selC end of the locus (Perna et al., 1998). 
 The regulation of the LEE is complex, with different regulatory systems 
specific to different operons (reviewed in Mellies and Lorenzen, 2014). The 
production of LEE proteins is tightly regulated by temperature and growth phase, 
with optimal expression occurring at 37 °C in the early logarithmic phase of growth 
(Rosenshine et al., 1996). Regulatory systems of the LEE include silencing by 
histone-like nucleoid-structuring protein, the LEE-encoded regulatory cascade, 
post-transcriptional regulation and control by phage- or plasmid-encoded regulators 
(reviewed in Mellies and Lorenzen, 2014). The function of each LEE-encoded gene 
in virulence, A/E lesion formation and T3SS activity has been systematically 
investigated in both EPEC E2348/69 and C. rodentium (Cepeda-Molero et al., 2017; 
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Figure 1.2. Schematic of the locus of enterocyte effacement from EHEC O157:H7 showing the five polycistronic operons and the 
genes encoded within them (from Stevens and Frankel, 2014). 
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1.1.3.2 The Type III secretion system 
 
 T3SSs are widely used by a range of Gram-negative pathogens of animals 
and plants (reviewed in Deng et al., 2017). There are at least five other well 
characterised secretion systems in Gram-negative bacteria (reviewed in Costa et al., 
2015) but the T3SS is particularly important for the purpose of this study. The T3SS 
in A/E E. coli is encoded by the LEE and is composed of Esc/Sep proteins as well as 
EspA, B and D (Elliott et al., 1998). It was discovered by Jarvis et al. (1995), who 
found that certain LEE-encoded proteins exhibited homology to proteins encoding 
T3SSs in other bacteria. T3SSs include flagella (reviewed in Deng et al., 2017) but 
for the purpose of this study, it is the translocation-associated T3SS that is being 
referred to. T3SSs belonging to this category can inject effector proteins directly into 
a host cell (Figures 1.3 and 1.4; reviewed in Stevens and Frankel, 2014). The effector 
proteins can be encoded both within the LEE and elsewhere in the chromosome, and 
significant effort has been expended to define the full repertoire of effectors (Tobe et 
al., 2006). The LEE-encoded T3SS consists of a region that spans both membranes 
of the bacterial cell, which is connected via EscF to the EspA filament and the 
translocon, which is composed of EspB and D (reviewed in Slater et al., 2018; 
Warawa et al., 1999). 
 The proteins SepL and D regulate the order of protein secretion through the 
T3SS, with mutations leading to hypersecretion of effector proteins rather than 
translocon components (Kresse et al., 2000; O’Connell et al., 2004; Wang et al., 
2008). EspZ halts effector translocation from inside the host cell, possibly by 
interacting with EspD (Berger et al., 2012; Creasey et al., 2003). The secretion of 
effector proteins via the T3SS is contact-dependent in some bacteria such as Yersinia 
(Rosqvist et al., 1994) but contact between the T3SS and host cells is not required for 
the secretion of effector proteins in E. coli (Kenny et al., 1997a). Various inhibitors 
of the T3SS have been identified, many of which are part of a family of salicylidene 
acylhydrazides that inhibit the transcription of T3SS encoding genes (Gauthier et al., 
2005; Rasko et al., 2008; Tree et al., 2009). This is in contrast to T3SS inhibitors that 
work against Shigella by interfering with T3SS protein assembly (Veenendaal et al., 























as the H7 flagellin have been shown to significantly reduce the shedding of EHEC 
O157:H7 in cattle faeces (McNeilly et al., 2010), consistent with a key role for this 
system in intestinal colonisation of cattle revealed by genome-wide and targeted 



















Figure 1.3. Schematic diagram of the LEE-encoded Type III secretion system 
showing the predicted location of proteins in attaching and effacing E. coli. 
Effector proteins are translocated through the needle complex spanning the inner and 
outer membranes, then through a translocon comprising the EspA filament, EspB and 





Figure 1.4. Schematic of EHEC adhering to an enterocyte and injecting various 
effector proteins into it via the Type III secretion system that affect the 
cytoskeleton. (A) The Tir:Nck pathway dependent on phosphorylation of the residue 
equivalent to Tyr474 of EPEC O127:H6 Tir, which is not present in EHEC O157:H7 
(see Section 1.1.3.7; from Stevens and Frankel, 2014). 
 
1.1.3.3 E. coli secretion/secretion of E. coli proteins 
 
 The Esc and Sep proteins are part of the same family but some Seps were 
renamed as Escs after Elliott et al. (1998) sequenced the LEE from EPEC E2348/69 
in order to conform with the naming convention of homologous Yersinia proteins. 
Esc/Sep proteins comprise the E. coli T3SS and are essential for the translocation of 
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effector proteins (Jarvis et al., 1995; reviewed in Stevens and Frankel, 2014). EscN is 
the most relevant of these proteins in terms of this study as EPEC strains lacking the 
escN gene (Garmendia et al., 2004; Cepeda-Molero et al., 2017) are used as 
T3SS-deficient controls. EscN is an ATPase that provides the energy for the 
secretion of effector proteins and the energy output of the protein increases when it 
oligomerises (Jarvis et al., 1995; Andrade et al., 2007). Two other proteins in this 
family that are important for the formation of A/E lesions are SepL and SepD, which 
act as gatekeeper proteins (Wang et al., 2008). These proteins form a complex in the 
bacterial inner membrane and SepL binds to Tir to prevent effector proteins from 
being secreted before translocator proteins such as EspA (Kresse et al., 2000; 
O’Connell et al., 2004; Wang et al., 2008). 
 
1.1.3.4 LEE-encoded effector proteins 
 
 The Esp series of proteins consists of a large number of proteins, the 
functions of some of which have been extensively studied (reviewed in Stevens and 
Frankel, 2014). EspA forms a hollow filamentous extension of the T3SS needle 
complex (Ebel et al., 1998; Knutton et al., 1998) that bridges the bacterial and host 
cells and allows the translocation of effector proteins such as Tir and EspB into the 
host cell (Kenny et al., 1997b; Wolff et al., 1998). EspA polymerises in a helical 
manner to form a channel that effector proteins can be secreted through (Daniell et 
al., 2003; Crepin et al., 2005). A/E E. coli lack these EspA filaments during intimate 
adhesion but the mechanism behind this is unknown (reviewed in Stevens and 
Frankel, 2014). EspB functions as both a component of the T3SS and an effector 
protein (Warawa et al., 1999; Taylor et al., 1998). It associates with EspD to form a 
pore in the host cell plasma membrane at the end of the EspA filament (Kresse et al., 
1999; Warawa et al., 1999; Wachter et al., 1999) but EspB is also injected into host 
cells by the T3SS (Wolff et al., 1998). As an effector protein it binds to myosin and 
inhibits the interaction of myosin with actin, resulting in microvillus effacement 
(Iizumi et al., 2007). 
 Studies using deletion mutants and clones of the LEE established that the 
LEE region alone is necessary and sufficient for A/E lesion formation by EPEC 
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E2348/69, but not by EHEC EDL933 (McDaniel and Kaper, 1997; Pósfai et al., 
1997). This is partly explained by the requirement for a non-LEE-encoded protein for 
pedestal formation by EHEC O157 termed EspFU (Campellone et al., 2004). Also 
known as Tir-cytoskeleton coupling protein (TccP), it binds to the insulin receptor 
tyrosine kinase substrate (IRTKS)/insulin receptor substrate p53 (IRSp53) complex 
and neural Wiskott-Aldrich syndrome protein (N-WASP), resulting in the formation 
of A/E lesions (Campellone et al., 2004; Garmendia et al., 2004; Brady et al., 2007; 
reviewed Stevens and Frankel, 2014). The homologous protein EspF has a wide 
range of functions including the disruption of mitochondrial function, cytoskeletal 
manipulation and the induction of apoptosis (Section 1.2.2.2; reviewed in Stevens 
and Frankel). EspG interacts with tubulin to deplete the microtubule cytoskeleton, 
which disrupts epithelial paracellular permeability and tight junction integrity 
(Matsuzawa et al., 2004; Shaw et al., 2005; Matsuzawa et al., 2005). It also disrupts 
tight junction integrity by targeting the tight junction protein tricellulin (Morampudi 
et al., 2016). EspG inhibits protein secretion by interacting with ADP-ribosylation 
factor, p21-activated kinases (PAKs), the Golgi matrix protein GM130 and Rab1 
GTPases, which blocks endoplasmic reticulum (ER)-to-Golgi trafficking (Selyunin et 
al., 2011; Germane and Spiller, 2011; Clements et al., 2011; Dong et al., 2012). The 
interaction of EspG with PAKs has recently been reported to be required for pedestal 
formation (Singh et al., 2019). There are many other proteins in the Esp family but 
those described above are the major proteins, with the exception of EspF, that are 
required for A/E lesion formation. Some Esp proteins modulate innate immune 
responses and are described in greater detail in Section 1.2.2.2. 
 Mitochondrial-associated protein (Map) has a number of functions. Map 
targets host cell mitochondria and alters their morphology, resulting in apoptosis 
(Kenny and Jepson, 2000; Papatheodorou et al., 2006). Map also activates Cdc42, 
which results in the transient formation of filopodia (Kenny et al., 2002; Berger et 
al., 2009; Huang et al., 2009). Lastly, Map contributes to diarrhoea by disrupting 
tight junction integrity and inhibiting the sodium-D-glucose co-transporter in 




1.1.3.5 Non-LEE-encoded (Nle) proteins 
 
 Extensive studies have been performed to map the full T3S effector repertoire 
of EPEC and EHEC, including the use of bioinformatics, proteomics, translocation 
assays and systematic knock-outs (Tobe et al., 2006; Iguchi et al., 2009; 
Cepeda-Molero et al., 2017). EPEC E2348/69 has been predicted to produce 
21 effector proteins, while the EHEC O157:H7 strain RIMD 0509952 was found to 
produce 39 effector proteins (Iguchi et al., 2009; Tobe et al., 2006). In addition to the 
LEE-encoded effector proteins, the Nle proteins are also secreted effector proteins, 
but are encoded outwith the LEE (reviewed in Stevens and Frankel, 2014). NleA 
disrupts tight junction integrity between enterocytes by inhibiting protein trafficking 
via COPII-dependent pathways, resulting in a breakdown of the intestinal epithelial 
barrier and causing diarrhoea (Thanabalasuriar et al., 2010). NleG acts in a similar 
manner to RING-like E3 ubiquitin ligases from eukaryotic cells and induces the 
degradation of HK2, which is known to inhibit apoptosis (Wu et al., 2010; Valleau et 
al., 2018). Many Nle proteins, including NleA, are involved in modulating the host 
immune response and are described in greater detail in Section 1.2.2.1. Cell cycle 
inhibiting factor (Cif) is also encoded outwith the LEE but is not present or 
functional in all EPEC and EHEC strains (Marchès et al., 2003; Loukiadis et al., 
2008). Cif causes cell cycle arrest in the G1/S and G2/M phases by deamidating 
ubiquitin or the ubiquitin-like protein NEDD8, which blocks the activation of the cell 
cycle (Marchès et al., 2003; reviewed in Taieb et al., 2011). Cif has also been 
reported to induce delayed apoptosis of IEC-6 cells, but the mechanism behind this 




 Intimin is a 94 kDa protein (Yu and Kaper, 1992) that is encoded by the E. 
coli attaching and effacing (eae) gene (Jerse et al., 1990) and has an 83 % amino acid 
homology between EPEC and EHEC strains (Yu and Kaper, 1992). The protein also 
has sequence homology with the invasin proteins in Yersinia pseudotuberculosis and 
Y. enterocolitica with the lowest homology at the N- and C-terminal ends (Jerse et 
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al., 1990; Yu and Kaper, 1992). The C-terminal end of intimin has been shown to 
bind to the surface of HeLa cells (Frankel et al., 1994; Deibel et al., 2001) and it has 
been suggested that the N-terminal end masks the C-terminus to prevent non-specific 
binding to host cells (Deibel et al., 2001). 
 Intimin is located in the bacterial outer membrane and primarily targets Tir, 
which is injected by the T3SS into host cells and located on their surface (Section 
1.1.3.7; Kenny et al., 1997b; Rosenshine et al., 1992; DeVinnney et al., 1999). 
Intimin is able to bind to the surface of epithelial cells independently of Tir by 
binding to host cell β1-integrins and cell surface-localised nucleolin (Frankel et al., 
1996; Sinclair and O’Brien, 2002). Intimin binds Tir preferentially but it is possible 
that nucleolin acts as a target for adhesion before Tir is translocated into host cells 
(Sinclair and O’Brien, 2004). Intimin and Tir are both critical for intestinal 
colonisation by A/E pathogens, as shown for example by testing isogenic deletion 
mutants of E. coli O157:H7 in calves (Vlisidou et al., 2006). 
 
1.1.3.7 Translocated intimin receptor 
 
 As mentioned above, Tir is required for intimin binding to host cells and the 
formation of A/E lesions (Kenny et al., 1997b; Rosenshine et al., 1992; DeVinnney 
et al., 1999). It was independently described as EspE in EHEC O26:H- strain 
413/89-1 and is translocated into host cells via the T3SS (Deibel et al., 1998; Kenny 
et al., 1997b). In EPEC O127:H6, actin assembly requires phosphorylation of Tyr474 
in Tir (Kenny, 1999), which results in the recruitment of the host cell proteins Nck, 
N-WASP and actin-related protein 2/actin-related protein 3 (Arp2/3; Gruenheid et 
al., 2001). The proteins CrkII and Grb2 are recruited in EPEC infection but not in 
EHEC infection (Goosney et al., 2001). 
 In EHEC O157:H7 strains, the phosphorylation of Tir is not required because 
these strains lack Tyr474 (DeVinney et al., 1999; DeVinney et al., 2001). Instead 
these strains utilise a 12 amino acid motif containing an Asn-Pro-Tyr sequence that 
recruits the proteins IRTKS, IRSp53, EspFU, N-WASP and Arp2/3 in a manner 
independent of Nck (Brady et al., 2007; reviewed in Stevens and Frankel, 2014). The 
tyrosine in the amino acid motif can be phosphorylated in EPEC strains to initiate 
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Nck-independent pedestal formation but at a much lower efficiency than in EHEC 
(Campellone and Leong, 2005). 
 
1.1.3.8 Type IV bundle-forming pili 
 
 Bundle-forming pili (BFP) are produced by typical EPEC and are part of the 
Type IV pili family, which are expressed by several bacterial pathogens (Girón et al., 
1991; reviewed in Strom and Lory, 1993). They are encoded on an ~97 kb EAF 
plasmid (Girón et al., 1991; Nataro et al., 1987) by a cluster of 14 bfp genes, several 
of which are homologous to genes required for Type IV pilus production in other 
Gram-negative bacteria (Sohel et al., 1996; Stone et al., 1996). BfpA is the major 
subunit of BFP (Donnenberg et al., 1992) and is produced as a preprotein before 
being cleaved into a functional form by BfpP (Zhang et al., 1994). The proteins 
BfpD and F bind nucleotides and act as ATPases to control pilin export and assembly 
(Sohel et al., 1996; Stone et al., 1996). 
 BFP expression is controlled by the EAF plasmid-encoded regulatory 
proteins BfpT, V and W as well as the chromosome-encoded protein DsbA (Tobe et 
al., 1996; Zhang and Donnenberg, 1996). DsbA stabilises BFP by catalysing the 
formation of disulphide bonds (Zhang and Donnenberg, 1996). Environmental 
signals also control BFP expression, with expression occurring optimally between 
35 and 37 °C during the exponential growth phase, in the presence of calcium 
(Puente et al., 1996). Puente et al. (1996) also found that ammonium suppresses the 
expression of BFP. 
 BFP are important virulence factors for the colonisation of hosts, including 
humans, by EPEC (Bieber et al., 1998) and are required for adhesion to epithelial 
cells and the formation and dispersal of micro-colonies (Girón et al., 1991 Knutton et 
al., 1999; Cleary et al., 2004). BFP bind to N-acetyllactosamine moieties on the 
surface of host enterocytes (Hyland et al., 2008) and also act in conjunction with E. 




1.1.3.9 Shiga toxin 
 
 The Stx family of cytotoxins is composed of two major groups, Stx1 and 
Stx2, which are produced in various combinations by EHEC (reviewed in Krause et 
al., 2018). Stx2, however, is more common in cases of haemorrhagic colitis and HUS 
(Ostroff et al., 1989; Boerlin et al., 1999; Frank et al., 2011). Stx1 is identical to Stx 
from Shigella dysenteriae serotype I and is highly conserved whereas Stx2 exhibits 
sequence variation and is separated into a series of subtypes (reviewed in Lee and 
Tesh, 2019). The stx genes are encoded by lysogenic lambdoid bacteriophages, 
which are integrated into the bacterial chromosome (O’Brien et al., 1984; Johansen 
et al., 2001). Stx2 production is induced by activation of the phage lytic cycle, for 
example, in response to DNA damage via the bacterial SOS response (Neely and 
Friedman, 1998). The regulation of Stx production is complex and growth phase 
dependent, with many different extrinsic factors affecting gene expression including 
antibiotics, reactive oxygen species, iron concentration, temperature and quorum 
sensing (reviewed in Pacheco and Sperandio, 2012). 
 Stx is an AB5 toxin consisting of an A subunit, which in turn is made from an 
A1 and A2 peptide, that is non-covalently bound to a pentameric ring of B subunits 
(Stein et al., 1992; Fraser et al., 1994). The Stx toxins are not secreted but are 
released as a result of phage-mediated lysis and via outer membrane vesicles 
(Toshima et al., 2007; Kolling and Matthews, 1999; Bielaszewska et al., 2017). The 
capacity of certain antibiotics to induce Stx production means that antibiotic use can 
be contraindicated in the treatment of EHEC infections as it risks increasing the 
severity of Stx-mediated pathology (Zhang et al., 2000). In humans, the B subunit 
pentamer binds to the Gb3 variant of the glycolipid receptor globotriaosylceramide 
that is present on the surface of Paneth cells in the intestine and kidney endothelial 
cells (Jacewicz et al., 1987; Lindberg et al., 1987). Stx2e, which is typically 
associated with porcine oedema disease, uses the Gb4 variant of this receptor (Pierard 
et al., 1991). Cattle lack the vascular Gb3 receptor meaning that EHEC infection in 
cattle is largely asymptomatic (Pruimboom-Brees et al., 2000). There is evidence to 
suggest that Gb3 can be found on crypt epithelial cells in cattle, however, Stx does 
not appear to be cytotoxic in these cells as it is localised in lysosomes (Hoey et al., 
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2003). Nevertheless, differences in the Stx types expressed by EHEC may underlie 
strain-specific differences in colonisation and host responses in cattle (Corbishley et 
al., 2014). 
 Once Stx binds to its receptor, it is endocytosed by both clathrin-dependent 
and independent mechanisms (Sandvig et al., 1989; Römer et al., 2007), and a 
protease sensitive loop connecting the A1 and A2 subunits is cleaved by the enzyme 
furin (Garred et al., 1995; Lea et al., 1999). The A subunits remain connected by a 
disulphide bond (Lea et al., 1999). Stx bypasses the late endocytic pathway to 
undergo retrograde transportation to the trans-Golgi network and then to the ER 
(Sandvig et al., 1992; Mallard et al., 1998). The remaining disulphide bond is 
reduced in the ER and the A1 subunit is translocated into the cytoplasm of the host 
cell (Tam and Lingwood, 2007). Once in the cytoplasm, the A1 subunit exhibits 
N-glycosidase activity and removes an adenine nucleotide from the 28S rRNA of 
host cell ribosomes, resulting in the inhibition of proteins synthesis and cell death 
(Endo et al., 1988). 
 Stx enters human Gb3-negative intestinal cells via macropinocytosis 
(Malyukova et al., 2009) and is translocated through the cells into the bloodstream in 
order to reach the kidneys (Acheson et al., 1996). Stx is also capable of retrograde 
transportation in these cells but does not inhibit protein synthesis (Schüller et al., 
2004). Instead it modulates NF-κB activation and suppresses the host immune 
response (Gobert et al., 2007). The effects of Stx on the host immune response are 
described in Section 1.2.4.2. 
 
1.2 Host immune responses to A/E E. coli and bacterial evasion of these 
responses 
 
 Bacteria in the gut interact with the host immune system at the intestinal 
mucosa and gut associated lymphoid tissue (Figure 1.5). A/E E. coli have evolved a 
number of strategies for subverting both the innate and adaptive immune responses, 





Figure 1.5. Schematic of the intestinal mucosa and gut associated lymphoid 
tissue, which includes Peyer’s patches, mesenteric lymph nodes (MLN) and 
isolated lymphoid follicles. IEL – intraepithelial lymphocyte (from Cassady-Cain et 
al., 2018). 
 
1.2.1 The innate immune response 
 
1.2.1.1 The intestinal epithelial barrier 
 
 The innate immune response is the first line of defence against infection with 
A/E E. coli and intestinal epithelial cells play a crucial role in the innate immune 
responses against these bacteria. Not only do they form a protective barrier to 
prevent infection via the secretion of mucus and antimicrobial proteins but they also 
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participate in regulating both the innate and adaptive immune responses (reviewed in 
Peterson and Artis, 2014; reviewed in Santos and Finlay, 2015). Goblet cells secrete 
mucins. The most abundant of these, MUC2, forms a fixed inner mucus layer in the 
colon that is impenetrable to most microbes (Johansson et al., 2008). Goblet cells 
also produce factors such as intestinal trefoil factor (ITF) and 
resistin-like-molecule-β (RELMβ) that regulate the mucus barrier (reviewed in 
Peterson and Artis, 2014). ITF cross-links mucins to increase the structural stability 
of mucus and also promotes epithelial cell repair, migration and resistance to 
apoptosis (reviewed in Peterson and Artis, 2014; Dignass et al., 1994; Taupin et al., 
2000). RELMβ promotes the expression of pro-inflammatory cytokines and major 
histocompatibility complex (MHC) class II in macrophages and regulates interferon 
(IFN)-γ expression in CD4+ T lymphocytes, although RELMβ may only be produced 
in response to nematode infections (Nair et al., 2008; Artis et al., 2004). Epithelial 
cells in the gastrointestinal tract also have a rapid turnover rate relative to other 
epithelial cells, which removes cells that have been infected/colonised by pathogens 
(reviewed in Kim et al., 2010). 
 A plethora of antimicrobial proteins are secreted by epithelial cells in the 
small intestine, some of which are expressed by enterocytes, while others, such as 
α-defensins and lysozyme, are expressed by specialised Paneth cells (reviewed in 
Gallo and Hooper, 2012). Antimicrobial proteins target essential features of bacterial 
physiology, for example by disrupting membranes, hydrolysing peptidoglycan, and 
chelating metals (reviewed in Gallo and Hooper, 2012). Lipocalin 2 is an 
antimicrobial protein that is broadly expressed by epithelial cell types and has been 
shown to protect against E. coli infection by sequestrating iron-laden siderophores 
(Flo et al., 2004). Intestinal epithelial cells also transport and secrete IgA antibodies 
produced in the lamina propria (reviewed in Johansen and Kaetzel, 2012). 
 M cells, located at Peyer’s patches and lymphoid follicles, and goblet cells 
are capable of transporting microbes and their products to antigen-presenting cells 
(APCs) in the lamina propria (reviewed in Mabbott et al., 2013; reviewed in McDole 
et al., 2012). Intestinal epithelial cells can themselves detect bacterial products via 
pattern recognition receptors (PRRs), which trigger the activation of the 
pro-inflammatory NF-κB and mitogen-activated protein kinase (MAPK) signalling 
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pathways, resulting in the expression of pro-inflammatory cytokines (reviewed in 
Santos and Finlay, 2015). In vitro studies have shown that expression of the cytokine 
interleukin (IL)-8, which recruits neutrophils to the site of infection to phagocytose 
and destroy the bacteria, is up-regulated in cells infected with EPEC and EHEC 




 Neutrophils and macrophages are drawn to the site of infection by 
chemoattractants, such as IL-8, where they phagocytose and destroy invading 
microbes (reviewed in Lim et al., 2017). Like epithelial cells, phagocytes detect 
bacterial products via PRRs, which include Toll-like and NOD-like receptors 
(reviewed in Brubaker et al., 2015; reviewed in Amarante-Mendes et al., 2018). 
PRRs recognise highly conserved bacterial features such as lipopolysaccharide 
(LPS), flagellin, muramyl dipeptide and the γ-D-glucose-mDAP motif of 
peptidoglycan (reviewed in Brubaker et al., 2015). Cis-phagocytosis involves the 
direct recognition of bacterial products, such as the recognition of LPS by 
macrophage class A scavenger receptors (Peiser et al., 2000). Trans-phagocytosis 
involves the detection of bacteria opsonised with the complement component iC3b or 
IgG antibodies, which are recognised by the CR3 complement receptor and FCγ 
immunoglobulin receptor respectively (Anderson et al., 1990; Ross et al., 1992). 
 In neutrophils, the pH of the phagosome rapidly increases during the first 5–
15 minutes after engulfment as NADPH oxidase 2 (NOX2) transfers electrons from 
the cytosol into the lumen of phagosomes to generate superoxide, which is converted 
into hydrogen peroxide by superoxide dismutase (Segal et al., 1981; Cech and 
Lehrer, 1984; Gabig et al., 1978). The fusion of azurophil granules with the 
phagosome releases myeloperoxidase, which catalyses the transformation of 
hydrogen peroxide into various reactive oxygen species (ROS) with potent 
antimicrobial activity, including hypochlorous acid, hydroxyl radical and singlet 
oxygen (reviewed in Prokopowicz et al., 2012). Neutrophils also synthesise nitric 
oxide, which diffuses into the phagosome. Nitric oxide itself has antimicrobial 
properties, which are increased when it reacts with superoxide to form reactive 
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nitrogen species (reviewed in Manda-Handzlik and Demkow, 2015). The rise in pH 
also facilitates the fusion of azurophil and gelatinase granules containing proteases, 
antimicrobial proteins and bactericidal/permeability-increasing proteins (Reeves et 
al., 2002; reviewed in van Kessel et al., 2014). After the initial pH increase, the 
phagosome is acidified owing to the action of vacuolar proton-translocating ATPases 
(V-ATPases; Jankowski et al., 2002). 
 Phagocytosed bacteria are also destroyed by macrophages using a range of 
proteases and glycosidases delivered by lysosomes, as well as V-ATPase-induced 
phagosome acidification (reviewed in Hirayama et al., 2018). ROS production plays 
a less significant role in the killing of phagocytosed bacteria in macrophages than it 
does in neutrophils as ROS production occurs mainly at the plasma membrane in 
macrophages (Berton et al., 1982; Yamaguchi and Kaneda, 1988). 
 
1.2.1.3 Antigen-presenting cells 
 
 Macrophages and dendritic cells can be found in the intestinal lamina propria 
where they receive antigens in a number of ways. Antigens can be delivered from the 
gut lumen via transcytosis by M cells, goblet cell-associated antigen passages and 
through paracellular leak, whereby antigens are permitted to the lamina propria 
through pores in epithelial cell tight junctions (reviewed in Knoop et al., 2013; 
reviewed in Allaire et al., 2018). Macrophages and dendritic cells can also directly 
sample the lumen using transepithelial dendrites during inflammation and acquire 
antigens from other macrophages (reviewed in Knoop et al., 2013; reviewed in 
Peterson and Artis, 2014; reviewed in Bekiari et al., 2014). 
 APCs phagocytose bacteria to degrade them and present antigens in the 
context of the major histocompatibility complex to adaptive immune cells (reviewed 
in Santos and Finlay, 2015). In dendritic cells, antigens are processed rather than 
completely degraded using various cathepsins and asparagine endopeptidase 
(Lennon-Duménil et al., 2002; Mohamadzadeh et al., 2004; Manoury et al., 1998). 
The degradation of antigens is controlled by protease inhibitors and low levels of 
NOX2 and V-ATPases maintain a neutral pH in the phagosome (Trombetta et al., 
2003; Savina et al., 2006). 
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Processed antigens are then loaded on both MHC class I and II molecules in 
dendritic cells where they are presented to CD8+ and CD4+ T cells respectively 
(review in Blum et al., 2013). Antigens are loaded onto MHC class II molecules in 
the phagosome while others are exported to the cytosol, further processed by the 
proteasome and sent to the ER for loading onto MHC class I molecules (reviewed in 
Blum et al., 2013). Macrophages present antigens on MHC class II molecules but 
require stimulation with IFN-γ or RELMβ in order to express MHC class II 
(McCormack et al., 1992; Nair et al., 2008). IFN-γ has also been shown to 
upregulate the expression of cathepsin S, a protease involved in MHC class II 
processing, in macrophages (van’s Gravesande et al., 2002). 
 
1.2.1.4 Humoral innate immunity 
 
Humoral innate immunity is comprised of the complement and contact 
cascades, naturally occurring antibodies and pentraxins (reviewed in Shishido et al., 
2012). The complement system consists of blood plasma and membrane-expressed 
proteins and can be activated by either the classical, alternative or mannose binding 
lectin pathways (reviewed in Merle et al., 2015a). These pathways converge at the 
point of C3 cleavage, generating C3b, which leads to the cleavage of C5. C5b 
generated from the cleavage of C5 recruits complement components C6–9 to form 
membrane attack complexes in the membranes of pathogens, which results in direct 
killing by osmotic stress (reviewed in Merle et al., 2015b). C3b bound to the surface 
of a pathogen can also be cleaved into iC3b, which opsonises the pathogen and aids 
phagocytosis (Cunnion et al., 2004; Section 1.2.1.2). 
The contact system consists of factor XII (FXII), plasma prekallikrein (PPK) 
and high molecular weight kininogen (HK) and is involved in the activation of the 
intrinsic coagulation pathway, the complement system, inflammation and the 
production of antimicrobial peptides (reviewed in Oehmcke-Hecht and Köhler, 
2018). Contact factors bind to a number of molecules on the surface of pathogens 
including the curli fibres expressed by certain E. coli strains (reviewed in 
Oehmcke-Hecht and Köhler, 2018; Nasr et al., 1996; Herwald et al., 1998). FXII 
cleaves PPK into plasma kallikrein (PK), which in turn cleaves HK into bradykinin 
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and a variety of HK-derived antimicrobial peptides (Nordahl et al., 2005; Frick et al., 
2006; Sonesson et al., 2011). Bradykinin and the cleavage product HKa stimulate the 
expression of pro-inflammatory cytokines (Tiffany and Burch, 1989; Pan et al., 
1996; reviewed in Lalmanach et al., 2010; Khan et al., 2006) and bradykinin can also 
directly activate macrophages and dendritic cells as well as control neutrophil 
migration (Sato et al., 1996; Aliberti et al., 2003; Paegelow et al., 2002). FXII and 
PK can also trigger inflammation by inducing pro-inflammatory cytokine expression 
in macrophages and by causing the aggregation and degranulation of neutrophils 
(Vorlova et al., 2017; Wachtfogel et al., 1983; Wachtfogel et al., 1986). 
Furthermore, FXII and PK can activate the classical and alternative complement 
pathways respectively (Ghebrehiwet et al., 1981; DiScipio, 1982; Irmscher et al., 
2018). 
Naturally occurring IgM, IgA and IgG antibodies are produced by B1 B 
lymphocytes in the absence of antigen stimulation and recognise a variety of 
pathogens, but with low affinity due to restricted epitope specificity (reviewed in 
Shishido et al., 2012). Pentraxins are a family of multimeric soluble pattern 
recognition receptors with a conserved C-terminal domain and consist of three major 
members – C-reactive protein, serum-amyloid P component (SAP) and pentraxin 3 
(reviewed in Ma and Garred, 2018). Like naturally occurring antibodies, pentraxins 
bind to multiple pathogens as well as intrinsic antigens (reviewed in Du Clos, 2013). 
Pentraxins act as opsonins as they are recognised by FCγ immunoglobulin receptors 
(Mold et al., 2001; Mold et al., 2002; Moalli et al., 2010). Human SAP has been 
shown bind to and neutralise recombinant Stx2 in vitro and protect mice from lethal 
toxicity caused by recombinant Stx2 in vivo, however, it is unclear why SAP does 
not protect humans against HUS (Kimura et al., 2001; Armstrong et al., 2006; 
Dettmar et al., 2014). Pentraxins are also capable of activating and regulating the 
various pathways of the complement system (reviewed in Ma and Garred, 2018). 
 
1.2.1.5 Natural killer (NK) cells and γδ T cells 
 
NK cells and γδ T cells are classically thought of as innate lymphoid cells but 
have been shown to possess a form of memory (reviewed in Pahl et al., 2018; 
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Sheridan et al., 2013) and therefore bridge the gap the between the innate and 
adaptive immune systems. Human NK cells are characterised as CD3- CD56+ 
lymphocytes (Lanier et al., 1989; Zocchi et al., 1989; Nagler et al., 1989), however, 
bovine NK cells lack CD56 and are characterised by the expression of CD335 
(Storset et al., 2004). Human NK cells can be subdivided into CD56dim cells, which 
account for the majority of NK cells in the peripheral blood (reviewed in Mandal and 
Viswanathan, 2015), and CD56bright cells, which are localised in secondary lymphoid 
tissue (Fehniger et al., 2003). These cell subsets are involed in cytotoxic killing and 
cytokine production respectively (reviewed in Mandal and Viswanathan, 2015).  
NK cell function is controlled by a number of activatory and inhibitory 
receptors (reviewed in Mandal and Viswanathan, 2015). The recognition of 
self-MHC class I is a major inhibitor of NK cell activity, allowing NK cells to target 
infected or cancerous cells where MHC expression has been downregulated (Kärre et 
al., 1986). NK cells induce apoptosis in target cells by releasing perforin and 
granzyme, similar to cytotoxic T cells (Kägi et al., 1994; Shresta et al., 1995). NK 
cells are generally thought to protect against intracellular pathogens and cancer cells, 
however, they have been shown to protect mice from infection with the A/E 
pathogen C. rodentium (Hall et al., 2013). NK cells were shown to prevent 
dissemination of the bacteria to extracolonic tissues via the recruitment of other 
immune cells and by direct cytotoxic killing of the bacteria (Hall et al., 2013). 
Wöchtl et al. (2017) reported a slight increase in the number of NK cells in the blood 
of gnotobiotic piglets infected with EHEC O157:H7 but the relevance of these during 
infection was unclear. 
γδ T cells differ from CD4+ and CD8+ T lymphocytes inthat they posses a γδ 
T cell receptor (TCR) rather than an αβ TCR (reviewed in Alcover et al., 2018). γδ T 
cells have a broad range of functions including the secretion of IFN-γ, cytotoxic 
killing and antigen presentation (reviewed in Lawand et al., 2017). As APCs, human 
and zebra fish γδ T cells have been shown to be capable of professional phagocytosis 
(Wu et al., 2009; Wan et al., 2017). γδ T cells are found mainly in mucosal tissues 
where they protect against infection and promote epithelial cell layer integrity 
(Mackay and Hein, 1989; Bandeira et al., 1990; Chen et al., 2002a; reviewed in 
McCarthy and Eberl, 2018). In cattle they also account for 60–80 % of the 
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circulating lymphocytes in calves, which decreases to 5–15 % with age, and are the 
major regulatory T cell subset in bovine peripheral blood (Mackay and Hein, 1989; 
Davis et al., 1996; Guzman et al., 2014). Studies in mice reported that γδ T cells 
produce IL-17 in response to intraperitoneal infection with laboratory adapted E. 
coli, resulting in the recruitment of neutrophils (Shibata et al., 2007). Schaut et al. 
(2019) also reported that the intramuscular vaccination of cattle with inactivated 
Stx-negative EHEC O157:H7 resulted in the proliferation of γδ T cells, which 
produced IFN- γ and IL-4. 
 
1.2.2 Innate immune evasion strategies by A/E E. coli 
 
Many effector proteins produced by A/E E. coli that modulate the innate 
immune system target three main functions: NF-κB signalling, to inhibit the 
expression of pro-inflammatory cytokines; phagocytosis, to prevent clearing of the 
bacteria; and apoptosis, to impede the rapid turnover of intestinal epithelial cells, 
which normally removes colonising bacteria. Studies of these effectors are often 
caveated however, as effectors are generally overexpressed, used singly and may not 
reflect their role during infection. 
 
1.2.2.1 Nle proteins 
 
Non-LEE encoded effectors modulate the immune response in intestinal 
epithelial cells in a number of ways (Figure 1.6). NleA prevents the de-ubiquitination 
of the inflammasome (protein complex involved in pro-inflammatory cytokine 
signalling) protein NLRP3 and therefore inhibits the secretion of IL-1β (Yen et al., 
2015). NleB is a glycosyltransferase that targets host cell death-domain-containing 
proteins including FADD, TRADD and RIPK1. It has been shown to N-glycosylate 
Arg117 of FADD and Arg235 of TRADD, which disrupts NF-κB signalling and 
prevents the expression of pro-inflammatory cytokines and apoptosis (Li et al., 
2013b; Pearson et al., 2013). Gao et al. (2013) reported that NleB O-glycosylates 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH). This was confirmed by El 
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Qaidi et al. (2017), who found that NleB glycosylates GAPDH at residues Arg197 and 
Arg200, which are required to stimulate TRAF2 ubiquitination. 
NleC, E and H also interfere with NF-κB signalling in different ways. NleC is 
a zinc metalloprotease that degrades the NF-κB members p50, p65 and c-Rel, which 
results in the inhibition of IL-8 secretion (Pearson et al., 2011). NleC has also been 
shown to act synergistically with NleE (Pearson et al., 2011). NleE methylates 
conserved cysteines in the Np14 zinc finger domains of the host proteins TAB2 and 
3, which prevents the downstream degradation of the NF-κB inhibitor IκB (Zhang et 
al., 2012; Nadler et al., 2010). NleH interferes with NF-κB signalling in multiple 
ways. It inhibits the phosphorylation of the NF-κB transcriptional complex ribosomal 
protein S3, preventing its translocation to the nucleus (Gao et al., 2009; Wan et al., 
2011), and suppresses the ubiquitination and subsequent degradation of IκB (Royan 
et al., 2010). NleH also inhibits apoptosis by binding the protein Bax inhibitor-1 






Figure 1.6. Schematic of EHEC adhering to an enterocyte and injecting various 
Nle proteins into it via the Type III secretion system. A number of Nle proteins 
inhibit the expression and secretion of pro-inflammatory cytokines. Inhibition of 
protein secretion by EspG also blocks cytokine secretion. NleD, F and H prevent 
apoptosis of the host cell induced by Map and EspF (from Stevens and Frankel, 
2014). 
 
 NleD is another zinc metalloprotease that cleaves the host proteins JNK and 
p38 MAPK to inhibit both apoptosis and pro-inflammatory cytokine expression via 
activator protein 1 (AP-1) activation (Baruch et al., 2011; Creuzburg et al., 2017). It 
has been shown to differentiate between the host substrates as a conserved arginine 
residue is required for the cleavage of p38 but not that of JNK (Creuzburg et al., 
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2017). NleF prevents apoptosis of infected cells by binding to caspases-4, 8 and 9, 
which it inhibits by inserting its C-terminus into the caspase active site (Blasche et 
al., 2013). It should be noted that the role of many of these proteins was determined 
using cell culture models with high multiplicity of infections, which does not reflect 




 As described in Section 1.1.3.4, EspB inhibits the interaction of myosin with 
actin, which has been shown to inhibit the phagocytosis of EPEC E2348/69 by 
murine bone marrow-derived macrophages (Iizumi et al., 2007). EspB also 
suppresses NF-κB activation (Hauf and Chakraborty, 2003), although it is unclear if 
this reflects a direct role or the requirement for EspB in injection of other effectors. 
EspZ inhibits apoptosis of epithelial cells early in infection by interacting with 
CD98, which mediates cell survival (Shames et al., 2010), and the translocase of 
inner mitochondrial membrane 17b, which prevents the release of cytochrome c from 
mitochondria (Shames et al., 2011; Roxas et al., 2012). EspL is a cysteine protease 
that cleaves within the receptor-interacting protein homotypic interaction motifs of 
the proteins RIPK1, RIPK3, TRIF and ZBP1/DAI to inhibit necroptosis and 
inflammation (Pearson et al., 2017). 
 EspF, H, and J are involved in the inhibition of phagocytosis (Stevens and 
Frankel, 2014). EspF has been shown to inhibit phosphoinositide 3-kinase 
(PI3K)-dependent phagocytosis by macrophages and translocation by M cells (Celli 
et al., 2001; Quitard et al., 2006; Martinez-Argudo et al., 2007). EspF interacts with 
sorting nexin 9, actin, profilin and annexin A6 (Marchès et al., 2006; Alto et al., 
2007; Peralta-Ramírez et al., 2008; Hua et al., 2017), suggesting that it inhibits 
phagocytosis by disrupting the actin cytoskeleton. Annexin A6 has been implicated 
in cell survival, proliferation, migration and inflammation (Grewal et al., 2016), 
suggesting a possible wider role for EspF in modulating the host immune response. 
EspH competes with Rho to bind the DH-PH domain of Rho guanine nucleotide 
exchange factors, preventing the activation of Rho and remodelling of the actin 
cytoskeleton (Dong et al., 2010). EspJ inhibits trans-phagocytosis by simultaneously 
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amidating and ADP-ribosylating members of the Src kinase family (Marchès et al., 
2008; Young et al., 2014; Pollard et al., 2018). 
 
1.2.2.3 Secreted protease of C1 esterase inhibitor from EHEC (StcE) 
 
 StcE is a Type II secreted zinc metalloprotease encoded on the pO157 
plasmid of EHEC O157:H7 (Lathem et al., 2002). It cleaves the serum protein 
C1-esterase inhibitor (C1-INH), which is an anti-inflammatory serine protease and 
major regulator of the classical complement pathway (Lathem et al., 2002; Caliezi et 
al., 2000). StcE has been shown to increase the activity of C1-INH by localising it to 
the surface of erythrocytes, protecting bacterial cells against complement-mediated 
lysis, but cleavage of C1-INH is not required for this activity (Lathem et al., 2004). 
Grys et al. (2006) reported that recombinant StcE did not cleave the mucins MUC2 
or MUC5AC in vitro. However, it was subsequently found that EHEC cleaved 
MUC2 in human colonic biopsy samples in a StcE-dependent manner (Hews et al., 
2017), suggesting that a co-factor is required for this cleavage. StcE also cleaves 
other O-glycosylated mucin-type proteins such as MUC7 and glycoprotein 340, 
contributing to the intimate adherence of EHEC O157:H7 to host epithelial cells 
(Grys et al., 2005 and 2006; Hews et al., 2017). 
 StcE has also been found to cleave the mucin-type glycoproteins CD43 and 
CD45, which are found on most haematopoietic cells (Szabady et al., 2009; reviewed 
in Rheinländer et al., 2018; Fukuda and Carlsson, 1986; Borche et al., 1987). 
Cleavage of CD43 and CD45 has been shown to increase the respiratory burst in 
neutrophils but the biological significance of this remains unknown (Szabady et al., 
2009). CD43 has anti-adhesive properties and is relocalised to the trailing end uropod 
of migrating neutrophils to release them from the extracellular matrix (Seveau et al., 
2000). The cleavage of CD43 by StcE increases adhesion at the leading edge of 
neutrophils, thus increasing adhesion to the extracellular matrix and impairing 
neutrophil migration (Szabady et al., 2009). Proteolytically inactive StcE was also 
found to increase adhesion by relocalising CD43 to the uropod and blocking its 
anti-adhesive function (Szabady et al., 2009). CD45 has also been reported to be 
important for cell adhesion and chemotaxis in neutrophils (Shivtiel et al., 2008; 
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Harvath et al., 1991), suggesting that cleavage by StcE may affect these functions 
(Szabady et al., 2009). It was also recently found that StcE cleaves CD55 on 
epithelial cells (Furniss et al., 2018). CD55 is responsible for the release of 
neutrophils from the apical surface of intestinal epithelial cells (Lawrence et al., 
2003) and cleavage of CD55 by StcE resulted in increased adhesion of neutrophils to 
Caco-2 monolayers (Furniss et al., 2018). Given that StcE has also been shown to 
cause aggregation of human T lymphocyte cell lines (Lathem et al., 2002), the 
cleavage of CD43 and CD45 may be responsible for this. CD45 also activates Src 
family kinases, which is an important step in TCR signal transduction (reviewed in 
Rheinländer et al., 2018), indicating a possible role for StcE in modulating the 
adaptive immune response. 
 
1.2.3 The adaptive immune response 
 
The adaptive immune system is composed of B and T lymphocytes, which 
possess immunological memory (reviewed in Marshall et al., 2018). B cells 
recognise antigens directly via the B cell receptor (an immunoglobulin molecule), 
which drives them to differentiate into memory B cells or antibody producing plasma 
cells. B cells can also be driven to proliferate by cytokines and can act as APCs 
(reviewed in Hoffman et al., 2016). T cells require seconadary stimulation from 
APCs in addition to the recognition of MHC-antigen complexes via the TCR 
(reviewed in Marshall et al., 2018). CD8+ T cells are cytotoxic and act to destroy 
infected or cancerous cells, in a similar manner to NK cells (reviewed in Zhang and 
Bevan, 2011). CD4+ T cells produce cytokines and can act as APCs. CD4+ T cells 
can be further catagorised into four main subsets: T helper (Th) 1 cells, which are 
involved in the elimination of intracellular pathogens; Th2 cells, which mount an 
immune response to extracellular parasites; Th17 cells, which mount an immune 
response to extracellular bacteria and fungi; and regulatory T cells, which negatively 




1.2.3.1 B lymphocyte response 
 
 The production of antibodies by B cells forms one part of the adaptive 
immune response against A/E E. coli. Children infected with EPEC have been shown 
to produce high levels of IgG against EspA and B, intimin and BfpA, which are all 
important for bacterial adherence (Martinez et al., 1999). People infected with EHEC 
have also been shown to produce serum antibodies against EspA and B, intimin and 
Tir (Li et al., 2000). The production of IgA antibodies against various bacterial 
components including O157 LPS, H7 flagellin and the outer membrane protein 
OmpC was observed in the rectal mucosa of cattle infected with EHEC O157:H7 
(Nart et al., 2008a). Such antibodies may aid clearance of infection as vaccination 
with the proteins EspA, intimin and Tir significantly reduced the shedding of EHEC 
O157:H7 in the faeces of cattle (McNeilly et al., 2010). Serum IgG raised by 
vaccinating calves with intiminC280, the C-terminal fraction of intimin-γ, EspB and a 
fusion protein of Stx2 B subunit and Brucella lumazine synthase was able to 
neutralise Stx2 toxicity, inhibit T3SS-induced erythrocyte lysis and prevent the 
adherence of EHEC O157:H7 to epithelial cells in vitro (Martorelli et al., 2017). 
DNA vaccines against LomW and the C-terminus of EscC have also been reported to 
stimulate IgA and IgG responses that are associated with the protection of mice 
against EHEC O157:H7 infection (Tapia et al., 2016; García-Angulo et al., 2014). 
There have been many other vaccine studies that have assessed the antibody 
responses of cattle and mice to EHEC antigens, however, few studies have used 
passive transfer of antibodies or Ig-deficient animals to prove the role of such 
antibodies in protective immunity (reviewed in García-Angulo et al., 2013). It should 
also be noted that EHEC infection studies in mice should be interpreted with care as 
EHEC strains do not effectively form A/E lesions in mice (Mundy et al., 2006; 
Girard et al., 2008; Eaton et al., 2017). 
 
1.2.3.2 T lymphocyte response 
 
 The T cell response against EPEC and EHEC is less well defined than that of 
B cells but studies have shown a role for T cells in A/E E. coli infection. Mice 
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depleted in CD4+ T cells failed to eradicate the murine A/E pathogen C. rodentium 
and had a diminished IgA and IgG response to EspA (Simmons et al., 2003). RAG1 
knock-out mice, which cannot produce T or B cells, also failed to clear C. rodentium 
infection, suggesting a role for these cell types in clearance (Vallance et al., 2002). 
Corbishley et al. (2014) found that T lymphocytes have a role in the bovine immune 
response to EHEC O157:H7. It was observed that CD4+ T cells skew the immune 
response towards a Th1 response, which involves intracellular killing, early in the 
infection. This skew towards a Th1 response has also been observed in mice infected 
with C. rodentium and occurs in an intimin-dependent manner (Higgins et al., 1999a; 
Higgins et al., 1999b). Moreover, EPEC intimin has been reported to bind CD4+ T 
cells via β1-integrins and co-stimulate these cells from murine Peyer’s patches, 
mesenteric lymph node and caecal follicles (Frankel et al., 1996; Gonçalves et al., 
2003). Intimin also co-stimulated proliferation of splenic CD4+ T cells but not lamina 
propria CD4+ T cells, which did not bind to intimin as strongly as T cells from other 
locations (Gonçalves et al., 2003). Schaut et al. (2019) reported that bovine CD4+ T 
cells proliferated and produced IFN-γ in response to intramuscular vaccination with 
inactivated EHEC O157:H7. Corbishley et al. (2014) also found that Type III 
secreted proteins triggered proliferation in CD8+ and γδ T cells ex vivo but that these 
cell types had reduced numbers in terminal rectal biopsies and so the role of these 
cells in infection is unclear. 
 
1.2.4 Adaptive immune evasion strategies of A/E E. coli 
 
1.2.4.1 Subtilase cytotoxin (SubAB) 
 
 SubAB is an AB5 toxin found in some A/E E. coli, but also LEE-negative 
Stx-producing strains (reviewed in Krause et al., 2018). The A subunit of the toxin is 
a serine protease that cleaves the ER chaperone BiP, activating the ER stress-induced 
unfolded protein response that triggers apoptosis (reviewed in Paton and Paton, 
2010). Other effects of SubAB include the inhibition of protein synthesis and cell 
cycle arrest in the G1 phase (reviewed in Paton and Paton, 2010). The pathology 
caused by SubAB is similar to that caused by Stx (Wang et al., 2007). However, 
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subcytotoxic concentrations of SubAB have been reported to inhibit NF-κB 
activation in murine macrophages (Harama et al., 2009). 
 SubAB has been shown to bind to murine macrophages, neutrophils and 
lymphocytes and induce apoptosis in these cell types (Wang et al., 2011). The 
apoptosis rates of CD4+ T cells and B220+ B cells in murine blood were found to be 
significantly different from the basal rate up to 6 hours after SubAB injection (Wang 
et al., 2011). SubAB has also been shown to inhibit antibody secretion in murine B 
cells (Hu et al., 2009). BiP is required for the assembly of immunoglobulin heavy 
and light chains in the ER (Bole et al., 1986; Knittler and Haas, 1992). The 
SubAB-cleaved C-terminal fragment of BiP strongly binds to newly synthesised light 
chains and prevents their assembly with heavy chains, causing the unassembled 




 Stx modulates both the innate and adaptive immune responses. As described 
previously, Stx inhibits NF-κB activation in human Gb3-negative epithelial cells 
(Gobert et al., 2007). Stx has also been shown to target bovine peripheral blood 
lymphocytes and intraepithelial lymphocytes, which display Gb3 receptors (Menge et 
al., 1999; Menge et al., 2003; Menge et al., 2004a). It directly inhibits the 
proliferation of mitogen-stimulated bovine T and B cells (Menge et al., 1999; Stamm 
et al., 2002; Menge et al., 2003), as well as bovine leukemia virus infected 
lymphocytes (Ferens and Hovde, 2000), without inducing cell death. Menge et al. 
(2004b) also found that EHEC O103:H2 producing Stx1 significantly reduced the 
number of CD8α+ T cells in bovine ligated ileal loops within 12 hours of infection in 
a Stx1-dependent manner, albeit differences in proliferative capacity, natural killer 
cell activity or the cytokine mRNA profile of isolated cells did not differ 
significantly. Studies in calves demonstrated that animals infected with 
Stx-producing EHEC strains did not mount an effective cellular immune response 
after re-infection (Hoffman et al., 2006). Stx delays the onset of a cellular immune 
response rather than downregulating it (Stamm et al., 2002; Hoffman et al., 2006) 
and appears to target T cells in particular in vivo (Hoffman et al., 2006). As well as 
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inhibiting adaptive immune responses in cattle, Stx has been shown to induce the 
expression of pro-inflammatory cytokines in human and murine macrophages, which 
is thought to contribute to pathology (Tesh et al., 1994; Leyva-Illades et al., 2012; 
Brandelli et al., 2015; Lee et al., 2016; reviewed in Lee and Tesh, 2019). Although 
studies have shown that Stx is not essential for the colonisation of sheep, mice and 
infant rabbits, these did not consider the nature of immune responses during such 




1.3.1 The discovery of lymphostatin 
 
 In 1995 Klapproth et al. discovered that lysates of certain EPEC strains were 
capable of dose-dependent inhibition of cytokine expression by human peripheral 
blood mononuclear cells (PBMCs), but that laboratory-adapted E. coli K-12 strains, 
other E. coli pathotypes and whole EPEC lacked this ability. Lysates of EHEC 
O157:H7 strain EDL933 were found to inhibit cytokine expression but were not 
tested in a dose-dependent manner. Only one EPEC strain tested, O119:H6 0659-79, 
did not have inhibitory activity against PBMCs, which may be due to known 
variation in EPEC strains (Levine and Edelman, 1984). Klapproth et al. (1995) 
determined that inhibitory activity was caused by a protein or proteins encoded on 
the bacterial chromosome. They also found, using lysates of an E. coli K-12 strain 
transformed with an EPEC cosmid (pIV-8-A), that these lysates inhibited cytokine 
expression in human peripheral blood lymphocytes irrespective of the mechanism of 
lymphocyte activation. These cosmid clone lysates could also inhibit the 
mitogen-stimulated proliferation of lymphocytes. The inhibition observed in these 
experiments was reportedly not due to cellular toxicity. 
 In 1996, further experiments by Klapproth et al. found that lysates of E. coli 
K-12 containing the EPEC pIV-8-A cosmid clone exhibited dose-dependent 
inhibition of IL-2 expression against human PBMCs and lamina propria 
mononuclear cells (LPMCs). The inhibition of cytokine synthesis was non-selective 
and the inhibition of lymphocyte proliferation was not caused by the inhibition of 
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IL-2 receptor expression. CD25 (α-chain of the IL-2 receptor) expression, which 
rapidly increases after T cell activation, was not inhibited in CD45RO+ cells 
(activated T cells) by lysates of E. coli K-12 containing pIV-8-A. It was found that 
the inhibitory effect of EPEC E2348/69 lysates was similar in mitogen-stimulated 
PBMCs and LPMCs. The culture supernatants of EPEC were also found to inhibit 
IL-2 and IL-5 expression in mitogen-stimulated PBMCs. Lastly, Klapproth et al. 
(1996) found that EPEC and cosmid clone lysates could inhibit cytokine expression 
in human lymphocytes activated by products of non-pathogenic E. coli. 
 Malstrom and James (1998) observed that EPEC E2348/69 lysates inhibited 
IL-2 expression in murine splenic cells stimulated with 12-myristate 13-acetate and 
phytohaemagglutinin without causing apoptosis. EPEC lysates inhibited multiple 
cytokines but increased the production of IL-10, which itself inhibits inflammatory 
cytokine expression. However, the inhibitory activity of EPEC lysates was 
independent of IL-10 and the regulatory cytokine TGF-β. Macrophages were also not 
required for the increased production of IL-10. IL-2 expression was inhibited by 
EPEC lysates in mitogen-stimulated Jurkat cells (an immortalised human T cell line) 
as well as small intestinal intraepithelial and Peyer’s patches lymphocytes. 
Pre-exposure of murine splenic cells to EPEC lysates resulted in decreased IL-2 and 
increased IL-10 expression when the cells were both mitogen- and 
antigen-stimulated. Malstrom and James (1998) also found that lysates of EHEC 
EDL933, RDEC-1 and C. rodentium had inhibitory activity against murine splenic 
lymphocytes and that this activity was not related to EspB, which was examined due 
its requirement for signal transduction in host cells and the activation of NF-κB 
transcription factors (Foubister et al., 1994; Savkovic et al., 1997). 
 In 2000 Klapproth et al. discovered the protein responsible for the inhibitory 
activity described above, which they named lymphostatin or lymphocyte inhibitory 
factor A (LifA) due its ability to specifically inhibit lymphocyte proliferation and 
cytokine expression. DNA sequencing of the pIV-8-A cosmid revealed the lifA gene 
to be 9,669 bp encoding a predicted 365,950 Da protein – the largest protein so far 
described in E. coli. Mutation of the lifA gene from EPEC E2348/69 abolished the 
inhibitory activity of bacterial lysates against human PBMCs but did not affect the 
 37 
ability of the strain to nucleate actin under sites of attachment in a fluorescent actin 
staining test, a proxy for A/E lesion formation (Klapproth et al., 2000). 
 
1.3.2 Homologous proteins and sequences to lymphostatin 
 
 In the same year as LifA was first described, Nicholls et al. (2000) discovered 
a protein in EHEC O111:H- strain E45035 that increased the adhesion of bacteria to 
Chinese hamster ovary (CHO) cells in vitro and named it EHEC factor for adherence 
1 (Efa1). Efa1 was identical in size to LifA and was predicted to be 99.9 % identical 
to LifA at a nucleotide level and 99 % identical at an amino acid level (Nicholls et 
al., 2000), with only a single amino acid difference between the two proteins. As 
such, LifA and Efa1 are considered to be the same protein and their names are used 
interchangeably in the literature. 
 LifA and homologous proteins have been found in EPEC, EHEC, RDEC, E. 
albertii, C. rodentium and various Chlamydia species (reviewed in Klapproth, 2010). 
An NCBI Blast search reveals that EPEC E2348/69 possesses a LifA homologue 
termed LifA-like protein, which is also present in EPEC O111:H- strain B171-8 and 
is predicted to be ~298 kDa in size. The LifA-like protein from EPEC E2348/69 
shares 34 % identity and 54 % similarity with amino acids (aa) 244–716 of LifA, and 
28 % identity and 48 % similarity with aa 707–2356 of LifA. The LifA-like protein 
from EPEC B171-8 shares 31 % identity and 51 % similarity with aa 62–716, and 
27 % identity and 47 % similarity with aa 728–2555 of LifA. EPEC B171-8 
LifA-like protein is also larger than the E2348/69 variant at ~339 kDa. The LifA-like 
protein, along with LifA, has recently been implicated in having an accessory role in 
the formation of actin pedestals and A/E lesions that is masked by other T3S effector 
proteins (Cepeda-Molero et al., 2017). 
 The prototype EHEC O157:H7 strain EDL933 does not produce LifA but 
rather encodes two homologous proteins termed Efa1 and ToxB. Efa1 is a truncated 
version of LifA that is encoded on open reading frames z4332 and z4333 on O-island 
122 of the chromosome of strain EDL933 (Hayashi et al., 2001; Perna et al., 2001). 
Efa1 shares 99 % identity and 99 % similarity with aa 1–433 of LifA and is identical 
to aa 437–711 of LifA (Hayashi et al., 2001; Perna et al., 2001). It is unclear if only 
38 
the 433 amino acid protein is made or if a 710 amino acid protein can be made via 
ribosome frameshifting. ToxB is of a similar predicted size to LifA and is encoded 
on the EHEC O157:H7 large plasmid pO157 (Burland et al., 1998; Makino et al., 
1998). ToxB shares 30 % identity and 48 % similarity with aa 48–3204 of LifA 
(Burland et al., 1998; Makino et al., 1998). ToxB sequences have also been found in 
non-O157 EHEC strains and EPEC (for example, Badea et al., 2003; Tozzoli et al., 
2005). Stevens et al. (2004) reported that the LifA homologues Efa1 and ToxB 
influenced the adherence of EHEC O157:H7 to HeLa cells but were not required for 
the colonisation of cattle or sheep. They also reported that mutations in the efa1 and 
toxB genes reduced the production and secretion of proteins encoded by the LEE4 
operon but did not affect the activity of the LEE1, 4 and 5 operon promoters. This is 
consistent with observations by Tatsuno et al. (2001) that suggest that ToxB affects 
expression and secretion of LEE-encoded proteins at a post-transcriptional level. 
Abu-Median et al. (2006) also performed experiments with efa1 and toxB mutants 
and reported that these proteins did not appear to confer lymphostatin-like activity 
against mitogen-stimulated peripheral blood lymphocytes, however, the assay relied 
on crude bacterial lysates and is relatively insensitive. Recent experiments by 
Cassady-Cain et al. (2017) have since shown that recombinant ToxB does inhibit the 
mitogen-stimulated proliferation of bovine T cells in a dose dependent manner, 
similar to LifA. 
 In Chlamydia, C. psittaci contains a single lifA homologue, C. muridarum 
possesses three copies and C. trachomatis contains a pseudogene with frameshift 
mutations (Xie et al., 2003). LifA homologues from Chlamydia species share ~34–
37 % identity with EPEC E2348/69 LifA. Belland et al. (2001) have shown that LifA 
homologues from C. trachomatis act as cytotoxins and suggested that it is possible 
that the immunomodulatory ability of LifA homologues may allow Chlamydia 
species to cause persistent infections. The Stevens laboratory has recently shown that 
a LifA homologue from C. pecorum, which shares ~36 % identity with LifA, inhibits 
the mitogen-stimulated proliferation of bovine T cells in a dose-dependent manner. 
This involved cloning, expression and affinity purification of the protein and 
inhibitory activity is not the result of cytotoxicity (Stevens Laboratory unpublished 
data). 
 39 
1.3.3 Secretion of lymphostatin 
 
 Little work has been carried out towards understanding the mechanism of 
secretion of LifA. Deng et al. (2012) reported that LifA appeared to be secreted by 
the LEE-encoded T3SS based on quantitative proteomic (SILAC) analysis of 
proteins secreted by EPEC O127:H6 strain E2348/69 and an isogenic LEE mutant. 
This involved mapping peptides across the protein and detecting them using mass 
spectrometry. Reporter assays using the N-terminal 50–100 amino acids of LifA 
fused to TEM-1/β-lactamase showed that this sequence of LifA was capable of 
directing the translocation of the TEM1 fusion protein into HeLa cells, which was 
detected by a change in fluorescence of a β-lactamase substrate. Due to the 
limitations of the cloning vector that was used, only the N-terminal 50–100 amino 
acids of LifA were used instead of the full-length protein. This was suitable for 
examining Type III secretion as Charpentier and Oswald (2004) found that as little as 
20 amino acids from the N-terminus of various T3S proteins are sufficient to mediate 
translocation through the T3SS. LifA was detected in the culture supernatant, but 
only when using a hypersecreting strain (Deng et al., 2012). The secretion of 
full-length LifA via the T3SS was recently confirmed by western blots of Type III 
secretion-induced EPEC E2348/69 culture supernatants and polyclonal LifA-specific 
antiserum (Bease, 2015). Efa1 was first identified by Tn5phoA mutagenesis, whereby 
an in-frame fusion of the gene encoding alkaline phosphatase to the first 533 amino 
acids of Efa1 was created (Nicholls et al. 2000). Alkaline phosphatase is only active 
in the bacterial periplasm and extracellularly, and the fact that the fusion was active 
against the chromogenic substrate 5-Bromo-4-chloro-3-indolyl phosphate indicates 
that at least part of the protein is located beyond the cytoplasmic membrane (Nicholls 
et al., 2000).  
 The mechanism of LifA secretion is important for understanding how it acts 
on host cells. Studies by Klapproth et al. (1995, 1996 and 2000), Malstrom and 
James (1998) and Stevens et al. (2002) have all shown that bacterial lysates 
containing LifA have inhibitory activity against lymphocytes and mononuclear cells, 
indicating that injection is unlikely to be needed for lymphostatin activity. Moreover, 
activity can be transferred to laboratory-adapted E. coli K-12 containing cloned LifA 
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even though it lacks the T3SS. Purified recombinant LifA has also been found to 
inhibit the mitogen-stimulated proliferation of lymphocytes (Bease, 2015; 
Cassady-Cain et al., 2016; Cassady-Cain et al., 2017), suggesting that 
T3SS-mediated injection into host cells is not required for LifA to function. It is 
unclear exactly how LifA is delivered to its target cells but possible mechanisms 
include: direct injection via the T3SS into intraepithelial lymphocytes; secretion into 
the gut lumen where it endocytosed by intraepithelial lymphocytes or crosses the 
epithelial cell layer via transcytosis or paracellular leak to reach gut associated 
lymphoid tissue; delivery across the epithelial cell layer into the circulation to act on 
lymphocytes before they reach the site of infection; and delivery via bacterial outer 
membrane vesicles, similar to Stx. 
 
1.3.4 Importance of lymphostatin as a virulence factor 
 
 LifA has been shown to be an important virulence factor in A/E pathogens 
(Stevens et al., 2002; Badea et al., 2003; Klapproth et al., 2005; Deacon et al., 2010). 
Stevens et al. (2002) found that deleting the lifA gene in EHEC O5:H- strain S102-9 
caused a 19-fold reduction in adherence to HeLa cells. A reduction in adherence was 
not observed in EPEC E2348/69 but this may have been due to the expression of 
BFP and elevated expression of the T3SS in this strain. Lysates of both EPEC 
E2348/69 and EHEC S102-9 were found to inhibit the mitogen-stimulated 
proliferation of bovine PBMCs, although the inhibition caused by EHEC may have 
been due to other toxins such as Stx. Stx is capable of inhibiting the proliferation of 
lymphocytes (Menge et al., 1999) and deleting the lifA gene did not relieve the 
inhibitory effect of the EHEC lysate. Deleting the lifA gene in EHEC S102-9 and 
E45035N significantly reduced the magnitude of faecal excretion of the bacteria in 
calves and adherence of the bacteria to the intestinal epithelium. It was also found 
that EHEC S102-9 ΔlifA mutants were reduced in their ability to produce and secrete 
EspA and Tir, but were still able to nucleate actin at sites of attachment. This 
suggests that the loss of LifA could have affected gut colonisation via indirect effects 
on Type III secretion, which is known to be vital for colonisation of the bovine gut 
by EHEC O157:H7 (Dziva et al., 2004; Naylor et al., 2005; Eckert et al., 2011). The 
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presence of lifA in atypical EPEC strains has also been strongly associated with 
diarrhoea and higher bacterial loads in the faeces of humans (Afset et al., 2006; 
Narimatsu et al., 2010; Slinger et al., 2017).  
 Badea et al. (2003) reported that LifA was necessary for the in vitro 
adherence of rabbit EPEC to epithelial cells. The rabbit EPEC strain used lacked 
BFP, which may have masked the effects of LifA. Rabbit EPEC with mutated lifA 
had reduced adherence to CHO and HeLa cells and polyclonal antibodies against 
LifA also reduced adherence. The mutation of the lifA gene did not disrupt EspA 
secretion, indicating that pleotropic effects of lifA mutation on the expression of 
LEE-encoded proteins may be strain-specific. It is noteworthy that lifA has been 
reported to be encoded immediately 3 of the LEE4 operon in the opposite direction 
in some strains (Ogura et al., 2009). 
 Klapproth et al. (2005) found that mutating the lifA gene in C. rodentium did 
not reduce the ability of the bacteria to colonise the colon of mice but did result in 
reduced pathology and accelerated clearance of the bacteria. In these experiments 
Klapproth et al. (2005) mutated putative glycosyltransferase and cysteine protease 
domains within LifA as well as a domain between these two that does not encode any 
known activity. However, later it was discovered that the mutations created stop 
codons at the site of the in-frame deletions, which resulted in the truncation of the 
LifA protein (Deacon et al., 2010). This means that the results were invalid in 
relation to the effects of the specific domains but still showed that the protein as a 
whole is required for colonic hyperplasia in mice. 
 Deacon et al. (2010) also investigated the importance of the putative 
glycosyltransferase and cysteine protease domains by substituting specific motifs 
within these domains in EHEC O26:H- strain 193. The strain used was incapable of 
producing Stx1 in order to prevent it from masking the effects of LifA. It was found 
that lifA null mutants had significantly reduced ability to colonise cattle but mutants 
of the putative glycosyltransferase and cysteine protease domains did not (Deacon et 
al., 2010). No effect of the lifA mutation on expression of EspA was observed in 
EHEC O26:H-. In contrast to Stevens et al. (2002), this shows that LifA has a direct 
role in gut colonisation independently of effects on EspA. LifA was not necessary to 
induce enteritis in bovine ligated ileal loops (Deacon et al., 2010). In contrast to 
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previous experiments, lifA null and motif mutants did not have significantly reduced 
adherence to HeLa cells or ability to inhibit the mitogen-stimulated proliferation of 
bovine lymphocytes. However, when the motif substitutions were transferred to the 
chromosome of EPEC E2348/69 it was observed that the ability to inhibit 
mitogen-stimulated proliferation of lymphocytes was significantly reduced in the 
motif mutants compared with the parental EPEC E2348/69 strain. 
 Vaccines using subunits of LifA from EHEC E45035 and the z4332 gene 
product generated an antibody response against these proteins but did not protect 
calves from infection with EHEC strains EDL933 or 193 of serogroups O157 or 
O26, respectively (van Diemen et al., 2007). However, immunisation of calves in 
this study with the cell binding domain of intimin subtypes β or γ also did not protect 
against infection despite inducing an antibody response. Subsequent studies using 
intimin vaccines have reported protection against infection (Martorelli et al., 2017), 
suggesting that the lack of protection observed by van Diemen et al. (2007) may be 
due to the experimental design, which involved inoculation with a high dose that 
may have overwhelmed immune responses. It is also possible that the LifA protein 
used in the vaccine was not properly folded or exposed pertinent epitopes required 
for an efficient response. In contrast to van Diemen et al. (2007), Riquelme-Neira et 
al. (2016) reported that vaccinating mice with DNA encoding Efa1 conferred 
protective immunity against EHEC O157:H7 colonisation, while also generating 
specific serum antibodies against the protein, and increasing the proliferative 
response of T cells against EHEC proteins and heat-killed bacteria. The plasmid 
containing the efa1 gene was reported to express FLAG-tagged recombinant protein, 
however, western blots of the protein were not published and therefore it remains 
unclear whether Efa1 is the product of both open reading frames z4332 and z4333 







1.3.5 Structural motifs of lymphostatin 
 
1.3.5.1 The glycosyltransferase domain 
 
 The N-terminal portion of LifA is ~40 % homologous over the first 470 
amino acids to the catalytic domains of large clostridial toxins (LCTs), including 
TcdA and B from Clostridium difficile, the lethal and haemorrhagic toxins (TcsL and 
TcsH) from C. sordellii, α-toxin (TcnA) from C. novyi and TpeL from C. perfringens 
(Klapproth et al., 2000; Nicholls et al., 2000; Busch et al., 1998; Amimoto et al., 
2007). This homologous region in LifA encompasses a catalytic DXD motif that is 
necessary for sugar binding in LCTs (Klapproth et al., 2000; Nicholls et al., 2000; 
Busch et al., 1998). The LCTs are known glycosyltransferases (Triadafilopoulos et 
al., 1987), most of which bind uridine diphosphate-glucose (UDP-Glc; Just et al., 
1995b and 1995c; Schirmer and Aktories, 2004). TcnA and TpeL can bind UDP-Glc 
but their primary substrate is uridine diphosphate-N-acetylglucosamine 
(UDP-GlcNAc; Selzer et al., 1996; Schrimer and Aktories, 2004; Nagahama et al., 
2011; Guttenberg et al., 2012). LCTs are known to act as cytotoxins by hydrolysing 
UDP-sugars and transferring the sugar moieties onto Rho GTPases, thereby 
inhibiting Rho GTPase activity and causing the collapse of the actin cytoskeleton 
(Just et al., 1995a, 1995b and 1995c; Selzer et al., 1996). However, LifA has never 
been shown to act in this manner or cause direct cytotoxicity, for example by assays 
for the release of lactate dehydrogenase or analysis of cell permeability by trypan 
blue exclusion (Klapproth et al., 1995 and 2000; Malstrom and James, 1998; 
Nicholls et al., 2000; Stevens et al., 2002; Bease, 2015; Cassady-Cain et al., 2016). 
 As described previously, an initial attempt to mutate the glycosyltransferase 
(GT) domain of LifA in C. rodentium by Klapproth et al. (2005) produced a 
truncated protein. Babbin et al. (2009) corrected the mutation and implicated the GT 
domain in causing the redistribution of ZO-1 and occludin from enterocyte tight 
junctions, compromising the intestinal epithelial cell barrier and suppressing Cdc42 
activity. However, this study did not investigate claims by Klapproth et al. (2005) 
that the GT domain is required for the effective colonisation of mice by C. 
rodentium, induction of colonic hyperplasia or inhibition of lymphocyte function. 
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Deacon et al. (2010) substituted the DXD motif of LifA in EHEC 193 for a triple 
alanine sequence and found that it did not affect the ability of the bacteria to colonise 
calves or to adhere to epithelial cells. When this substitution was transferred to the 
chromosome of EPEC E2348/69, there was a significant reduction in the ability of 
bacterial lysates to inhibit mitogen-stimulated T cell proliferation. 
 Recently, recombinant LifA was found to bind UDP-GlcNAc but not 
UDP-Glc (Bease, 2015; Cassady-Cain et al., 2016). Purified LifA containing a 
DXD-AAA substitution was found to be structurally similar to the wild-type protein, 
but its ability to bind UDP-GlcNAc and inhibit T cell proliferation was abolished 
(Bease, 2015; Cassady-Cain et al., 2016). This suggests that LifA acts as a 
glycosyltransferase but the target(s) of this activity in host cells remains unknown. 
The GT domain was predicted to contain a Mn2+ ion as incubating recombinant LifA 
with MnCl2 increased the thermal stability of the protein (Cassady-Cain et al., 2016). 
The DXD motif is absent from the truncated version of LifA found in many E. coli 
O157:H7 strains (z4332) and this may explain the lack of phenotype of efa1 deletion 
mutants in assays of mitogen-activated lymphocyte proliferation (Abu-Median et al., 
2006). Given that glycoproteins modified with GlcNAc are required for cell-cell and 
cell-matrix interactions in Drosophila (Sakaidani et al., 2011), and that E. coli are 
known to bind mannose and N-acetyllactosamine moieites on host cell surfaces via 
Type I fimbriae (Ofek et al., 1977) and BFP (Hyland et al., 2008) respectively, this 
raises the possibility that GlcNAc binding by LifA may be linked to its reported role 
as an adhesin. 
 
1.3.5.2 The cysteine protease domain 
 
 In addition to the GT domain, LifA also contains a C58 cysteine protease 
(CP) domain and is a member of the YopT-like cysteine protease superfamily (Shao 
et al., 2002). YopT is a virulence factor from Yersinia that cleaves host cell Rho 
GTPases, resulting in the collapse of the actin cytoskeleton (Shao et al., 2002). As 
stated above, LifA does not appear to act as a direct cytotoxin, which suggests 
another role for the CP domain of LifA. The CP domain of another C58 protease, 
AvrPphB from Pseudomonas syringae, cleaves the host protein PBS1 but is also 
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required for the autocatalytic cleavage of AvrPphB (Shao et al., 2002 and 2003a). 
Therefore, a possible role for CP domain of LifA may be to mediate autoproteolysis. 
Shao et al. (2002) found that C58 proteases require a C/H/D catalytic triad for 
proteolysis and this triad is also found in the sequences of LifA and ToxB. C58 
proteases have little homology beyond the C/H/D catalytic triad and the sequence 
that most closely matches the LifA CP domain outwith the various LifA homologues 
is the CP domain of PaTox from Photorhabdus asymbiotica (Jank et al., 2013; 
Bogdanović et al., 2018). A predicted structural model of the LifA CP domain was 
produced by Dr Liz Blackburn (Edinburgh Protein Production Facility (EPPF), 
Centre for Translational & Chemical Biology, University of Edinburgh) by 
alignment of the LifA sequence with the crystal structure of a C1865A PaTox CP 















Figure 1.7. Predicted structure of the LifA cysteine protease domain based on 
the crystal structure of the PaToxC1865A cysteine protease domain from 
Photorhabdus asymbiotica. The predicted catalytic cysteine, histidine and aspartic 
acid residues can be identified by their respective sulphur (yellow), nitrogen (blue) 
and oxygen (red) atoms (created by Dr Liz Blackburn, EPPF). 
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 LCTs also have CP domains that, like AvrPphB, are required for autocatalytic 
cleavage (Pfeifer et al., 2003; Egerer et al., 2007; Guttenberg et al., 2011 and 2012). 
Although the CP domains of LCTs are not homologous to the C58 proteases, given 
the N-terminal homology between LifA and LCTs, this lends further weight to the 
hypothesis that the CP domain of LifA is required for autoproteolysis. 
 As with previous experiments concerning the GT domain, the first CP 
domain mutants made by Klapproth et al. (2005) were invalid. Babbin et al. (2009) 
corrected the mutation and implicated the CP domain in causing the redistribution of 
β-catenin and E-cadherin at enterocyte apical junctions, and the activation of RhoA, 
but again did not investigate its role in gut colonisation or inhibition of lymphocyte 
function. Deacon et al. (2010) deleted a 369 bp section of the EHEC O26:H- strain 
193 lifA gene that encompassed the C/H/D motif, which was marked with a triple 
alanine sequence. In a similar manner to the DXD motif, the CP domain was found 
not to be required for the intestinal colonisation of calves by this strain but was 
required for lymphostatin activity in EPEC E2348/69. In contrast to Babbin et al. 
(2009), Deacon et al. (2010) did not detect the activation of Rho by any of the 
wild-type or ΔlifA bacterial strains. Unlike the DXD motif mutant, the CP domain 
mutant had over 100 amino acids removed from the sequence and so it is possible 
that the results observed by Deacon et al. (2010) are the consequence of structural 
abnormalities in the mutant protein rather than mutation of the specific motif. 
 
1.3.6 Recent advances in understanding the mode of action of lymphostatin 
 
 LifA clones are unstable and under-represented in cosmid libraries (Klapproth 
et al., 2000; Janka et al., 2002). Nicholls et al. (2000) reported that they were unable 
to assemble the full-length lifA/efa1 gene from cloned N- and C-terminal fragments 
and that the protein may be toxic to the E. coli cell. Recent work by Cassady-Cain et 
al. (2016) has enabled the further study of LifA. Through the use of tightly inducible 
expression vectors, it has been possible to create a stable plasmid encoding 
recombinant LifA with a 6 x His tag. This recombinant LifA has been purified and 
biophysically characterised. It is capable of inhibiting the concanavalin A (ConA)- 
and antigen-stimulated proliferation of bovine T cells and IL-4-stimulated B cells in 
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a dose-dependent manner (Cassady-Cain et al., 2016 and 2017). The recombinant 
protein inhibited proliferation in all major T cell subsets in bovine peripheral blood 
as well as the expression of IL-2, 4, 10, 17A and IFN-γ. Cassady-Cain et al. (2017) 
also found that T cell proliferation was inhibited up to 18 hours after transient 
exposure to LifA and that, although LifA inhibits ConA-stimulated proliferation, T 
cells treated with lymphostatin proliferated normally when stimulated with PMA and 
ionomycin. A rabbit polyclonal antibody has also been produced against this 
recombinant LifA, allowing for the sensitive detection of the protein by western 
blotting (Cassady-Cain and Bease, unpublished observations). A robust system for 
expression, purification and functional characterisation of LifA also allowed for the 
investigation of the glycosyltransferase activity of LifA (Bease, 2015; Cassady-Cain 
et al., 2016). 
 
1.4 T lymphocyte modulation by other enteric bacteria 
 
 A number of virulence factors employed by enteric pathogens to interfere 
with T cell processes have now been described. These tend to act on host cells in one 
of three ways: modulation of lymphocyte activation and proliferation; interference in 
lymphocyte chemotaxis; and the induction of apoptosis (Figure 1.8; reviewed in 





















Figure 1.8. Summary of the virulence factors produced by enteric bacteria that 
modulate T lymphocyte functions (grey boxes) and the molecules/processes that 
they interfere with. sAg – superantigens; CT – cholera toxin; LT – ETEC heat labile 
toxin; STM3106 – S. Typhimurium L-asparaginase II; GGT – Helicobacter and C. 
jejuni γ-glutamyl transferase; YopH – Yersinia outer protein H; VacA – H. pylori 
vacuolating cytotoxin A; IpgD – S. flexneri invasion plasmid gene D (from 




 Superantigens cross-link MHC class II molecules from APCs with the 
Vβ-chain of the TCR, resulting in non-specific T cell activation (reviewed in 
Krakauer, 2013). This leads to the CD95-mediated death of T cells and the residual 
activated T cells become functionally unresponsive, thereby suppressing an effective 
 49 
T cell response (reviewed in Krakauer et al., 2016). Superantigens are capable of 
activating a large number of T cells even at low concentrations (Choi, et al., 1989; 
reviewed in Krakauer et al., 2016). Superantigens have been best characterised in 
Staphylococcus aureus, which produce a number of superantigens (reviewed in 
McKay, 2001), but are also produced by Yersinia enterocolitica and Y. 
pseudotuberculosis (Stuart and Goodward, 1992; Abe et al., 1993). The superantigen 
Y. pseudotuberculosis-derived mitogen A (YPMa) is associated with strains that 
cause Far Eastern scarlet-like fever and has been shown to increase the virulence of 
Y. pseudotuberculosis in mice (Fukushima et al., 2001; reviewed in Amphlett, 2016; 
Carnoy et al., 2000). YPMa has also been reported to cause the release of perforin 
and granzyme from CD4+ T cells in the spleen and liver of mice, resulting in 
hepatotoxicity (Goubard et al., 2015). 
 
1.4.2 Helicobacter pylori vacuolating cytotoxin A (VacA) 
 
 VacA has been shown in multiple studies to inhibit the proliferation of T cells 
as well as exerting effects on a variety of other cell types including epithelial cells, 
neutrophils and macrophages (Boncristiano et al., 2003; Gebert et al., 2003; Sundrud 
et al., 2004; reviewed in Utsch and Haas, 2016). VacA is expressed as a 140 kDa 
protein, which is cleaved into an 88 kDa form and secreted via the Type V secretion 
pathway (reviewed in Foegeding et al., 2016). The 88 kDa toxin is composed of two 
domains that are both required for cell entry (Torres et al., 2005). The exact 
mechanism of cell entry is unclear but CD18 has been identified as a receptor for 
VacA on T cells (Sewald et al., 2008). Endocytosis is mediated by protein kinase C 
(PKC) and requires the activation of T cells (Sewald et al., 2010). Once inside the 
host cell, VacA inhibits the activation and nuclear translocation of the transcription 
factor NF-AT and has also been shown to block calcium flux, which is important for 
T cell signalling (Boncristiano et al., 2003; Gebert et al., 2003; Kern et al., 2015). 
The inhibition of NF-AT prevents IL-2 expression in Jurkat cells but not to as great 
an extent in primary human CD4+ T cells, suggesting that the inhibition of 
proliferation is IL-2 independent (Boncristiano et al., 2003; Gebert et al., 2003; 
Sundrud et al., 2004). The initial colonisation of mice was reported to be impaired in 
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a ΔvacA H. pylori mutant but the bacterial load and intestinal inflammation 
developed to the same level as the wild-type strain once the infection became 
established (Salama et al., 2001). However, since murine T cells do not express the 
appropriate receptor for VacA (Sewald et al., 2008), this observation was likely to be 
independent of the effects of VacA on lymphocyte proliferation. 
 
1.4.3 Yersinia YopH, invasin and YpkA 
 
 YopH is a Type III secreted tyrosine phosphatase produced by Yersinia 
species including Y. enterocolitica and Y. pseudotuberculosis (Cornelis et al., 1989; 
Guan and Dixon, 1990; Cornelis et al., 1998). YopH inhibits the proliferation and 
expression of IL-2 by T cells and has also been shown to suppress the activation of B 
cells stimulated via the B cell receptor (Yao et al. 1999; Sauvonnet et al., 2002). In T 
cells, YopH has been shown to dephosphorylate Lck, Fyb and the p85 subunit of 
PI3K, as well as interact with numerous signalling proteins, which are likely used to 
localise YopH to the proximity of its targets (Alonso et al., 2004; de la Puerta et al., 
2009). Since Lck is located upstream of most tyrosine phosphorylation events in the 
signalling cascade of T cells, dephosphorylation of only a few Lck molecules is 
predicted to have a significant impact on signalling (Alonso et al., 2004). How YopH 
inhibits B cell activation is unknown but given that Lck has been reported to be 
involved in B cell activation (Talab et al., 2013; Zhou et al., 2018), the mechanism 
may be similar to that in T cells. YopH has also been reported to cause the 
breakdown of mitochondria in T cells, resulting in apoptosis, but little is known 
about the mechanism of this activity (Bruckner et al., 2005). YopH-deficient Y. 
enterocolitica was previously found to have a marked reduction in its ability to 
colonise mice after oral infection (Trülzsch et al., 2004). This attenuation was 
confirmed for intravenous infection with Y. enterocolitica and intranasal infections 
with Y. pseudotuberculosis (Trülzsch et al., 2004; Fisher et al., 2007). 
 Much less is known about the roles of invasin and YpkA. Invasin, which is 
homologous to intimin from A/E pathogens, induces T cell migration and is thought 
to cause lymphocytes to disseminate from sites of infection (Leo et al., 2015; 
Arencibia et al., 1997). YpkA, also known as YopO, is thought to modulate the 
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cytoskeleton by interacting with actin and Rho GTPases but has also been shown to 
induce apoptosis in Jurkat cells via disruption of the mitochondrial membrane 
potential (Park et al., 2007). 
 
1.4.4 Helicobacter and Campylobacter jejuni γ-glutamyl transferase (GGT) 
 
 Upon activation, T cells undergo metabolic reprogramming that requires the 
uptake of extracellular amino acids, one of which is glutamine (reviewed in Patel and 
Powell, 2017; reviewed in MacIver et al., 2013). GGTs are threonine N-terminal 
nucleophile hydrolases that degrade glutathione and related compounds (Suzuki et 
al., 1986). Bacterial and mammalian homologues are highly conserved and in 
particular, GGT from Helicobacter species and C. jejuni exhibit a high degree of 
similarity (Rossi et al., 2012). GGT from H. pylori has been shown to inhibit both 
the CD3/CD28- and PMA/ionomycin-stimulated proliferation of human T cells, 
causing G1 cell cycle arrest and the inhibition of c-Myc and c-Raf signalling 
(Schmees et al., 2007). c-Myc and IRF4 are downregulated in T cells as GGT 
deprives the extracellular space of glutamine, which is required for these signalling 
pathways (Wüstner et al., 2015). GGT from H. suis has also been found to inhibit the 
proliferation of Jurkat cells as well as CD3/CD28-stimulated murine T cells and 
anti-IgM-stimulated B cells (Zhang et al., 2013a). It is also essential for the gastric 
colonisation of mice by H. pylori (Chevalier et al., 1999). 
 GGT is known to play an important role in the colonisation of the avian gut 
by C. jejuni (Barnes et al., 2007) but little is known about its effects on T cells. Floch 
et al. (2014), however, demonstrated that C. jejuni GGT inhibited the proliferation of 
human T cells in vitro, causing cell cycle arrest in the G0/G1 phase. 
 
1.4.5 Salmonella enterica serovar Typhimurium L-asparaginase II 
 
 Another amino acid that is required for T cell metabolic reprogramming is 
asparagine (Torres et al., 2016). Originally, S. Typhimurium was shown to inhibit the 
CD3/CD8- and PMA/ionomycin-stimulated proliferation of murine T cells in a 
contact-dependent manner (van der Velden et al., 2005). Expression of the β-chain of 
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the TCR was also downregulated in T cells infected with S. Typhimurium, which 
was thought to explain the inhibition of proliferation (van der Velden et al., 2008). 
L-asparaginase II, encoded by the gene STM3106 (ansB), was later found to be the 
cause of suppressed T cell proliferation and TCR-β expression, and S. Typhimurium 
ΔansB mutants exhibited attenuated virulence in mice (Kullas et al., 2012). 
L-asparaginase II is an asparagine hydrolase that catabolises asparagine, depriving T 
cells of this amino acid and suppressing mTOR signalling, which regulates metabolic 
reprogramming (Torres et al., 2016; McLaughlin et al., 2016). In contrast to 
experiments with mice, a screen of S. Typhimurium transposon insertion mutants in 
pigs, calves and chickens did not find L-asparaginase II to be required for intestinal 
colonisation (Chaudhuri et al., 2013). 
 
1.4.6 Shigella flexneri invasion plasmid gene D (IpgD) 
 
 Another strategy employed by enteric pathogens to modulate the host T cell 
response is to interfere with lymphocyte chemotaxis. Konradt et al. (2011) found that 
S. flexneri were capable of invading PMA-stimulated CD4+ T cells and suppressing 
their response to the chemoattractant CXCL12 without affecting expression of the 
CXCL12 receptor CXCR4. It was found that the T3S protein IpgD, which promotes 
uptake into and survival within epithelial cells (reviewed in Parsot, 2009), 
hydrolysed intracellular phosphatidylinositol 4, 5-bisphosphate (PIP2), causing 
dephosphorylation of the proteins ezrin, radixin and moesin (Konradt et al., 2011). 
This in turn prevents T cells from becoming polarised in response to 
chemoattractants. In vivo experiments confirmed that S. flexneri invade CD4+ T cells 
in murine mesenteric lymph nodes and impairs their migration (Salgado-Pabón et al., 
2013). Only activated T cells are invaded by S. flexneri (Konradt et al., 2011), 
however, recent studies have shown that CD4+ and CD8+ T cells, as well as B cells, 
are largely targeted by the T3SS of extracellular bacteria (Pinaud et al., 2017). 
Additionally, it was found that lamina propria lymphocytes were targeted, suggesting 
the bacteria affect the chemotaxis of lymphocytes responding to the infection without 
the prior requirement of invasion (Pinaud et al., 2017). 
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1.4.7 Vibrio cholerae cholera toxin (CT) and ETEC heat labile enterotoxin (LT) 
 
 CT and LT are structurally related toxins that cause diarrhoea and eliminate T 
cells by inducing apoptosis (Gill et al., 1981; reviewed in Spangler, 1992). CT and 
LT are Type II secreted AB5 toxins, of which both subunits are required for toxicity 
(Sandkvist et al., 1997; Tauschek et al., 2002; reviewed in Spangler, 1992). The B 
subunit ring binds the ganglioside GM1 on epithelial cells and once inside the cell, 
the A subunit ADP ribosylates adenylate cyclase, leading to diarrhoea (reviewed in 
Baldauf et al., 2015). The B subunit of CT has been shown to induce apoptosis in 
murine T cells in vitro independently of the A subunit and preferentially targets the 
CD8+ subpopulation (Yankelevich et al., 1996). CT-induced apoptosis of murine T 
cells was confirmed by Arce et al. (2005), but the preferential targeting of the CD8+ 
subpopulation was not observed. In this same study, CT was found to inhibit the 
proliferation of CD4+ T cells without inducing apoptosis. 
 Arce et al. (2005) also found that LTIIa induced apoptosis in CD8+ T cells 
and proposed that this may be caused by the toxin cross-linking the ganglioside 
receptor. When injected into mice, LT caused an increase in circulating 
corticosterone, which in turn induced apoptosis in immature T and B cell populations 
(Tamayo et al., 2005). The route of administration of the toxin was reported to affect 
the induction of apoptosis and it was also found that the enzymatic function of LT 
was required for this process (Tamayo et al., 2005). Further studies revealed that LT 
induces apoptosis by different mechanisms in mature and immature lymphocytes 
(Tamayo et al., 2009). 
54 
1.5 Aims and objectives 
 
A working model of lymphostatin in colonisation is illustrated in Figure 1.9, 
















Figure 1.9. Schematic of the working model of lymphostatin (LifA) in gut 
colonisation by EPEC/EHEC. 1. LifA acts on T lymphocytes to inhibit 
proliferation and the production of pro-inflammatory cytokines (Klapproth et al., 
2000). It may be injected directly into intraepithelial lymphocytes or secreted into the 
gut lumen where it is taken up by lymphocytes or transported across the epithelium 
to gut associated lymphoid tissue or circulating blood. 2. LifA is injected into 
enterocytes/colonocytes via the Type III secretion system (T3SS) where it is reported 
to have an accessory role in the formation of actin pedestals (Cepeda-Molero et al., 
2017). 3. LifA influences bacterial adhesion either by direct binding between 
bacterial and host cells (normal arrow) or via indirect effects on Type III secretion 
(dashed arrow; Nicholls et al., 2000), and has been reported to disrupt apical junction 
complexes (Babbin et al., 2009). 
 
 55 
 There are a number of outstanding questions regarding the role of 
lymphostatin in colonisation, which include: 
 
 Which domains/motifs are required for the three activites attributed to 
LifA? 
 To what extent are these activites the cause of attenuation of lifA mutants? 
 Is the impact of LifA on adherence direct? 
 Can the role of LifA in colonisation be explained by its impact on T cells, 
given the time at which lymphocytes respond during an infection? 
 
 Given that little is understood about the molecular mechanisms underlying 
lymphostatin activity, this study sought to determine which portions of the protein 
are required for activity, to investigate the role of the putative cysteine protease 
domain and to identify possible targets of the predicted glycosyltransferase activity 
of LifA. The overall objectives of this study were to: 
 
1. Identify functional domains of LifA by: 
a) Cloning and purifying recombinant fragments of LifA based on 
putative domains previously identified by limited tryptic proteolysis. 
b) Determining whether these fragments can inhibit mitogen-stimulated 
T cell proliferation. 
c) Identifying which fragments, if any, are required for T lymphocyte 
binding. 
 
2. Probe the role of a predicted C/H/D motif within the putative cysteine 
protease domain of LifA by: 
a) Creating a C1480A mutant and purifying the mutant protein. 
b) Biophysically characterising the mutant protein and comparing it 
with wild-type LifA protein. 
c) Comparing the ability of the C1480A mutant LifA protein to 
inhibit the ConA-stimulated proliferation of bovine T lymphocytes 
with the wild-type protein. 
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d) Determining whether LifA is processed in bovine T cells and if so, 
whether the C/H/D motif is required for this event. 
 
3. Identify putative interacting partners of LifA by: 
a) Using shotgun mass spectrometry to identify peptides that have 
increased by the mass of GlcNAc from LifA-treated T cells and 
are thus candidate targets of glycosylation. 
b) Using protein pull-down assays and mass spectrometry to identify 
proteins that may interact with LifA. 
c) Investigating the impact of LifA on post-translational 
modifications of the key cellular kinase Akt. 
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2 Materials and Methods 
 
2.1 Preparation of bovine lymphocytes and T cell enrichment 
 
 Peripheral venous blood (50–200 mL) was collected into heparinised bags 
from 12–18-month old Holstein-Friesian calves in accordance with the requirements 
of the Animals (Scientific Procedures) Act 1986 under project licence P803DD07A. 
Blood was centrifuged at 1200 x g for 15 minutes with no brake and the lymphocyte 
interfaces were removed, pooled into two centrifuge tubes, and made up to 30 mL 
with phosphate-buffered saline (PBS). Each 30 mL was overlaid onto 20 mL 
Ficoll-Paque Plus density medium (GE Healthcare Life Sciences) and centrifuged at 
1200 x g for 25 minutes with no brake. The lymphocyte cells at the interface were 
removed and pooled for each donor and made up to 50 mL with PBS and centrifuged 
at 1200 x g for 10 minutes. Where the cells were contaminated with erythrocytes, the 
pellet was resuspended in 1 mL of red blood cell lysis buffer (see Appendix 1) and 
then made up to 50 mL with RPMI-1640 medium (Gibco) with 10 % (v/v) foetal calf 
serum (FCS; Gibco), 20 mM HEPES (Sigma-Aldrich), 1mM sodium pyruvate 
(Gibco), 2 mM L-glutamine (Gibco) and 100 µg/mL penicillin/streptomycin 
(Sigma-Aldrich; RPMI-CT). The cells were washed twice in RPMI-CT and 
resuspended in 2 mL RPMI-CT. The cells were then counted by trypan blue 
exclusion (0.4 % (w/v) trypan blue; HyClone) using disposable haemocytometer 
grids (Kova International). 
 To enrich for T cells, nylon wool fiber columns (Polysciences Inc.) were used 
owing to differences in the ability of leukocytes to adhere to the nylon wool matrix, 
where T cells are relatively non-adherent but B cells and antigen-presenting cells are 
retained (Eisen et al., 1972; reviewed in Hathcock, 2001). Columns were conditioned 
by adding 10 mL RPMI-CT, tapping to remove air bubbles, and draining the 
medium. The column was washed twice with RPMI-CT, filled with 5 mL RPMI-CT, 
sealed and incubated at 37 °C, 5 % CO2 for 1 hour. The medium was drained from 
the column, cells were applied at a density of 1 x 108 cells/mL and run into the 
column. The column was sealed and incubated at 37 °C, 5 % CO2 for 1 hour. The 
non-adherent T cells were eluted from the column, which was then washed twice 
58 
with RPMI-CT to enhance recovery of the cells. The cells were counted as described 
above and the concentration was adjusted for the appropriate experiment. 
 
2.2 Flow cytometry 
 
 Samples of 0.2 x 107 cells were taken before and after T cell enrichment, 
centrifuged at 425 x g for 10 minutes and washed in FCS buffer (PBS with 2 % (v/v) 
FCS). Cells were fixed by incubating them with 4 % (w/v) paraformaldehyde (PFA) 
on ice for 30 minutes before being resuspended in FCS buffer and stored at 4 °C until 
required. 
 Samples were split into two aliquots, one of which was incubated with 
2 µg/mL monoclonal MM1A IgG1 anti-CD3 antibody specific to T cells 
(Monoclonal Antibody Center, Washington State University) for 1 hour on ice then 
washed three times with FCS buffer. Both aliquots were then incubated with 
4 µg/mL monoclonal fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
IgG1 (Invitrogen) for 1 hour on ice before a final three washes with FCS buffer. 
Cells were resuspended in 300 µL of FCS buffer and the purity of T cells in each 
sample was measured using FACScalibur and Fortessa X20 cytometers (both from 
BD Biosciences) with gates for live cells, single cells and T cells. A minimum of 
10,000 events were sampled. Data was analysed using FlowJo® v10 software 
(FlowJo, LLC). T cells typically accounted for 50–60 % of the pre-enriched cell 
population and 70–90 % of the post-enriched cell population. 
 
2.3 T lymphocyte proliferation assays 
 
 Wells of a 96 well plate were seeded in triplicate with 2 x 105 cells in 50 µL 
RPMI-CT. Proteins at the final concentrations specified in figures were added to the 
appropriate wells in triplicate in 25 µL. The buffers that the proteins were dissolved 
in (see Appendix 1) were used as controls. Concanavalin A (ConA; Sigma-Aldrich) 
at a stock concentration of 4 µg/mL was added to the cells in a volume of 25 µL 
RPMI-CT to make a final concentration of 1 µg/mL. A background control was set 
up using 100 µL RPMI-CT. Cells alone and cells with ConA, made up to 100 µL 
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with RPMI-CT, were used as negative and positive controls respectively. Empty 
wells were filled with PBS to reduce evaporation of the media during incubation. 
 The plates were incubated at 37 °C, 5 % CO2 for 3 days and, at 16 hours 
before the end of the assay, 20 µL CellTitre 96 AQueous One Solution (Promega) was 
added to each well. This reagent contained a tetrazolium compound and electron 
coupling reagent such that in the presence of proliferating cells a formazan 
compound was formed that could be measured by colorimetry. Absorbance was read 
at 492 nm using a Multiskan Ascent Spectrophotometer (Thermo Scientific). Ratios 
of the absorbance value for each titration against the positive control (proliferation 
indices) were calculated using averaged experimental (E), maximum proliferation 
(Mp) and background (B) absorbance values with the following formula: 
 
 Proliferation index = (E – B)/(Mp – B) 
 
 Proliferation index values were plotted against the concentration of protein or 
type of protein added with standard deviations using Microsoft Excel 2013. The 
mean of three technical replicates from each blood donor was used to calculate the 
mean and standard deviation from at least three independent studies. The effective 
dose at which 50 % inhibition of ConA-stimulated proliferation was observed (ED50) 
for certain experiments was calculated using R with the drc package (Ritz et al., 
2015). The standard error of the mean was calculated for each ED50 using Minitab 
17. Mann-Whitney tests were used to determine statistically significant differences 
between the ED50 values using Minitab 17. P values ≤ 0.05 were taken to be 
statistically significant. 
 
2.4 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
 Proteins were analysed by SDS-PAGE using the Novex (Life Technologies) 
gel system. Where the detection of full-length LifA was required, 3–8 % 
Tris-Acetate gels (Novex) were used. For analysis of proteins < 100 kDa, 4–12 % 
Tris-Glycine gels (Novex) were used. The Tris-Acetate and Tris-Glycine gels were 
run with 1 x Tris-Acetate SDS running buffer (Novex), with 0.25 % (v/v) antioxidant 
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(Invitrogen) in the buffer that was in contact with the anode of the gel tank, and 
1 x Tris-Glycine SDS running buffer (Novex) respectively. HiMark pre-stained 
protein standards (Invitrogen) and Precision Plus Protein pre-stained standards 
(Bio-Rad) were used with the Tris-Acetate and Tris-Glycine gels respectively. The 
gels were typically run at 180 V until the dye front had left the bottom of the gel. 
Gels were analysed by staining with Coomassie stain (Bio-Rad), according to the 
manufacturer’s instructions, or by western blotting. Where the gels were stained, the 
images were captured using a Gel Doc EZ system (Bio-Rad). 
 
2.5 Western blotting 
 
 Proteins were transferred to polyvinylidene fluoride (PVDF) membranes 
(Amersham Hybond) for western blotting. The gels were soaked in 2 x transfer 
buffer (Novex) with 0.04 % (w/v) SDS (Sigma-Aldrich) for 15 minutes while PVDF 
membranes were washed in methanol then distilled water before being soaked and 
gently rocked in 1 x transfer buffer with 10 % (v/v) methanol (Fisher Scientific) and 
0.1 % (v/v) antioxidant (Novex) for 15 minutes. To get efficient transfer of large 
proteins (> 100 kDa), gels were transferred using a wet transfer at 25 V for 
75 minutes, using a Mini Blot Module (Life Technologies). For enhanced 
chemiluminescence (ECL) detection, which relies on production of a 
chemiluminescent product by horseradish peroxidase (HRP)-conjugated secondary 
antibodies, membranes were blocked in Tris-buffered saline/0.1 % (v/v) Tween® 20 
(TBS-T; VWR International) and 5 % (w/v) bovine serum albumin (BSA; Merck 
Millipore) for 1 hour on a rocking platform, then rinsed briefly with TBS-T and 
washed for 15 minutes, followed by an additional two washes of 5 minutes. For blots 
using fluorophore conjugated antibodies, membranes were treated as described for 
ECL blots but the TBS-T/5 % BSA block was replaced with Odyssey® Blocking 
Buffer in TBS (LI-COR Biosciences). Membranes were incubated at 4 °C overnight 
with antibodies as indicated at the appropriate dilutions. 
 ECL blots were washed with TBS-T as above but for fluorescent blots the 
final wash was performed with PBS/0.1 % Tween® 20 (PBS-T). Membranes were 
incubated at room temperature for 1 hour with secondary antibodies as indicated at 
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the appropriate dilutions. ECL and fluorescent blots were washed with TBS-T and 
PBS-T respectively as above. ECL blots were dried and developed using SuperSignal 
West Pico Chemiluminescent Substrate (Thermo Scientific) following the 
manufacturer’s instructions and exposed to Amersham Hyperfilm for various times 
to achieve clear images. Films were developed using an SRX-101A film processor 
(Konica Minolta). Blots using fluorophore-conjugated antibodies were scanned using 
a LI-COR Odyssey blot imager and images were analysed in Image Studio Lite v5.2 
(both from LI-COR Biosciences). 
 
2.6 T lymphocyte protein association assays 
 
 Enriched T cells were serum starved at a density of 8 x 106 cells/mL in 
serum-free RPMI medium with 25 mM HEPES (Sigma-Aldrich) at 37 °C, 5 % CO2 
for 1 hour. Cells were divided into 1.5 mL aliquots in microcentrifuge tubes and 
proteins were added to the cells at a final equimolar concentration of 5.45 nM, 
equivalent to 2 µg/mL of wild-type (WT) recombinant LifA (rLifA), before the 
samples were incubated at 37 °C for the indicated times. Buffer treated cells were 
used as negative controls and protein in medium without cells was used a control to 
ensure that protein was not binding to the microcentrifuge tubes. 
 Samples were centrifuged at 17,949 x g, 4 °C for 1 minute to collect the T 
cells and the supernatant was discarded. Samples were centrifuged for a further 
15 seconds to collect and aspirate residual supernatant. Cells were resuspended in 
100 µL of ice-cold PBS and transferred to clean microcentrifuge tubes then 
centrifuged as described above. This process was repeated a second time. Cells were 
lysed with 90 µL of NP-40 lysis buffer (see Appendix 1) and incubated on ice for 
30 minutes. Lysates were centrifuged at 17,949 x g, 4 °C for 10 minutes and the 
supernatants were transferred into clean microcentrifuge tubes for further processing. 
Protein samples (supernatants) were denatured by the addition of an appropriate 
volume of 1 x sample reducing agent and 1 x lithium dodecyl sulphate (LDS) sample 
buffer (both from Novex) and heated at 70 °C for 10 minutes. Samples were stored at 
-20 °C until analysis. Before analysis, samples were mixed and heated at 70 °C for 
2 minutes then centrifuged briefly to sediment insoluble material. Western blots used 
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rabbit polyclonal anti-LifA antibody (Stevens Laboratory, Clone 45) at a dilution of 
1/20,000, which was detected using HRP-conjugated goat anti-rabbit secondary 
antibody (Bio-Rad), applied at a dilution of 1/10,000 in TBS-T/2 % (w/v) skimmed 
milk powder (Chem Cruz). 
 
2.7 Bacterial growth media and chemicals 
 
 Bacterial strains were cultured in suspension using lysogeny broth (LB) or on 
LB agar plates (Sigma-Aldrich) and supplemented with antibiotics as indicated. 
Antibiotics were used at the following final concentrations: Kanamycin (Kan), 
30 µg/mL; Ampicillin (Amp), 25 µg/mL; Nalidixic acid (Nal), 20 µg/mL. Where 
indicated, cultures were supplemented with 0.5 % (w/v) D-glucose. Glycerol stocks 
for bacteria were prepared from fresh liquid cultures and supplemented with glycerol 
at a final concentration of 15 % (v/v). To induce Type III secretion, bacteria were 
grown in Dulbecco’s Modified Eagle Medium supplemented with 4.5 g/L D-glucose, 
L-glutamine and sodium bicarbonate (DMEM; Sigma-Aldrich; Kenny et al., 1997a). 
 
2.8 Bacterial strains, plasmids and oligonucleotides 
 
 The strains and plasmids used in this study are listed in Tables 2.1 and 2.2 
respectively. The pRham-LifA-6 x His plasmid encodes the lifA gene, which is 
controlled by a rhamnose-inducible and glucose-repressible promoter (Cassady-Cain 
et al., 2016). The pRham empty vector was used as a negative control. The 
oligonucleotides used for cloning, site-directed mutagenesis and double-stranded 
sequencing are shown in Table 2.3. EPEC E2348/69 clones from Taylor (1970) and 
Cepeda-Molero et al. (2017) were provided and PCR validated by Professor Brendan 
Kenny, The Institute for Cell and Molecular Biosciences, Newcastle University.
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EPEC O127:H6 ΔpE2348-2 
gyrA, ftsK, φhflD-purB. 
NalR 
Levine et al. (1978); Levine et 
al. (1985) 
E. coli E2348/69 
ΔlifA 
E2348/69a with a complete 
deletion of lifA. 
NalR Stevens et al. (2002) 
E. coli E2348/69 
ΔescN::KanR 
E2348/69a with a deletion of 
escN, encoding an ATPase of 
the LEE-encoded T3SS, and 
the insertion of a Kan 
resistance cassette. 
KanR Garmendia et al. (2004) 
E. coli 
E2348/69b 
Wild-type EPEC O127:H6 
strain. 
StrR 
Taylor (1970); Prof. Brendan 
Kenny 
E. coli E2348/69 
ΔlifA 
Derivative of the E2348/69b 
strain from B. Kenny with a 
deletion of lifA. 
StrR 
Cepeda-Molero et al. (2017); 
Prof. Brendan Kenny 
E. coli E2348/69 
ΔlifA-like 
Derivative of the E2348/69b 
strain from B. Kenny with a 
deletion of the lifA-like gene. 
StrR 
Cepeda-Molero et al. (2017); 
Prof. Brendan Kenny 
E. coli E2348/69 
ΔlifA ΔlifA-like 
Derivative of the E2348/69 
strain from B. Kenny with 
deletions of both lifA and 
lifA-like genes. 
StrR 
Cepeda-Molero et al. (2017); 
Prof. Brendan Kenny 
E. coli E2348/69 
ΔescN 
Derivative of the E2348/69b 
strain from B. Kenny with a 
deletion of escN. 
StrR 
Cepeda-Molero et al. (2017); 
Prof. Brendan Kenny 
E. cloni® 10G 
Chemically-competent cells 
for transformation and protein 
expression. F- mcrA Δ(mrr-
hsdRMS-mcrBC) endA1 
recA1 φ80dlacZΔM15 
ΔlacX74 araD139 Δ(ara, 
leu)7697 galU galK rpsL 






for transformation. TetR 
Δ(mcrA)183 Δ(mcrCB-
hsdSMR-mrr)173 endA1 
supE44 thi-1 recA1 gyrA96 
relA1 lac Hte [F´ proAB 
laclqZΔM15 Tn10 (TetR) Amy 
CamR] 
TetR, CamR Agilent Technologies 
 
a is a Nal resistant clone derived from the original EPEC E2348/69 clone b. 
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Encodes LifA tagged at the 
C-terminus with 6 x His under a 
rhamnose-inducible promoter. 
KanR Cassady-Cain et al. (2016) 
pRham empty 
Re-ligated pRham vector 
backbone. 
KanR Cassady-Cain et al. (2016) 
pRham-LifA-6 x 
His DXD-AAA 
As pRham-LifA-6 x His but 
with a DXD-AAA substitution 




Cassady-Cain et al. (2016) 
pRham-LifA-6 x 
His F1 
Encodes F1 fragment of LifA 
(aa 1–1620) with C-terminal 6 x 
His tag under a 
rhamnose-inducible promoter. 
KanR Made in this study 
pRham-LifA-6 x 
His F3 
Encodes F3 fragment of LifA 
(aa 2111–2900) with C-terminal 
6 x His tag under a 
rhamnose-inducible promoter. 
KanR Made in this study 
pRham-LifA-6 x 
His F5 
Encodes F5 fragment of LifA 
(aa 2901–3223) with C-terminal 
6 x His tag under a 
rhamnose-inducible promoter. 
KanR Made in this study 
pRham-LifA-6 x 
His GT 
Encodes GT domain of LifA (aa 
221–1033) with N-terminal 6 x 
His tag under a 
rhamnose-inducible promoter. 
KanR Made in this study 
pRham-LifA-6 x 
His C1480A 
As pRham-LifA-6 x His but 
with a C1480A substitution in 
the cysteine protease domain. 
KanR Made in this study 
pWhitescript 
Mutagenesis control. Allows for 
colour screening. 
AmpR Agilent Technologies 
pUC18 
Transformation control. Allows 
for colour screening. 
AmpR Agilent Technologies 
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Table 2.3. Oligonucleotides used in this study. 
 
Primer Sequence (5' to 3') Purpose Source 





Cloning of the F1 fragment of LifA 
with C-terminal 6 x His tag 
Sigma- 
Aldrich 





As LifA F1 CT forward 
Sigma- 
Aldrich 





Cloning of the F3 fragment of LifA 
with N-terminal 6 x His tag 
Sigma- 
Aldrich 





As LifA F3 NT forward 
Sigma- 
Aldrich 





Cloning of the F3 fragment of LifA 
with C-terminal 6 x His tag 
Sigma- 
Aldrich 





As LifA F3 CT forward 
Sigma- 
Aldrich 





Cloning of the F5 fragment of LifA 
with N-terminal 6 x His tag 
Sigma- 
Aldrich 





As LifA F5 NT forward 
Sigma- 
Aldrich 





Cloning of the F5 fragment of LifA 
with C-terminal 6 x His tag 
Sigma- 
Aldrich 





As LifA F5 CT forward 
Sigma- 
Aldrich 





Cloning of the GT domain of LifA 
with N-terminal 6 x His tag 
Sigma- 
Aldrich 





As LifA GT NT forward 
Sigma- 
Aldrich 





Cloning of the GT domain of LifA 
with C-terminal 6 x His tag 
Sigma- 
Aldrich 






























Replication of pRham plasmids and 







As pRham forward Lucigen 
LifA FL For1 
GCAGGAAAGATAGCTG
GTAAC 
Forward primer for sequencing of 
the lifA genes 
Sigma- 
Aldrich 
LifA FL For2 
GTTCCCCACCTGAAAGC
ATT 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For3 
GGTGAAAACCGCATTTC
AAT 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For4 
CGTGGGCTCAATGGATT
CATG 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For5 
CCTGTTCAAAGATGTTT
CAAC 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For6 
GACTCCTGAAAACTGG
GAAG 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For7 
CGGACTAGGAATAACT
GGTG 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For8 
GGATTACCAACTATTGC
CG 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For9 
CCAACGAATCGCTACTA
CA 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For10 
CTGTCCCGCACAGTTCT
GAC 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For11 
CCGAAGCAACTCTCGGC
AGC 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For12 
CAGTCTCCTCCTCTCTT
GC 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For13 
CCGGAAGAGTTTCCGCT
CACC 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For14 
CAGGCTGTTTATCCGGA
AG 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For15 
GGTCATACACCAACGGT
AAAC 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For16 
GAACAGCCAGGTATCG
GCAG 




Primer (cont.) Sequence (5' to 3') Purpose Source 
LifA FL For17 
CTTATCCGAAATCCCTC
AG 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL For18 
GCGGCTACCAAGTGTAT
TATC 
As LifA FL For1 
Sigma- 
Aldrich 
LifA FL Rev1 
GGAATAGAGCTCGCCCT
GATG 
Reverse primer for sequencing of 
the lifA genes 
Sigma- 
Aldrich 
LifA FL Rev2 
GCCAGATTCAGAACGC
CATC 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev3 
CAGATACAGACGTGAA
TAGG 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev4 
GCCAGTATGATTTGTGT
CGG 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev5 
CAAACTCAGCTCAAAG
GCGAC 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev6 
CTCTCAGGGGAAGTACT
GTG 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev7 
CAGCCATTGTGTATGCC
GTTC 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev8 
GTACTGTCTTCGTGCCC
CTG 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev9 
CATCACCGTTGAGACGC
AGAG 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev10 
GCGGTCTTATGTAGTAG
CG 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev11 
GGGTTGCATCGGCAATA
GTTG 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev12 
CGATCAAGAAGTCTATC
GTA 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev13 
CGCAAGAAAGCCTTTTA
TGG 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev14 
CTGATATCTGGAGGGTG
CTC 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev15 
CCATCAGATATTGCACG
ACG 
As LifA FL Rev1 
Sigma- 
Aldrich 
LifA FL Rev16 
GTAGCATAAAGCTCTCT
GAG 




2.9 Plasmid DNA purification 
 
Plasmid DNA was prepared from small-scale stationary phase bacterial 
cultures (5–10 mL; Miniprep) or larger-scale cultures (50–100 mL; Midiprep) using 
alkaline lysis followed by affinity purification of plasmid DNA. To perform a 
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Miniprep, 3 mL from overnight cultures were each added to two 1.5 mL 
microcentrifuge tubes and centrifuged at 17,949 x g for 10 minutes. DNA from the 
pellets was purified using a QIAprep Spin Miniprep Kit (Qiagen) following the 
manufacturer’s instructions. One QIAprep spin column was used for each 3 mL 
culture and columns were left to dry for 10 minutes. The DNA was eluted in 30 µL 
of nuclease-free distilled water (nH2O), which was left to stand for 5 minutes before 
being centrifuged for 1 minute. 
 To perform a Midiprep, 50 mL overnight cultures were centrifuged at 
6000 x g, 4 °C for 15 minutes. Plasmid DNA from the pellets was purified using a 
QIAprep Spin Midiprep Kit with filter cartridges (Qiagen) following the 
manufacturer’s instructions and the final DNA pellet was dissolved in 50 µL of 
nH2O.  
The DNA concentrations were measured by the A260/A280 ratio using a 
NanoDrop (ND-1000) Spectrophotometer (Thermo Scientific), which displays 




 Expression constructs for the LifA fragments were created using an 
Expresso® Rhamnose Cloning and Expression System kit (Lucigen) following the 
manufacturer’s instructions. Primers were designed according to the manufacturer’s 
instructions for both N- and C-terminal 6 x His tagged variants of the proteins (see 
Table 2.3), with the exception of F1, which we predicted may undergo N-terminal 
processing in E. coli. Polymerase chain reaction (PCR) was used to amplify the 
desired fragments of lifA, using the sequence-validated pRham-LifA-6 x His plasmid 
containing full-length lifA from E2348/69 as a template (Cassady-Cain et al., 2016). 
Three 100 µL PCR reactions were performed for each fragment, with 100 ng of 
pRham-LifA-6 x His template being mixed with 1 x PCR master mix. The master 
mix contained 1 x HF buffer (Thermo Scientific), 10 µM of forward and reverse 
primers for the appropriate fragments (see Table 2.3), 10 mM dNTPs, 2 U/µL long 
range Phusion Hot Start II High-Fidelity Polymerase (Thermo Scientific) and nH2O 
to make up the 100 µL reaction volume. Separate no-template negative control and 
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parent plasmid DNA pRham-LifA-6 x His positive control reactions were also 
included. The PCR parameters are listed in Table 2.4. The PCR products were 
analysed on a 0.8 % (w/v) agarose (Invitrogen) gel against a 1 kb DNA ladder 
(Promega). Gels were run at 120 V for 20 minutes, stained with SYBR® Safe 
(Invitrogen) and imaged using a FluorChem® HD2 chemiluminescent imager (Alpha 
Innotech). 
 
Table 2.4. PCR programme used for amplifying lifA fragments for cloning and 
screening potential recombinants. 
 
Segment No. of cycles Temperature (°C) Time 
1 1 98 10 seconds 
  
98 10 seconds 
2 25 55 15 seconds 
  
72 10 minutes 
3 1 72 10 minutes 
4 1 4 ∞ 
 
 Amplicons for each fragment were excised and split into two microcentrifuge 
tubes with ~300 mg of gel in each. The DNA was extracted from the gel by 
silica-membrane-based purification using a QIAquick® Gel Extraction Kit (Qiagen) 
following the manufacturer’s instructions and the final DNA pellet was dissolved in 
30 µL of nH2O. 
 E. cloni® 10G chemically-competent cells were thawed on ice and prepared 
according to the manufacturer’s instructions. Reactions for lifA amplicons mixed 
with pRham were added to separate aliquots of cells. Quantities of 50 ng of N-His 
Positive Control A Insert and 25 ng of C-His Positive Control B Insert were added to 
aliquots of cells and the corresponding pRham N-His or pRham C-His vector to 
determine the transformation efficiency. Vector alone was used as a negative control. 
The transformation reactions were gently swirled and incubated on ice for 
30 minutes, followed by heat shock at 42 °C for 30 seconds and incubation on ice for 
2 minutes. The cells were suspended in the Recovery Medium provided with the kit 
and incubated at 37 °C for 1 hour with shaking at 225–250 rpm to allow recovery 
and expression of plasmid-mediated antibiotic resistance. Transformed cells were 
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then spread onto LB/Kan agar with 0.5 % (w/v) glucose and incubated at 37 °C 
overnight. Cloning is ligation-independent and recombination of the vector and lifA 
amplicons occurs within the host cell. Candidate recombinants were screened for the 
desired inserts as described in Section 2.12. 
 
2.11 Site-directed mutagenesis of the C/H/D motif of lymphostatin 
 
 Mutagenesis of the C/H/D motif was performed using a QuikChange II XL 
Site-Directed Mutagenesis Kit (Agilent Technologies) following the manufacturer’s 
instructions with some modifications. The primers LifA-C1480A-1 (forward) and 
LifA-C1480A-2 (reverse; see Table 2.3) were designed using the QuikChange 
Primer Design Program (www.agilent.com/genomics/qcpd), with the aim of 
replacing the predicted catalytic cysteine at amino acid position 1480 of E2348/69 
lifA with an alanine residue using a codon that would simultaneously create a BsrDI 
restriction site. PCR was performed using 10 ng of the pRham-LifA-6 x His plasmid 
as a template, 1 x reaction buffer, 125 ng of each of the forward and reverse primers, 
2 % (v/v) dNTP mix, 6 % (v/v) QuikSolution reagent and nH2O to make up to 50 µl 
reaction volume. PfuUltra High-Fidelity DNA polymerase was added to the reaction 
mixture at 2.5 U/µL. PCR was used to introduce the alanine residue by complete 
replication of the plasmid, followed by digestion of the parent plasmid using 
10 U/µL DpnI, which digests methylated template DNA but not DNA generated in 
the PCR reaction. A commercial pWhitescript plasmid was used as a positive 
mutagenesis control, using primers (sequence not disclosed by manufacturer) that 
repair a mutation in the β-galactosidase gene, which can be detected by blue-white 
screening using a chromogenic β-galactosidase substrate. The PCR parameters used 
are listed in Table 2.5. 
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Table 2.5. PCR programme used for site-directed mutagenesis of the 
pRham-LifA-6 x His plasmid. 
 
Segment No. of cycles Temperature (°C) Time 
1 1 95 1 minute 
  
95 50 seconds 
2 18 68 50 seconds 
  
68 13 minutes (1 minute/kb of plasmid) 
3 1 68 7 minutes 
4 1 15 ∞ 
 
 XL 10-Gold Ultracompetent cells were thawed on ice and prepared according 
to the manufacturer’s instructions. The DpnI-treated DNA samples were added to 
separate aliquots of cells. A quantity of 0.01 ng of pUC18 plasmid was added to an 
aliquot of cells to determine the transformation efficiency. The transformation 
reactions were gently swirled and incubated on ice for 30 minutes to ensure 
maximum transformation efficiency, heat shocked at 42 °C for 30 seconds and then 
incubated on ice for 2 minutes. The cells were suspended in NZY+ broth (see 
Appendix 1), which was used as a recovery medium before plating, and incubated at 
37 °C for 1 hour with shaking at 225–250 rpm. The cells transformed with the 
mutant plasmid were spread onto LB/Kan agar with 0.5 % (w/v) glucose and cells 
transformed with the pWhitescript and pUC18 plasmids were spread onto LB/Amp 
agar. The LB/Amp plates also had 250 µL of 80 µg/mL X-gal 
(5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside; Promega) and 250 µL of 
20 mM IPTG (isopropyl β-D-1-thiogalactopyranoside; Sigma-Aldrich) spread onto 
the agar before the cells were added to allow for blue-white screening. The plates 
were incubated at 37 °C for > 16 hours. 
 
2.12 PCR screening of putative recombinants 
 
2.12.1 Screening of whole plasmids 
 
 Putative clones of the lifA fragments and the cysteine protease mutant were 
initially screened by PCR to verify that they contained the appropriate inserts. 
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Glycerol stocks were made from each of the cultures, which were stored at -80 °C for 
further use and 2 µL of each culture was lysed in 198 µL of nH2O. The lysed cells 
were mixed with 1 x PCR master mix, which contained 1 x HF buffer, 10 µM pRham 
forward primer, 10 µM pETite reverse primer (see Table 2.3), 10 mM dNTPs and 
2 U/µL Phusion polymerase to make up 20 µL reaction volume. PCR and agarose gel 
screening were performed as described previously for cloning. 
 
2.12.2 BsrDI digests of plasmids 
 
 PCR was used to amplify a region of putative pRham-LifA-6 x His C1480A 
plasmids containing the cysteine protease domain using primers LifA FL For3 and 
LifA FL Rev8 (see Table 2.3). BsrDI was used to distinguish between mutated lifA, 
which contains an additional BsrDI restriction site at the location of the C1480A 
substitution, and false positives, which contain only two naturally-occurring BsrDI 
restriction sites between the chosen primer sites. Amplicons were mixed with 
1 x BsrDI master mix, which contained 1 x NEBufferTM 2.1 (50 mM NaCl, 10 mM 
Tris-HCl, pH 7.9, 10 mM MgCl2, 100 µg/mL BSA) and 0.5 U/µL BsrDI (both from 
New England BioLabs® Inc.). A negative and positive control of nH2O and 
pRham-LifA-6 x His plasmid, amplified with primers LifA FL For3 and LifA FL 
Rev8, were also treated with BsrDI. The DNA was digested at 65 °C for 1 hour and 
the digestion products were analysed on a 0.8 % (w/v) agarose gel against a 1 kb 
DNA ladder. Gels were run as previously described. Clones positive for the mutation 
were archived and plasmid DNA was prepared as described in Section 2.12.3 for 
sequencing.  
 
2.12.3 Sanger sequencing of plasmids 
 
 Plasmids containing fragments of lifA or the predicted C1480A substitution 
were verified by conventional Sanger sequencing by GATC Biotech, Source 
BioScience and Edinburgh Genomics. The LifA forward primers FL For1–18, the 
reverse primers FL Rev1–16, the pRham forward primer and the pETite reverse 
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primer were used to sequence the plasmids, as appropriate to the insert (see 
Table 2.3). 
 The sequences were assembled using Lasergene SeqMan Pro (DNASTAR). 
Briefly, the sequence was clipped using SeqMan Pro to remove any areas of low 
sequence quality. The complete sequences were constructed by creating contigs of 
overlapping sequences in SeqMan Pro and differences in the original sequences were 
resolved by comparison of overlapping sequences with reference to sequencing 
chromatograms if needed. The complete sequences were compared with the 
wild-type E. coli E2348/69 genome using NCBI Blast (Iguchi et al., 2009; reviewed 
in Madden, 2013) to identify any unintended mutations that may have been 
introduced to the sequence. 
 
2.13 Pilot-scale protein expression assays 
 
 Protein was overexpressed in E. cloni® 10G cells transformed with 
pRham-based plasmids encoding fragments of lifA, and XL 10-Gold Ultracompetent 
cells transformed with the pRham-LifA-6 x His C1480A plasmid. E. cloni® 10G with 
the pRham empty plasmid was used as a negative control. Fresh 10 mL LB 
subcultures were made from overnight cultures inoculated with single colonies. The 
subcultures were incubated at 30 °C until they reached an absorbance at 600 nm 
(A600) between 0.5 and 0.6. Samples of uninduced cultures were collected and held 
on ice, then 0.2 % (w/v) L-rhamnose was added to cultures to induce protein 
production. At 3 hours post-induction, the induced and uninduced samples were 
centrifuged at 17,949 x g, 4 °C for 10 minutes and the pellets were lysed with 100 µL 
of BugBuster MasterMix (Novagen). The lysates were mixed at room temperature 
for 10 minutes then centrifuged again at 17,949 x g, 4 °C for 10 minutes. The 
supernatants were collected and the insoluble pellet was resuspended in 100 µL of 
BugBuster for analysis by SDS-PAGE. 
 Protein concentration was quantified using the Direct Detect system (Merck 
Millipore) according to the manufacturer’s instructions using BugBuster as the buffer 
control. The samples were then denatured in sample reducing agent and LDS sample 
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buffer as described in Section 2.6. Samples were stored at -20 °C and centrifuged 
briefly as described previously before SDS-PAGE analysis. 
 
2.14 Optimisation of protein production  
 
 Overnight cultures of E. cloni® 10G transformed with the various plasmids, 
grown in LB/Kan broth were separately diluted 10-fold in either LB/Kan or 
2 x tryptone/yeast extract (2xTY)/Kan broth and grown at 37 °C to an A600 of 0.5. 
Cultures were either grown normally or stimulated to overproduce chaperones by 
heat/cold shock. Heat/cold shock cultures were grown to an A600 of 0.2, incubated in 
a 42 °C water bath for 15 minutes then left to recover at room temperature for 
20 minutes. These cultures were then incubated in ice water for 15 minutes then left 
to recover again at room temperature for 20 minutes before resuming growth at 
37 °C to an A600 of 0.5. 
 Cultures were cooled to the appropriate induction temperature and induced 
with the addition of 0.2 % (w/v) L-rhamnose when the A600 reached 0.6. The cultures 
were incubated at either 20 or 30 °C and A600 measurements were taken 1, 2, 3 and 
4 hours after induction. Aliquots of 1 mL of culture were taken at each time point. 
The aliquots were centrifuged at 12,500 x g in a benchtop centrifuge for 10 minutes, 
the supernatant was discarded and the pellets were stored at -20 °C until ready for 
further processing. The pellets were dissolved in 6 µL of BugBuster for every 
0.01 A600 unit measured. A volume of 5 µL from each lysate was mixed with 5 µL of 
10 x sample reducing agent and 5 µL of 4 x LDS sample buffer then boiled at 100 °C 
for 2 minutes and run on a 4–12 % Tris-Glycine gel (Bio-Rad) at 250 V for 
22 minutes as described in Section 2.4. 
 Once optimal conditions for induction were defined, large-scale protein 
production was carried out by first inoculating 3 x 25 mL LB/Kan overnight cultures 
with a single colony of the appropriate strain. From these overnight cultures, 5 mL 
was added to each of 12 x 500 mL LB or 2xTY and grown at 30 °C for 3 hours with 
0.2 % (w/v) L-rhamnose. The cultures were centrifuged at 6000 x g, 4 °C for 
20 minutes, the supernatant was discarded, and the pellets were flash frozen in liquid 
nitrogen and stored at -80 °C until required for protein purification. 
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2.15 Purification of recombinant proteins 
 
2.15.1 Four-step purification 
 
 Recombinant proteins were purified to varying degrees using a four-step 
process using ion metal affinity chromatography (IMAC), size exclusion 
chromatography (SEC), anion exchange chromatography and a desalt column on a 
fast protein liquid chromatography (FPLC) unit (ÄKTA Explorer 10 UV900 and 
ÄKTA pure LC systems; GE Healthcare Life Sciences ÄKTA). All buffers used 
throughout the purification process were filtered and degassed to remove particulate 
matter (see Appendix 1). The presence of the proteins in samples throughout the 
purification process was monitored using SDS-PAGE and UV absorbance at 280 nm. 
The production and purification of the recombinant glycosyltransferase domain 
(rGT) was performed by Dr Liz Blackburn, Edinburgh Protein Production Facility 
(EPPF), Centre for Translational and Chemical Biology, University of Edinburgh. 
 Initially, the protein lysate was subjected to HiTrap nickel-Sepharose® IMAC 
column chromatography (GE Healthcare Life Sciences). Cell pellets from 
Section 2.14 were thawed, resuspended in IMAC lysis buffer (IMAC buffer A (see 
Appendix 1) with 500 mM 3-(1-pyridinio)-1-propansulphonate, 1 protease inhibitor 
tablet/1 L of cell culture, 0.1 mg/mL benzamidine and 0.1 % (v/v) 
phenylmethanesulphonylfluoride to prevent protein degradation) and lysed further by 
cell disruption under pressure (25 kpsi; Constant Cell Disruption Systems). The 
lysates were centrifuged at 50,000 x g, 4 °C for 1 hour and filtered using a 0.22 µm 
filter then run over the nickel-Sepharose® column at a flow rate of 1 mL/minute, 
followed by a wash of 22 column volumes (cv) of 4 % IMAC buffer B (see 
Appendix 1), equivalent to 20 mM imidazole. The recombinant proteins were eluted 
with 3 cv of 100 % IMAC buffer B containing 500 mM imidazole and collected in 
1 mL fractions. 
 The fractions of the IMAC filtrates that contained recombinant protein were 
pooled and applied to a HiLoad 16/600 Superdex 200pg (rF5), Superdex 200pg 
10/300 GL (rGT and rF3), Superose 6pg 10/300 GL (rF1) or Superose 6pg 
XK16/600 SEC column (WT rLifA and rLifAC1480A; all columns from GE Healthcare 
76 
Life Sciences), for size exclusion chromatography as appropriate to the protein to be 
purified, using SEC buffer. The purest IMAC fractions, determined by SDS-PAGE, 
were run through the column first, followed by the less pure fractions. 
 The fractions of the SEC filtrates that contained recombinant protein, 
determined by SDS-PAGE, were run through a HiPrep 26/10 desalt column (GE 
Healthcare Life Sciences) in a 50 mM NaCl low-salt buffer to remove excess salt 
that may interfere with binding to the anion exchange chromatography column. 
 The desalt fractions containing recombinant protein, determined by UV 
absorbance at 280 nm, were applied to a Mono Q 5/50 GL anion exchange column 
(GE Healthcare Life Sciences) to separate proteins based on their net charge. The 
concentration of NaCl in the column was increased from 0 to 500 mM over 30 cv, 
then sharply to 1 M. The purest fractions of each protein were pooled. Protein 
concentration was quantified using a NanoDrop Lite Spectrophotometer (Thermo 
Scientific). Protein for biophysical experiments was stored at 4 °C until required and 
protein for cellular assays had glycerol added up to 20 % (v/v) then was flash frozen 
and stored at -80 °C until required. WT rLifA and rLifAC1480A were desalted into 
either assay buffer or CD buffer (see Appendix 1) before use in the biophysical 
characterisation experiments. 
 
2.15.2 IMAC optimisation 
 
 IMAC was performed in batch to find the optimal conditions for capturing 
recombinant F1 protein (rF1). HiTrap free resin (GE Healthcare Life Sciences) was 
charged with either nickel, cobalt, copper or zinc and equilibrated with IMAC 
buffers A and B with a pH of either 7 or 8. A volume of 1 mL of lysate was added to 
each resin batch and incubated on ice for 10 minutes. Samples were centrifuged at 
500 x g, 4 °C for 5 minutes then washed twice with 4 % IMAC buffer B. Protein was 
eluted by washing the resin three times with 100 % IMAC buffer B. Samples of 





2.16 Matrix assisted laser desorption ionisation time-of-flight (MALDI-TOF) 
mass spectrometry of purified proteins 
 
 A quantity of 2 µg of purified protein was run on a gel in triplicate. Protein 
species of interest were excised, flash frozen and stored at -80 °C until required. 
Samples were thawed and incubated at room temperature in 200 mM NH4HCO3 
(ABC; Sigma-Aldrich) with 50 % (v/v) acetonitrile (ACN; Fisher Scientific) for 
30 minutes to remove SDS. This was repeated a further two times. Samples were 
incubated at 32 °C in 20 mM dithiothreitol (DTT), 200 mM ABC, 50 % ACN for 
1 hour to reduce the protein then washed three times with 200 mM ABC, 50 % ACN. 
Cysteine residues were alkylated by incubating the samples in 50 mM iodacetamide 
(Sigma-Aldrich), 200 mM ABC, 50 % ACN at room temperature for 20 minutes in 
the dark. Samples were washed three times with 20 mM ABC, 50 % ACN then 
centrifuged at 12,500 x g in a benchtop centrifuge for 2 minutes. Gel pieces were 
covered with ACN until they turned white then the ACN was decanted and the gel 
pieces were air dried. Gel pieces were rehydrated in 20 µg/mL Trypsin Gold 
(Promega) at 4 °C then incubated at 32 °C for 16–24 hours to digest the protein. 
 Before mass spectrometry, samples were sonicated for 1 minute then spotted 
onto a MALDI plate and covered with an α-cyano-4-hydoxycinnamic acid matrix 
(see Appendix 1). Peptide fragments were identified by an ultrafleXtremeTM 
MALDI-TOF mass spectrometer (Bruker). The spectral data were processed using 
Data Explorer software (Applied Biosystems) and peptide mass lists were searched 
against the Mascot NCBIprot database (Matrix Science). The parameters used in 
each search were: taxonomy – Escherichia coli; missed cut = 1; fixed cysteine 
carbamidomethylation modification; variable methionine oxidation modification; and 
a peptide mass tolerance of 20 ppm. 
 
2.17 Dynamic light scattering (DLS) 
 
 DLS was used to determine the size distribution and extent of aggregation of 
purified proteins. Assay buffer with 1.1 µM of either WT rLifA or rLifAC1480A was 
passed through a 0.22 µm Ultrafree-MC filter (Merck Millipore) and centrifuged at 
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12,000 x g, 4 °C for 15 minutes. The mean hydrodynamic radius of both proteins was 
measured using a Zetasizer Automated Plate Sampler (Malvern Instruments, UK) 
equipped with a 50 mW laser light source, with a wavelength of 830 nm. DLS data 
were collected at a scattering angle of 90° for 10 seconds at 25 °C. This was repeated 
13 times in triplicate and the values were averaged. Autocorrelation data were fitted 
to a model of a multiple-exponential form suitable for polydisperse solutions using 
the protein-specific software supplied with the instrument. This generated a 
distribution of particles by size (Maslon et al., 2010). Assay buffer was used as a 
background control. 
 
2.18 Circular dichroism (CD) 
 
 CD spectra of purified proteins were collected to define aspects of their 
secondary structure. Samples of 0.11 µM WT rLifA and rLifAC1480A in CD buffer 
(see Appendix 1) were centrifuged at 12,000 x g, 4 °C for 15 minutes. The mean 
residue ellipticity ([θ]) for each protein was measured using a J-810 
Spectropolarimeter (Jasco; Kelly et al., 2005) between wavelengths of 185 and 
285 nm. The [θ] for each protein was plotted against wavelength using Microsoft 
Excel 2013. The percentages of different secondary structure motifs were determined 
using DichroWeb (http://dichroweb.cryst.bbk.ac.uk/html/home.shtml; Lobley et al., 
2002). 
 
2.19 Thermal denaturation assays (TDAs) 
 
 The thermal denaturation characteristics of rLifA and rLifAC1480A were 
measured to assess their folding. Each protein was used at a concentration of 0.1 µM 
in assay buffer and mixed with 5 x SYPRO Orange in a 96 well plate, with a buffer 
only control in parallel. The plate was sealed and centrifuged at 3220 x g for 
2 minutes to remove air bubbles then put into an IQ5 Multicolor Real-Time PCR 
Detection System (Bio-Rad). The temperature was increased from 15 to 70 °C in 
0.5 °C increments every 30 seconds and the fluorescence was recorded at each 
increment. Normalised relative fluorescence units (RFU) for each sample were 
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plotted against temperature using Microsoft Excel 2013. The unfolding transition 
temperature (Tm) of each protein was calculated from the steepest part of the melting 
curve. To find the steepest part of the melting curve, the curves were differentiated 
with respect to temperature (T; -dRFU/dT), therefore the Tm of each protein was the 
average of the lowest -dRFU/dT values. 
 
2.20 Fluorescent labelling of proteins 
 
 In order to study binding and uptake of purified proteins upon interaction 
with T cells, proteins were directly labelled with a tetrafluorophenyl (TFP) ester 
using an Alexa Fluor® 488 Microscale Protein Labelling Kit (Invitrogen) according 
to the manufacturer’s instructions. A volume equal to 100 µg of protein in NaH2PO4, 
pH 7.6 buffer was mixed with a 1/10 volume of 1 M NaHCO3. The volume of TFP 
ester dye added to the protein was calculated using the following formula, where the 
molar ratio of dye:protein was based on that required for the optimal degree of 
labelling of a 150 kDa protein (Invitrogen, 2006) and 11.3 nmol/µL was the 
concentration of the dye: 
 
Volume of dye = ((µg of protein/protein molecular mass) x 1000 x molar ratio)/11.3 
 
 The protein/dye mixture was incubated at room temperature for 15 minutes 
and excess dye was removed by spin filtering the mixture at 16,000 x g for 1 minute 
through the Bio-Gel P-6 fine resin provided with the kit. 
 
2.21 Protein transfection 
 
2.21.1 Transfection of T cells with recombinant LifA fragments 
 
 Proteins were transfected into bovine T cells using XfectTM Protein 
Transfection Reagent (Clontech Laboratories Inc.) according to the manufacturer’s 
instructions with some modifications. PBS was used to dilute 1 x Xfect Protein 
Transfection Reagent rather than deionised water (dH2O) to reduce osmotic stress on 
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the cells. An appropriate volume of Xfect Protein Buffer was added to 5 µg of the 
tested proteins in a volume of 100 µL. The protein/buffer mix was added to 100 µL 
of diluted transfection reagent and incubated at room temperature for 30 minutes. T 
cells at a density of 8 x 106 cells/mL in serum-free RPMI were added in a volume of 
400 µL to each transfection reaction then incubated at 37 °C, 5 % CO2 for 1 hour. 
Cells were then centrifuged at 425 x g for 10 minutes then washed with PBS. Cells 
were resuspended in 400 µL of RPMI-CT, counted as described in Section 2.1, then 
diluted to a density of 4 x 106 cells/mL and seeded in 50 µL in a 96 well plate. A 
volume of 50 µL of RPMI-CT or 2 µg/mL ConA in RPMI-CT was added to the 
appropriate wells and the assay was continued as for standard T cell proliferation 
assays to determine if the transfected fragments were able to inhibit 
mitogen-stimulated proliferation. Negative controls with the transfection reagent but 
no proteins were used to determine the effects of the transfection reagent on 
ConA-stimulated proliferation and WT rLifA was used as a positive control. As a 
control to demonstrate that the transfection reagent was active, β-galactosidase 
supplied with the reagent was used as a positive control to determine transfection 
efficiency by blue-white screening as below. 
 
2.21.2 X-gal staining of transfected cells 
 
Blue-white screening for the presence of β-galactosidase in transfected T 
cells was performed using a Beta-Galactosidase Staining Kit (Clontech Laboratories 
Inc.) following the manufacturer’s instructions. Cells were centrifuged at 425 x g for 
10 minutes then washed with 1 x PBS. Cells were incubated in Fixing Buffer at room 
temperature for 10 minutes then washed twice with 1 x PBS. Cells were then 
incubated in X-Gal Staining Mix (see Appendix 1) overnight at 37 °C, 5 % CO2. 
Cells were washed and resuspended in PBS then attached to poly-L-lysine 
coated slides (BD Biosciences) by centrifugation at 300 rpm for 5 minutes in a 
Cytospin 3 centrifuge (Shandon). Coverslips were mounted using ProLong® Gold 
Antifade Mountant (Life Technologies) and left to cure overnight. Cells were 
examined for the presence of intracellular β-galactosidase (blue staining) by light 
microscopy and images were analysed in Zen 2011 (Carl Zeiss). Transfection 
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efficiency was determined by counting both the total number of cells and number of 
blue-stained cells. 
 
2.21.3 Confocal microscopy 
 
 T cells treated with fluorescently-labelled lymphostatin, or fragments thereof, 
were prepared as described in Section 2.6 and imaged by confocal laser scanning 
microscopy. After incubation with the labelled protein, cells were centrifuged at 
425 x g for 10 minutes then washed three times with PBS. Cells were fixed by 
incubating them with 4 % (w/v) PFA on ice for 30 minutes, centrifuged at 425 x g 
for 10 minutes then washed three times with PBS. Cells were counter-stained with 
DAPI (4′,6-diamidino-2-phenylindole) at a dilution of 1/10,000 then washed with 
dH2O. Cells were attached to poly-L-lysine coated coverslips as described for X-gal 
staining. Images were obtained using a Nikon EC-1 inverted confocal microscope 
and analysed using ImageJ (National Institutes of Health). 
 
2.22 Analysis of lymphostatin processing in cells 
 
2.22.1 Culture of J774A.1 cells 
 
 J774A.1 murine macrophage-like cells were cultured at 37 °C, 5 % CO2 in 
RPMI-1640 medium (Gibco) with 10 % (v/v) FCS (Gibco), 2mM L-glutamine 
(Gibco) and 100µg/mL penicillin/streptomycin (Sigma-Aldrich; RPMI-CJ). The cells 
were grown to a confluence of 80–90 % then passaged into fresh medium as follows. 
The cell monolayer was dislodged from the flask with a cell scraper then centrifuged 
at 290 x g for 10 minutes at room temperature. Cells were resuspended in fresh 
medium, counted by trypan blue exclusion (0.4 % (w/v) trypan blue; HyClone) using 
disposable haemocytometer grids (Kova International) and re-seeded at a density of 
0.5 x 106 cells/mL in a T175 filter cap flask (Fisher Scientific). For long-term storage 
at -150 ºC, cells were spun down and resuspended in 90 % (v/v) FCS/10 % (v/v) 
dimethyl sulphoxide (DMSO; Sigma-Aldrich) at a density of 1 x 107 cells/mL, frozen 
in a cell freezer at -80 ºC overnight, followed by transfer to -150 ºC. 
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2.22.2 Detection of lymphostatin cleavage in J774A.1 cells 
 
 J774A.1 cells were seeded at a density of 1 x 106 cells/mL in a 12 well plate 
and cultured for 24 hours at 37 °C, 5 % CO2 in RPMI-CJ. Cells were serum starved 
in serum-free DMEM for 1 hour. The medium was removed from the cells and WT 
rLifA or rLifAC1480A was added to the medium at a final concentration of 1 µg/mL. 
The medium was mixed by vortexing and reapplied to the cells. Buffer treated cells 
were used as a negative control. After 1 hour of incubation, treated cells were lysed 
with 120 µL of NP-40 lysis buffer and incubated on ice for 30 minutes. Lysates were 
transferred to microcentrifuge tubes then centrifuged at 17,949 x g, 4 °C for 
10 minutes and the supernatants were transferred into clean microcentrifuge tubes. 
Lysates were processed as described for T cells in Section 2.6.  
 Western blots used rabbit polyclonal anti-LifA antibody at a dilution of 
1/20,000 or mouse monoclonal anti-6 x His antibody (BioLegend) at a dilution of 
1/1000. Primary antibodies were detected using DyLightTM 800 4X PEG-conjugated 
goat anti-rabbit IgG (1/30,000 dilution) and DyLightTM 800-conjugated goat 
anti-mouse IgG (1/10,000 dilution) antibodies respectively (both from Cell Signaling 
Technology). 
 
2.23 Treatment of T lymphocytes with inhibitors of endosome acidification 
 
 These experiments were carried out as described for T lymphocyte protein 
association assays (Section 2.6) but T cells were incubated with either bafilomycin 
A1 (at a final concentration of 0.0005–50 µM; LC Laboratories) or chloroquine 
diphosphate (over a range of 0.0125–1250 µM; Sigma-Aldrich) during the serum 
starving step. DMSO and PBS were used as carrier controls for bafilomycin A1 and 
chloroquine respectively. 
 Western blots used rabbit polyclonal anti-LifA antibody at a dilution of 
1/20,000 and mouse monoclonal anti-β-actin as a protein loading control (GeneTex) 
at a dilution of 1/5000. Primary antibodies were detected using DyLightTM 800 4X 
PEG-conjugated goat anti-rabbit IgG (1/30,000 dilution) and DyLightTM 
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680-conjugated goat anti-mouse IgG (1/15,000 dilution) antibodies respectively 
(both from Cell Signaling Technology). 
 Densitometry was performed on the putative N-terminal cleavage product of 
rLifA and -actin signal using Image Studio Lite v5.2 and Microsoft Excel 2013. 
Linear regression analysis was carried out using Minitab 17. Average regression 
slopes were tested for statistical significance using a one-sample T-test. P values 
≤ 0.05 were taken to be statistically significant. 
 
2.24 Detection of GlcNAcylated proteins in bovine T lymphocytes in the 
presence or absence of lymphostatin 
 
2.24.1 Western blotting for detection of O-GlcNAc-modified proteins 
 
 These experiments were carried out as described for T lymphocyte protein 
association assays (Section 2.6), with T cells being treated with a final concentration 
of 2 µg/mL WT rLifA or rLifADTD/AAA. Buffer-treated cells were used as a negative 
control. SDS-PAGE was carried out using three different gel systems with different 
molecular weight resolutions: 3–8 % Tris-Acetate gels (Novex) for proteins in the 
range of 71–460 kDa; 4–12 % Tris-Glycine gels (Novex) for proteins of 25–
250 kDa; and 4–12 % Tris-Glycine gels (BioRad) for proteins of 10–150 kDa. 
Western blots were performed using mouse monoclonal anti-O-GlcNAc antibody 
(Novus Biologicals) at a dilution of 1/1000, which was detected using DyLightTM 
800-conjugated goat anti-mouse IgG antibody (Cell Signaling Technology) at a 
dilution of 1/10,000. 
 
2.24.2 Shotgun mass spectrometry 
 
 T cells were treated as described above for western blot analysis and lysed 
with 8 M urea. Protein concentrations were determined using Bradford reagent 
(BioRad) according to the manufacturer’s instructions. Samples were incubated for 
30 minutes at room temperature in 2 M urea, 25 mM ABC and 5 mM DTT to 
denature and reduce the protein. Cysteine residues were alkylated by incubating the 
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samples at room temperature with 12.5 mM iodacetamide (Sigma-Aldrich) for 1 hour 
in the dark. Trypsin (0.4 µg; Worthington Biochemical Corporation) digestion was 
performed overnight at room temperature. Peptide extracts were cleaned on Omix 
reverse stage phase tips (Agilent Technologies). Samples were dried by Speedvac 
and stored a -20 °C until required. Samples were reconstituted in 0.05 % (v/v) 
trifluoroacetic acid (Fisher Scientific) and filtered using a 0.45 µm Millex® filter 
(Merck Millipore). 
 Shotgun mass spectrometry was performed using an online system of a 
nano-HPLC (DionexTM UltiMateTM 3000 RSLC; Fisher Scientific) coupled to a 
QExactive mass spectrometer (Fisher Scientific) with a 300 µm internal diameter 
(I.D.) x 5 mm pre-column (5 µm particle size; Acclaim Pepmap) joined with a 75 µm 
I.D. x 50 cm column (3 µm particle size; Acclaim Pepmap). Peptides were separated 
using a multi-step gradient of 2–98 % buffer B (80 % (v/v) ACN and 0.1 % (v/v) 
formic acid (Merck Millipore)) at a flow rate of 300 nL/minute over 90 minutes. 
Buffer A was 2 % ACN and 0.1 % formic acid. Data from mass spectrometry spectra 
were searched against a Bos taurus protein database using Mascot. The parameters 
used in each search were: missed cut = 2; fixed cysteine carbamidomethylation 
modification; variable methionine oxidation and N- and O-linked GlcNAc 
modifications; peptide mass tolerance of 10 ppm; and a fragment mass tolerance of 
0.05 Da. Search results were exported using a significance threshold (P value) of less 
than 0.05 and a peptide score cutoff of 20. Mascot searches were able to detect either 
one or two GlcNAc modifications to either Asn, Ser or Thr residues within a single 
peptide. 
 This experiment was repeated a second time using 3.6 x 108 cells/sample for 
WT rLifA and buffer-treated cells. In-solution protein digestion and data collection 
and analysis were performed by Lisa Imrie, Kinetic Parameter Facility (KPF), Centre 
for Synthetic and Systems Biology, University of Edinburgh. 
 
2.24.3 Glycoprotein enrichment 
 
 T cells were treated with WT rLifA or buffer as described in Section 2.24.1. 
Glycoprotein enrichment was performed using a wheat germ agglutinin (WGA) 
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Glycoprotein Isolation Kit (Thermo Scientific) according to the manufacturer’s 
instructions. T cell lysates containing 1–1.5 mg of total protein were diluted 1/4 with 
5 x Binding/Wash Buffer stock solution. Lysates were added to WGA resin columns 
pre-equilibrated with 1 x Binding/Wash Buffer and incubated for 10 minutes at room 
temperature on a rocking platform. The columns were centrifuged at 1000 x g for 
1 minute and the flowthrough was discarded. Columns were then washed twice with 
1 x Binding/Wash Buffer, incubated at room temperature for 5 minutes on a rocking 
platform and then centrifuged at 1000 x g for 1 minute. Glycoproteins were eluted 
from the columns into clean microcentrifuge tubes by twice incubating the columns 
with Elution Buffer at room temperature for 10 minutes on a rocking platform, 
followed by centrifugation at 1000 x g for 1 minute. The protein concentration of 
pre- and post-enrichment lysates was measured using Bradford reagent 
(Sigma-Aldrich) according to the manufacturer’s instructions. Equal concentrations 
of pre- and post-enrichment lysates were examined by western blotting using mouse 
monoclonal anti-O-GlcNAc antibody (Novus Biologicals) at a dilution of 1/1000, 
which was detected by HRP-conjugated goat anti-mouse IgG antibody (AbD 
Serotec) at a dilution of 1/10,000 in TBS-T/2 % (w/v) skimmed milk powder (Chem 
Cruz). 
 To remove detergent, glycoprotein enriched lysates were run on a BoltTM 4–
12 % Bis-Tris Plus gel (Invitrogen) at 200 V until all of the sample had run into the 
gel. Gel pieces were excised and destained by three 15 minute washes with 50 mM 
ABC, 50 % ACN then shrunk in methanol for 10 minutes. SDS was removed by 
alternate 10 minute washes with 50 mM ABC and methanol. Proteins were reduced 
by incubation at 60 °C with 20 mM DTT, 50 mM ABC. Gels pieces were washed 
with methanol for 10 minutes then incubated with 50 mM iodacetamide, 50 mM 
ABC at room temperature for 1 hour in the dark to alkylate cysteine residues. Gel 
pieces were covered with methanol until they turned white then the methanol was 
decanted and the gel pieces were air dried. Gel pieces were rehydrated in 20 µg/mL 
trypsin (Worthington Biochemical Corporation) at 4 °C then incubated at room 
temperature overnight to digest the protein. Digest solutions were transferred to clean 
tubes and additional peptides were extracted from the gel pieces by 15 minute 
incubations with 1 % (v/v) formic acid followed by 1 % (v/v) formic acid, 50 % (v/v) 
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methanol then methanol alone. Peptide extracts were added to the digest solutions, 
dried by Speedvac, resuspended in 0.05 % (v/v) trifluoroacetic acid and filtered 
before shotgun mass spectrometry as described in Section 2.24.2. In-gel trypsin 
digests and shotgun mass spectrometry data collection and analysis were performed 
by Lisa Imrie, KPF. 
 
2.25 Protein pull-downs to detect LifA-interacting partners in T cells 
 
2.25.1 Anti-His protein pull-downs 
 
 Anti-His protein pull-downs were performed using a PierceTM Pull-Down 
PolyHis Protein:Protein Interaction Kit (Thermo Scientific) according to the 
manufacturer’s instructions. A quantity of 150 µg of rLifA, or the equivalent volume 
of buffer, was added to a HisPurTM cobalt resin column pre-equilibrated with wash 
solution (1:1 ratio of BupHTM TBS and Pierce Lysis Buffer with 10 mM imidazole) 
and incubated for 30 minutes at 4 °C on a rocking platform. Columns were 
centrifuged at 1250 x g, 4 °C for 1 minute then washed four times with wash 
solution. T cells (2 x 108 cells) from three independent donors were centrifuged at 
500 x g for 5 minutes, washed and resuspended in 2.5 mL/g wet weight of cells in ice 
cold TBS with 1 x HaltTM protease inhibitor cocktail (Thermo Scientific). Cells were 
lysed in an equal volume of Pierce Lysis Buffer and incubated for 30 minutes on ice 
with periodic inversions. Lysates were centrifuged at 12,000 x g, 4 °C for 5 minutes 
and 4 M Imidazole Stock Solution was added to the supernatant to make final 
concentration of 10 mM. Clarified lysate or wash solution was added to the 
appropriate columns and incubated for 30 minutes at 4 °C on a rocking platform. 
Columns were centrifuged at 1250 x g, 4 °C for 1 minute then washed a further five 
times. Proteins were eluted from the columns three times by the addition of 290 mM 
imidazole elution buffer, incubation for 5 minutes at 4 °C on a rocking platform 
followed by centrifugation at 1250 x g, 4 °C for 1 minute. Protein samples were 
denatured by the addition of an appropriate volume of 1 x sample reducing agent and 
1 x LDS sample buffer and heated at 70 °C for 10 minutes. Samples were stored at 
-20 °C until analysis. 
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2.25.2 Silver staining 
 
Pull-down eluates were subjected to SDS-PAGE using three different gel 
systems with different molecular weight resolutions: 3–8 % Tris-Acetate gels 
(Novex) for 71–460 kDa; 4–12 % Tris-Glycine gels (Novex) for 25–250 kDa; and 4–
12 % Tris-Glycine gels (BioRad) for 10–250 kDa. Gels were stained using a 
PierceTM Silver Stain Kit (Thermo Scientific) according to the manufacturer’s 
instructions. Gels were washed twice in dH2O for 5 minutes then fixed for 
30 minutes with 30 % (v/v) ethanol (Fisher Scientific), 10 % (v/v) acetic acid (Fisher 
Scientific). Gels were washed twice in 10 % (v/v) ethanol followed by a further two 
washes with dH2O before incubation with Silver Stain Sensitizer (1/500 dilution) for 
1 minute. Gels were washed twice with dH2O then incubated for 30 minutes with 
1 part Silver Stain Enhancer, 50 parts Silver stain. Gels were washed twice with 
dH2O for 20 seconds then incubated with 1 part Silver Stain Enhancer, 50 parts 
Silver Stain Developer for 2.5 minutes. Development was stopped with 5 % (v/v) 
acetic acid. 
 
2.25.3 Liquid chromatography mass spectrometry (LC-MS) to identify candidate 
interacting partners 
 
 The maximum possible volumes of pull-down eluates were run in triplicate 
on a gel. Protein species of interest were excised from silver stained gels, cut into 
pieces of ~1 x 1 mm and processed according to Shevchenko et al. (2006). Gel 
pieces were destained by three 15 minute washes with 50 mM ABC, 50 % ACN then 
shrunk in neat ACN for 10 minutes. Proteins were reduced by incubation at 56 °C 
with 10 mM DTT, 100 mM ABC for 1 hour. Gels pieces were washed with ACN for 
10 minutes then incubated with 55 mM iodacetamide, 100 mM ABC at room 
temperature for 20 minutes in the dark to alkylate cysteine residues. Gel pieces were 
covered with ACN until they turned white then the ACN was decanted and the gel 
pieces were air dried. Gel pieces were rehydrated in 13 µg/mL trypsin (Promega), 
10 mM ABC, 10 % ACN at 4 °C then incubated at 37 °C overnight to digest the 
protein. Digest solutions were transferred to clean tubes and additional peptides were 
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extracted from the gel pieces by 15 minute incubations with 1 % (v/v) formic acid, 
2 % ACN then ACN alone. Digested peptide extracts were purified using StageTips 
(Rappsilber et al., 2007). 
 Nanoflow LC-MS/MS was performed using an online system of a 
nano-HPLC (UltiMateTM 3000 RSLC; Fisher Scientific) coupled to a micrOTOF-II 
mass spectrometer (Bruker). Tryptic digests were delivered to a 100 μm I.D. × 2 cm 
trap column (5 μm particle size; Acclaim PepMap100) at a flow rate of 20 μL/minute 
in 100 % buffer A (0.1 % (v/v) formic acid in LCMS grade water). Following a brief 
washing step, peptides were transferred to a 75 μm I.D. × 25 cm analytical column 
(3 μm particle size; Acclaim PepMap100) and resolved on a 60 minute gradient of 7–
35 % buffer B (0.1 % (v/v) formic acid in ACN) at a flow rate of 300 nL/minute. The 
eluent from LC was passed onto the nano electrospray source of the micrOTOF-II, 
which was operated in data-dependent mode, automatically switching between MS 
and MS/MS mode. The m/z values of tryptic peptides were measured from an MS 
scan (300–2000 m/z), followed by MS/MS scans of the six most intense peaks. 
Rolling collision energy for fragmentation was selected based on the precursor ion 
mass and a dynamic exclusion was applied for 30 seconds. 
 Raw spectral data were processed using DataAnalysis software (Bruker). 
Data from mass spectrometry spectra were searched against the Uniprot B. taurus 
protein sequence database, NCBI whole database and the EPEC E2348/69 LifA 
sequence using Mascot. The parameters used in each search were: missed cut = 1; 
fixed cysteine carbamidomethylation modification; variable methionine oxidation 
and deamidation modifications; peptide mass tolerance of 25 ppm; fragment mass 
tolerance of 0.08 Da; and peptide charges were set to 2+ and 3+. In-gel digestion and 
LC mass spectrometry data collection and analysis were performed by Dr Dominic 
Kurian, Proteomics and Metabolomics Facility, The Roslin Institute. 
 
2.25.4 Immunoprecipitation of putative LifA-protein complexes 
 
T cells were serum starved in serum-free RPMI for 1 hour. A total of 1 x 107 cells, at 
a density of 4 x 106 cells/mL, were incubated with a final concentration of 1 µg/mL 
rLifA or the equivalent volume of buffer at 37 °C for 1 hour. Cells were washed with 
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ice-cold PBS and transferred to clean microcentrifuge tubes as described for protein 
association assays (Section 2.6). Cells were lysed in 500 µL of NP-40 lysis buffer 
and incubated on ice for 30 minutes. Lysates were centrifuged at 17,949 x g, 4 °C for 
10 minutes and the supernatants were transferred into clean microcentrifuge tubes. 
Lysates were incubated with 25 µL of PierceTM Protein A Plus agarose beads 
(Thermo Scientific), pre-equilibrated with NP-40 lysis buffer, at 4 °C for 1 hour on a 
rotator to remove proteins that may bind non-specifically to the beads. Samples were 
centrifuged at 2500 x g, 4 °C for 3 minutes and the supernatants were transferred to 
clean microcentrifuge tubes. Samples were then incubated with either rabbit 
polyclonal anti-INPP5E antibody (Proteintech) at a dilution of 1/500 or rabbit 
polyclonal anti-glutathione peroxidase 1 antibody (Abcam) at a dilution of 1/10 at 
4 °C overnight on a rotator. 
 Samples were centrifuged at 2500 x g, 4 °C for 3 minutes and the 
supernatants were discarded. Beads were resuspended in 12.5 µL of NP-40 lysis 
buffer. Protein samples were denatured by the addition of 12.5 µL of 10 x sample 
reducing agent and 12.5 µL of 4 x LDS sample buffer and heated at 70 °C for 
10 minutes. Samples were stored at -20 °C until analysis. Immunoprecipitated 
material was run alongside protein pull-down eluates on a 4–12 % Tris-Glycine gel. 
Anti-INPP5E and anti-glutathione peroxidase 1 antibodies bound to PierceTM Protein 
A Plus agarose beads alone were included as antibody controls. Western blots were 
performed using rabbit polyclonal anti-INPP5E antibody at a dilution of 1/500 and 
rabbit polyclonal anti-glutathione peroxidase 1 antibody at a dilution of 1/1000. 
Primary antibodies were detected using DyLightTM 800 4X PEG-conjugated goat 
anti-rabbit IgG antibody at a dilution of 1/30,000. 
 
2.26 Analysis of Akt phosphorylation 
 
2.26.1 Incubation with rLifA proteins prior to mitogen stimulation 
 
 T cells were serum starved in serum-free RPMI for 1 hour then 6 x 106 cells, 
at a density of 4 x 106 cells/mL, were incubated with a final concentration of 
1 µg/mL WT rLifA, rLifADTD/AAA, rLifAC1480A or the equivalent volume of buffer at 
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37 °C for 1 hour. Cells were then stimulated with ConA at a final concentration of 
5 µg/mL for the indicated times then processed as described for protein association 
assays (Section 2.6). Unstimulated cells were used as a negative control. Western 
blots were performed using rabbit monoclonal anti-pan Akt antibody (Cell Signaling 
Technology) at a dilution of 1/1000 in TBS-T/5 % (w/v) BSA or rabbit polyclonal 
anti-phospho-Akt (Ser473) antibody (Cell Signaling Technology) at a dilution of 
1/1000 in TBS-T/5 % (w/v) BSA. As a protein loading control, blots treated with 
anti-phospho-Akt (Ser473) antibody were also probed with mouse monoclonal 
anti-β-actin antibody at a dilution of 1/5000. Primary antibodies were detected using 
DyLightTM 800 4X PEG-conjugated goat anti-rabbit IgG antibody at a dilution of 
1/30,000 and DyLightTM 680-conjugated goat anti-mouse IgG antibody at a dilution 
of 1/15,000. 
 Densitometry was performed using Image Studio Lite v5.2 and Microsoft 
Excel 2013. Phospho-Akt1 (Ser473) signals for each sample were normalised against 
their respective actin protein-loading controls. Data were then further normalised 
against the ‘cells alone’ samples at each stimulation time point to provide fold 
changes in normalised phospho-Akt1 (Ser473) signal in comparison to cells alone. 
Data were transformed using log10 and one-way ANOVAs were used to determine 
statistically significant differences between samples at each time point using 
Minitab 17. Post hoc Dunnett tests were used to calculate 95 % confidence intervals 
and confirm significance. Densitometry values derive from three independent 
biological replicates. P values ≤ 0.05 were taken to be statistically significant. 
 
2.26.2 Incubation with rLifA proteins after mitogen stimulation 
 
 T cells were serum starved in serum-free RPMI for 1 hour then 6 x 106 cells, 
at a density of 4 x 106 cells/mL, were stimulated with 5 µg/mL ConA for 15 minutes 
as above. Cells were then incubated with 1 µg/mL rLifA or the equivalent volume of 
buffer at 37 °C for the indicated times. Unstimulated cells and cells stimulated with 
ConA but without rLifA/buffer treatment were used as negative and positive controls 
respectively. Cells were processed for western blotting and as described in 
Section 2.26.1. Densitometry data from each replicate were normalised to the protein 
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loading control as described in Section 2.26.1, then the fold change to the positive 
control of ConA-stimulated buffer-treated T cells was calculated. Data were 
transformed using log10 and two-sample T-tests were used to determine statistically 
significant differences between samples at each time point using Minitab 17. 
Densitometry values derive from four independent biological replicates. P values 
≤ 0.05 were taken to be statistically significant. 
 
2.26.3 Infection of T cells with EPEC strains 
 
 EPEC E2348/69 wild-type bacteria, and isogenic mutant strains with single or 
double mutations in lifA and lifA-like genes or escN (Table 2.1) were grown in static 
DMEM cultures at 37 °C for ~5 hours to induce Type III secretion. The A600 of each 
culture was measured, with an A600 of 1 taken to reflect ~1 x 10
9 bacteria/mL based 
on prior analysis of the relationship between culture absorbance and viable counts 
detected by direct plating. T cells were serum starved in serum-free RPMI for 1 hour 
then 6 x 106 cells, at a density of 4 x 106 cells/mL, were incubated with bacteria at a 
multiplicity of infection (MOI) of 200:1 (bacteria:T cells) at 37 °C for the indicated 
times. Cells were stimulated with a final concentration of 5 µg/mL ConA for 
15 minutes where indicated and processed as described previously. Unstimulated 
cells and cells stimulated with ConA, but without EPEC infection, were used as 
negative and positive controls respectively. Cells were processed for the detection of 
pan-Akt, Ser473-phosphorylated Akt and -actin as described previously.  
 Densitometry was performed as described previously and data from each 
replicate were normalised first to the β-actin loading control and the fold change was 
calculated relative to the positive control. Statistical analysis was performed as 
described in Section 2.26.1. Experiments involving EPEC E2348/69 NalR strains 
used post hoc Fisher tests in addition to Dunnett tests to calculate 95 % confidence 
intervals and confirm significance. Densitometry values derive from three 





2.26.4 Immunoprecipitation of Akt and analysis of its post-translational 
modifications 
 
 T cells were serum starved in serum-free RPMI for 1 hour. A total of 
1 x 107 cells, at a density of 4 x 106 cells/mL, were incubated at 37 °C with either 
1 µg/mL rLifA/buffer for the indicated times or EPEC E2348/69 strains at an MOI of 
200:1 for 1 hour. Cells were stimulated with 5 µg/mL ConA for 15 minutes. 
Unstimulated cells and cells stimulated with ConA, but without rLifA/buffer 
treatment or EPEC infection, were used as negative and positive controls 
respectively. Immunoprecipitation of Akt was performed as described previously 
using rabbit monoclonal anti-pan Akt at a dilution of 1/50. Beads were resuspended 
in 25 µL of NP-40 lysis buffer. Protein samples were denatured by the addition of 
25 µL of 10 x sample reducing agent and 25 µL of 4 x LDS sample buffer and heated 
at 70 °C for 10 minutes. Whole cell lysate samples in 500 µL of NP-40 lysis buffer 
were also made for each immunoprecipitation condition. Samples were stored at 
-20 °C until analysis. Rabbit monoclonal anti-pan Akt antibody bound to PierceTM 
Protein A Plus agarose beads alone were included as antibody controls. Western 
blots were performed using rabbit monoclonal anti-pan Akt antibody at a dilution of 
1/1000 in TBS-T/5 % (w/v) BSA, rabbit polyclonal anti-phospho-Akt (Ser473) 
antibody at a dilution of 1/1000 in TBS-T/5 % (w/v) BSA and mouse monoclonal 
anti-O-GlcNAc antibody at a dilution of 1/1000. Primary antibodies were detected 
using DyLightTM 800 4X PEG-conjugated goat anti-rabbit IgG antibody at a dilution 
of 1/30,000 and DyLightTM 800-conjugated goat anti-mouse IgG antibody at a 
dilution of 1/10,000. 
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In silico analysis of the lymphostatin (LifA) protein from the prototype EPEC 
O127:H6 strain E2348/69 reveals several Pfam domains with homology to other 
proteins (Figure 3.1). The N-terminal amino acids (aa) 20–1144 are homologous to 
the nucleotide-binding domain of reticulocyte binding/rhoptry proteins expressed by 
Plasmodium species (22 % identity and 39 % similarity over 1124 amino acids). 
These proteins are involved in adhesion to reticulocytes (Galinski et al., 1992; 
Triglia et al., 2001), which may potentially be significant as lymphostatin is near 
identical in sequence to EHEC factor for adherence (Efa1), which has been reported 
to influence adherence of EHEC O111:H- to Chinese hamster ovary (CHO) cells 
(Nicholls et al., 2000). Located within this region is also a glycosyltransferase (GT) 
domain (aa 314–754) that shares homology with the large clostridial toxins (LCTs) 
TcdA and B (as described in Section 1.3.5.1) and a TcdB N-terminal helical domain 
(aa 219–280), thought to be involved in substrate recognition. Between amino acid 
residues 1465–1646 lies a YopT-like cysteine protease (CP) domain, described in 
Section 1.3.5.2, and at the C-terminal end of the protein (aa 2181–3107) is a 





Figure 3.1. In silico predicted domains of lymphostatin from EPEC O127:H6 strain E2348/69. NCBI Blast identified five domains 
with homology to other known proteins including reticulocyte binding/rhoptry protein (NBD94 superfamily, aa 20–1144), a 
glycosyltransferase domain (GT, aa 314–754), a TcdB N-terminal helical domain (Tc, aa 219–280), a YopT-like cysteine protease domain 
(aa 1465–1646) and a domain of unknown function (DUF3491 superfamily, aa 2181–3107). 
 95 
Other domains and motifs of lymphostatin have also been previously 
reported. Klapproth et al. (2005) described an aminotransferase II motif in LifA from 
C. rodentium that is also present in EPEC E2348/69 LifA between amino acid 
residues 1947–1956. Nicholls et al. (2000) identified a number of predicted motifs in 
Efa1 from EHEC O111:H- (which is 99 % identical to E2348/69 lymphostatin) 
including two potential prepilin peptidase processing sites between residues 15–16 
and 772–773 that are homologous to EPEC BfpA and V. cholerae TcpB respectively, 
both of which are Type IV pilus precursors (Donnenberg et al., 1992; Ng et al., 
2016). A predicted transmembrane domain was also identified by Nicholls et al. 
(2000) between residues 2001–2033 of Efa1, however, this region of LifA has no 
homology to the transmembrane domain from LCTs that is required for the 
translocation of the LCT glycosyltransferase domain into the cytoplasm from the 
endosome (Nicholls et al., 2000; Qa’dan et al., 2000; Barth et al., 2001). In contrast 
to the NBCI Blast analysis, Nicholls et al. (2000) reported that only the initial 
500 amino acids of LifA had 36 % homology to reticulocyte binding protein 2 from 
Plasmodium vivax. Other reported proteins with homologous regions to LifA include 
interaptin from Dictyostelium discoideum (21 % identity, 43 % similarity, aa 850–
1150), Mycoplasma pneumoniae cytadherence high molecular weight protein 2 
(HMW2; 32 % identity, 48 % similarity, aa 1766–1806) and Streptococcus pyogenes 
M5 protein (32 % identity, 65 % similarity, aa 1052–1095; Nicholls et al., 2000). 
In our previous research, limited tryptic proteolysis of recombinant LifA 
(rLifA) from EPEC E2348/69 produced five major fragments (Figure 3.2A), which 
were identified by matrix-assisted laser desorption ionisation time-of-flight 
(MALDI-TOF) mass spectrometry (Figure 3.2B; Cassady-Cain et al., 2016). 
However, the contribution of these fragments to the overall function and activity of 
LifA is unknown. The largest fragment, designated F1, which encompasses the 
putative GT and CP domains, is richer in basic amino acids over the first 100 aa than 
full-length lymphostatin, which enabled us to separate F1 from other digest products 
by anion exchange chromatography (Cassady-Cain et al., 2016). The F1 fragment, 
purified in this way, did not inhibit the concanavalin A (ConA)-stimulated 
proliferation of bovine T lymphocytes (Cassady-Cain et al., 2016). Interestingly, 
several LifA fragments derived by limited trypsin proteolysis were eluted in the same 
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fractions from a size exclusion chromatography column (Walkinshaw Laboratory, 
unpublished data), suggesting that they may be capable of associating with each 
other despite not being covalently bonded. 
It was hypothesised that predicted globular domains released by limited 
proteolysis may represent functional domains, and that if these fragments were 
capable of associating with each other, the resulting complexes may retain 
lymphostatin activity against T cells. In this chapter, I cloned, expressed and purified 
a selection of LifA fragments and assayed their ability to bind to T lymphocytes and 
inhibit their mitogen-activated proliferation. 
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Figure 3.2. Tryptic digests revealed predicted globular domains of lymphostatin. (A) Limited trypsin proteolysis of rLifA produced 
five major fragments, designated F1–5. (B) The approximate amino acid boundaries of the five fragments were determined by 
MALDI-TOF mass spectrometry, which revealed that fragments F2 and F4 were sub-fragments of F1 and F3 respectively (from 
Cassady-Cain et al., 2016). 
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3.2 Development of a robust assay for lymphocyte proliferation 
 
Early experiments studying lymphostatin activity used bulk peripheral blood 
mononuclear cells (PBMCs) treated with crude bacterial lysates to examine the 
effects of LifA on mitogen-stimulated proliferation as no stable expression clone 
existed (Klapproth et al., 1995, 1996 and 2000; Malstrom and James, 1998; Stevens 
et al., 2002; Abu-Median et al., 2006; Deacon et al., 2010). Cassady-Cain et al. 
(2016) were the first to use highly-purified recombinant lymphostatin in proliferation 
assays. In order to establish whether enriching T cells was necessary for testing the 
activity of LifA fragments, I first compared the activity of wild-type (WT) rLifA 
against ConA-stimulated bulk PBMCs and enriched T cells from three independent 
donors using a colorimetric plate-based assay. The assay measured the conversion of 
MTS (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulphophenyl)-2H-tetrazolium) into a coloured formazan product by metabolically 
active cells, the absorbance of which was detected at around 490 nm. The quantity of 
formazan produced was directly proportional to the metabolic activity of dividing 
cells in the culture (Cory et al., 1991; Promega, 2012). 
 In both cell populations, rLifA inhibited ConA-stimulated proliferation in a 
concentration-dependent manner, producing typical sigmoidal curves where at high 
concentrations inhibitory activity was saturated and at low concentrations the activity 
was titrated away (Figure 3.3). The proliferation index (the ratio of proliferation of 
cells treated with rLifA + ConA/ConA alone), with standard deviation, of PBMCs 
decreased gradually from 0.99 ± 0.06 at 0.001 ng/mL of rLifA to 0.51 ± 0.06 at 
0.1 ng/mL, then the curve leveled out to 0.56 ± 0.03 at 100 ng/mL. T cells produced 
a curve that was level between 0.001 and 0.01 ng/mL of rLifA, decreased sharply 
from 0.95 ± 0.24 at 0.01 ng/mL to 0.47 ± 0.12 at 0.1 ng/mL, then leveled out to 
0.43 ± 0.13 at 100 ng/mL. The effective dose at which 50 % of cell proliferation was 
inhibited by rLifA (ED50), with standard error of the mean, was 0.01 ± 0.001 ng/mL 
for PBMCs and 0.04 ± 0.02 ng/mL for T cells (W = 8, P = 0.3827). Despite there 
being no statistically significant difference between the ED50s, enriched T cells were 
used in all further experiments as the PBMCs did not consistently produce a fold 
induction of proliferation ≥ 2, which was used as a quality control for each 
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proliferation assay. The buffer that rLifA was dissolved in was used as a carrier 
control. The volumes of buffer added to cells were equal to those of the different 
concentrations of rLifA. The buffer did not affect cell proliferation. 
 
 
Figure 3.3. Concentration-dependent inhibition of proliferation of 
ConA-stimulated peripheral bovine PBMCs and T lymphocytes by recombinant 
LifA. An absolute number of 200,000 cells were seeded into the wells of a 96 well 
plate. Titrations were carried out in triplicate and the results are the average obtained 
from 3 independent experiments using separate donors. Data were normalised against 
cells with ConA alone to produce a proliferation index. Error bars indicate the 
standard deviation of the average proliferation indices from across the 3 experiments. 
 
3.3 Development of an assay to detect the association of LifA with T cells 
 
In order to detect interactions between LifA and T lymphocytes, whether by 
binding of the protein to the plasma membrane or uptake into the cells, bovine T 
cells were incubated in the presence of rLifA for various time points and the cell 
lysates were analysed using a polyclonal anti-LifA antibody (Stevens Laboratory, 
clone 45). Despite some reactivity of the antiserum to T cell proteins, it recognised a 


























associated with the T cells at all time points between 5 minutes and 2 hours 
(Figure 3.4A) However, through investigation of additional controls, it was 
subsequently found that rLifA was bound to the microcentrifuge tubes when no cells 
were present (Figure 3.4B). Attempts to remove this non-specific binding by 
repeated washing with PBS or transferring the cells to a clean tube once failed 
(Figure 3.4C), as did using Eppendorf® LoBind or bovine serum albumin-coated 
microcentrifuge tubes (data not shown). It was found that washing the cells and 
transferring them to clean tubes twice was sufficient to remove the non-specifically 
bound rLifA (Figure 3.4D). 
Once the assay method had been optimised, bulk PBMCs and enriched T 
cells were incubated with rLifA from 5 minutes up to 24 hours (Figure 3.5). As with 
the pilot experiments, rLifA was observed to associate with PBMCs/T cells at all 
time points. This provided a useful assay for detecting interactions between T cells 
















Figure 3.4. The development of an assay to detect the association of rLifA with T lymphocytes. (A) Lysates from T cells treated with 
rLifA for varying time points appeared to show that rLifA associated with T cells from as little as 5 minutes to at least 2 hours. (B) A 
medium + rLifA control with no T cells revealed that rLifA non-specifically bound to the microcentrifuge tubes. (C) Washing tubes with 
PBS or transferring the cells to a clean tube once did not remove non-specific binding. (D) Washing and transferring the cells to a clean 
tube twice was sufficient to remove non-specifically bound rLifA. A quantity of 2 ng of rLifA was used a positive control. Proteins were 

































































































































































































































































































































































Figure 3.5. Association of rLifA with PBMCs/T cells. rLifA associated with bulk 
PBMCs and enriched T cells from as little as 5 minutes to at least 24 hours. A 
quantity of 2 ng of rLifA was used a positive control. Proteins were detected using a 
polyclonal anti-LifA antibody (Stevens Laboratory, clone 45). 
 
3.4 Generation of pRham-LifA-6 x His fragment clones 
 
 As noted in Section 3.1, three putative structural fragments of LifA (F1, F3 
and F5) and two smaller subfragments (F2 and F4) were identified by limited 
proteolysis (Cassady-Cain et al., 2016) but the contribution of these fragments to the 
overall function and activity of lymphostatin is unknown. Expression clones were 
therefore made for modified versions of the three largest fragments that span the 
majority of the LifA protein (Figure 3.6). These subunits were the N-terminal 
putative catalytic fragment (F1, aa 1–1620), which contains the predicted putative 
GT and CP domains, the C-terminal large fragment (F3, aa 2111–2900) and 
C-terminal small fragment (F5, aa 2901–3223). The regions cloned in this study were 
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longer than the tryptic fragments for which the boundaries had been mapped by 
MALDI-TOF in order to preserve predicted secondary structure at the boundary and 
fully encompass predicted catalytic domains (secondary structure analysis performed 
by Dr Liz Blackburn, Edinburgh Protein Production Facility (EPPF), Centre for 
Translational & Chemical Biology). The N-terminal fragment was extended to the 
beginning of the protein to account for any possible processing events. An expression 
clone was also made for the glycosyltransferase domain (aa 221–1033) based on the 
predicted structural alignment of LifA with LCTs and the known boundaries of the 
GT domain of LCTs (Cassady-Cain et al., 2016). In all cases, the predicted open 
reading frame for LifA fragments was cloned in-frame to both N- and C-terminal six 
histidine (6 x His) tags for affinity purification of the proteins. In the case of the F1 
fragment, this was cloned with only a C-terminal tag to ensure that the affinity tag 












Figure 3.6. Schematic of the full-length LifA protein and the relative positions of fragment proteins. F1 – N-terminal fragment 
encompassing GT and CP domains; GT – glycosyltransferase domain; F3 – C-terminal large fragment; F5 – C-terminal small fragment. 
Numbers indicate amino acid positions within the full-length protein. CP – cysteine protease domain (aa 1442–1619) as defined by 
homology with other C58 cysteine proteases (Walkinshaw Laboratoty, unpublished data), which was encompassed by F1 but was not made 
into a recombinant protein itself. 
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 PCR amplicons encoding the LifA fragments, which were confirmed to be of 
the expected size by gel electrophoresis, were fused to N- or C-terminal 6 x His tags 
using the ExpressoTM Rhamnose Cloning and Expression System. All of the cloned 
fragments were under the control of a rhamnose-inducible glucose-repressible 
promoter that we previously established affords tight control of rLifA expression 
(Cassady-Cain et al., 2016) and adopted due to concerns from published studies 
regarding the instability of lifA clones (Klapproth et al., 2000; Nicholls et al., 2000). 
Putative recombinants for each expression clone were screened by colony PCR to 
determine if they contained the expected fragments. Positive colonies were validated 
by double-stranded sequencing of the inserts (see Appendix 2) and one validated 















Figure 3.7. PCR screen of the expression clones chosen for further experiments. 
All expression clones contained gene inserts of the appropriate sizes (GT – 2460 bp; 
F1 – 4878 bp; F3 – 2391 bp; F5 – 990 bp; plus 150 bp to each insert from the vector 
amplified by the pRham Forward and pETite Reverse primers). Nuclease-free 
distilled water was used as a negative control. The full-length LifA insert (9687 bp + 
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3.5 Production of LifA fragment proteins 
 
Pilot-scale protein production used one expression clone for each LifA 
fragment to determine whether recombinant fragments could be expressed at the 
optimal conditions known for rLifA production as previously described 
(Cassady-Cain et al., 2016). Recombinant LifA fragments of the expected sizes were 
observed in the soluble and insoluble bacterial lysate fractions of each expression 
clone (Figure 3.8). The rF1 expression clone produced not only the expected 
~188 kDa fragment but also a unique ~150 kDa protein that was also reactive to the 
polyclonal anti-LifA antibody. rF5 was not observed in the soluble lysate fraction by 
western blotting, possibly due to its small size (~38 kDa). 
Protein expression was optimised before large-scale production by examining 
the effects of growth medium (LB or 2xTY), post-induction temperature (20 or 
30 °C), time (1, 2, 3 or 4 hours) and the pre-induction over-expression of chaperones 















Figure 3.8. E. cloni® 10G chemically competent cells produced LifA fragments when induced with 0.2 % L-rhamnose. Soluble and 
insoluble fractions of bacterial cell lysates were examined by (A) Coomassie staining and (B) western blotting using a polyclonal anti-LifA 
antibody (Stevens Laboratory, clone 45). Soluble rGT (~96 kDa), rF1 (~188 kDa) and rF3 (~89 kDa) were observed in the western blot. 
rF5 (~38 kDa) was observed in the insoluble fraction but not the soluble fraction, possibly due to its small size. A protein of ~150 kDa was 
observed only in cells producing rF1, suggesting that this protein may be derived from rF1, for example by processing, internal initiation of 
translation or premature termination. Cells transformed with the pRham empty plasmid were used as a negative control and 2 ng of rLifA 
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Heat/cold shock required 
rGT LB 30 3 No 
rF1 2xTY 30 3 No 
rF3 LB 30 3 No 
rF5 LB 30 3 Yes 
 
3.6 Protein purification 
 
3.6.1 LifA fragment purification 
 
 Large-scale production of the recombinant LifA fragments was carried out 
once the optimal expression conditions had been determined. Prior to purification, 
the optimal IMAC capture conditions for rF1 were determined to be the use of a 
nickel-Sepharose® column and IMAC buffers at pH 8. rF1, rF3 and rF5 were purified 
using only a two-step process of ion metal affinity chromatography (IMAC) and size 
exclusion chromatography (SEC). Figures for the purification of rF1 are shown as an 
example (Figures 3.9 and 3.10). rF1 could not be further purified by anion exchange 
chromatography using the same conditions as for F1 released by tryptic digestion 
(Cassady-Cain et al., 2016; data not shown). The recombinant GT domain was 
purified to a higher degree using anion exchange by Dr Liz Blackburn, EPPF. 
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Figure 3.9. IMAC purification of rF1 protein using Ni2+-Sepharose®. The absorbance of elution buffer at 280 nm shows the presence of 
rF1 where the concentration of imidazole was increased from 20 to 500 mM (marked with an arrow) to elute the protein from the 
nickel-Sepharose® beads. The large absorbance peak between ~0 and 200 mL corresponds to large cell debris that did not bind the column. 
The small peak before 230 mL corresponds to non-specifically bound proteins washed off by the increase in imidazole concentration from 
10 to 20 mM. Inset: Coomassie stain of 8 µL from 1 mL IMAC filtrate fractions showing the rF1 protein eluted. The dominant protein 
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Figure 3.10. Purification of rF1 protein by size exclusion chromatography (SEC). The leading edges of the large absorbance peaks 
(marked with an arrow) correspond to the presence of rF1 in the filtrates of the Superose 6pg 10/300 SEC column used to filter the pooled 
IMAC fractions. SEC 1 – less pure IMAC fractions. SEC 2 – purest IMAC fractions. Inset: Coomassie stains of 8 µL from 0.5 mL SEC 
filtrate fractions showing the rF1 protein eluted. The rF1 protein of 188 kDa (expected size indicated by arrows) was no longer visible 
above the dominant ~150 kDa protein. rF1 was eluted earlier than it should for a globular protein of the same size, suggesting it could be 




































8 µL of 0.5 mL fractions spanning 
the leading edge of peak 
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 The recombinant LifA fragments were found to be eluted from the SEC 
columns in multiple forms. A protein of ~150 kDa was the dominant protein in the 
rF1 preparation after purification, while the presence of full-length rF1 was reduced, 
suggesting that full-length rF1 may be processed into a lower molecular mass 
product (Figure 3.11). rGT and anion exchange purified rF3 (made by Dr Liz 
Blackburn, EPPF) were analysed by size exclusion chromatography-multi-angle light 
scattering (SEC-MALS) and found to contain not only the monomeric proteins but 
also heptamer and trimer forms respectively. This suggests that these proteins are 
capable of associating into multimeric forms under normal buffer conditions. rF5 
was eluted as a large aggregate protein, with a mass between 75–440 kDa, across 
70 mL of SEC column eluate. Despite a large absorbance peak at the expected 
monomeric size of rF5, the protein was only observed in the multimer-containing 
elution fractions by western blotting. The size, purity and reactivity of rF1, rF3, rF5 
and rGT proteins to anti-LifA antibody is shown in Figure 3.12. The identity of each 
recombinant fragment was confirmed by MALDI-TOF mass spectrometry of tryptic 
digests of the proteins. Details of the identified peptides are listed in Table 3.2 and 
mapped peptides are illustrated in Appendix 3. Mass spectrometry data for rGT was 



















Figure 3.11. Coomassie stain (left) and western blot (right) of recombinant F1 
purification steps. Full-length rF1 (~188 kDa) was observed in the whole cell lysate 
but after purification the ~150 kDa variant of rF1 became the dominant protein in the 
eluate. Full-length rF1 was still observed after SEC purification by western blotting. 
Quantities of 200 ng and 2 ng of rLifA were used as positive controls in the 
Coomassie stain and western blot respectively. The position of the ~188 kDa and 















































































































Figure 3.12. Coomassie stain (left) and western blot (right) of recombinant LifA 
fragments. rGT (~96 kDa), rF3 (~89 kDa) and full-length LifA (~365 kDa) were 
observed at the expected positions. The pure and impure fractions of rF1 (~188 kDa) 
showed almost only the ~150 kDa form of rF1 after purification. rF5 (~38 kDa) was 
not observed in the fractions suspected to contain monomeric rF5 but was seen in 
fractions suspected to contain a multimeric form. Proteins of the expected sizes and 
~150 kDa rF1 are marked with arrows. 
 
Table 3.2. Summary of the MALDI-TOF mass spectrometry results for the 
recombinant LifA fragments. 
 
Protein Mascot score Peptide matches Amino acid range Coverage (%) 
rGT 318 49 18–804 58 
rF1 279 30 251–1017 23 
rF3 135 19 241–286 22 































































































3.6.2 LifA fragment co-purification 
 
 In order to determine whether the recombinant LifA fragments could 
associate with each other as observed previously with fragments from limited 
proteolysis (Walkinshaw Laboratory, unpublished data), rF1, rF3 and rF5 were 
produced and purified together. Bacterial lysates of the three expression clones were 
pooled then purified by IMAC and SEC. Proteins of the expected sizes appeared in 
some of the same SEC elution fractions (Figure 3.13). However, the presence of rF5 
was not as clear as the other fragments, and given that both rF3 and rF5 are known to 
form multimers it could not be concluded that a genuine association was observed.
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Figure 3.13. SEC co-purification of rF1, rF3 and rF5. The recombinant fragments were co-purified using a Superose 6pg XK16/600 
SEC column to determine whether they were capable of associating. Proteins of the expected sizes (rF1 – 150 kDa form; rF3 – ~89 kDa; 
rF5 – ~38 kDa) were observed in elution fractions at the expected elution volume for an ~277 kDa protein (~90 mL; rLifA elutes at 
~80 mL). However, rF5 appeared just under the 37 kDa ladder on previous gels/blots and given that rF3 and rF5 are known to form a 





































3.7 T cell proliferation assays using rLifA fragments 
 
 rLifA and the recombinant fragments were added to cells at a concentration 
of 2.73 nM, equivalent to 1 µg/mL of rLifA. None of the fragments exhibited 
lymphostatin activity when exogenously applied to T cells in either isolation or in 
combination (Figure 3.14). The proliferation indices, with standard deviations, for 
cells treated with each protein were 0.19 ± 0.03 (rLifA), 1.06 ± 0.1 (rGT), 
0.96 ± 0.04 (rF1), 0.96 ± 0.08 (rF3), 1.01 ± 0.13 (rF5) and 0.86 ± 0.03 (rF1, rF3 and 
rF5 in combination). Although the proliferation index of the fragments in 
combination was found to be statistically significantly different from cells with 
ConA alone (W = 120, P = 0.0027), the fragments clearly did not inhibit proliferation 
to a similar degree as rLifA. This significance was not observed in experiments 
where the quantity of rF5 was increased or when uridine 
diphosphate-N-acetylglucosamine (UDP-GlcNAc) was mixed with the fragments 




Figure 3.14. The recombinant LifA fragments do not exhibit lymphostatin 
activity in isolation or in combination against bovine T lymphocytes. An absolute 
number of 200,000 cells were seeded into the wells of a 96 well plate. Equimolar 
concentrations of protein were added to cells in triplicate and the results are the 
average obtained from 3 independent experiments using separate donors. Data were 
normalised against cells with ConA alone to produce a proliferation index. Error bars 
indicate the standard deviation of the average proliferation indices from across the 3 
experiments. rF1, 3, 5 represents rF1, rF3 and rF5 combined in a molar ratio of 1:1:1. 
Asterisks indicate proliferation indices that were statistically significantly different 
from cells with ConA alone. 
 
3.8 Protein transfection 
 
 Although the recombinant LifA fragments lacked lymphostatin activity when 
applied exogenously to T cells, it was hypothesised that rGT and rF1 may retain their 
activity when introduced into cells by protein transfection. This hypothesis reflects 
previous studies with LCTs, which established that the N-terminal GT region is 
sufficient to cause the collapse of the actin cytoskeleton when introduced into 

























penetrate the plasma membrane of eukaryotic cells when combined with anthrax 
toxin protective antigen (Hofmann et al., 1997; Busch et al., 2000; Rupnik et al., 
2005; Spyres et al., 2001). 
 
3.8.1 X-gal staining 
 
 The commercially available XfectTM Protein Transfection Reagent was tested 
on bovine T cells using purified β-galactosidase as a control. All imaged cells treated 
with both transfection reagent and β-galactosidase were heavily stained blue by the 
X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside) substrate of 
β-galactosidase (Figure 3.15), indicating that β-galactosidase had been transfected 
into the cells. Cells without transfection reagent or β-galactosidase and cells with 
transfection reagent alone appeared clear. Cells treated with β-galactosidase alone 
exhibited staining that was far less intense, which may have been due to 





















Figure 3.15. β-galactosidase can be transfected into bovine T lymphocytes. As a 
positive control for the XfectTM Protein Transfection Reagent, β-galactosidase was 
transfected into T cells and detected by X-gal staining. Low level staining was 
observed in some cells treated with β-galactosidase but without transfection reagent, 
possibly caused by the protein sticking to the cell surface. All cells observed that 
were treated with both β-galactosidase and transfection reagent were heavily stained 
by comparison, demonstrating that the transfection reagent functioned as expected. 
Scale bar = 10 µm. All light microscopy images are of the same scale. 
 
3.8.2 Confocal microscopy of T cells treated with rLifA fragments 
 
 To establish if the transfection reagent was capable of transfecting rF1 into T 
cells, cells were treated with fluorescently labelled rF1 and the XfectTM Protein 




































Transfection Reagent and examined by confocal microscopy. Labelled rF1 was 
observed inside T cells, which had been optically sectioned at 1 µm (Figure 3.16), 
indicating that it had been introduced into the cells. Labelled rF1 was not visible in T 

















Figure 3.16. rF1 was transfected into bovine T lymphocytes. Fluorescently labelled rF1 (green channel) was transfected into T cells 
(bright-field channel) using the XfectTM Protein Transfection Reagent. The nuclei of lymphocytes (blue channel; stained with DAPI 
(4′,6-diamidino-2-phenylindole)) occupies most of the cells but labelled rF1 can be seen within the area of the plasma membrane 
(composite), indicating the reagent is capable of inserting rF1 into the cells. rF1 is not observed in cells without transfection reagent. Scale 
bar = 10 µm. All confocal microscopy images are of the same scale. 
























3.8.3 Transfection assays 
 
 T cell proliferation assays were performed using cells treated with 
transfection reagent and rF1. The assay required optimising due to cytotoxic effects 
of the transfection reagent and did not yield consistent results. Ultimately, an assay 
performed by Dr Robin Cassady-Cain at The Roslin Institute using rGT revealed that 
the transfection reagent was capable of stimulating T cells without the addition of 
ConA (Figure 3.17). Despite the transfection reagent being able to insert protein into 
T cells, the proliferation assay was not a suitable system for measuring the potential 
inhibitory activity of transfected recombinant LifA fragments. 
 
 
Figure 3.17. XfectTM Protein Transfection Reagent interfered with T cell 
proliferation. An absolute number of 200,000 cells, treated with transfection reagent 
and protein, were seeded into the wells of a 96 well plate. Titrations were carried out 
in triplicate. The absorbance at 492 nm revealed that the transfection reagent 
appeared to stimulate T cells that had not been treated with ConA, making the assay 
unsuitable for measuring proliferation. Error bars indicate the standard deviation of 
the triplicate wells from one donor. Absorbance units are shown rather than 
proliferation indices as they show how the proliferation of cells – reagent and 
cells + reagent compares in the presence/absence of ConA separately. Data were 





















- ConA + ConA
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3.9 Association of LifA fragments with T cells 
 
 Association assays were performed to determine whether the recombinant 
LifA fragments were capable of associating with T cells, similar to full-length rLifA. 
Proteins species of the expected sizes for rGT and rF1 (~150 kDa variant) were 
observed in lysates of T cells treated using the optimised protocol from Section 3.3 
but rF3 and rF5 could not be detected, even after a long exposure in the 
chemiluminescent detection method used (Figure 3.18). It is possible that the regions 
of LifA encompassed by rF3 and rF5 are not capable of associating with T cells 
unless they are part of an intact protein, or that these two fragments were below the 
limit of detection for the antibody. A protein species between 100 and 150 kDa that 
is reactive to anti-LifA antibody was observed only in rLifA treated T cells, 
















Figure 3.18. rGT and rF1 associated with T cells. T cells were treated with molar equivalents of protein (P)/buffer (B) and incubated at 
37 °C for 1 hour. Assays were performed using the same donor on the same day but films were exposed to the membranes for either 
5 minutes (rLifA and rF1) or 15 minutes (rGT, rF3 and rF5) to achieve the clearest blots. Full-length rLifA (~365 kDa), rGT (~96 kDa) and 
rF1 (~150 kDa; marked with arrows) were observed in treated T cell lysates but rF3 (~89 kDa) and rF5 (~38 kDa) could not be detected. A 
quantity of 2 ng of rLifA was used as a positive control (not shown on blot). The red arrow indicates a putative processed form of rLifA. 
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 125 
3.10 Association of LifA fragments with T cells in the presence of UDP-GlcNAc  
 
 As our previous research established that WT rLifA can bind to 
UDP-GlcNAc (Cassady-Cain et al., 2016) and GlcNAc moieties are abundant on 
cellular glycosaminoglycans and surface glycoproteins, we sought to determine if 
binding of rGT or rF1 to T cells may be competitively inhibited by free 
UDP-GlcNAc. We hypothesised that increasing the concentration of exogenous 
UDP-GlcNAc would competitively inhibit the interaction between the fragments and 
cell surface-bound GlcNAc. To investigate this, rGT and rF1 as well as rLifA were 
pre-incubated with different concentrations of UDP-GlcNAc before being exposed to 
T cells from three independent donors. 
The concentrations of UDP-GlcNAc used were based around the dissociation 
constant (Kd) of UDP-GlcNAc with rLifA (120 ± 30 µM; Cassady-Cain et al., 2016), 
the concentration at which 50 % of the UDP-GlcNAc is bound to rLifA. The highest 
concentration (1 mM) was chosen, as at ~10 times the Kd, > 90 % of the 
UDP-GlcNAc should be bound to the proteins (reviewed in Price et al., 2007). The 
concentrations of 50 and 250 µM were chosen so that concentrations above and 
below the Kd were included. 
The association of rLifA with T cells was not affected by exogenous 
UPD-GlcNAc. rGT and rF1 associated with T cells in a manner independent of 
UDP-GlcNAc concentration (Figure 3.19), suggesting that the fragments did not bind 
to GlcNAc moieties on the T cell surface, or that insufficient exogenous 






















Figure 3.19. The association of rGT and rF1 with T cells was not inhibited by 
exogenous UDP-GlcNAc. Equimolar concentrations of protein were pre-incubated 
with different concentrations of UDP-GlcNAc before incubation with T cells. 
Experiments were performed using 3 separate donors and representative blots are 
shown. Even at 1 mM, ~10 times the Kd of UDP-GlcNAc with rLifA (Cassady-Cain 
et al., 2016), the fragments associated with T cells, suggesting that the association 




 Toward an understanding of the structure and function of lymphostatin, 




















































































































recombinant LifA fragments did not reconstitue lymphostatin activity when applied 
exogenously to bovine T cells, either in isolation or in combination. Based on our 
knowledge of large clostridial toxins homologous to LifA, it is possible that this is a 
consequence of having separated the putative catalytic domain(s) of LifA from the 
region(s) involved in cell binding and intracellular processing. To address this, we 
sought to introduce the predicted glycosyltransferase domain (rGT and rF1) directly 
into T cells, mindful that a similar strategy for LCTs could rescue the cytotoxic 
activity of the native toxin (Hofmann et al., 1997; Busch et al., 2000; Rupnik et al., 
2005; Spyres et al., 2001). Despite rF1 being successfully transfected into T cells, the 
transfection reagent used interfered with the proliferation of the lymphocytes, 
rendering the T cell proliferation assay unsuitable for measuring lymphostatin 
activity. Microinjection was suitable for experiments with LCTs as these measured 
morphological changes in cells (Hofmann et al., 1997; Busch et al., 2000; Rupnik et 
al., 2005), however, the number of T cells required for a proliferation assay make 
this an unsuitable delivery system for the recombinant fragments. Creating a fusion 
protein of the fragments and the N-terminal 255 amino acids of anthrax toxin lethal 
factor, then combining them with anthrax toxin protective antigen may be a more 
effective way of transfecting the proteins into large numbers of T cells. Protective 
antigen facilitates the translocation of lethal factor and the adjoined protein across 
the endosomal membrane (Arora and Leppla, 1993; Milne et al., 1995). This method 
has been shown to be effective at delivering the N-terminal 556 amino acids of TcdB 
into CHO cells (Spyres et al., 2001), suggesting that it can be used for large proteins 
such as rGT and rF1. 
 There are also a number of methods that could be used to transfect genetic 
material into cells, which will then express the gene product. A plasmid encoding 
rGT or rF1 could be transiently transfected into T cells for short-term expression, or 
alternatively, stable transfection, in which the plasmid is inserted into the host cell 
genome, could be used (reviewed in Kim and Eberwine, 2010). However, stable 
transfection is not suitable for primary T cells as it requires an immortalised cell line 
that can be cultured and selected for using an additional selection marker, such as 
neomycin resistance (reviewed in Stepanenko and Heng, 2017). Jurkat cells could be 
used as a T cell model for stable transfection but they could not be used in 
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proliferation assays as they are immortal and therefore proliferate continuously. 
However, there is evidence that rLifA inhibits interleukin expression in Jurkat cells, 
which could be used as a method for examining the activity of the fragments 
(Malstrom and James, 1998; Stevens Laboratory, unpublished data). One major 
drawback of stable transfection is that the DNA vector is inserted randomly into the 
host cell genome, which can disrupt host cell genes and cause non-specific effects 
(reviewed in Stepanenko and Heng, 2017). Viruses such as herpes simplex virus and 
adenovirus can be used for stable transfection but are limited by size of the DNA 
package (reviewed in Kim and Eberwine, 2010). Recombinant, replication deficient 
adenovirus has been used to efficiently transfect lacZ into both primary T cells and 
Jurkat cells. It is unclear what effect this had on proliferation but phorbol myristate 
acetate (PMA)/ionomycin-stimulated cytokine production was not affected (Chen et 
al., 2002b). While no evidence could be found of herpes simplex virus being used for 
transfection of T cells, the viral protein Us3 is known to inhibit T cell activation and 
increase expression of the anti-inflammatory cytokine IL-10 (Sloan and Jerome, 
2007; Yang et al., 2015). Therefore, any viral vectors used for transfection would 
have to be screened for potential effects on lymphocyte proliferation. 
 Alternatively, chemical reagents, such as calcium phosphate, DEAE-dextran 
or lipofectin can be used for transient transfection. These are not limited by DNA 
size but have a lower transfection efficiency than viral vectors and can be cytotoxic 
(reviewed in Kim and Eberwine, 2010; reviewed in Stepanenko and Heng, 2017). 
The transient transfection of RNA is another possible transfection method. RNA of 
rF1 and rGT could be produced using a commercially available in vitro transcription 
kit, which would allow for rapid expression of the encoded proteins since 
transcription is not required (reviewed in Kim and Eberwine, 2010). However, there 
are certain elements of mRNA that are not present in DNA, such as the 5 cap and 
poly-A tail, as well as nucleoside modifications that must be taken into account when 
a plasmid is designed for in vitro transcription (Elango et al., 2005; Rozenski et al., 
1999). 
Rather than measuring the effect of transfected proteins on T cell 
proliferation, an alternative read-out could be used. LifA has been reported to inhibit 
the expression of multiple cytokines in T cells including IL-2, IL-4 and IFN-γ 
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(Klapproth et al., 1995, 1996 and 2000; Malstrom and James, 1998; Cassady-Cain et 
al., 2017). Therefore, measuring cytokine expression could be used to detect effects 
of transfected rGT and rF1 using an enzyme-linked immunosorbent assay. 
Appropriate controls could be included to ensure that the transfection reagent does 
not affect cytokine expression. 
 The lack of lymphostatin activity with the rF1 fragment is consistent with 
previous observations using F1 released by limited trypsin proteolysis and purified 
by anion exchange chromatography (Cassady-Cain et al., 2016). Previously, and in 
these studies, protein species of the expected sizes for rF1, rF3 and rF5 were 
observed in the same elution fractions of a size exclusion column, suggesting that 
they may be able to associate. However, no lymphostatin activity was detected on T 
cells treated with a mixture of the fragments and since rF3 and rF5 are known to 
form multimers it could not be concluded that the fragments were genuinely 
associating with each other under the assay conditions. It is possible that 
co-transformation of the expression strain with each fragment plasmid, so that all 
fragments are present at genesis, may be required for the recombinant fragment to 
associate. 
rGT and rF1 were capable of associating with T cells and did so in a 
GlcNAc-independent manner. LCTs bind host cell receptors via multiple domains 
located in C-terminal portion of the proteins (von Eichel-Streiber and Sauerborn, 
1990; Schorch et al., 2014; LaFrance et al., 2015; Manse and Baldwin, 2015; Tao et 
al., 2016; Lambert and Baldwin, 2016) and therefore I hypothesised that the 
C-terminus may be required for LifA binding and cell entry. If the C-terminus is 
required for receptor binding in LifA, it is unclear why rGT and rF1 were observed 
to associate with T cells while the two C-terminal fragments did not. Using a 
fluorescent secondary antibody in these assays may reveal low concentrations of 
bound rF3 and rF5 however. It is possible that, just as multiple domains are required 
for LCT binding, the N-terminus of LifA may also play a role in cell binding. In 
silico analysis of LifA has shown that the N-terminus shares homology with the 
nucleotide binding domain of reticulocyte binding proteins from Plasmodium, which 
are responsible for adherence to reticulocytes (Galinski et al., 1992; Triglia et al., 
2001; Grüber et al., 2011). The N-terminal amino acid residues 1052–1095 of LifA 
130 
also share 32 % homology with M5 protein from S. pyogenes, which is thought to 
bind CD46 on keratinocytes (Courtney et al., 2002). However, LifA is only 
homologous to the N-terminal amino acids 86–126 of M5 protein, whereas it is the 
conserved C-terminal end of M proteins that is implicated in the adhesion of S. 
pyogenes to keratinocytes (Okada et al., 1995; Perez-Casal et al., 1995). LifA also 
exhibits homology to HMW2, which is required for adherence of M. pneumoniae to 
cells, however, the role of HMW2 may be indirect as it is part of the Mycoplasma 
cytoskeleton (reviewed in Balish, 2014). Similarly, interaptin plays a role in the 
cytoskeleton of D. discoideum, linking actin to intracellular membrane compartments 
(Rivero et al., 1998). Therefore, the significance of the homology between LifA and 
the proteins HMW2 and interaptin is unclear. It is also possible that rGT and rF1 are 
able to bind to T cells via regions of the proteins that are not normally exposed in 
full-length LifA. 
The association assay is limited in that it cannot distinguish proteins bound to 
the outer membrane of T cells with those that have been taken up by the cells. 
Therefore, it is unclear whether rGT and rF1 are adhering to the surface of the T cells 
or are being endocytosed. Fixing T cells before treating them with the recombinant 
LifA fragments could be used but carries the risk that receptors may be denatured by 
the fixative. Similarly, future binding experiments could be conducted at low 
temperature or in the presence of specific inhibitors of uptake pathways. 
Alternatively, quenching reagents such as trypan blue could be used to distinguish 
between surface-bound and internalised fragments (Loike and Silverstein, 1983; 
Sahlin et al., 1983). T cells could be treated with FITC-labelled rGT or rF1 for 
varying durations then quenched with trypan blue. Flow cytometry could then be 
used to quantitatively determine whether the fragments are internalised over time 
(Vranic et al., 2013). Had rGT and rF1 associated with T cells in a 
GlcNAc-dependent manner, it could be inferred that they are still capable of binding 
the sugar. However, as this is not the case, no conclusions can be made about the 
sugar binding ability of rGT and rF1. The possibility of these proteins binding to 
other sugars besides GlcNAc on the T cell surface cannot be ruled out, as the sugar 
binding ability of rLifA has only been tested using UDP-GlcNAc and UDP-Glc 
(Cassady-Cain et al., 2016). Future studies could examine the ability of the rF1 and 
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GT fragments to bind UDP-GlcNAc by measuring changes in tryptophan 
fluorescence, as we previously described (Bease, 2015; Cassady-Cain et al., 2016). 
There were a number of limitations with the experiments using the 
recombinant LifA fragments, one of which was the purity of the proteins. With the 
exception of rGT, all of the fragments used in these experiments were only purified 
by IMAC and SEC, whereas full-length rLifA is purified with an additional anion 
exchange step. This lower purity affects the concentration measurement, which is 
used to determine the quantity of protein required for each experiment. Therefore, 
negative results may have been the consequence of less protein being used and 
failure to achieve equimolar amounts to rLifA. Additionally, contaminating proteins 
may affect T cell proliferation. The low purity of the fragments also prevented any 
structural data from being gathered. rLifA and the DXD mutant variant rLifADTD/AAA 
were biophysically characterised by a number of experiments when they were 
originally produced (Bease, 2015; Cassady-Cain et al., 2016). These biophysical 
characterisation experiments require the tested proteins to be of a high purity, which 
could not be achieved with rF1 and rF5. Despite rGT and rF3 being purified to a 
higher degree using anion exchange chromatography by Dr Liz Blackburn, no 
biophysical measurements were made for these proteins. Therefore, the only data 
regarding whether the fragments were correctly folded is derived from the SEC 
purification traces, which provides an approximate size for the proteins. However, 
the SEC purification of rF5 demonstrates that the protein likely forms aggregates. 
Additionally, an attempt to purify rF1 by anion exchange chromatography shows that 
the recombinant protein has different properties from the fragment released by the 
tryptic digest of full-length rLifA, which was purified using the same method 
(Cassady-Cain et al., 2016). 
 If the purification of the recombinant fragments could be optimised, the 
proteins could be subjected to the same biophysical experiments performed with 
rLifA and rLifADTD/AAA. Dynamic light scattering could be used to determine 
whether the proteins had aggregated and circular dichroism could provide 
information on the secondary structure of the proteins. It would be particularly useful 
to compare the circular dichroism spectra of rF1 and tryptic digest F1 to determine 
how these two fragments differ. Thermal denaturation assays would allow for the 
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examination of the thermal stability of the recombinant fragments, giving an 
indication as to whether they were correctly folded. 
 The apparent shortening of rF1 from ~188 to ~150 kDa was an unexpected 
result that may have unintended consequences for the protein as the part of the 
protein that is lost may be required for activity. It is not clear what portion of the 
protein is lost, or by which process this happens, but it was hypothesised that the CP 
domain may be involved. MALDI-TOF analysis of tryptic fragments of the 
~150 kDa species of rF1 may help to delineate which region is absent. In LCTs, a CP 
domain mediates autocatalytic cleavage of the proteins between the GT and CP 
domains (Egerer et al., 2007; Pruitt et al., 2009; Guttenberg et al., 2011; Rupnik et 
al., 2005; Kreimeyer et al., 2011) and a similar process could occur in LifA (see 
Chapter 4). This process occurs after a conformational change in LCTs inside cells 
(Qa’dan et al., 2000 and 2001; Barth et al., 2001) and can be challenging to 
reproduce in vitro owing to the potential requirement for low pH-induced structural 
changes and a co-factor. Although there were concerns that rF1 may be cleaved at 
the potential prepilin peptidase sites identified by Nicholls et al. (2000), the products 
produced by cleavage at these sites would be shorter than the observed ~150 kDa 
form of rF1. 
 Other structural abnormalities may also account for the inactivity of the 
recombinant LifA fragments. The additional methionine residues at the N-terminus 
of rF3 and rF5 as well as the C-terminal polyhistidine tags on rF1 and rF3 interrupt 
the normal amino acid sequence of LifA. In particular, since the sequences for rF3 
and rF5 are joined in the full-length protein, the extra amino acids inserted between 
them could disrupt interactions necessary for the fragments to associate. Such issues 
could be resolved by using cleavable tags. N-terminal His-tags can be cleaved using 
a number of enzymes such as the TAGZyme system, which uses dipeptidyl peptidase 
I, glutamyl cyclotransferase and pyroglutamyl aminopeptidase (Pedersen et al., 1999; 
Schäfer et al., 2002; reviewed in Waugh, 2011). Alternatively, where it is unsuitable 
to use an N-terminal His-tag, C-terminal His-tags with tobacco etch virus or tobacco 
vein mottling virus protease cleavage sites can be used (Eschenfeldt et al., 2010). It 
is also possible to remove the methionine residues attached to the N-termini of rF3 
and rF5. A modified form of methionine aminopeptidase has been reported to 
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remove the N-terminal methionine from bulky and acidic penultimate residues, as 
well as from small residues such as the penultimate glycine and proline found in rF3 
and rF5 respectively (Liao et al., 2004). The main drawback of these techniques is 
that they require separation of the recombinant proteins from the proteases, which 
would likely dilute the proteins. 
 Although the recombinant fragments represent the three main tryptic digest 
fragments of rLifA, they do not cover the whole amino acid sequence of LifA. No 
recombinant fragment was made for aa 1621–2110. Given that this region is 
predicted to contain an aminotransferase II motif and a transmembrane domain 
(Klapproth et al., 2005; Nicholls et al., 2000), it may be required for the function of 
the full-length protein. Producing and purifying this sequence could be useful in 
order to determine whether this region can rescue lymphostatin activity when mixed 
with the other fragments. A lack of lymphostatin activity, even when fragments 
representing the whole sequence of the full-length protein are combined, would 
likely be indicative that these recombinant fragments do not associate. Alternatively, 
if the tryptic digest LifA fragments could be produced in sufficient quantities, they 
could be tested for inhibitory activity against T cells since there is evidence that these 
fragments actually associate.  
 Lastly, there appeared to be a lack of epitope affinity of anti-LifA antibody 
for rF5. This may be due to the small size of rF5 or that the F5 sequence is normally 
buried within the full-length protein, which may explain the apparent low solubility 
of rF5 and why it forms aggregates. This is consistent with previous attempts to 
detect the C-terminal end (aa 1897–3223) of Efa1 from EHEC O111:H- cloned into 
E. coli K-12 with an anti-6 x His (Abu-Median et al., 2006). 
 In conclusion, while the recombinant fragments of lymphostatin may yet 
prove useful for structural studies, their use in cellular assays is limited. Future 
studies of functional domains of lymphostatin will require the adoption of either 









 Lymphostatin contains a cysteine protease (CP) domain that is homologous to 
the CP domain of Yersinia YopT and other C58 family proteases (Shao et al., 2002). 
The protease activity of these proteins is dependent on a catalytic triad consisting of 
Cys, His and Asp residues. Such residues are present in LifA at amino acid positions 
1480, 1581 and 1596 respectively (Shao et al., 2002). Some C58 proteases, such as 
Yersinia YopT and LopT from Photorhabdus luminescens, cleave Rho GTPases 
within target cells and act as cytotoxins (Shao et al., 2002; Brugirard-Ricaud et al., 
2005). LifA, however, has not been reported to exhibit cytotoxicity in studies using 
diverse cell types (Klapproth et al., 1995 and 2000; Malstrom and James, 1998; 
Nicholls et al., 2000; Bease, 2015; Cassady-Cain et al., 2016). Other C58 proteases, 
such as Pseudomonas syringae AvrPphB and Rhizobium NopT, undergo CP 
domain-mediated autoproteolysis (Shao et al., 2002; Dai et al., 2008). 
 Large clostridial toxins (LCTs), which have N-terminal homology to LifA, 
also possess a CP domain with a D/H/C orientated catalytic triad (reviewed in 
Chandrasekaran and Lacy, 2017). After entering host cells by receptor-mediated 
endocytosis (Papatheodorou et al., 2010), LCTs undergo a pH-induced 
conformational change in the endosome resulting in pore formation in the membrane 
and insertion of the N-terminus into the host cell cytosol (Qa’dan et al., 2000 and 
2001; Barth et al., 2001; Figure 4.1). The CP domain of LCTs then autocatalytically 
cleaves the protein to release the glucosyltransferase domain, which targets Rho 
GTPases (Pfeifer et al., 2003; Egerer et al., 2007; Guttenberg et al., 2011; reviewed 
in Chandrasekaran and Lacy, 2017). The autocatalytic cleavage of LCTs is 
dependent on the cellular co-factor inositol hexakisphosphate (InsP6; Reineke et al., 
2007), but previous attempts to induce autocatalytic cleavage of rLifA using InsP6 in 




Figure 4.1. Schematic representation of the uptake and processing of large 
clostridial toxins (LCTs) in host cells. LCTs are taken up by receptor-mediated 
endocytosis. Acidification of the endosome results in a conformational change in the 
proteins and insertion through the membrane. The proteins are autocatalytically 
cleaved by the cysteine protease domain, an event that requires the co-factor inositol 
hexakisphosphate, and the N-terminal glucosyltransferase domain is released into the 
cytoplasm where it glucosylates Rho GTPases resulting in the collapse of the actin 
cytoskeleton (from Jank and Aktories, 2008). 
 
 Few studies have been carried out to investigate the role of the CP domain of 
LifA and those that have were limited by a lack of precise mutagenesis and structural 
information on the mutant protein. For example, the CP domain of LifA was 
previously reported to be required for the colonisation of mice by C. rodentium 
(Klapproth et al., 2005). However, the method used to generate a CP domain mutant 
introduced a stop codon to the lifA gene resulting in protein truncation rather than an 
in-frame deletion as claimed by the authors. This was corrected in a second study by 
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the same laboratory, which implicated the CP domain in LifA-mediated 
redistribution of β-catenin and E-cadherin at enterocyte apical junctions and the 
activation of RhoA during C. rodentium infection (Babbin et al., 2009). The 
relevance of such events to pathogenesis is unclear and the study did not investigate 
the impact of the CP domain mutation on intestinal colonisation or lymphostatin 
activity. In another study, it was independently reported that a deletion of over 
100 amino acids, encompassing the entire C/H/D motif, marked by a triple alanine 
sequence in EPEC E2348/69 abolished the inhibitory activity of LifA against 
ConA-stimulated PBMCs (Deacon et al., 2010). However, since no biophysical 
information was obtained for this protein, it cannot be ruled out that loss of 
lymphostatin activity was caused by structural changes to the protein. 
 Given that CP domains homologous to that of LifA are known to be required 
for autoproteolysis in a number of bacterial virulence factors, it was hypothesised 
that LifA is taken up by cells and undergoes CP domain-mediated processing to 
release the glycosyltransferase domain into the cytosol, similar to LCTs. The 
detection of a circa (c.) 140 kDa protein in the lysates of rLifA-treated T cells that 
was reactive to anti-LifA antibody (see Section 3.9) suggests that this may happen. 
To test this hypothesis, I substituted the predicted catalytic Cys1480 residue for an 
alanine residue using the existing pRham-LifA-6 x His plasmid by site-directed 
mutagenesis, then expressed and purified the protein. The mutant protein was 
assayed for its ability to inhibit mitogen-stimulated T cell proliferation and to be 
processed within different cell types. Biophysical properties of the protein were also 
analysed relative to wild-type (WT) lymphostatin. It was predicted that the mutation 
would abolish lymphostatin activity against T cells and prevent the appearance of the 
suspected cleavage product. 
 
4.2 Generation of the pRham-LifA-6 x His C1480A clone 
 
 QuikChange site-directed mutagenesis was performed using the existing 
pRham-LifA-6 x His plasmid as a template to create the C1480A substitution in the 
lifA gene (Figure 4.2). An alanine substitution was chosen because alanine residues 
are small, non-polar and unreactive, which should allow the mutant protein to fold 
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correctly and be structurally similar to the WT protein. Previous experiments using 
this method were successful in substituting the DXD motif of the glycosyltransferase 
domain with a triple alanine sequence, which abolished UDP-GlcNAc binding and 
lymphostatin activity without affecting the structure of the protein (Bease, 2015; 
Cassady-Cain et al., 2016). Primers were designed to create a C1480A substitution 
and introduce a BsrDI restriction site at the same location in the plasmid 
(Figure 4.2A; see Section 2.8). Template plasmid with no primers and primers with 
no template plasmid were used as negative controls for the PCR. The pWhitescript 
plasmid and oligonucleotide control primers were used as a positive mutagenesis 
control. The oligonucleotide control primers repair a mutation in the β-galactosidase 
gene, which can be detected by blue-white screening using a chromogenic 
β-galactosidase substrate. The pUC18 plasmid was used as a positive transformation 
control because it contains part of the E. coli lac operon, which complements the 
host cell’s defective lacqZΔM15 gene, and can also be detected by blue-white 
screening using a chromogenic β-galactosidase substrate. 
 Sixty-four transformants were obtained with DpnI digested DNA derived 
from the PCR reaction to introduce the C1480A substitution into the 
pRham-LifA-6 x His plasmid. This was within the expected range of 10–
1000 colonies per plate. The transformants were cultured overnight to make glycerol 
stocks. Two colonies grew on the plate with cells transformed with the ‘no template’ 
control. The pWhitescript control had a mutagenesis efficiency of 95.4 %. 
 Ten of the putative C1480A substitution clones were screened by colony 
PCR, using primers to amplify the full-length lifA gene and vector, and analysed by 
agarose gel electrophoresis. All 10 tested positive for the presence of the full-length 
lifA gene and plasmid (data not shown). The colonies were screened against purified 
parental plasmid as a positive control and a no template negative control. To test 
whether these transformed colonies contained the C1480A mutation and were not 





















Figure 4.2. The process of creating the C1480A substitution mutant of LifA. (A) 
Nucleotide and amino acid sequence of the part of the catalytic C/H/D motif within 
the putative cysteine protease domain of LifA, highlighting the codon that was 
targeted for site-directed mutagenesis in order to create an alanine substitution 
mutant. It was also possible to incorporate a new BsrDI restriction site 
(GCAATGGG) at this location. (B) Schematic of the procedure for QuikChange 
Mutagenesis. Mutant strand synthesis is carried out using the mutagenic primers to 
replicate the entire plasmid using PCR. This is followed by DpnI digestion of 
methylated and hemimethylated template DNA to remove the parental plasmid DNA. 
Finally, the mutated plasmid is transformed into chemically competent cells (adapted 




 In the WT lifA sequence amplified by primers LifA FL For3 and LifA FL 
Rev8, there are two BsrDI restriction sites, whereas an additional BsrDI site was 
expected to be introduced within this amplicon with the C1480A substitution 
(Figure 4.3), thereby providing a rapid screen to identify putative mutant clones. 
Digestion of amplicons generated by PCR with LifA FL For3 and LifA FL Rev8 was 
expected to give fragments of ~1686, 1258, 1051 and 174 bp on a gel if the plasmid 
was mutated successfully (Figure 4.3). If the mutant insert was not present, bands of 
~2735, 1258 and 174 bp would be expected. All but one of the clones tested were 
found to contain the mutant insert. The clones were screened against BsrDI digested 
template plasmid, amplified with primers LifA FL For3 and LifA FL Rev8, and a ‘no 
template’ negative control. The two colonies that grew on the ‘no template’ control 
plate were also screened and found not to contain the pRham-LifA-6 x His plasmid. 
Excess plasmid from the PCR reaction was observed at ~10 kb. 
 From the putative mutant clones identified, three clones were verified by 
sequencing, initially at the site of mutation using primers LifA FL For7, LifA FL 
For8, LifA FL Rev10 and LifA FL Rev11 to confirm that the expected sequence was 
present. Once this was confirmed, the entire lifA gene of two clones was sequenced 
to verify that no additional mutations were introduced during the mutagenesis 
process. Both clones were verified to contain the appropriate mutation, however, one 
clone was found to contain a G-T substitution at position 6999 of the gene sequence, 
resulting in a glycine-cysteine substitution. The other clone contained the expected 
sequence of the mutated EPEC E2348/69 lifA gene and was carried forward for 
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Figure 4.3. BsrDI digestion of amplicons from putative pRham-LifA-6 x His 
C1480A plasmid clones. (A) Of the 64 colonies that grew on a kanamycin plate, 10 
were selected to be screened by BsrDI digestion of amplicons generated by PCR 
using primers LifA FL For3 and LifA FL Rev8. Two colonies that grew on a 
negative control plate were tested to confirm that they were false positives. 
Nuclease-free water was used as a negative control. Digested parent plasmid was 
included as a control. Excess plasmid from the PCR reaction can be seen at ~10 kb. 
Out of the 10 putative C1480A substitution clones selected, all but one tested 
positive for the presence of the C1480A mutation. (B) Schematic showing the 
expected sizes of amplified lifA gene products of BsrDI digestion. The 174 bp 
fragment produced by positive and negative clones is too faint to be visualised on the 
gel and so the image has been cropped to the limit of the lowest marker. 
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4.3 Production of recombinant LifAC1480A protein 
 
 Pilot protein expression assays were performed in parallel to the sequencing 
analysis using the three clones that were verified for the C1480A substitution. The 
pRham-LifA-6 x His C1480A plasmids were examined for their ability to produce 
recombinant LifAC1480A (rLifAC1480A) when induced by rhamnose. Clones were 
grown under the conditions previously identified as optimal for the production of 
WT rLifA and rLifADTD/AAA (Bease, 2015; Cassady-Cain et al., 2016). Uninduced 
samples from the mutant plasmid-containing cells were used to ensure that the 
rLifAC1480A was not produced without rhamnose induction. 
 In pilot experiments, cells transformed with the mutant plasmids were 
capable of producing a protein of the expected size of full-length rLifAC1480A 
(~365 kDa) when induced by the addition of rhamnose to the culture, and the 
rLifAC1480A protein could be found in the soluble and insoluble cell lysate fractions 
by western blotting (Figure 4.4). rLifAC1480A was not present in the uninduced mutant 
plasmid-containing cells. While the size of the main reactive species in insoluble 
fractions of clones 1 and 2 appeared to be lower than that produced by clone 3, this 
was not evident upon analysis of the soluble fractions and is inferred to be a gel 
artefact (Figure 4.4). 
 The pRham-LifA-6 x His C1480A plasmid from clone 1 was transformed 
into E. cloni® 10G cells. These cells were found to express more protein than XL-10 
Gold Ultracompetent cells and have been used previously for the expression of WT 
rLifA and derived proteins (Bease, 2015; Cassady-Cain et al., 2016; see Chapter 3). 
They have also previously been shown to be the best expresser of full-length rLifA in 
comparison to other expression strains tested (Walkinshaw Laboratory, unpublished 
data). E. cloni® 10G cells were examined to determine the optimal post-induction 
time for rLifAC1480A production. It was found that 3 hours was the optimal 
post-induction time for rLifAC1480A production (data not shown), the same as for WT 










































































































































Figure 4.4. Pilot protein expression assay of LifAC1480A. Three clones that tested 
positive for the C1480A mutation by BsrDI digestion were grown at 30 °C until the 
A600 was between 0.5 and 0.6. Protein expression was induced by the addition of 
0.2 % L-rhamnose and samples were taken from each clone at 3 hours 
post-induction. The insoluble and soluble fractions of lysates from the clones were 
analysed by western blotting using polyclonal anti-LifA antiserum. Uninduced 
samples were used as negative controls. All three clones were shown to produce 
full-length LifAC1480A. 
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4.4 rLifAC1480A purification 
 
Large-scale production of rLifAC1480A was carried out using the previously 
described conditions for WT rLifA production (Cassady-Cain et al., 2016) and the 
protein was isolated to a high purity via a four-step process, which was monitored at 
each step. WT rLifA was also produced and purified in parallel so that it could be 
compared with rLifAC1480A in biophysical experiments. rLifAC1480A was eluted from 
the IMAC, SEC and anion exchange chromatography columns in a single absorbance 
peak (Figures 4.5–4.7). The multiple peaks observed between 120 and 160 mL on the 
IMAC trace are likely to have been caused by air passing over the column. 
rLifAC1480A was eluted from the SEC column at the same volume as WT rLifA, 
indicating that the two proteins are of similar size and are folded in a similar manner. 
Anion exchange chromatography was able to separate full-length rLifAC1480A from 
truncated versions of the protein. Only the fractions of highest purity after anion 
exchange were taken forward for biophysical characterisation. After purification, the 



























































Absorbance at 280nm Imidazole concentration
Figure 4.5. Ion metal affinity chromatography (IMAC) purification of rLifAC1480A using Ni2+-Sepharose®. The absorbance of elution 
buffer at 280 nm shows the presence of rLifAC1480A where the concentration of imidazole was increased from 20 to 500 mM (marked with 
an arrow) to elute the protein from the nickel-Sepharose® beads. The large absorbance peak between ~0 and 130 mL corresponds to large 
cell debris that did not bind the column. Inset: Coomassie stain of 8 µL from 1 mL IMAC filtrate fractions analysed by SDS-PAGE 
showing the rLifAC1480A eluted. The protein appeared to have a lower molecular weight than expected due to being run on a Tris-Glycine 


































































































Figure 4.6. Purification of rLifAC1480A by size exclusion chromatography (SEC). 
The absorbance peaks marked with arrows correspond to the presence of rLifAC1480A 
in the filtrates of the Superose 6pg XK16/600 SEC columns used to filter (A) the 
purest IMAC fractions and (B) the less pure IMAC fractions. rLifAC1480A was eluted 
from the columns at the same volume as WT rLifA, giving confidence that the 
mutant protein was the same size as the WT. Inset: Coomassie stains of 8 µL from 
0.5 mL SEC filtrate fractions analysed by SDS-PAGE showing the rLifAC1480A 
eluted. The protein appeared to have a lower molecular weight than expected due to 













































































































































































Absorbance at 280 nm NaCl concentration
Figure 4.7. Purification of rLifAC1480A by anion exchange chromatography. (A) The elution profile of WT rLifA. (B) The elution 
profile of rLifAC1480A. The absorbance peak marked with an arrow corresponds to the presence of rLifAC1480A in the filtrate of the Mono Q 
5/50GL column used to filter the SEC fractions. The purest and less pure fractions were pooled into separate aliquots after the anion 
exchange chromatography but only the purest aliquot was used for further experiments. Both the WT and mutant proteins were eluted with 
~140 mM NaCl. The small absorbance peak to the right of the marked peak corresponds to truncated rLifAC1480A. Inset: Coomassie stains 
of 8 µL from 0.25 mL anion exchange filtrate fractions analysed by SDS-PAGE showing the rLifAC1480A eluted. The protein appeared to 
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Figure 4.8. Coomassie stain (left) and western blot (right) of purified WT rLifA 
and rLifAC1480A analysed by SDS-PAGE. Quantities of 2 µg and 2 ng of anion 
exchange purified protein were used for the Coomassie stain and western blot 
respectively. The estimated purity of rLifAC1480A was > 90 %. 
 
4.5 Biophysical characterisation 
 
In order to determine whether the rLifAC1480A protein was folded and behaved 
in the same manner as the WT rLifA protein, a number of biophysical measurements 
were made, including analysis of dynamic light scattering (DLS), circular dichroism 
(CD) and thermal denaturation assays (TDAs). All biophysical measurements were 




4.5.1 DLS showed that rLifAC1480A was of a similar size to WT rLifA 
 
 DLS was used to determine the size and state of the rLifAC1480A protein. DLS 
works by measuring the different intensities of laser scattering caused by the 
Brownian motion of particles in suspension. This allows protein-specific software 
supplied with the Zetasizer Auto Plate Sampler to calculate the velocity of the 
Brownian motion and therefore the size of the particles by using the Stokes-Einstein 
relationship (Malvern, 2015; Folta-Stogniew and Williams, 1999). This allows an 
approximate size determination and gives some insight into whether the protein is 
aggregated or multimeric. 
 Thirteen scans of WT rLifA and rLifAC1480A were performed in triplicate. The 
size distribution of the proteins was measured by the intensity of light scattering and 
by volume (Figure 4.9). The distribution by volume provides a more accurate size of 
the protein and distribution by the intensity of light scattering was used to detect 
large aggregates, which scatter light at much higher intensity than monomeric 
protein. Both distribution graphs had tight peaks between 9 and 30 nm. The mode 
hydrodynamic radius of rLifAC1480A as measured by intensity and volume was 15.78 
and 11.94 nm respectively, compared to 17.3 and 11.63 nm for WT rLifA. DLS also 
provided approximate molecular weights for rLifA and rLifAC1480A based on their 
size, 308.7 ± 48 and 301.7 ± 15.6 kDa respectively, but these measurements are less 
accurate than measuring the molecular weight by SEC-MALS. rLifAC1480A appeared 
to have some aggregation but the peak between 100 and 1000 nm may have been 
caused by dust as subsequent DLS experiments performed with rLifAC1480A by Dr 
Liz Blackburn, EPPF, did not show any sign of aggregation (data not shown). A 
small peak was observed at ~5 nm on the rLifAC1480A distribution by volume trace, 



















































Figure 4.9. The size distribution by intensity and by volume of rLifAC1480A compared to WT rLifA, measured by dynamic light 
scattering (DLS). rLifA and rLifAC1480A at a concentration of 1.1 µM were measured by DLS to determine the size of the mutant protein 
and ensure that any loss of function was not caused by the protein forming large aggregates. (A) The distribution by the intensity of light 
scattering is used to detect aggregation. (B) The distribution by volume provided a more accurate size of the protein. Slight aggregation of 
LifAC1480A was observed but the majority of the protein was monomeric. The proteins were scanned 13 times and the measurements were 
averaged. This was repeated in triplicate. 
(A) (B) 
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4.5.2 CD showed that rLifAC1480A had a similar secondary structure to WT rLifA 
 
 CD was used to determine if the rLifAC1480A protein had folded correctly on a 
secondary structure level and to observe whether it deviated significantly from the 
profile for the WT protein. CD works by detecting the difference in absorption 
between clockwise and anti-clockwise polarised light. CD signals only arise where 
the absorption of radiation occurs and therefore spectral bands can be assigned to 
distinct structural features of a molecule. The different secondary structures of a 
protein can be detected because they give rise to characteristic CD spectra in the far 
UV (Kelly et al., 2005). NaF was used in the CD buffer instead of NaCl as chloride 
ions interfere with CD at short wavelengths. 
 The CD profile confirmed that rLifAC1480A had folded in a manner not 
significantly different from WT rLifA (Figure 4.10). The mean residue ellipticity 
peak and trough on the graph were indicative of a protein with a high α-helix content. 
The percentage of α-helices and β-sheets in rLifAC1480A were 46 ± 5 % and 13 ± 2 % 
respectively, compared with 44 ± 5 % and 16 ± 2 % in WT rLifA. The percentage of 
turns and unstructured amino acids in rLifAC1480A were 13 ± 6 % and 28 ± 7 % 
respectively, compared with 13 ± 6 % and 27 ± 3 % in WT rLifA. Overall, it can be 
concluded that rLifAC1480A was folded and had a very similar structural profile to that 



















































Figure 4.10. Far UV spectrum of rLifAC1480A compared to WT rLifA. rLifA and 
LifAC1480A at a concentration of 0.11 μM were measured by CD to compare the 
secondary structure of the proteins. The mean residue ellipticity peak and trough 
indicated that both proteins had a high α-helix content. Each protein was scanned 5 
times and the measurements were averaged. The data were analysed using 
DichroWeb (http://dichroweb.cryst.bbk.ac.uk/html/home.shtml; Lobley et al., 2002). 
The mutant protein had a similar spectrum to that of the WT protein. 
 
4.5.3 TDAs showed that rLifAC1480 had a similar mid-point melting temperature to 
WT rLifA 
 
TDAs were used to measure the thermal stability of rLifAC1480A in 
comparison to the WT protein. This was carried out by using a fluorescence-based 
assay with the fluorophore SYPRO Orange, which fluoresces weakly in hydrophilic 
conditions and strongly in hydrophobic conditions, across a range of temperatures. 
As the temperature increases and the target protein unfolds it reveals hydrophobic 
amino acid chains that cause the SYPRO Orange to increase its fluorescence. The 
fluorescence intensity is proportional to the degree of protein unfolding (Lo et al., 
2004; Pantoliano et al., 2001). 
 The mid-point melting temperatures (Tm) of WT rLifA and rLifA
C1480A were 
41.3 and 41 °C respectively (Figure 4.11). The slight decrease in Tm may have been 
 
rLifA (%) rLifAC1480A (%) 
Helix 44 ± 5 46 ± 5 
Strand 16 ± 2 13 ± 2 
Turns 13 ± 6 13 ± 6 























the result of minor structural instability caused by the C1480A substitution and was 
consistent with the reduction in Tm observed with the rLifA
DTD/AAA mutant protein 
(Bease, 2015; Cassady-Cain et al., 2016). Overall, the thermal stability of 
rLifAC1480A was largely unaffected by the substitution. 
 
 
Figure 4.11. Thermal denaturation assays to evaluate the mid-point melting 
temperature (Tm) of WT rLifA and rLifAC1480A. The fluorescence of SYPRO 
Orange dye mixed with 0.1 μM rLifA and rLifAC1480A was measured over a 
temperature range of 15–70 °C to determine the Tm of each protein. Each 
fluorescence measurement was performed in triplicate. A reproducible Tm of ~41 °C 
was observed in both proteins. These results are from a single experiment. 
 
4.6 Analysis of the ability of rLifAC1480A to inhibit mitogen-stimulated T cell 
proliferation 
 
 Peripheral blood T lymphocytes from five independent donors were used to 
test the activity of purified rLifAC1480A against ConA-stimulated T cells in 
comparison to the WT rLifA. Titration of WT LifA produced a sigmoid curve, with 
higher concentrations of LifA causing an increase in inhibition (Figure 4.12). The 
proliferation index, with standard deviation, decreased sharply from 0.91 ± 0.08 at 
0.001 ng/mL of rLifA to 0.27 ± 0.15 at 0.1 ng/mL, then the curve leveled out and 
 
Tm (°C) 
rLifA 41.3 ± 0.6 
rLifA

























decreased to a proliferation index of 0.23 ± 0.17 at 100 ng/mL. rLifAC1480A produced 
a curve that saw the proliferation index, with standard deviation, gradually decrease 
from 0.95 ± 0.05 at 0.1 ng/mL to 0.48 ± 0.14 at 10 µg/mL. It required an 
~100,000-fold increase in concentration for rLifAC1480A to have the same inhibitory 
effect as that of the WT protein, which was comparable to the glycosyltransferase 
mutant rLifADTD/AAA (Bease, 2015; Cassady-Cain et al., 2016). The ED50s, with 
standard errors, for WT rLifA and rLifAC1480A were 0.013 ± 0.004 ng/mL and 
1215.3 ± 684.1 ng/mL respectively (W = 15, P = 0.0097). This experiment combined 
with the biophysical data showed that the predicted catalytic Cys1480 of the CP 
domain was required for the inhibitory activity of LifA and that loss of activity was 
not associated with major structural abnormalities relative to the WT protein. 
 
 
Figure 4.12. Concentration titration of recombinant WT rLifA and rLifAC1480A 
against ConA-stimulated peripheral bovine T lymphocytes. An absolute number 
of 200,000 cells were seeded into the wells of a 96 well plate. Titrations were carried 
out in triplicate and the results are the average obtained from 5 independent 
experiments using separate donors. Data were normalised against cells with ConA 
alone to produce a proliferation index. Error bars indicate the standard deviation of 




4.7 Detection of putative autocatalytic cleavage of LifA 
 
4.7.1 Detection of LifA cleavage in bovine T lymphocytes 
 
 A protein species reactive to anti-LifA antibody of ~140 kDa was previously 
observed in lysates of bovine T cells treated with rLifA but not buffer or recombinant 
LifA fragments (see Section 3.9, Figure 3.18). This same protein was also observed 
in lysates of T cells treated with the glycosyltransferase mutant rLifADTD/AAA (data 
not shown). It was suspected that this c. 140 kDa species was produced by a cleavage 
event within the T cells that required the CP motif. To determine if this protein was 
produced by C1480-mediated cleavage, T cells from two independent donors were 
treated with either WT rLifA or rLifAC1480A for various durations. For cells treated 
with rLifAC1480A, the 15 minute time point was replaced with a 2 hour time point to 
determine whether putative cleavage occurred at a slower rate than for the WT 
protein. 
 The putative cleavage product was observed at ~140 kDa in T cells treated 
with WT rLifA from 15 minutes and appeared to increase in concentration up to 
1 hour (Figure 4.13). No proteins of this size were detected in lysates from T cells 
treated with rLifAC1480A, even after 2 hours. This suggests that the detected protein of 
~140 kDa was a processed form of LifA, the production of which required an intact 
CP motif. A second protein fragment of ~225 kDa, corresponding to the other half of 
LifA, was expected but never observed in T cell lysates. Attempts to identify the 
C-terminal portion of the protein using anti-6 x His antibodies and InVisionTM 















































































































































Figure 4.13. Cleavage of lymphostatin in T cells was dependent on the cysteine 
protease motif. Western blot of lysates from T cells (1.2 x 107 cells) treated with 
2 µg/mL WT rLifA or rLifAC1480A for the times indicated. A volume equivalent to 
2 x 106 cells was run in each well. A predicted c. 140 kDa cleavage product of WT 
rLifA was visible at 15 minutes post-incubation and increased in concentration up to 
1 hour after treatment (marked with an arrow), while no cleavage product was 
observed in rLifAC1480A-treated T cells even after 2 hours. This experiment was 
performed with 2 separate donors and a representative blot is shown. 
 
4.7.2 Detection of LifA cleavage in J774A.1 murine macrophage-like cells 
 
 Cell types other than primary T lymphocytes have previously been used in 
experiments to test the effects of LifA. EPEC E2348/69 lysates have been reported to 
inhibit IL-2 secretion by mitogen-stimulated Jurkat cells (Malstrom and James, 1998) 
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and WT rLifA has been shown to inhibit the IL-4-induced proliferation of bovine B 
lymphocytes (Cassady-Cain et al., 2017). EPEC lysates did not inhibit the 
proliferation of epithelial cells in a LifA-dependent manner (Klapproth et al., 2000). 
However, EPEC E2348/69 has been reported to modulate signalling in epithelial and 
J774A.1 macrophage-like cells in a manner dependent on Type III secretion but 
independent of LEE-encoded and several non-LEE-encoded effectors 
(Ruchaud-Sparagano et al., 2007; Amin, 2017), suggesting a possible role for LifA. 
Therefore, I sought to determine whether cell types other than bovine T lymphocytes 
could be used to detect processed forms of LifA. 
 Jurkat cells were used initially, and although a protein of ~140 kDa was 
observed in the lysates of rLifA-treated Jurkats, full-length rLifA was not observed 
as it is in T cells (data not shown). J774A.1 murine macrophage-like cells were used 
subsequently. Cleavage products of ~140 and 225 kDa were detected in the lysates of 
J774A.1 cells treated with WT rLifA but not rLifAC1480A for 1 hour (Figure 4.14A). 
The product of ~225 kDa was also detected with anti-6 x His antibody, indicating 
that it was the C-terminal portion of the protein (Figure 4.14B). The quantity of 
full-length WT rLifA in the lysates was reduced in comparison to rLifAC1480A, most 
likely due the protein being processed into the observed cleavage products. 
Full-length rLifAC1480A was not detected by the anti-6 x His antibody in J774A.1 
cells despite being visible on the anti-LifA blot, possibly due to there being less 































































































































Figure 4.14. Lymphostatin was processed by J774A.1 cells into N- and 
C-terminal forms of ~140 and 225 kDa respectively. Western blots of lysates from 
J774A.1 macrophage-like cells (1 x 106 cells) treated separately with rLifA or 
rLifAC1480A for 1 hour. A volume equivalent to 2.5 x 105 cells was run in each well. 
(A) An anti-LifA blot revealed the fragment of ~140 kDa previously observed in T 
cells as well as the predicted fragment of ~225 kDa (marked with arrows), the 
presence of which were dependent on an intact cysteine protease motif. The quantity 
of full-length rLifA in the cell lysate was reduced in comparison to rLifAC1480A, 
likely due to the processing of rLifA into the lower molecular weight forms. (B) The 
c. 225 kDa fragment was reactive to anti-6 x His antibody (marked by arrow), 
indicating that it was the C-terminal portion of rLifA. Quantities of 2 ng of WT 
rLifA and rLifAC1480A were used as positive controls. Western blots are from a single 
experiment.
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4.8 Impact of inhibitors of endosome acidification on predicted autocatalytic 
cleavage 
 
 Given that LifA underwent CP domain-mediated cleavage in T and J774A.1 
cells, it was thought that this process may have required endosome acidification to 
initiate a conformational change in the protein, as with LCTs (Qa’dan et al., 2000 
and 2001; Barth et al., 2001). To test this, T cells were pre-treated with two different 
inhibitors of endosomal acidification, bafilomycin A1 and chloroquine, before 
treatment with rLifA.   
 
4.8.1 Bafilomycin A1 
 
 Bafilomycin A1 is an inhibitor of V-ATPases, which acts by binding to and 
preventing the rotation of V-ATPase C subunits (Bowman et al., 1988 and 2004). 
Bafilomycin A1 concentrations were informed by previous studies and pilot western 
blots. Qa’dan et al. (2000) and Wu et al. (2015) used 0.5 and 5 nM bafilomycin A1 
respectively, however, a western blot revealed that production of the c. 140 kDa 
cleavage product was not inhibited at 5 nM. Partial and total inhibition was observed 
at 0.5 and 50 µM bafilomycin A1 respectively (data not shown), therefore 
bafilomycin A1 was titrated from 50 µM down to 0.0005 µM. 
 Western blot analysis showed that the appearance of the c. 140 kDa cleavage 
product remained constant with increasing bafilomycin A1 concentration from 
0.0005 to 0.5 µM but was reduced at concentrations of 5 and 50 µM (Figure 4.15). 
Densitometry from five independent donors showed that the fold change in 
normalised fluorescent signal of the cleavage product in comparison to the DMSO 
control, with standard deviation, decreased gradually from 1.21 ± 0.19 at 0.0005 µM 
bafilomycin A1 to 1.07 ± 0.23 at 0.05 µM, then decreased sharply to 0.19 ± 0.14 at 
50 µM (Figure 4.16). The overall loss of protein at 50 µM, indicated by the actin 
control, suggested that bafilomycin A1 became toxic to T cells at this concentration. 
The average linear regression slope was found to be statistically significantly 
different from a horizontal line representing no change in normalised fluorescent 

















































































Figure 4.15. Bafilomycin A1 inhibited lymphostatin cleavage in a 
concentration-dependent manner (western blot). An absolute number of 
1.2 x 107 cells were incubated with the indicated concentrations of bafilomycin A1 
then treated with rLifA for 1 hour. A volume equivalent to 2 x 106 cells was run in 
each well. Western blot analysis of bafilomycin A1-treated T cells showed that the 
appearance of the cleavage product (red box) was reduced with increasing inhibitor 
concentration. DMSO was used as a diluent only control. A quantity of 2 ng of rLifA 
was used as a positive control for the anti-LifA antibody. Actin was used as a loading 




Figure 4.16. Bafilomycin A1 inhibited lymphostatin cleavage in a 
concentration-dependent manner (densitometry). Densitometry was performed on 
the western blots and the cleavage product signal at each inhibitor concentration was 
normalised against its respective actin signal to account for overall loss of protein. 
Data were normalised again against the DMSO control to give a fold change in 
normalised signal compared to untreated cells. The average fold change in 
normalised signal of bafilomycin A1-treated T cells decreased as the concentration 
increased. Error bars indicate the standard deviation of the average fold changes from 




 Chloroquine is a lysosomotropic agent that can freely diffuse across 
cytoplasmic vesicles in its unprotonated form. Once inside acidic vesicles, 
chloroquine becomes protonated and is trapped, thereby raising the pH of the vesicle 
(reviewed in Al-Bari, 2015). The concentrations of chloroquine used were informed 
by a study using PK-15 (porcine kidney) cells in which 125 µM chloroquine was 
reported to be the maximum concentration that did not affect cell viability (Misinzo 





































 Western blot analysis showed that the appearance of the c. 140 kDa cleavage 
product remained constant when increasing the chloroquine concentration from 
0.0125 to 1.25 µM and was reduced at 12.5 µM. The c. 140 kDa cleavage product 
appeared to be absent in T cells treated with 125 and 1250 µM chloroquine 
(Figure 4.17). Densitometry from five independent donors showed that the fold 
change in normalised fluorescent signal of the cleavage product in comparison to the 
PBS control, with standard deviation, decreased gradually from 1.19 ± 0.19 at 
0.0125 µM chloroquine to 1.08 ± 0.24 at 12.5 µM, then decreased sharply to 
0.09 ± 0.15 at 1250 µM (Figure 4.18). The overall loss of protein at 1250 µM, 
indicated by the actin control suggested that chloroquine became toxic to T cells at 
this concentration. The average linear regression slope was found to be statistically 
significantly different from a horizontal line representing no change in normalised 
fluorescent signal as the concentration of chloroquine increases (T(4) = -13.71, 
P < 0.001). 
 Taken together with the results from experiments using bafilomycin A1, these 























































































Figure 4.17. Chloroquine inhibited lymphostatin cleavage in a 
concentration-dependent manner (western blot). An absolute number of 
1.2 x 107 cells were incubated with the indicated concentrations of chloroquine then 
treated with rLifA for 1 hour. A volume equivalent to 2 x 106 cells was run in each 
well. Western blot analysis of chloroquine-treated T cells showed that presence of 
cleavage product (red box) remained constant between 0.0125–12.5 μM but was 
reduced at higher concentrations. PBS was used a diluent only control. A quantity of 
2 ng of rLifA was used as a positive control for the anti-LifA antibody. Actin was 
used as a loading control. Data were generated from 5 independent donors and blots 
are shown from a representative donor. 
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Figure 4.18. Chloroquine inhibited lymphostatin cleavage in a 
concentration-dependent manner (densitometry). Densitometry was performed on 
the western blots and the cleavage product signal at each inhibitor concentration was 
normalised against its respective actin signal to account for overall loss of protein. 
Data were normalised again against the PBS control to give a fold change in 
normalised signal compared to untreated cells. The average fold change in 
normalised signal of chloroquine-treated T cells remained constant between 0.0125–
12.5 µM but decreased at higher concentrations. Error bars indicate the standard 
deviation of the average fold changes from across 5 experiments. 
 
4.8.3 Proliferation assays using inhibitor-treated bovine T cells 
 
 To determine whether inhibitors of endosome acidification could block 
lymphostatin activity against mitogen-stimulated T cells, cells were pre-treated with 
bafilomycin A1 or chloroquine at the concentrations described previously and used 
in proliferation assays. T cells were treated with buffer or 1 µg/mL of rLifA for an 
hour then washed with PBS to remove the inhibitors before ConA stimulation. It was 
expected that the proliferation indices of rLifA treated cells would increase as the 







































 In contrast to what was expected, the proliferation indices of rLifA-treated 
cells remained constant at all inhibitor concentrations and became highly variable at 
the highest concentrations (data not shown). To determine whether these results were 
due to toxicity, the absorbance values of buffer-treated cells with and without the 
addition of ConA were examined (Figure 4.19). Proliferation was normal from 
0.0005–0.5 µM bafilomycin A1 and 0.0125–12.5 µM chloroquine but reduced at 
higher concentrations. The concentrations at which proliferation was inhibited were 
the same concentrations at which the c. 140 kDa cleavage product was absent in the 
western blots of T cell lysates. Therefore, proliferation assays are not a suitable 





































































Figure 4.19. Concentration titration of bafilomycin A1 and chloroquine against 
ConA-stimulated peripheral bovine T lymphocytes. An absolute number of 
200,000 cells were seeded into the wells of a 96 well plate. T cells were pre-treated 
with 10-fold dilutions of (A) bafilomycin A1 (BafA) or (B) chloroquine (Chlq) 
before incubation in the presence/absence of ConA. DMSO and PBS were used as 
carrier controls for bafilomycin A1 and chloroquine respectively. Comparing the 
absorbance values of stimulated and unstimulated cells revealed that high 
concentrations of the inhibitors appeared to be toxic to the cells. Titrations were 
carried out in triplicate and the results are the average obtained from 3 independent 
experiments using separate donors. Error bars indicate the standard deviation of the 






 The putative YopT-like CP domain of lymphostatin, including a conserved 
C/H/D catalytic triad, was hypothesised to be required for autoproteolysis and 
activity of the protein. To investigate this, a C1480A substitution mutant was created, 
expressed and purified. The mutant protein was found to be structurally identical to 
WT rLifA by the methods used for biophysical characterisation but was substantially 
impaired in its ability to inhibit ConA-stimulated lymphocyte proliferation. The 
inhibition observed at high concentrations may have been due to residual activity or 
contaminants, as even lysates of E. coli K-12 with empty plasmids can inhibit the 
ConA-stimulated proliferation of PBMCs at high concentrations (Klapproth et al., 
2000; Deacon et al., 2010). Within T cells, rLifA is cleaved into N- and C-terminal 
products of ~140 and 225 kDa respectively in a processing event that requires both 
the predicted catalytic Cys1480 and endosome acidification. These observations are 
consistent with the notion that LifA enters cells and is processed in a manner akin to 
the LCTs. 
 Unfortunately, attempts to confirm whether rLifAC1480A retained its ability to 
bind UDP-GlcNAc using the previously described method of measuring changes in 
intrinsic tryptophan fluorescence (Bease, 2015; Cassady-Cain et al., 2016) were 
inconclusive. The fluorescence of intrinsic Trp residues can either decrease via 
quenching (reviewed in Price and Nairn, 2009) or increase (Weljie and Vogel, 2000), 
which is detected by a spectrophotometer. Fluorescence quenching occurs when an 
excited Trp residue loses energy by either colliding with molecules in the solvent 
(collisional quenching) or by forming long-lasting interactions with molecules (static 
quenching; reviewed in Price and Nairn, 2009). The exposure of each Trp residue to 
the quenching molecule determines how easily it is quenched (Eftink and Ghiron, 
1976). Intrinsic Trp fluorescence increases when a protein undergoes a 
conformational change that exposes Trp residues to the solvent, but is stabilised by 
the binding of another molecule, such as UDP-GlcNAc, that prevents quenching 
(Weljie and Vogel, 2000). An increase in fluorescence has previously been observed 
when UDP-GlcNAc was added to WT rLifA (Bease, 2015; Cassady-Cain et al., 
2016). The assay is technically difficult, however, since lymphostatin contains 
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36 Trp residues, which can mask the subtle change in fluorescence of a single 
residue. Due to the difficulty of detecting UDP-GlcNAc binding with WT rLifA and 
the reagent intensive nature of the assay, this experiment was ultimately abandoned. 
Given that WT rLifA and rLifAC1480A were found to be structurally identical by the 
various methods of biophysical characterisation, it was thought that the C1480A 
substitution was unlikely to affect UDP-GlcNAc binding. 
 Only the N-terminal cleavage product was observed in T cell lysates, possibly 
due to the C-terminal end being retained in the endosome and degraded or being 
centrifuged out of the lysate with the insoluble material. T cells were treated with 
WT rLifA and rLifAC1480A in parallel to the J774A.1 cells and a volume equivalent to 
4 x 106 cells was run the same gel as the J774A.1 cells. There appeared to be a 
protein species in the lysate of rLifA-treated T cells on the anti-LifA blot at 
~225 kDa but it was too faint to be conclusive (data not shown). Given that some 
transmembrane proteins, such as the growth factor receptor ErbB-1, are known to be 
degraded by the ubiquitin-proteasome pathway from the endosome, treating T cells 
with proteasome inhibitors, such as β-lactone or MG-132, may reveal more of the 
LifA C-terminus (Levkowitz et al., 1998; van Kerkhof et al., 2001). Using these two 
different inhibitors would be useful, as peptide aldehydes like MG-132 can also 
inhibit lysosomal degradation (Rock et al., 1994; Craiu et al., 1997). Double the 
quantity of rLifA was applied to eight times the number of T cells compared to 
J774A.1 cells, with a volume equivalent to 16 times more T cells then J774A.1 cells 
being loaded into the gel. Despite this, more of each cleavage product and less 
full-length rLifA was observed in the lysates of J774A.1 cells compared to T cells. 
Although densitometry would be required to make a definite conclusion regarding 
this, the blot suggests that J774A.1 cells uptake more rLifA than T cells, which could 
provide a useful model for future studies of LifA cleavage. Full-length rLifAC1480A 
was detected by anti-LifA antibodies in J774A.1 cells but not anti-6 x His antibodies, 
likely as there are more epitopes for anti-LifA binding present on rLifA proteins than 
for anti-6 x His binding. However, given that the C-terminal portion of WT rLifA 
could be detected with anti-6 x His, this suggestes that there was either less 
full-length rLifAC1480A present in the lysates compared to WT rLifA C-terminus or 
there was inconsistent staining with this antibody. Detection of proteins with 
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anti-6 x His antibody was generally poor when attempted, hence it was not used 
more extensively. 
 In parallel to the experiments investigating LifA cleavage, experiments were 
conducted to determine whether LifA might cleave host cell proteins like other 
virulence factors containing C58 protease domains (Shao et al., 2002 and 2003a; 
Brugirard-Ricaud et al., 2005). The detection of LifA protease activity was attempted 
using a commercially available Protease Fluorescent Detection Kit (Sigma-Aldrich), 
which uses a protocol modified from Twining (1984). Proteins exhibiting protease 
activity cleave the FITC-labelled casein substrate. After incubation, trichloroacetic 
acid is used to precipitate undigested casein, which is centrifuged out. The 
supernatant is neutralised and small fragments of labelled casein that are not 
precipitated can be detected by measuring the fluorescence intensity with excitation 
and emission wavelengths of 485 and 535 nm respectively (Sigma-Aldrich, 2019). A 
trypsin control was provided with the kit and papain was used as a cysteine protease 
control. Protease activity was not detected at any concentration of rLifA, however, 
the trypsin control failed to produce the expected standard curve, even after trouble 
shooting, and the assay was deemed unsuitable. Even if LifA does exhibit protease 
activity against a host protein(s), it cannot be guaranteed that it would act on the 
casein substrate. The C58 proteases YopT and AvrPphB require specific recognition 
sequences at their respective cleavage sites and such a sequence may be required for 
LifA protease activity (Shao et al., 2003a and 2003b). Although western blots 
suggest that the CP domain of LifA is required for autoproteolysis, AvrPphB uses its 
CP domain for both autocatalytic cleavage and cleavage of the host cell protein PBS1 
(Shao et al., 2002 and 2003a). This could mean a dual role for the CP domain of 
LifA but this would likely require cleavage to occur to the C-terminal end of the 
C/H/D motif rather than between the CP and glycosyltransferase domains as it does 
in LCTs (Rupnik et al., 2005; Kreimeyer et al., 2011; Guttenberg et al., 2011). The 
sizes of the cleavage products, however, suggest that cleavage of LifA occurs 
between these two domains, similar to the LCTs. 
 Autocatalytic cleavage of LCTs requires the co-factor InsP6 and occurs 
optimally between pH 7 and 8, although they have also been reported to cleave in the 
presence of DTT and β-mercaptoethanol (Reinke et al., 2007; Egerer et al., 2007; 
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Rupnik et al., 2005). Attempts to initiate the autocatalytic cleavage of rLifA in vitro, 
however, have been unsuccessful despite the range of conditions used, including 
different pHs, incubation times, and the presence or absence of InsP6 and DTT 
(Cassady-Cain et al., 2016; Walkinshaw Laboratory, unpublished data). An 
experiment was performed to determine whether the putative co-factor of LifA was 
proteinaceous. T cell lysates without protease inhibitors were either incubated at 
70 °C for 10 minutes, the same conditions used to denature protein for SDS-PAGE, 
or prepared immediately before the addition of rLifA and incubation at 37 °C for 
1 hour. However, western blots revealed a complex ladder of protein species reactive 
to the anti-LifA antibody from lysates with and without heat treatment, making the 
c. 140 kDa cleavage product impossible to detect (data not shown). This may have 
been due to active proteases that survived the heat treatment cleaving rLifA, or host 
cell proteins that contain anti-LifA antibody reactive peptides, as experiments of this 
nature using LCTs heated lysates at 96 °C for 30 minutes (Reinke et al., 2007). 
 To confirm the requirement of endosome acidification for LifA cleavage, a 
number of approaches could be used. T cells could be pre-incubated with inhibitors, 
incubated with rLifA for 1 hour then acid pulsed, which may allow the protein to 
translocate across the plasma membrane (Qa’dan et al., 2000 and 2001). An 
alternative method would be to allow rLifA to bind T cells at 4 °C, briefly incubate 
the cells with inhibitor then replace the medium with fresh medium at a lower pH 
(Barth et al., 2001). Additional experiments performed by Qa’dan et al. (2000 and 
2001) with the LCTs TcdB and TcsL could be used to obtain data relating to 
pH-induced conformational changes in LifA. Tryptophan fluorescence assays, used 
previously to detect UDP-GlcNAc binding with LifA (Bease, 2015; Cassady-Cain et 
al., 2016), can be used to detect changes in tryptophan fluorescence if differences in 
pH cause structural changes to the protein (Qa’dan et al., 2000 and 2001). rLifA 
could also be subjected to TNS (2-(p-Toluidinyl) naphthalene-6-sulphonate) 
fluorescence analysis to identify pH-induced changes in hydrophobicity. Similar to 
SYPRO Orange used in TDAs, TNS fluoresces at a greater intensity in hydrophobic 
environments, which can be measured between 380 and 500 nm (McClure and 
Edelman, 1966; Qa’dan et al., 2000). This method or TDAs could reveal structural 
changes that make rLifA more hydrophobic. The pH-induced structural changes in 
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TcdB and TcsL were also found to be reversible, as protein shifted from pH 4 to 7 
exhibited normal background fluorescence (Qa’dan et al., 2000 and 2001). 
Membrane insertion of LifA could be studied using the acid pulse method described 
above from Barth et al. (2001). Cells could be pre-loaded with 86Rb+, the release of 
which would be measured after protein treatment, indicating whether LifA forms a 
pore in the endosomal membrane like LCTs (Barth et al., 2001). Lastly, digestion of 
rLifA at different pHs with the pH stable Staphylococcus aureus V8 protease may 
reveal different digest profiles, confirming that previously unavailable digestion sites 
become exposed under acidic conditions (Qa’dan et al., 2000). 
 Attempts to determine the effects of endosome acidification inhibition on the 
biological activity of LifA were unsuccessful, as the concentrations of bafilomycin 
A1 or chloroquine required to inhibit LifA cleavage also inhibited T cell 
proliferation. An experiment using two-fold dilutions of bafilomycin A1 (0.15625–
5 µM) or chloroquine (3.90625–125 µM) was carried out to look for subtle changes 
in proliferation that may have been missed in previous experiments. The proliferation 
index of rLifA treated T cells increased as the concentration of bafilomycin A1 
increased but toxicity was observed at as low as 1.25 µM (data not shown). Toxicity 
caused by chloroquine did not become apparent until a concentration of 62.5 µM but 
the proliferation index remained constant as the concentration of chloroquine 
increased (data not shown). Although the effects of bafilomycin A1 on T cell 
proliferation have not been previously reported, the effects of chloroquine have. 
Schmidt et al. (2017) reported that 0.6 µM chloroquine reduced the proliferative 
capacity of human CD4+ T cells to ~80 % of that of untreated cells, and by 10 µM it 
was reduced to ~30 %. It was also reported that the relative viability of activated T 
cells was not affected up to a concentration of 10 µM chloroquine but decreased to 
~30 % at 100 µM (Schmidt et al., 2017). 
Taken together, the work presented in this chapter identified a key role for the 
Cys1480 residue in intracellular processing and activity of lymphostatin in the absence 
of obvious effects on the biophysical properties of the protein relative to WT rLifA. 
However, it cannot be concluded if the loss of activity reflects a requirement for 
autocatalytic cleavage to release the catalytic domain from endosomal membranes, 
allowing it to reach its cellular target (as for LCTs), or a direct role for cysteine 
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protease activity against a cellular target that results in inhibition of T cell 
proliferation.
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 Although the inhibitory effects of lymphostatin on T cells were first observed 
over two decades ago, before the protein responsible was formally identified 
(Klapproth et al., 1995), the target(s) of lymphostatin activity remains unknown. 
Given that LifA binds UDP-GlcNAc and that mutation of the DXD motif within the 
glycosyltransferase (GT) domain abolishes this binding, as well as inhibitory 
activity, it was hypothesised that LifA acts as a glycosyltransferase (Bease, 2015; 
Cassady-Cain et al., 2016). Given the N-terminal homology between LifA and large 
clostridial toxins (LCTs), Rho GTPases that regulate the cytoskeleton may seem like 
a plausible target for LifA. However, LifA does not exhibit direct cytotoxicity or 
alter the morphology of treated cells (Klapproth et al., 1995 and 2000; Stevens et al., 
2002; Bease, 2015; Cassady-Cain et al., 2016), which is associated with the 
glycosylation of Rho GTPases by LCTs (Just et al., 1994 and 1995a; Selzer et al., 
1996). There is only limited evidence to suggest that LifA targets Rho GTPases 
(Babbin et al., 2009), which could not be confirmed by subsequent studies (Deacon 
et al., 2010). These experiments only examined well studied Rho GTPases however, 
and so LifA may target lesser studied Rho GTPases that have functions aside from 
regulating cell morphology. 
 As LifA inhibits the mitogen- and antigen-stimulated proliferation of T cells 
(Cassady-Cain et al., 2016 and 2017), it is possible that it targets part of the T cell 
signalling cascade. T cell signalling begins at the T cell receptor (TCR). T 
lymphocytes can be classed as either αβ or γδ depending on the class of proteins that 
make up the TCR (reviewed in Alcover et al., 2018). αβ T cells are activated against 
antigens by the interaction of the TCR with peptide-MHC complexes and 
co-stimulation from other cells, particularly antigen-presenting cells (APCs; 
reviewed in Courtney et al., 2017; reviewed in Attanasio and Wherry, 2016). The 
TCR of γδ T cells however, either interacts with antigens directly or MHC proteins 
that do not belong to either MHC class I or II (Adams et al., 2005; reviewed in 
Vermijlen et al., 2018). The TCR forms a complex with CD3, which itself is formed 
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from γε, δε and ζζ subunits (Brenner et al., 1985; Samelson et al., 1985; Sussman et 
al., 1988), which acts as the intracellular signalling portion of the receptor. In αβ T 
cells, when the TCR interacts with a peptide-MHC complex the TCR co-receptors 
CD4 and CD8 bring the Src kinase Lck into contact with its substrates, which are the 
immunoreceptor tyrosine-based activation motifs (ITAMs) of the CD3 γ-, δ-, ε- and 
ζ-chains (Rudd et al., 1988; Veillette et al., 1988; Baniyash et al., 1988; Barber et 
al., 1989). The Src kinase Fyn also phosphorylates CD3 ITAMs but to a lesser extent 
than Lck (Denny et al., 2000). The phosphorylation of CD3 ITAMs results in the 
recruitment and Lck-dependent phosphorylation of ZAP70 (Iwashima et al., 1994; 
Neumeister et al., 1995; Chan et al., 1995). This in turn triggers a complex series of 
phosphorylation/dephosphorylation events in the linker for activation of T cells 
(LAT) signalosome that results in the remodelling of the cell cytoskeleton, signal 
transduction to the nucleus and binding to APCs (Figure 5.1; reviewed in Huse, 




Figure 5.1. The early TCR signalling pathway. The interaction of the TCR with 
peptide-MHC complexes results in the recruitment and activation of various proteins 
that are responsible for cytoskeleton remodelling, APC binding and co-stimulation 
and changes in gene expression (from Brownlie and Zamoyska, 2013). 
 
 Remodelling of the actin cytoskeleton occurs when the TCR is activated by 
an APC and results in areas of the T cell plasma membrane spreading across the 
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surface of the APC (reviewed in Kumari et al., 2014). Wiskott-Aldrich syndrome 
protein (WASP) is recruited to the LAT signalosome by Nck, where it is activated by 
the Rho GTPase Cdc42, which itself is activated first by Vav1 (Zeng et al., 2003). 
Vav1 also activates a second Rho GTPase, Rac1, which in turn activates WASP 
family veprolin homologous protein (Wave2; Crespo et al., 1996 and 1997; Nolz et 
al., 2006). WASP and Wave2 then recruit the actin-related protein 2/3 complex, 
which triggers actin polymerisation (reviewed in Kumari et al., 2014). 
 While cytoskeletal remodelling provides a large surface area for T cell-APC 
interaction, the upregulation of integrins, particularly lymphocyte function-associated 
antigen 1, results in the adhesion of the two cells (Bachmann et al., 1997). This 
allows for the co-stimulation of the T cell, which is necessary for effective 
stimulation. Typically, the T cell co-stimulatory receptor CD28 binds with the 
ligands CD80 or CD86 on APCs, which promotes proliferation, cell survival and 
cytokine production (reviewed in Esensten et al., 2016). 
 Gene expression after TCR activation is influenced by the protein PLCγ1, 
which controls the calcium ion, NF-κB and MAPK signalling pathways (reviewed in 
Cantrell, 2015). These three pathways respectively result in the transcription factors 
NF-AT, NF-κB and AP-1 upregulating the expression of IL-2, which is responsible 
for proliferation as well as the differentiation of naïve T cells into memory or 
effector T cells (reviewed in Cantrell, 2015; reviewed in Ross and Cantrell, 2018). 
The TCR is also capable of activating the mammalian target of rapamycin (mTOR) 
pathway through phosphoinositide 3-kinase (PI3K), which promotes cell survival 
and proliferation (Gorentla et al., 2011; Sinclair et al., 2008). 
 Recent studies provide some insight into the action of LifA on the T cell 
activation pathway. rLifA inhibits the proliferation of T cells that have been 
stimulated by the mitogen ConA (Cassady-Cain et al., 2016 and 2017), which 
activates T cells by interacting with the T3/antigen receptor complex, initiating the 
calcium ion signalling pathway (Kanellopoulos et al, 1985; Weiss et al, 1987; 
reviewed in Weiss et al, 1986). However, rLifA does not block the stimulation of T 
cells by phorbol myristate acetate (PMA) and ionomycin (Cassady-Cain et al., 2017). 
PMA activates protein kinase C (PKC) and ionomycin is a Ca2+ ionophore that 
activates both PKC and calmodulin (CaM; Castagna et al., 1982; Chatila et al., 
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1989). This suggests that the target of LifA may lie downstream of the TCR but 
upstream of PKC and CaM (Figure 5.2). Cassady-Cain et al. (2017) also found that 
rLifA inhibited the IL-2 stimulated proliferation of T cells. IL-2 signalling has some 
downstream effects in common with TCR signalling, such as the activation of mTOR 
and the activation of Ras through the phosphorylation of SHC1, which associates 
with growth factor receptor-bound protein 2 (Grb2; reviewed in Ross and Cantrell, 
2018). rLifA also inhibits the IL-4-stimulated proliferation of B cells but to a lesser 
degree than T cells (Cassady-Cain et al., 2017). It does not, however, inhibit the 
IL-12/IL-18-stimulated production of IFN-γ by NK cells, suggesting that the target(s) 
of LifA may be expressed in different quantities in different cell types, and/or that 
uptake and processing of LifA may vary between cell types in a way that dictates 
how much of the protein reaches the cellular target(s). The target(s) of LifA may also 
only be important in certain cell types. Additionally, LifA may not affect NK cells if 
its target(s) is not involved in IL-12/IL-18 signalling. 
 In this chapter, I sought to identify potential targets of glycosylation in 
rLifA-treated T cells. Since there were no suspected targets of LifA, a broad 
approach was employed to identify unique glycosylation events using western 
blotting and shotgun mass spectrometry. In addition, protein pull-downs were used to 
identify potential interacting partners and targets of LifA, including receptors and 




Figure 5.2. Overview of T cell signalling. ConA stimulates the T cell receptor 
(TCR) while PMA activates protein kinase C (PKC), which normally requires 
calcium for activation. The Ca2+ ionophore ionomycin activates PKC and calmodulin 
(CaM). It may be hypothesised that LifA acts by glycosylating a protein in the 
signalling pathway somewhere between the TCR and PKC and CaM, allowing to it 
to inhibit proliferation stimulated by ConA but not PMA and ionomycin (from Cell 
Signaling Technology®, 2014). 
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5.2 The bovine T lymphocyte O-GlcNAc profile 
 
5.2.1 Western blotting 
 
 Initially, to identify possible targets of glycosylation and observe changes in 
the O-GlcNAcome, western blots were performed using the lysates of either T cells 
alone, rLifA-treated T cells, or T cells treated with the GT mutant rLifADTD/AAA. T 
cells were treated with protein at a final concentration of 2 μg/mL, as this 
concentration of rLifA achieves inhibition of ConA-stimulated proliferation at 
saturation. Lysates were run on three different gel systems to provide the best 
resolution at different molecular weights, with ranges of 10–150 kDa, 25–250 kDa 
and 71–460 kDa. Blots were probed with an anti-O-GlcNAc antibody, which detects 
O-linked GlcNAc. As there are currently no antibodies available that can detect 
N-linked GlcNAc, an examination of this modification by western blotting was not 
possible. No obvious changes were detected in the O-GlcNAc profile of 
rLifA-treated T cells in comparison to untreated or rLifADTD/AAA-treated T cells 
(Figure 5.3). Additionally, no O-GlcNAcylated proteins were detected below 
50 kDa, even when the brightness and contrast of the image were increased. 
 Since no changes were detected in the O-GlcNAc profile of rLifA-treated T 
cells, untreated and rLifA-treated T cell lysates were subjected to glycoprotein 
enrichment using a commercially available kit. Wheat germ agglutinin (WGA) beads 
were used to isolate glycoproteins from the lysates with the intention of enhancing 
the detection of O-GlcNAcylated proteins and removing proteins that might bind to 
the anti-O-GlcNAc antibody non-specifically. It was also predicted that the 
glycoprotein enrichment would aid the identification of GlcNAcylated peptides by 
shotgun mass spectrometry (see Section 5.2.2). Despite a modest enrichment of some 
proteins in enriched lysates there was still no detectable change in the O-GlcNAc 
profile of rLifA-treated cells in comparison to untreated cells (Figure 5.4). Again, no 























Figure 5.3. The O-GlcNAc profile of bovine T lymphocytes in the presence or 
absence of rLifA. T cells were treated with buffer, rLifA or rLifADTD/AAA at a final 
concentration of 2 μg/mL and the lysates were probed with an anti-O-GlcNAc 
antibody to identify changes in the O-GlcNAc profile. Lysates were run on three 
different gel systems to provide the best resolution at different molecular masses. No 
obvious changes in the O-GlcNAc profile were detected in cells treated with rLifA 
compared to cells alone or treatment with rLifADTD/AAA, and no O-GlcNAcylated 














































































































































Figure 5.4. The O-GlcNAc profile of enriched T cell lysates in the presence or 
absence of rLifA. T cells were treated with buffer or rLifA at a final concentration 
of 2 μg/mL. Lysates were enriched for O-GlcNAcylated proteins using wheat germ 
agglutinin beads. Equal quantities of total protein from pre- and post-enriched lysates 
were run on two different gel systems to look for changes in the O-GlcNAc profile at 
different molecular mass ranges. While some glycoproteins were modestly enriched, 
there was an overall loss of protein diversity during the enrichment process. Again, 
there were no obvious differences in the O-GlcNAc profiles of cells treated with 












































































































































































5.2.2 Shotgun mass spectrometry 
 
 Published research to identify the target of LCT activity used electrospray 
mass spectrometry to determine both the sugar substrate and the particular amino 
acid that is glycosylated on RhoA (Just et al., 1995b and 1995c; Selzer et al., 1996). 
However, at the time of these experiments, RhoA was suspected of being a target 
since the toxins TcdA and B were known to cause actin depolymerisation similar to 
that observed in cells treated with C. botulinum C3 toxin, which ADP-ribosylates 
Rho GTPases (Quilliam et al., 1989). Additionally, treatment of cells with TcdA and 
B inhibited the ADP-ribosylation of RhoA by C3 toxin (Just et al., 1994 and 1995a). 
Unlike these experiments, there is currently no putative target protein of 
lymphostatin activity, as LifA treatment does not cause morphological changes and 
is not known to interfere with other effectors. Therefore, I used shotgun mass 
spectrometry to examine lysates of T cells treated, or not, with rLifA to detect 
peptides modified with GlcNAc, allowing for different types of linkage and multiple 
GlcNAc moieties. 
 Three independent sets of samples were sent to the Kinetic Parameter Facility 
(KPF) at the University of Edinburgh for analysis by Lisa Imrie: pellets of 
1.2 x 107 T cells treated with buffer, rLifA or rLifADTD/AAA at a final concentration of 
2 μg/mL for 1 hour; pellets of 3.6 x 107 T cells treated with buffer or rLifA at a final 
concentration of 2 μg/mL for 1 hour; and T cell lysates subjected to glycoprotein 
enrichment from Section 5.2.1 (Tables 5.1–5.3). Peptides were searched for 
modifications with one or two GlcNAc molecules on either N-linkages, which occur 
on Asn residues, or O-linkages, which occur on Ser and Thr residues. The overall 
number of unique proteins and peptides detected in the two sets of cell pellets was 
between 399–744 and 1565–3259 respectively, but the number of unique 
GlcNAcylated peptides detected was much lower than expected. Shotgun mass 
spectrometry was expected to detect > 700 proteins from eukaryotic cell pellets of 
the sizes used (Lisa Imrie, personal communications). Only one unique N-linked 
modified peptide was detected that possessed the consensus sequence of 
Asn-Xaa-Ser/Thr/Cys, where Xaa is any amino acid other than proline, which is 
required for N-linked glycosylation (Pless and Lennarz, 1977; Bause and Legler, 
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1981). This peptide was detected in T cells treated with rLifADTD/AAA, however, 
meaning that it could not have been modified in a GT domain-dependent manner. 
From the two sets of cell pellets a total of four peptides were detected with O-linked 
GlcNAc on Ser residues and two peptides had O-linked GlcNAc on Thr residues. No 
GlcNAc modified peptides were detected in the glycoprotein enriched samples, 
which also had lower numbers of unique proteins and peptides detected. A quality 
control sample of Ostreococcus tauri proteins was run on the spectrometer before 
each experimental sample, which tracked the retention times, intensities of the base 
peaks and number of proteins identified. All quality control samples performed as 
expected (Lisa Imrie, personal communications). Detailed information on the 
proteins/peptides identified can be found in Appendix 5. 
 
Table 5.1. Proteins and peptides detected in pellets of 1.2 x 107 T cells by 
shotgun mass spectrometry. Data were collected and analysed by Lisa Imrie, KPF. 
 
Sample 
No. of unique 
proteins 
Total No. of 
peptides 
No. of unique 
peptides 
No. of unique glycosylated 
peptides 
Cells alone 686 119839 2965 
4 N-linked modified peptides 




598 143953 2649 
7 N-linked modified peptides 
(none have correct linkage 
site), 2 O-linked (S) peptides, 
1 O-linked (S & T) peptide 
Cells + 
rLifADTD/AAA 
697 161510 3012 
8 N-linked modified peptides 
(none have correct linkage 
site), 1 O-linked (S) peptide, 1 
N-linked & O-linked (T) 
peptide 
 183 
Table 5.2. Proteins and peptides detected in pellets of 3.6 x 108 T cells by 
shotgun mass spectrometry. Data were collected and analysed by Lisa Imrie, KPF. 
 
Sample 
No. of unique 
proteins 
Total No. of 
peptides 
No. of unique 
peptides 




744 45067 3259 
2 N-linked modified peptides 
(none have correct linkage site), 1 
O-linked (S) peptide 
Cells + 
rLifA 
399 18315 1565 0 
 
Table 5.3. Proteins and peptides detected in glycoprotein enriched T cell lysates 




No. of unique 
proteins 
Total No. of 
peptides 
No. of unique 
peptides 




85 21366 322 0 
Cells + 
rLifA 
80 4087 303 0 
 
 Only three GlcNAcylated peptides were detected that were unique to T cells 
treated with WT rLifA but these were not repeatedly detected in independent 
replicates. Eukaryotic initiation factor 4A-III (EIF4A3) and histone H2B were found 
to have O-GlcNAc modifications on Ser368 and Ser20 respectively. EIF4A3 is an 
RNA helicase that is involved in RNA splicing (Chan et al., 2004) but no evidence 
could be found in the literature that it can be regulated by O-GlcNAcylation. Histone 
H2B is known to be O-GlcNAcylated in a manner that regulates transcription, but 
this occurs on Ser112 (Fujiki et al., 2011). Although both of these proteins have the 
potential to affect T cell proliferation, they act at a transcriptional level and would 
therefore likely be affected by PMA/ionomycin stimulation, which is not inhibited by 
rLifA (Cassady-Cain et al., 2017). 
 The third GlcNAc modified peptide was derived from glyceraldehyde 
3-phosphate dehydrogenase (GAPDH). In pellets of 1.2 x 107 cells treated with WT 
rLifA, there is an O-linked GlcNAc on one of three possible Thr residues (Thr141, 
Thr151 or Thr152) and another on either Ser146 or Ser149. However, this peptide was not 
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consistently detected in pellets of 3.6 x 108 cells treated with rLifA. This peptide 
sequence was detected in rLifADTD/AAA-treated T cells but with different 
modifications. Again, there was an O-linked GlcNAc on one of three Thr residues, 
but there was also an N-linked modification on either Asn139 or Asn 147, rather than a 
Ser modification. GAPDH exists in a tetrameric form in the cytoplasm and has been 
shown to regulate calcium flux in kidney cells by interacting with IP3R and 
delivering NADH, which stimulates IP3R-mediated intracellular Ca
2+ release 
(Patterson et al., 2005). O-GlcNAcylation of GAPDH disrupts its tetrameric form, 
allowing it to be translocated to the nucleus, however, this modification is known to 
occur on Thr227 (Park et al., 2009). It is possible that LifA may GlcNAcylate 
GAPDH at a unique site however. It is also not clear whether GAPDH plays a major 
role in calcium flux caused by T cell activation. GAPDH is an attractive candidate 
for lymphostatin activity given its potential role in calcium flux and that it is targeted 
by the glycosyltransferase NleB as an innate immune evasion strategy (Gao et al., 
2013; El Qaidi et al., 2017). Inhibiting GAPDH expression in macrophages has been 
shown to reduce IFN-γ production (Yamaguchi et al., 2016) but in T cells, GAPDH 
binds to and inhibits the translation of IFN-γ transcripts unless it is recruited for 
glycolysis (Chang et al., 2013). Calcium flux is also important for NK cell signalling 
(Bryceson et al., 2006) yet expression of IFN-γ by these cells did not appear to be 
affected by LifA treatment (Cassady-Cain et al., 2017). It is therefore unclear as to 
whether GAPDH is targeted by LifA. 
 Given the small number of GlcNAcylated peptides detected using shotgun 
mass spectrometry, it was decided that this method (or the equipment available) may 
not be sufficiently sensitive to identify potential targets of LifA activity and that 








5.3 Protein pull-downs 
 
5.3.1 Identifying candidate LifA interacting partners by silver staining and liquid 
chromatography mass spectrometry (LC-MS) 
 
 To detect proteins that interact with LifA, lysates of T cells were passed 
through a column on which His-tagged rLifA was immobilised on Co2+-agarose 
beads (Thermo Fisher Scientific Inc., 2013a; reviewed in Puckett, 2015). Control 
columns on which rLifA alone was immobilised, or where T cell lysate was passed 
with no rLifA loaded on the column, were respectively used to distinguish putative 
interacting proteins from degraded forms of rLifA and proteins that bind 
non-specifically to the beads. Eluted proteins were analysed on three different gel 
systems to provide the best resolution at different molecular weights, with ranges of 
10–250 kDa, 25–250 kDa and 55–460 kDa. Silver staining revealed potential 
interacting partners of rLifA at ~70, 100 and 180 kDa (Figures 5.5 and 5.6). The 
c. 180 kDa protein was consistently observed using T cells from three independent 
donors while the other proteins were not. In Figures 5.5 and 5.6, the c. 180 kDa 
appeared at the same size as a protein species in the rLifA alone control but appeared 
slightly below this species on other silver-stained gels. The presence of the 
c. 180 kDa protein appeared to remain consistent at each elution step, whereas very 
little of the rLifA species was eluted after the first elution step. No putative 
interacting partners of rLifA were detected below 50 kDa (Figure 5.7). 
 The c. 180 kDa protein and the corresponding area from the T cells alone 
control were excised and analysed by LC-MS by Dr Dominic Kurian, Proteomics 
and Metabolomics Facility, The Roslin Institute. Most of the peptides identified were 
from various forms of keratin, which is a common contaminant, or other proteins that 
are not involved in T cell signalling. Peptides from lymphostatin were detected when 
the c. 180 kDa protein was searched against the whole NCBI database and the EPEC 
E2348/69 LifA sequence, indicating that some of the protein at this position in the 
gel is derived from rLifA. Two proteins detected by searching the Uniprot B. taurus 
database were unique to the c. 180 kDa gel band from the rLifA pull-down but not 
the T cell only control. These were found to be involved directly in lymphocyte 
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signalling, however, only a single peptide was detected for each protein and both 
proteins are smaller than 180 kDa. One was derived from Calpain 7, an ~93 kDa 
protein that is activated by calcium and has been reported to be required for T cell 
proliferation, the expression of proinflammatory cytokines and lymphocyte 
function-associated antigen-1-mediated adhesion (Smith et al., 2011; Stewart et al., 
1998). However, further examination of the peptide ion fragmentation pattern gave 
little confidence that this peptide was genuine. 
 The second protein located at c. 180 kDa in the rLifA pull-down but not the T 
cell only control was inositol polyphosphate-5-phosphatase E (INPP5E), also known 
as pharbin, which is predicted to be ~72 kDa. INPP5E regulates protein kinase B 
(Akt) phosphorylation by hydrolysing phosphatidylinositol (3,4,5)-triphosphate 
(PIP3), PI(3,5)P2 and PI(4,5)P2, which is converted into PIP3 by PI3K (reviewed in 
Eramo and Mitchell, 2016). PIP3 is required for the Ser
473 phosphorylation of Akt1 
by mTORC2 (Sarbassov et al., 2005; Gan et al., 2011), and given that Akt1 Ser473 
phosphorylation was found to be reduced in rLifA-treated T cells in independent 
studies (Stevens Laboratory, unpublished data; see Chapter 6), this made INPP5E an 
attractive candidate for future work. INPP5E has been reported to be phosphorylated 
by aurora kinase A, which increased its phosphatase activity (Plotnikova et al., 
2015). It can also be O-GlcNAcylated by O-GlcNAc transferase but the effect of this 
on its activity is not known (Tian and Qin, 2019). Analysis of the peptide ion 
fragmentation also gave confidence that the peptide detected by LC-MS was 
genuine, despite the difference in molecular weight. Therefore, further experiments 
with INPP5E were carried out as described in Section 5.3.3. Detailed information on 





















Figure 5.5. Pull-down assays using rLifA immobilised on columns to capture T 
cell proteins (55–460 kDa). rLifA or buffer was captured on cobalt resin beads and 
T cell lysate was then mixed with the resin. Proteins were eluted from the resin three 
times and silver staining was used to detect protein species that were unique to rLifA 
with T cell lysate or found in greater quantities than in lysate alone. rLifA was 
captured and mixed with lysis buffer to determine which protein species were 
products of rLifA. Two unique protein species were detected at ~100 and 180 kDa 
(marked with arrows). Although the c. 180 kDa protein appears at roughly the same 
position as a protein from the rLifA alone control, this protein was seen consistently 
in multiple replicates below the rLifA alone band. A quantity of 2 ng of rLifA was 
used to show the position of full-length rLifA. This experiment was performed with 














































































































Figure 5.6. Pull-down assays using rLifA immobilised on columns to capture T 
cell proteins (25–250 kDa). The c. 180 kDa protein species detected on the previous 
gel was also observed on this gel type. The c. 100 kDa protein could not be seen 
using this gel system but another protein species was detected at ~70 kDa. Unique 
protein species are marked with arrows. A quantity of 2 ng of rLifA was used to 
show the position of full-length rLifA. This experiment was performed with 3 













































































































Figure 5.7. Pull-down assays using rLifA immobilised on columns to capture T 
cell proteins (10–250 kDa). Using a gel to achieve resolution at the lowest 
molecular weights did not reveal any unique protein species below 25 kDa (the limit 
of the gel system used in Figure 5.6). Even the proteins of higher molecular weights 
observed using other gel types could not be seen. This experiment was performed 
with 3 independent donors and a representative gel is shown. 
 
5.3.2 Shotgun mass spectrometry of pull-down eluates 
 
 Whole eluates from the same donor used in the experiments shown in Figures 
5.5–5.7 were used for shotgun mass spectrometry, performed by Lisa Imrie, KPF. 
Eluates from the first elution step were used as these contained the most protein. 






















































































observed when searching for GlcNAc modified peptides (Tables 5.4 and 5.5). The 
same quality controls were applied to these analyses as described in Section 5.2.2. 
Detailed information on the proteins/peptides identified can be found in Appendix 5. 
 
Table 5.4. Proteins and peptides detected in protein pull-down eluates by 
shotgun mass spectrometry. Data were collected and analysed by Lisa Imrie, KPF. 
 
Sample No. of unique proteins Total No. of peptides No. of unique peptides 
Cells alone 12 43 12 
rLifA + 
cells 
8 24 8 
 191 
Table 5.5. Identities of proteins and peptide sequences detected in protein 
pull-down eluates by shotgun mass spectrometry. Green cells highlight proteins 
unique to the ‘rLifA + cells’ sample. Most proteins were detected in both samples but 
some were identified by different peptide sequences. Data were collected and 
analysed by Lisa Imrie, KPF. 
 
Sample Protein name Peptide sequence 
Cells alone 
Actin, alpha cardiac muscle 1 AGFAGDDAPR 
Antithrombin-III RVWELSK 
Apolipoprotein A-I VQPYLDEFQKK 
Cationic trypsin SSGTSYPDVLK 
Complement C3 LPYSVVR 
Epidermal growth factor receptor (Fragment) IPLENLQIIR 
Fibronectin STTPDITGYR 
Gelsolin AALKTASDFISK 
Inter-alpha-trypsin inhibitor heavy chain H3 GHVSFKPSLDQQR 
ITIH2 protein TILDDLR 
Lumican ILGPLSYSK 
Serum albumin LGEYGFQNALIVR 
rLifA + cells 
Antithrombin-III EVALNTIIFMGR 
Cationic trypsin SSGTSYPDVLK 
Complement C3 LPYSVVR 
Fibronectin STTPDITGYR 
Gelsolin AGKEPGLQIWR 
Glutathione peroxidase FLVGPDGIPVMR 
ITIH2 protein FYNQVSTPLLR 
Serotransferrin DLLFRDDTK 
 
 Despite the low number of proteins/peptides detected, two proteins were 
unique to the sample where T cell lysate was mixed with rLifA bound to 
Co2+-agarose beads. The first was serotransferrin, which is an ~77 kDa protein that is 
N-glycosylated. It transports Fe3+ ions, which are required for cell replication, but it 
is unlikely to interact with LifA in T cells as it is a blood plasma glycoprotein 
(reviewed in Clerc et al., 2016). The second is glutathione peroxidase (GPx), which 
is ~24 kDa and is known to protect cells from reactive oxygen species 
(ROS)-induced oxidative stress as well as regulate various signalling pathways 
(reviewed in Brigelius-Flohé and Maiorino, 2013). ROS promote T cell proliferation 
and GPx deficient CD4+ T cells exhibit increased proliferation and are driven 
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towards a Th1 response (Won et al., 2010). Human GPx activity can be regulated by 
phosphorylation of Tyr96 by the non-receptor tyrosine kinases ABL1 and 2 (Cao et 
al., 2003), but this residue is not present in the bovine homologue. GPx can also be 
O-GlcNAcylated within the C-terminal 100 amino acids, which increases binding 
with ABL1 and 2 and therefore phosphorylation (Yang et al., 2010). If LifA 
O-GlcNAcylates GPx at this known site, thereby increasing its activity and lowering 
proliferation, this would coincide with the observations made in Chapter 6, where 
rLifA inhibited Akt1 Ser473 phosphorylation. This is because overexpression of GPx 
has been reported to suppress Akt1 Ser473 phosphorylation (McClung et al., 2004; 
Handy et al., 2009). In contrast, however, Akt1 Ser473 phosphorylation has also been 
reported to be downregulated in GPx deficient cells (Taylor et al., 2004; Taylor et 
al., 2005). 
 Since GPx was the only plausible candidate identified by shotgun mass 
spectrometry, further experiments were carried out with this protein as described in 
Section 5.3.3. 
 
5.3.3 INPP5E and GPx do not appear to specifically interact with rLifA 
 
 Given that it was uncertain whether rLifA targeted or interacted with INPP5E 
or GPx, western blotting using polyclonal antibodies against these proteins was used 
to determine whether they were specifically pulled down from T cell lysates by 
rLifA. Eluates from the first elution step were used as these contained the most 
protein. However, reactivity at the expected positions was not obvious (Figure 5.8A), 
except for INPP5E when the brightness was increased (Figure 5.8B). This suggested 
that INPP5E was present in both the eluate from the column with rLifA plus T cell 
lysate, as well as the column with T cell lysate alone. 
 Whole T cell lysates were originally used as positive controls for the 
antibodies but INPP5E and GPx could not be detected (data not shown). To resolve 
this, immunoprecipitation (IP) was used to isolate both proteins from T cell lysates 
and concentrate them prior to western blot analysis. IP was performed on T cells 
treated with buffer or rLifA to determine whether rLifA caused any changes in 
protein expression. At the expected positions in the gel for INPP5E, similar reactivity 
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was observed for the IP sample of rLifA-treated T cells relative to the IP sample of T 
cells alone (red box in Figure 5.8A), however, reactivity to GPx was neither clear nor 
specific. The bulk of reactivity observed was due to detection of the antibodies used 
for immunoprecipitation. A protein species was detected at ~180 kDa with the 
anti-INPP5E antibody, however, this was also detected in the IP controls, making it 
unclear as to whether a peptide from INPP5E was at that position. No proteins were 
detected below 20 kDa. Given that full-length INPP5E was detected in both 
pull-down eluates, that GPx was not convincingly detected in either, and that the 
presence of the INPP5E peptide at ~180 kDa could not be confirmed, it was decided 


















Figure 5.8. Detection of inositol polyphosphate 5 phosphatase E (INPP5E) and 
glutathione peroxidase (GPx) in eluates from columns loaded with rLifA (or 
diluent) and used to capture T cell proteins. (A) Protein pull-down eluates were 
probed for INPP5E (43–250 kDa) and GPx (20–43 kDa). Immunoprecipitation (IP) 
was performed on the lysates of T cells treated with buffer/rLifA to provide positive 
controls for INPP5E (~72 kDa; marked with box) and GPx (~24 kDa; no clear band). 
IP was performed using polyclonal anti-INPP5E and anti-GPx1 antiodies. INPP5E 
and GPx could not be detected at the expected sizes initially, although a band was 
observed at ~180 kDa on the anti-INPP5E blot, around the same size as the protein 
species used for mass spectrometry that identified a peptide belonging to INPP5E. 
Anti-INPP5E and anti-GPx antibodies bound to protein A beads were used to show 
the position of the antibody heavy chains at ~50 kDa. Arrows indicate the expected 
sizes of INPP5E and GPx. Asterisk indicates the antibody heavy chain. (B) 
Increasing the brightness of the western blot revealed protein species at the expected 
size for INPP5E in both pull-down eluates, suggesting it is not unique to rLifA with 





















































































































































 Despite previous studies providing an insight into where LifA is likely to act 
in the T cell signalling cascade, a target of LifA glycosyltransferase activity has yet 
to be identified. Various methods were employed to detect putative targets of 
GlcNAc modification and other proteins that LifA may interact with. However, 
inconsistent results meant that the few proteins identified could not be confirmed as 
genuine targets/interacting partners. 
 Anti-O-GlcNAc western blotting detected far fewer O-GlcNAc modified 
proteins than anticipated, as mammalian cells have been reported to contain over 
1000 O-GlcNAcylated proteins (Trinidad et al., 2012; Qin et al., 2017). However, 
western blots performed on murine T cells with the same antibody used in this study 
(Swamy et al., 2016) detected a number of proteins comparable to that in Section 
5.2.1. This suggests that many of the predicted O-GlcNAcylated proteins in 
mammalian cell lysates may be present at concentrations below the limit of detection 
for this antibody or are only transiently modified. Additionally, anti-O-GlcNAc 
antibodies recognise specific peptide sequences with O-GlcNAc modifications, not 
solely the O-linked sugar moiety, meaning that other proteins may have been 
identified if several different antibodies had been used (reviewed in Ma and Hart, 
2014). Swamy et al. (2016) reported that O-GlcNAcylated proteins were upregulated 
after CD3/CD28 activation for 24 hours. However, in experiments using 
ConA-stimulated T cells, no changes to the O-GlcNAc profile were detected and the 
overall protein concentration was reduced by 1 hour post-incubation and completely 
absent by 24 hours post-incubation (data not shown). This may have been caused by 
incubating the cells in serum-free medium for the entire duration of the experiment. 
Detecting GlcNAc modified peptides by western blotting is limited by the lack of 
antibodies against N-linked GlcNAc. The anti-O-GlcNAc IgM clone CTD110.6, 
however, has been reported to cross-react with N-GlcNAc (Isono, 2011), which 
could be used to identify previously undetected modifications. N-GlcNAc 
modifications could then be distinguished from O-GlcNAc by treating T cell lysates 
with PNGase F, which cleaves between N-GlcNAc and the adjoined Asn residue 
(Plummer Jr et al., 1984). 
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 Like the western blot approach, shotgun mass spectrometry identified far 
fewer GlcNAcylated proteins than expected. Given that mass spectrometry 
approaches have previously identified over 1000 O-GlcNAcylated proteins (Trinidad 
et al., 2012; Qin et al., 2017), it is possible that the mass spectrometer used in this 
study may not have been sensitive enough to detect all of the modified peptides. A 
study using human primary T cells identified 214 O-GlcNAcylated proteins, which is 
still far more than detected in this study (Lund et al., 2016). The digestion of the 
samples with trypsin may also be responsible for the lack of detected GlcNAcylated 
peptides. Some O-GlcNAcylation sites are located in sequences with clustered 
Ser/Thr residues and few Arg and Lys residues, which trypsin cleaves between, 
resulting in long peptides that are not easily detected. Proteolysis using chemicals, 
such as cyanogen bromide, or digestion with other enzymes such as Asp-N or Glu-C 
may improve the detection of such sequences (reviewed in Ma and Hart, 2014). A 
method that may improve the detection of O-GlcNAcylated peptides would be to 
subject T cell lysates to β-elimination followed by Michael addition of dithiothreitol 
(DTT). This method enzymatically removes O-GlcNAc moieties and replaces them 
with DTT. The bond between DTT and Ser/Thr residues is more stable than the 
glycosidic bond and does not break during peptide fragmentation, allowing for 
detection of the modified peptide (Nika et al., 2013; Lund et al., 2016). This 
technique would be particularly useful as the form of shotgun mass spectrometry 
used at the KPF (electrospray ionisation-collision induced dissociation (higher 
energy collisional dissociation)-quadropole time-of-flight tandem mass 
spectrometry) is known to break glycosydic bonds during peptide fragmentation 
(reviewed in Ma and Hart, 2014). The use of this form of mass spectrometry may 
explain the low the number of O-GlcNAcylated peptides detected. Other 
GlcNAcylated residues may be missed since all proteins in the sample do not exhibit 
100 % peptide coverage. Top-down proteomics is an approach that could be taken to 
overcome this. Top-down proteomics allows for the analysis of whole proteins by 
mass spectrometry, provides 100 % coverage and does not cause the loss of 
post-translational modifications (reviewed in Cui et al., 2011; reviewed in 
Catherman et al., 2014). However, top-down proteomics does have some limitations, 
such as the inability to detect insoluble proteins, a lack of robust methods for protein 
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separation and difficulty analysing proteins > 70 kDa (reviewed in Gregorich and Ge, 
2014). 
 Isolating GlcNAc modified proteins using WGA enrichment did not allow for 
the detection of a greater number of GlcNAcylated proteins using shotgun mass 
spectrometry. This may be due to the method of enrichment. WGA preferentially 
binds GlcNAc but also has affinity for sialic acid, which is commonly found at 
terminal positions of glycans (Thermo Fisher Scientific Inc., 2013b; reviewed in 
Varki et al., 2017). Therefore, GlcNAc modified proteins may have been 
competitively inhibited from binding to the WGA beads due a large number of 
glycoproteins with terminal sialic acid moieties. This could be rectified by using 
succinylated WGA, which is an acidic form of WGA that binds normally to GlcNAc 
but not sialic acid (Monsigny et al., 1980). Greater enrichment of GlcNAcylated 
proteins may also be achieved by using combined antibody/lectin enrichment. Lee et 
al. (2016) developed this method, which uses WGA and multiple anti-O-GlcNAc 
antibodies attached to resin beads, and were able to identify 990 O-GlcNAcylated 
proteins alone. Given that O-GlcNAc modifications are a common signalling 
mechanism in mammalian cells and can be removed by O-GlcNAcase, pre-treating 
cells with O-GlcNAcase inhibitors, such as PUGNAc or thiamet-G, may prevent the 
removal of putative LifA-mediated O-GlcNAc modifications (Horsch et al., 1991; 
Yuzwa et al., 2008). However, many of these inhibitors are analogues of GlcNAc 
(reviewed in Gloster and Vocadlo, 2010) and so should be tested to determine 
whether they might bind to LifA and inhibit its activity. Considering the long-lasting 
effects of LifA on T cells (Cassady-Cain et al., 2017), however, it is likely that 
predicted GlcNAc modifications made by LifA are not removed by O-GlcNAcase. 
 It is also possible that proteins modified by LifA were not detected using 
western blotting or shotgun mass spectrometry approaches because only N- and 
O-linked GlcNAcylation was investigated. These are the most common forms of 
glycosylation but sugars can bond to other amino acids. NleB has been shown to 
GlcNAcylate arginine residues in GAPDH (El Qaidi et al., 2017). S-linked GlcNAc 
is attached to the sulphur atom in cysteine residues and has recently been identified 
in mammals (Maynard et al., 2016). GlcNAc has also been shown to be transferred 
onto hydroxyproline and phosphate groups attached to serine residues in D. 
198 
discoideum (Teng-umnuay et al., 1999; Mehta et al., 1996) but this is not known to 
occur in mammalian cells. It should also be noted that while LifA has been shown to 
bind UDP-GlcNAc (Cassady-Cain et al., 2016), we cannot preclude the possibility 
that it binds other sugar donors, and that transfer of a different sugar is responsible 
for lymphostatin activity. 
 Further evidence of issues with the sensitivity of the shotgun mass 
spectrometry conducted herein is the low number of proteins/peptides identified in 
protein pull-down eluates. Originally, eluates were fractionated by SDS-PAGE and 
gel sections of whole wells were sent for analysis by shotgun mass spectrometry. 
However, no peptides were detected using this method despite protein species being 
visible on silver stained gels. This led to the analysis of whole eluates, which 
contained a larger quantity of protein. Given that the ‘rLifA + cells’ and ‘cells alone’ 
samples contained ~39 and 49 µg of protein respectively, it is unlikely that the 
quantity of protein was too low to detect. This can be assumed because the 
glycoprotein enriched samples contained as little as 10 µg of protein yet still allowed 
for the detection of hundreds of unique peptides. Both shotgun mass spectrometry 
and LC-MS can be further complicated by the fact that bands on a silver stained gel 
may not all represent proteins. Silver stain is known to also bind nucleic acids, 
proteolipids and lipopolysaccharide that cannot be matched to the protein databases 
used to analyse mass spectra (Somerville and Wang, 1981; Cochary et al., 1990; Tsai 
and Frasch, 1982). Silver staining is also not sensitive to all types of proteins 
(Friedman, 1982), which suggests that interacting partners of LifA could remain 
unseen using this staining method. Negative stains or fluorescent dyes could 
potentially be used to search for proteins not detected by silver staining (reviewed in 
Gauci et al., 2011). Another drawback of silver staining is that glutaraldehyde in the 
sensitising reagent cross-links proteins (Shevchenko et al., 1996) meaning that the 
mass of cross-linked peptides will not be accurately matched to protein databases. It 
is unclear why a peptide unique to bovine INPP5E was detected ~100 kDa above its 
expected position in the gel. This may have been due to a degraded peptide binding 
to another protein or it may simply not have been a genuine result. 
 The detection of GPx in pull-down eluates was complicated by the fact that 
there are eight GPx isoforms (reviewed in Brigelius-Flohé and Maiorino, 2013), and 
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that Uniprot did not state which of these was detected. The polyclonal antibody used 
to detect GPx was raised against GPx1, which is ubiquitously expressed and is the 
most studied isoform (reviewed in Brigelius-Flohé and Maiorino, 2013). However, 
later in silico analysis of the protein identified by shotgun mass spectrometry 
revealed that the isoform was actually GPx5. This protein has only ~47 % identity 
and~59 % similarity to GPx1 between amino acids 18–201, which may explain why 
GPx was not detected in the pull-down eluates. However, GPx5 would not be 
expected to be found in T cells as previous studies using mice, rats, pigs, humans, 
macaques and cattle have shown that it is expressed specifically in the male 
reproductive tract (Rejraji et al., 2002; Williams et al., 1998; Barranco et al., 2016; 
Hall et al., 1998; Légaré et al., 2017). 
 Interactions between LifA and other proteins, especially targets of GlcNAc 
modification, may be transient and therefore difficult to detect using standard protein 
pull-downs. The detection of interacting partners is also dependent on the strength of 
the interaction and whether the buffer used disrupts these interactions. Chemical 
cross-linking could be used in conjunction with protein pull-downs to capture 
transient interactions (reviewed in Leitner, 2016). A cross-linking reagent could be 
used to label rLifA at specific surface bound amino acid residues before performing 
protein pull-downs, which should then be permanently bound to interacting partners 
from T cell lysates (Thermo Fisher Scientific Inc., 2010). Selecting an appropriate 
cross-linking reagent is dependent on the desired amino acid target and the spatial 
proximity of potential interacting proteins (reviewed in Leitner, 2016). A 
compromise is often required between selecting a large cross-linking reagent, which 
is more likely to form a cross-link with another protein but is less specific, and a 
smaller reagent, which is less likely to form a cross-link but be more likely to bind a 
true interacting partner (reviewed in Leitner, 2016). Not all cross-linked interacting 
proteins can be isolated by SDS-PAGE as their size prevents them from entering the 
gel (reviewed in Leitner, 2016), however, some cross-linking reagents contain tags, 
such as biotin, to facilitate the isolation of protein complexes (Trester-Zedlitz et al., 
2003). Isolated protein complexes could then be subjected to LC-MS (reviewed in 
Leitner, 2016). 
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 The approaches used in this chapter were unable to conclusively identify 
putative targets/interacting partners of lymphostatin. Unlike studies that identified 
the targets of the LCTs and NleB, where targets of glycosylation were already 
suspected, no proteins were confidently predicted to interact with LifA at the 
beginning of this study. As such, methods were used that had the potential to identify 
interacting partners from complex T cell lysates. However, since no interacting 
partners were identified this way, I decided to pursue a candidate approach and 
investigate a protein that was independently shown to be affected by LifA (see 
Chapter 6). 
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6 Analysis of the impact of lymphostatin on phosphorylation of the 




 Due to the inconclusive results obtained in the previous chapter, a candidate 
approach to investigating putative targets of LifA was taken. Initially, Vav1 was 
considered for investigation as it plays an important role in both T and B cell 
signalling (reviewed in Bustelo, 2014). Vav1 is a guanine nucleotide exchange factor 
for Rho GTPases and affects the calcium flux, ERK and NF-κB signalling pathways 
in T cells (Costello et al., 1999). Its activity is regulated by phosphorylation of three 
tyrosine residues (López-Lago et al., 2000). Vav1 deficient Jurkat and murine T cells 
exhibit reduced IL-2 expression and proliferation, which is observed in LifA-treated 
T cells (Costello et al., 1999; Cao et al., 2002; Klapproth et al., 1995, 1996 and 
2000; Malstrom and James, 1998; Stevens et al., 2002; Deacon et al., 2010; 
Cassady-Cain et al., 2016 and 2017). Costello et al. (1999) also found that 
ionomycin partially rescues the proliferative capacity of Vav1 deficient T cells and 
similarly rLifA does not inhibit the proliferation of PMA/ionomycin-stimulated 
bovine T cells (Cassady-Cain et al., 2017).  Experiments by Dr Robin Cassady-Cain, 
The Roslin Institute, revealed that Vav1 was O-GlcNAcylated in both rLifA-treated 
and untreated bovine T cells (data not shown). While the possibility that 
lymphostatin modifies Vav1 by addition of a sugar moiety on other linkages (for 
which antibodies are lacking) cannot be precluded, it was elected not to pursue Vav1 
further. 
 Further experiments by Dr Robin Cassady-Cain using a Proteome Profiler 
Human Phospho-Kinase Array Kit (R&D systems) with highly purified bovine γδ T 
cells, highlighted a number of signalling proteins with reduced phosphorylation in 
ConA-stimulated cells treated with rLifA (Figures 6.1 and 6.2; Stevens Laboratory, 
unpublished data). One protein of particular interest was protein kinase B (PKB), 
also known as Akt. Akt has three isoforms that act on a variety of substrates to 
regulate metabolism and promote cell survival, growth and proliferation (Figure 6.3; 
reviewed in Manning and Toker, 2017). In T cells, Akt can be activated by the TCR 
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and Lck kinase through PI3K and Rac1, which causes the nuclear translocation of 
NF-κB and inhibits NF-AT dephosphorylation by glycogen-synthase kinase 3 
(GSK3; Genot et al., 2000; Prasad et al., 1993; Jones et al., 2000; Reif et al., 1997; 
Lafont et al., 2000). Akt can also be activated through CD8 co-stimulation, which 
has the same down-stream effects as TCR-induced activation and is known to result 
in increased IL-2 expression (Okkenhaug et al., 2001; Burr et al., 2001; 
Coudronniere et al., 2000; Kane et al., 2001; Cross et al., 1995; Beals et al., 1997). 
The kinase activity of Akt1 is regulated by phosphorylation at multiple sites, 
with the major two being Thr308 and Ser473 (Alessi et al., 1996; Hart and Vogt, 2011; 
reviewed in Manning and Toker, 2017). Phosphorylation occurs on the homologous 
residues Thr309 and Ser474 of Akt2 and on Thr305 and Ser472 of Akt3 (Meier et al., 
1997; Brodbeck et al., 1999; Nakatani et al., 1999). Chemical inhibitors against PI3K 
and mTORC2, which are required for the phosphorylation of Akt1 Thr308 and Ser473 
(Alessi et al., 1996; Tsuchiya et al., 2014; Sarbassov et al., 2005; Gan et al., 2011), 
have been shown to inhibit the CD3/CD8-stimulated proliferation of human T cells 
in a dose dependent manner (Herrero-Sánchez et al., 2016). This was not the result of 
increased apoptosis and the inhibition of proliferation produced sigmoid curves akin 
to those from rLifA-treated bovine T cells (Herrero-Sánchez et al., 2016; 
Cassady-Cain et al., 2016 and 2017). Blocking Akt phosphorylation also inhibited 
the secretion of IL-2, -4 and -10, and IFN-γ, similar to observations by Cassady-Cain 
et al. (2017), as well as IL-6 and TNF-α (Herrero-Sánchez et al., 2016). 
Akt1 activation is also regulated by O-GlcNAcylation. Akt1 is 
O-GlcNAcylated at multiple sites, some of which inhibit the phosphorylation of 
Thr308 and Ser473, while others inhibit phosphorylation of other amino acids (Wang et 
al., 2012; Gandy et al., 2006). O-GlcNAcylation of the residues Thr305 and Thr312 
disrupts the interaction between Akt1 and 3-phosphoinositide-dependent protein 
kinase-1 (PDPK1), which inhibits Thr308 phosphorylation (Wang et al., 2012). 
O-GlcNAcylation of Ser473 inhibits phosphorylation of this residue and has been 
found to cause apoptosis in murine pancreatic β cells (Kang et al., 2008). Shi et al. 
(2015) also claimed that both Thr308 and Ser473 are O-GlcNacylated, resulting in 
apoptosis of multiple cell types, but did not explicitly identify the GlcNAcylated 
residues as was done by Kang et al. (2008) and Wang et al. (2012). 
 203 











Figure 6.1. rLifA inhibited the phosphorylation of various kinases in bovine γδ T cells. γδ T cells were incubated with buffer or 
1 μg/mL rLifA for 1 hour at 37 °C, washed twice then stimulated with 5 μg/mL ConA for 15 minutes. T cell lysates were used in 
experiments with the Proteome Profiler Human Phospho-Kinase Array Kit according to the manufacturer’s instructions. The array 
comprises immobilised antibodies specific for phosphorylated variants of the kinases shown on the right, which capture the proteins from 
cell lysates. Once unbound proteins have been removed, captured proteins are then detected with a cocktail of biotinylated detection 
antibodies, streptavidin-horse radish peroxidase and chemiluminescent detection reagents. A representative set of western blots of the 
kinase array from 1 of 3 independent donors is shown. Red boxes – duplicate spots of Akt1 Ser473 (also reacts with Akt2 Ser474 and Akt3 
Ser472). Blue boxes – duplicate spots of other proteins with noticeably reduced phosphorylation in rLifA-treated cells relative to control 
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Figure 6.2. Densitometry analysis of the phosphorylation level of proteins 
detected using the Proteome Profiler Human Phospho-Kinase Array Kit. Pixel 
density data from duplicate spots of western blots was detected using Image Studio 
Lite v5.2. Data from cells + rLifA + ConA were normalised against cells + ConA to 
produce a phosphorylation index. Data is from at least 2 independent donors and 
shown for a subset of kinases detected by the array where reliable detection was 
possible. Blue and red bars denote the phosphorylation indices of individual 
replicates where data were collected from only 2 donors. Green bars denote the mean 
phosphorylation index where data were collected from 3 independent donors. Error 
bars indicate the standard deviation of indices across these donors. Data were 





























Figure 6.3. Overview of Akt signalling in T cells showing its downstream effects. 
PI3K can also be activated by Lck kinase in T cells. PI3K activates both PDPK1 (not 
seen in diagram) and mTORC2, which phosphorylate Akt1 Thr308 and Ser473 (and 
corresponding Akt2/3 residues) respectively (from Coquillard et al., 2015). 
 
EPEC have been known to modulate the PI3K/Akt pathway in phagocytes for 
some time with effectors such as EspF, but this protein was not responsible for the 
observed inhibition of Akt1 Ser473 phosphorylation (Celli et al., 2001; Quitard et al., 
2006). Quitard et al. (2006) also reported that the inhibition of Akt1 Ser473 
phosphorylation was dependent on the bacterial T3SS. Ruchaud-Sparagano et al. 
(2007) reported that EPEC inhibited the TNF-α-stimulated phosphorylation of Akt1 
Ser473 in Caco-2 cells in a manner dependent on EspA but not intimin. A more 
detailed study found that EPEC suppressed Akt1 Ser473 phosphorylation in both 
HeLa cells and J774A.1 murine macrophage-like cells in a manner dependent on the 
T3SS but not intimin, six LEE effectors or 14 non-LEE encoded effectors (Amin, 
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2017). Recent personal communications with Professor Brendan Kenny, Institute for 
Cell and Molecular Biosciences, Newcastle University, appear to confirm the 
T3SS-dependent inhibition of Akt1 Ser473 phosphorylation in J774A.1 cells. 
Preliminary evidence from experiments in the Kenny Laboratory using EPEC mutant 
strains lacking various effector proteins (Cepeda-Molero et al., 2017) also suggested 
that this inhibition was dependent on LifA and the homologous LifA-like protein 
(data not shown). It was also reported by Professor Kenny that the inhibition of Akt1 
Ser473 phosphorylation in this manner coincided with the O-GlcNAcylation of the 
protein (data not shown). 
 Given the apparent effects of LifA on Akt1 Ser473 phosphorylation and the 
reported LifA dependent O-GlcNAcylation of the protein in J774A.1 cells, it was 
hypothesised that lymphostatin inhibits Akt1 Ser473 phosphorylation by 
O-GlcNAcylation of this residue. Western blot analysis was used in a number of 
experiments to investigate the role of rLifA and live EPEC in the inhibition of Akt1 
Ser473 phosphorylation and putative O-GlcNAcylation. Since the anti-phospho-Akt1 
Ser473 antibody used in the following experiments also reacts with Akt2 Ser474 and 
Akt3 Ser472, the general term Akt Ser is used to refer to this phosphorylation site for 
the purposes of this study. It should be noted that Akt possesses a number of other 
Ser residues that can be phosphorylated (reviewed in Manning and Toker, 2017), 
which are not relevant to this study. 
 
6.2 Effect of recombinant lymphostatin on Akt Ser phosphorylation 
 
6.2.1 Pre-treatment of bovine T lymphocytes with rLifA inhibited ConA-stimulated 
phosphorylation of Akt Ser in a manner dependent on catalytic motifs 
 
 Highly purified γδ T cells from bovine peripheral blood were used for the 
kinase array experiments, but the method was costly and reagent intensive. 
Therefore, I first investigated whether this form of enrichment was necessary to 
detect Akt Ser phosphorylation by western blot analysis. ConA-treated γδ T cells did 
not show any greater level of Akt phosphorylation than ConA-treated T cells 
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enriched using a nylon wool column, nor any greater suppression of phosphorylation 
when treated with rLifA (data not shown).  
 T cells from three independent donors were pre-treated with either buffer, 
wild-type (WT) rLifA, rLifADTD/AAA or rLifAC1480A, at final concentrations of 
1 μg/mL, then stimulated with ConA for various times. The cell lysates were probed 
by western blotting, using a polyclonal antibody, which although raised against 
murine Akt1 phospho-Ser473, was also known to recognise Akt2 phospho-Ser474 and 
Akt3 phospho-Ser472. Western blot analysis showed that while Akt Ser 
phosphorylation was markedly increased upon ConA stimulation of buffer-treated 
cells, it was reduced to levels only slightly above unstimulated cells in rLifA-treated 
cells (Figure 6.4). In cells treated with rLifADTD/AAA or rLifAC1480A, Akt Ser 
phosphorylation was comparable to that of ConA-stimulated controls when T cells 
were stimulated for 5 minutes but appeared to decrease gradually with time. 
Densitometry showed that the fold change in normalised Akt phospho-Ser (pAkt) 
signal, with standard deviation, from WT rLifA-treated cells was consistently lower 
than buffer-treated T cells at all time points after ConA stimulation (0.61 ± 0.05 at 
5 minutes; 0.13 ± 0.02 at 15 minutes; 0.17 ± 0.12 at 30 minutes) in comparison to 
untreated cells (Figure 6.5). The fold change in normalised pAkt signal, with 
standard deviation, from rLifADTD/AAA-treated cells decreased gradually (0.99 ± 0.29 
at 5 minutes; 0.86 ± 0.35 at 15 minutes; 0.86 ± 0.03 at 30 minutes) and was more 
variable in rLifAC1480A-treated cells (0.83 ± 0.05 at 5 minutes; 0.57 ± 0.12 at 
15 minutes; 1.05 ± 0.9 at 30 minutes). The fold change in normalised pAkt signal 
was found to be statistically significantly different from buffer-treated cells in cells 
treated with WT rLifA (F(3, 8) = 49.16, P < 0.001 at 5 minutes post-stimulation; 
F(3, 8) = 33.76, P < 0.001 15 minutes; F(3, 8) = 5.49, P = 0.021 at 30 minutes) but 
not with the mutant proteins. 
 These experiments confirmed observations made using the Proteome Profiler 
Human Phospho-Kinase Array that lymphostatin could inhibit the phosphorylation of 
Akt Ser in bovine T cells and indicated that this event was dependent on the 



















Figure 6.4. The ConA-stimulated phosphorylation of Ser of Akt in bovine T cells 
was inhibited by rLifA in a manner dependent on the DXD motif and C1480 
(western blot). An absolute number of 6 x 106 T cells were treated with 1µg/mL 
rLifA, rLifADTD/AAA, rLifAC1480A or buffer for 1 hour then stimulated with ConA for 
the times indicated. A volume equivalent to 1 x 106 cells was analysed by 
SDS-PAGE in each well. The phospho-Akt (pAkt) signal was greatly reduced after 
stimulation at all times in cells pre-treated with rLifA in comparison to untreated 
cells. The pAkt signal from cells treated with rLifADTD/AAA and rLifAC1480A decreased 
with time following ConA stimulation but not to the same extent as with rLifA. 
Unstimulated cells were used as a negative control. Pan Akt and actin signals were 
used as loading controls. Data were generated from 3 independent donors and blots 





































































































































































































Figure 6.5. The ConA-stimulated phosphorylation of Ser of Akt in bovine T cells 
was inhibited by rLifA in a manner dependent on the DXD motif and C1480 
(densitometry). Densitometry was performed on the western blots and the pAkt 
signal from each sample was normalised against its respective actin signal to account 
for overall loss of protein. Data were then normalised against the appropriate cells 
alone controls to give a fold change in normalised signal compared to untreated cells. 
The average fold change in normalised signal of rLifA-treated cells was reduced at 
all time points while there was no significant difference between the normalised 
signal of cells alone and cells treated with rLifADTD/AAA or rLifAC1480A. Error bars 
denote the standard deviation of the average fold changes from across 3 experiments. 
Asterisks indicate fold changes in normalised signal that were statistically 
significantly different from ConA-stimulated cells alone. 
 
6.2.2 Treatment of bovine T lymphocytes with rLifA after ConA stimulation did 
not suppress Akt Ser phosphorylation 
 
 To determine whether LifA could suppress Akt phosphorylation in T cells 
that had already been activated by ConA, akin to phenotypes observed in J774A.1 
cells (Professor Brendan Kenny, personal communications), T cells from four 
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1 μg/mL rLifA for various time points. rLifA did not suppress Akt Ser 
phosphorylation at a faster rate than the natural loss of phosphorylation observed in 
buffer-treated cells (Figure 6.6). The fold change in normalised pAkt signal, with 
standard deviation, increased slightly from 1.46 ± 0.43 at 0 minutes post-treatment to 
1.52 ± 0.47 at 5 minutes in buffer-treated cells and from 1.58 ± 0.58 at 0 minutes to 
1.65 ± 0.65 at 5 minutes in rLifA-treated cells (Figure 6.7). It then gradually 
decreased to 0.58 ± 0.23 at 60 minutes in buffer-treated cells and 0.33 ± 0.26 at 
60 minutes in rLifA-treated cells. The fold change in normalised pAkt signal in 
rLifA-treated cells was not statistically significantly different at any time point from 
that in buffer-treated cells (T(5) = -0.18, P = 0.862 at 0 minutes post-incubation; 
T(5) = -0.26, P = 0.808 at 5 minutes; T(5) = 0.55, P = 0.605 at 15 minutes; 

















Figure 6.6. rLifA did not inhibit Akt Ser phosphorylation in bovine T cells 
pre-stimulated with ConA (western blot). An absolute number of 6 x 106 T cells 
were stimulated with ConA for 15 minutes then treated with buffer or 1µg/mL rLifA 
for the times indicated. A volume equivalent to 1 x 106 cells was analysed by 
SDS-PAGE in each well. The pAkt signal decreased over time and the addition of 
rLifA did not appear to reduce the pAkt signal at a faster rate than in buffer-treated 
cells. Unstimulated cells were used as a negative control and cells stimulated with 
ConA for 15 minutes, but without buffer/rLifA treatment, were used as a positive 
control. Pan Akt and actin signals were used as loading controls. Data were 





























































































































































Figure 6.7. rLifA did not inhibit Akt Ser phosphorylation in bovine T cells 
pre-stimulated with ConA (densitometry). Densitometry was performed on the 
western blots and the pAkt signal from each sample was normalised against its 
respective actin signal to account for overall loss of protein. Data were then 
normalised against the positive control to give a fold change in normalised signal 
compared to buffer-treated cells. Error bars denote the standard deviation of the 
average fold changes from across 4 experiments. 
 
6.2.3 rLifA did not appear to O-GlcNAcylate Akt in bovine T lymphocytes 
 
 Given that Akt was observed to be O-GlcNAcylated in J774A.1 cells by 
EPEC in a LifA-dependent manner (Professor Brendan Kenny, personal 
communications), I sought to determine whether this could be detected in bovine T 
cells using recombinant protein. Cells from two independent donors were treated 
with buffer or 1 μg/mL rLifA for various times then stimulated with ConA. 
Immunoprecipitation (IP) was performed on the lysates using the anti-pan Akt 
antibody. Western blot analysis revealed that at times when Akt Ser phosphorylation 
was inhibited by rLifA, no proteins of the expected size of Akt (~56 kDa) could be 
detected with the anti-O-GlcNAc antibody (Figure 6.8). Protein species detected at 
~50 kDa in the IP samples correspond to the heavy chain of the anti-pan Akt 
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being concentrated during the IP procedure. Contrary to the hypothesis, these 
experiments suggested that Akt was not O-GlcNAcylated in bovine T cells as a result 




















Figure 6.8. rLifA did not appear to O-GlcNAcylate Akt in bovine T 
lymphocytes. An absolute number of 1 x 107 T cells were treated with buffer or 
rLifA for the times indicated then stimulated with ConA for 15 minutes. IP was 
performed using the pan Akt antibody and these samples were compared with whole 
cells lysates (WCL). At 60 and 120 minutes, when the pAkt signal was reduced in 
cells treated with rLifA, no O-GlcNAcylated proteins could be detected at the 
expected size for Akt (~56 kDa). Unstimulated cells were used as a negative control. 
The heavy chain of the anti-pan Akt antibody was observed at ~50 kDa in the IP 
samples (indicated by asterisks). Arrows indicate Akt. This experiment was 



































































































































































































































6.3 Effects of live EPEC on Akt phosphorylation 
 
6.3.1 Pre-incubation of bovine T lymphocytes with EPEC inhibited 
ConA-stimulated phosphorylation of Akt Ser in a T3SS-dependent manner 
 
 Although LifA did not appear to O-GlcNAcylate Akt it was clear that it 
inhibited ConA-induced Ser phosphorylation (see Section 6.2). However, the 
concentration of rLifA applied to T cells in these experiments was likely far in 
excess of what would be encountered during an infection. Therefore, live EPEC 
E2348/69 NalR (Levine et al., 1978 and 1985) and derived mutant strains constructed 
by the Stevens Laboratory were used to infect T cells at a multiplicity of infection 
(MOI) of 200:1, akin to experiments by Amin (2017). EPEC E2348/69 ΔlifA 
(Stevens et al., 2002) was used to assess the role of lymphostatin, while E2348/69 
ΔescN::KanR, which cannot produce the T3SS-associated ATPase EscN (Garmendia 
et al., 2004), was used as a T3SS-deficient control. Initially, T cells were incubated 
with bacteria cultured under T3S-inducing conditions for various time points but not 
stimulated to determine whether EPEC caused an initial activation of Akt followed 
by inhibition, as seen in J774A.1 cells (Amin, 2017). However, the EPEC strains did 
not cause an initial activation of Akt in T cells (data not shown). 
 In further experiments, T cells from three independent donors were 
stimulated with ConA after incubation with the bacteria at an MOI of 200:1 for 0, 15, 
30 or 60 minutes, as was done with rLifA-treated cells. The pAkt signal from both 
cells infected with WT and ΔlifA EPEC decreased rapidly from 0–60 minutes 
post-infection (Figure 6.9). The pAkt signal from cells infected with the 
ΔescN::KanR strain decreased at a slower rate. This was likely due to the decreasing 
pan Akt signal, which may have been caused by cell death as a result of the bacteria 
acidifying the medium. The fold change in normalised pAkt signal, with standard 
deviation, of cells treated with the WT, ΔlifA and ΔescN::KanR strains decreased 
from 0.62 ± 0.43, 0.73 ± 0.42 and 2.03 ± 1.12 respectively at 0 minutes 
post-infection to 0.08 ± 0.05, 0.14 ± 0.23 and 0.29 ± 0.28 respectively at 60 minutes 
(Figure 6.10). The fold change in normalised pAkt signal from E2348/69 
ΔlifA-infected cells was not statistically significantly different from WT 
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E2348/69-infected cells at any time (F(2, 6) = 3.9, P = 0.673 at 0 minutes 
post-infection; F(2, 6) = 3.43, P = 0.798 at 15 minutes; F(2, 6) = 4.38, P = 0.73 at 
30 minutes; F(2, 6) = 0.93, P = 0.584 at 60 minutes). The fold change in normalised 
pAkt signal from E2348/69 ΔescN-infected cells was statistically significantly 
different from WT E2348/69-infected cells at 0 and 30 minutes post-infection but not 
at 15 or 60 minutes (F(2, 6) = 3.9, P = 0.04 at 0 minutes post-infection; 
F(2, 6) = 3.43, P = 0.054 at 15 minutes; F(2, 6) = 4.38, P = 0.034 at 30 minutes; 
F(2, 6) = 0.93, P = 0.463 at 60 minutes). These experiments showed that the 
inhibition of Akt Ser phosphorylation by EPEC in bovine T cells was dependent on 


















Figure 6.9. Akt Ser phosphorylation induced by ConA was inhibited by prior 
incubation with live EPEC in a manner dependent on the Type III secretion 
system but not LifA (western blot). An absolute number of 6 x 106 T cells were 
incubated with EPEC E2348/69 NalR strains at an MOI of 200:1 for the times 
indicated then stimulated with ConA for 15 minutes. A volume equivalent to 
1 x 106 cells was analysed by SDS-PAGE in each well. The pAkt signal decreased 
with time with both the wild-type (WT) and ΔlifA strains but remained elevated with 
the ΔescN::KanR (ΔescN) strain until 60 minutes, at which point the pan Akt signal 
also decreased. Unstimulated cells were used as a negative control and cells 
stimulated with ConA for 15 minutes, but without EPEC treatment, were used as a 
positive control. Pan Akt and actin signals were used as loading controls. Data were 




































































































































































Figure 6.10. Akt Ser phosphorylation induced by ConA was inhibited by prior 
incubation with live EPEC in a manner dependent on the Type III secretion 
system but not LifA (densitometry). Densitometry was performed on the western 
blots and the pAkt signal from each sample was normalised against its respective 
actin signal to account for overall loss of protein. Data were then normalised against 
the positive control to give a fold change in normalised signal compared to 
uninfected cells. Error bars denote the standard deviation of the average fold changes 
from across 3 experiments. Asterisks indicate fold changes in normalised signal that 
were statistically significantly different from cells treated with wild-type (WT) EPEC 
E2348/69. 
 
6.3.2 Inhibition of Akt Ser phosphorylation in bovine T lymphocytes by EPEC was 
not dependent on LifA or LifA-like protein 
 
Due to claims of functional redundancy between LifA and LifA-like protein 
in respect of their ability to modulate Akt activation (Professor Brendan Kenny, 
personal communications), experiments from Section 6.3.1 were repeated using the 
original EPEC E2348/69 StrR strain (Taylor, 1970) and derived mutants 
(Cepeda-Molero et al., 2017) provided by Professor Brendan Kenny, Newcastle 
University. WT, ΔlifA and ΔescN strains in the E2348/69 StrR background were used 






































ΔlifA ΔlifA-like strains in the E2348/69 StrR background. Each strain was incubated 
with T cells from three independent donors at an MOI of 200:1 for 0, 15 or 
30 minutes. The 60 minute incubation was omitted since Akt Ser phosphorylation 
was previously observed to be reduced at this time even with the T3SS-deficient 
mutant. 
 In contrast to observations made by the Kenny Laboratory with J774A.1 
cells, the ΔlifA ΔlifA-like double mutant inhibited ConA-stimulated Akt Ser 
phosphorylation in bovine T cells (Figure 6.11). The fold change in normalised pAkt 
signal, with standard deviation, from cells infected with the WT strain decreased 
from 0.16 ± 0.08 at 0 minutes post-infection to 0.02 ± 0.02 at 30 minutes (Figure 
6.12). The fold change in normalised pAkt signal, with standard deviation, from cells 
infected with the ΔlifA, ΔlifA-like and ΔlifA ΔlifA-like strains decreased from 
0.24 ± 0.09, 0.22 ± 0.08 and 0.18 ± 0.07 respectively at 0 minutes to 0.1 ± 0.02, 
0.09 ± 0.03 and 0.08 ± 0.02 respectively at 15 minutes, then increased slightly to 
0.12 ± 0.07, 0.13 ± 0.14 and 0.1 ± 0.1 respectively at 30 minutes. The fold change in 
normalised pAkt signal, with standard deviation, from E2348/69 ΔescN-infected 
cells also decreased from 0.64 ± 0.13 at 0 minutes post-infection to 0.59 ± 0.27 at 
15 minutes, then increased again to 0.76 ± 0.79 at 30 minutes. The fold change in 
normalised pAkt signal from E2348/69 ΔlifA-, ΔlifA-like- or ΔlifA ΔlifA-like-infected 
cells was not statistically significantly different from WT E2348/69-infected cells at 
any time. The fold change in normalised pAkt signal from E2348/69 ΔescN-infected 
cells was statistically significantly different from WT E2348/69-infected cells at all 
time points (F(4, 10) = 6.18, P = 0.004 at 0 minutes post-incubation; 
F(4, 10) = 18.73, P < 0.001 at 15 minutes; F(4, 10) = 4.75, P = 0.005 at 30 minutes). 
These results suggested that while recombinant lymphostatin can inhibit 
ConA-stimulated Akt Ser phosphorylation, this effect was not obvious when T cells 
were pre-incubated with EPEC prior to stimulation. However, T3SS-dependent 
inhibition of Akt Ser phosphorylation upon ConA stimulation could be observed and 















Figure 6.11. The inhibition of ConA-stimulated Akt Ser phosphorylation by prior incubation with live EPEC was independent of 
LifA and LifA-like protein (western blot). An absolute number of 6 x 106 T cells were incubated with EPEC E2348/69 StrR strains at an 
MOI of 200:1 for the times indicated then stimulated with ConA for 15 minutes. A volume equivalent to 1 x 106 cells was analysed by 
SDS-PAGE in each well. The pAkt signal decreased with time with all strains except the ΔescN strain, where the signal only began to 
decrease at 30 minutes, at which point the pan Akt signal also decreased. Unstimulated cells were used as a negative control and cells 
stimulated with ConA for 15 minutes, but without EPEC treatment, were used as a positive control. Pan Akt and actin signals were used as 








































































































































































































































Figure 6.12. The inhibition of ConA-stimulated Akt Ser phosphorylation by 
prior incubation with live EPEC was independent of LifA and LifA-like protein 
(densitometry). Densitometry was performed on the western blots and the pAkt 
signal from each sample was normalised against its respective actin signal to account 
for overall loss of protein. Data were then normalised against the positive control to 
give a fold change in normalised signal compared to uninfected cells. Error bars 
denote the standard deviation of the average fold changes from across 3 experiments. 
Asterisks indicate fold changes in normalised signal that were statistically 
significantly different from cells treated with wild-type (WT) EPEC E2348/69. 
 
6.3.3 EPEC did not appear to O-GlcNAcylate Akt in bovine T lymphocytes 
 
Since recombinant LifA did not appear to O-GlcNAcylate Akt, I sought to 
determine whether another putative effector protein was responsible for the 
observations made by the Kenny Laboratory. Given that EPEC appeared to cause 
inhibition of Akt Ser phosphorylation independently of LifA/LifA-like, it was 
hypothesised that the protein responsible for this may O-GlcNAcylate Akt. 
 Bacteria were incubated with T cells from a single donor at an MOI of 200:1 
for 1 hour (the time at which O-GlcNAcylation was detected by the Kenny 









































observations made with rLifA, live EPEC did not appear to O-GlcNAcylate Akt 
(Figure 6.13). As observed previously, the phospho-Akt signal was reduced by WT 



















Figure 6.13. EPEC did not appear to O-GlcNAcylate Akt in bovine T 
lymphocytes. An absolute number of 1 x 107 T cells were incubated with EPEC 
E2348/69 StrR strains at an MOI of 200:1 for 1 hour then stimulated with ConA for 
15 minutes. No O-GlcNAcylated proteins at the expected size of Akt could be 
detected in IP samples from T cells infected with EPEC strains at the same time as 
they inhibited Akt phosphorylation. Unstimulated cells were used as a negative 
control. The heavy chain of the anti-pan Akt antibody was observed at ~50 kDa in 




















































































































































 Evidence from several previous studies suggested that lymphostatin inhibits 
the phosphorylation of Akt1 at Ser473 and corresponding residues in Akt2/3. To test 
the hypothesis that Akt is a cellular target of lymphostatin, directly or indirectly, 
recombinant lymphostatin and live EPEC were assessed for their ability to inhibit 
Akt Ser phosphorylation and O-GlcNAcylate Akt in primary bovine T cells. rLifA 
was found to inhibit Akt Ser phosphorylation in a manner dependent on its catalytic 
DXD motif and C1480 residue. This inhibition was only detected when T cells were 
treated with rLifA before stimulation with ConA and not after, which contrasts with 
the findings of the Kenny Laboratory. They found that EPEC suppressed Akt Ser 
phosphorylation in J774A.1 cells after an initial activation caused by the bacteria 
(Amin, 2017; Professor Brendan Kenny, personal communications), however, this 
may have been the result of different signalling pathways that act on Akt in T cells 
and macrophages. J774A.1 cells are also an immortalised cell line, which do not 
necessarily reflect the cellular biology of their progenitor cells. It should also be 
noted that although T cell enrichment using nylon wool columns was more efficient 
than using anti-γδ TCR antibodies, this would result in some contamination from B 
cells and monocytes/macrophages, which may have affected the results. In further 
contrast to the findings of the Kenny Laboratory, recombinant LifA did not appear to 
O-GlcNAcylate Akt in bovine T cells at a time and concentration previously shown 
to inhibit ConA-stimulated proliferation and suppress Akt Ser phosphorylation. This 
study used the RL2 anti-O-GlcNAc antibody clone, as did the Kenny Laboratory, 
however, antibodies were sourced from different suppliers with different maximum 
recommended dilutions. As such, this study used an antibody dilution of 1/1000, 
whereas the Kenny Laboratory used 1/500, which may have been responsible for the 
difference in results. The concentration of protein applied to the T cells was also not 
reflective of the quantity of protein that is taken up by cells. Therefore, an apparent 
lack of O-GlcNAcylation may have been due to low quantities of the LifA 
N-terminus acting within cells. 
  I then sought to replicate the experiments of the Kenny Laboratory using 
bovine T cells and live EPEC strains to determine whether the concentrations of LifA 
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produced by the bacteria were sufficient to inhibit Akt Ser phosphorylation. 
Although the T3SS-dependent inhibition of Akt Ser phosphorylation could be 
confirmed using this model, the inhibition observed was independent of LifA and 
LifA-like protein. It is possible that another Type III secreted effector(s) was 
responsible for the inhibition observed, as other effectors from EPEC are known to 
modulate Akt phosphorylation. Both Tir and EspZ have been reported to indirectly 
enhance Akt Ser phosphorylation and thus promote the survival of kidney and 
epithelial cells respectively (Sason et al., 2009; Shames et al., 2010). However, with 
the exception of Stx (Gobert et al., 2007), which is not produced by EPEC, no other 
effector proteins from A/E E. coli have been identified that inhibit Akt Ser 
phosphorylation. LifA and its homologues ToxB and Efa1 have been shown to 
affect the expression and secretion of Type III secreted proteins in some strains 
(Stevens et al., 2002 and 2004), which raises the possibility that the effect of lifA 
during EPEC infection may be indirect. One method of studying any direct effects of 
LifA in EPEC on Akt would be to re-insert the lifA gene into the EPEC0 strain, 
which possesses a functional T3SS but lacks all Type III secreted effectors 
(Cepeda-Molero et al., 2017). 
 In order to determine whether the disparities between this study and the 
observations of the Kenny Laboratory were caused by the difference in cell types 
used, EPEC infections of J774A.1 cells were attempted. EPEC appeared to inhibit 
the phosphorylation of Akt Ser in a manner dependent on the T3SS but not 
LifA/LifA-like (data not shown). However, Akt Ser phosphorylation was also 
decreased by 30 minutes post-infection with an E. coli K-12 strain that lacks LifA 
(HB101) to a level similar to that of the EPEC E2348/69 strains. It is possible that 
changes to the experimental procedures used by our laboratories could be responsible 
for this, including in the number of J774A.1 cells used and the extent to which they 
were serum starved. Akt Ser phosphorylation was not reduced at 1 hour 
post-infection in E2348/69 ΔescN-infected cells, which is consistent with previous 
observations. An alternative explanation for this observation may be that E2348/69 
ΔescN causes sustained activation of Akt by an unknown mechanism, rather than fail 
to inhibit it. Putative O-GlcNAcylation of Akt was not observed in EPEC-infected 
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J774A.1 cells either (data not shown) and the reasons for the discordance between 
studies remain unclear. 
 Proliferation assays in which T cells were incubated with EPEC E2348/69 
strains for 1 hour before ConA stimulation were attempted to determine whether live 
bacteria could inhibit T cell proliferation. Previous assays have used either bacterial 
lysates or recombinant protein (Klapproth et al., 1995, 1996 and 2000; Malstrom and 
James, 1998; Stevens et al., 2002; Deacon et al., 2010; Bease, 2015; Cassady-Cain et 
al., 2016 and 2017). After incubation with the bacteria, T cells were washed and 
resuspended in fresh medium with antibiotics. However, despite streptomycin being 
the only antibiotic known that these strains were resistant to, the bacteria were found 
to be capable of surviving in 100 μg/mL gentamicin when 80 μg/mL has been 
reported to be sufficient kill E. coli (Marchès et al., 2003). It was thought that the 
bacteria may have been capable of invading the T cells and re-emerging as they have 
been reported to invade epithelial cells (Donnenberg et al., 1989). However, high 
concentrations of kanamycin, which penetrates cells, also did not kill the bacteria. 
They survived in 250 μg/mL kanamycin as well as combinations of antibiotics 
including chloramphenicol and ceftazidime. It is unclear how the bacteria were able 
to survive multiple classes of antibiotics, but this prevented the measurement of 
proliferation as the T cells were killed by the acidified medium due to bacterial 
outgrowth. 
 Other experiments were also attempted to assess the potential role of Akt as a 
target for LifA during this study. An in vitro glycosylation assay was attempted using 
recombinant 6 x His-tagged human Akt1 (rAkt1; Novus Biologicals) and conditions 
based in on the in vitro glucosylation assay described by Donald et al. (2013) for 
RhoA and the large clostridial toxins (LCTs) TcdA and B. Conditions were designed 
to mimic the host cell cytoplasm and UDP-GlcNAc was used in place of UDP-Glc. 
However, on western blots rAkt1 appeared as a complex ladder of proteins instead of 
a single band at ~56 kDa. This may have been the result of a poor quality batch, as 
the supplier’s website showed the protein to be of the expected size. Alternatively, it 
is possible that this was due to rAkt1 being produced in E. coli rather than 
mammalian or insect cells as may be required for the proper folding of a mammalian 
protein. Even if rAkt1 was biophysically normal and was a target for LifA, there are 
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a number of other potential reasons why in vitro glycosylation may not occur. 
Although full-length rLifA is known to bind UDP-GlcNAc (Bease, 2015; 
Cassady-Cain et al., 2016) it is unclear whether it can transfer the sugar in this form. 
The homologous LCTs can transfer their sugar substrates in their full-length form 
(Just et al., 1995b and 1995c; Selzer et al., 1996; Busch et al., 1998; Nagahama et 
al., 2011), but given that rLifA is processed within T cells (see Section 4.7), it may 
require cleavage for the N-terminal glcosyltransferase domain to become active. 
Other co-factors, such as ATP or metal ions, may also be required for the 
glycosylation reaction. The reaction was attempted in T cell lysates, as done by 
Selzer et al. (1996), to ensure that the necessary co-factors were present but again, 
rAkt did not appear at the expected size (data not shown). 
 Another experiment was performed to determine whether the LifA-mediated 
inhibition of T cell proliferation was caused by the inhibition of Akt Ser 
phosphorylation. T cells were treated with titrations of either rLifA or the inhibitor 
OSU-03012 (AR-12; APExBIO) for 1 hour. AR-12 prevents the phosphorylation of 
Akt Thr and Ser by inhibiting PDPK1 activity (Zhu et al., 2004; Cen et al., 2007). 
However, AR-12 may also target p21-activated kinases and aurora kinase A (Porchia 
et al., 2007; Silva et al., 2014), meaning that the effects of this inhibitor may not be 
specific to Akt. AR-12 at a concentration of 2.5 μM inhibited Akt Ser 
phosphorylation to a level comparible with 1 μg/mL rLifA in a single donor (data not 
shown). AR-12 concentrations lower than 2.5 μM (0.1–1 μM) did not appear to 
inhibit Akt Ser phosphorylation, while higher concentrations (5–10 μM) were toxic. 
However, this observation could not be confirmed in additional donors due to 
toxicity issues at 2.5 μM. Toxicity at 5 μM and above was not unexpected as this has 
previously been reported in human macrophages (Hoang et al., 2014), however, this 
was after a 72 hour incubation. Cytotoxicity was < 10 % at 2.5 μM AR-12 in this 
same study. It is possible that the toxicity observed at 2.5 μM in bovine T cells was 
due to differences in the sensitivities of different cell types, species or donors to 
AR-12. A proliferation assay was performed with a different single donor in which T 
cells were treated with titrations of either rLifA or AR-12. AR-12 at 2.5 μM was not 
cytotoxic in the proliferation assay but the effect on Akt Ser phosphorylation was not 
measured. However, at this concentration the proliferation index was only reduced to 
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0.71, comparible to 0.01 ng/mL rLifA (data not shown). Although caveats existed, 
these experiments suggested that LifA does not act by solely inhibiting Akt Ser 
phosphorylation. 
 Taken together, the observations made in this study suggest that lymphostatin 
does not directly target Akt in bovine T cells, at least not via O-GlcNAcylation. 
rLifA did not reduce Akt Thr phosphorylation to the same degree as Ser 
phosphorylation in experiments by Dr Robin Cassady-Cain. It is possible that the 
cellular target of LifA lies upstream of Akt Thr and Ser phosphorylation but has a 
greater effect on Ser phosphorylation. No kinases from the subset identified with 
reliable detection (Figure 6.2) lie directly upstream of Akt. GSK3, WNK1 and p27 
are all possible substrates for Akt (reviewed in Manning and Toker, 2017) but have 
variable levels of phosphorylation. There is potentially cross-talk between the TCR 
and PI3K/Akt signalling pathways however (see Section 7.2.4), which may make 




Lymphostatin is a large protein produced by A/E E. coli that inhibits the 
mitogen- and antigen-stimulated proliferation of T lymphocytes. In this study, I 
sought to better understand the mode of action of lymphostatin by attempting to 
identify functional domains and possible targets of the protein, as well as 
investigating the role of the putative cysteine protease domain. 
 
7.1 Analysis of lymphostatin structure and function 
 
Recombinant fragments of lymphostatin representing putative structural 
domains did not possess inhibitory activity when applied exogenously to T cells in 
isolation or in combination. Direct transfection of T cells with the predicted catalytic 
N-terminal proteins rGT and rF1 did not produce conclusive results with regards to 
the inhibition of mitogen-activated proliferation. However, these two proteins were 
found to interact with T cells in a manner insensitive to exogenous GlcNAc, while 
the C-terminal proteins rF3 and rF5 did not. Experiments seeking to define the roles 
of structural domains of lymphostatin were limited by several factors. rF3 and rF5 
formed multimers, making it difficult to determine using SEC whether or not they 
associated with each other. Further, rF1 and rF5 could not be purified to a higher 
degree using anion exchange chromatography, which prevented biophysical 
measurements from being taken. We cannot preclude the possibility that the absence 
of activity was a consequence of improper folding of the proteins.  
 
7.1.1 Structural analysis 
 
 Currently, there is only limited experimental structural information on the 
N-terminal portion of LifA, which was gathered by Cassady-Cain et al. (2016). The 
N-terminal half of lymphostatin was predicted by PSIPRED (Buchan et al., 2013) to 
contain the majority of the α-helix content of the protein. PSIPRED predicted that the 
F1 fragment released by limited trypsin proteolysis was composed of 52 % α-helix, 
5 % β-sheet and 43 % coil (Cassady-Cain et al., 2016). CD analysis of F1 yielded 
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similar results to the PSIPRED predictions but with a higher β-sheet content 
(51 ± 5 % α-helix, 13 ± 3 % β-sheet, 37 ± 7 % coil) and confirmed that the α-helix 
content was higher in F1 than in full-length LifA (37 ± 3 % α-helix). Cassady-Cain et 
al. (2016) also made structural predictions about the GT domain of LifA. Through 
alignment of the LifA primary sequence with that of various LCTs it was predicted 
that the GT domain of LifA consists of a catalytic core with α-helical/unordered 
insertions. The catalytic core is thought to be involved in substrate binding and the 
insertions involved in target recognition (Figure 7.1). An XNX motif at the base of 
the β-hairpin in the substrate binding site is thought to confer sugar specificity 
(Figure 7.2). The LCTs TcdA and B and TcsL have an INQ sequence at this position, 
allowing them to bind UDP-Glc but not UDP-GlcNAc. The LNG sequence at this 
position in LifA has more similarity to the sequences of the UDP-GlcNAc binding 
LCTs TcnA and TpeL, and it is hypothesised that this sequence is what allows for 
the accommodation of the acetyl group of GlcNAc (Cassady-Cain et al., 2016).  
If time and resources were invested in optimising the purification conditions 
for the recombinant LifA fragments, there are a number of methods, besides those 
described in Section 3.11, which could be used to gather structural information on 
lymphostatin. X-ray crystallography could be used to determine the structure of LifA 
or domains within. X-rays are diffracted by protein crystals to produce a series of 
spots, which can be used to determine the original crystal structure using Bragg’s 
Law (reviewed in Wang and Wang, 2017). To complete the structural model, further 
information is obtained by computational methods or by molecular replacement, 
which uses information from homologous proteins to make inferences about the 
structure of the protein under investigation (reviewed in Taylor, 2010). This 
technique has been used to determine the structure of the TcdA glucosyltransferase 
domain (Pruitt et al., 2012), the cysteine protease domain of PaTox (Bogdanović et 
al., 2018), and TcdA lacking the receptor binding domain (Chumbler et al., 2016). 
However, X-ray crystallography requires highly ordered protein crystals and so far 
attempts to produce crystals of full-length rLifA and rGT have been unsuccessful 
despite testing diverse conditions (Walkinshaw Laboratory, unpublished data). 
Producing crystals of rLifA is technically difficult due the size of the protein. 
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TcdA GT domain Model of LifA GT domain (A) (B)  
 
Figure 7.1. The glycosyltransferase (GT) domains of the large clostridial toxin 
TcdA and lymphostatin. (A) Representation of the crystal structure of the GT 
domain of C. difficile TcdA (Pruitt et al., 2012) bound to UDP-Glc. (B) Model of the 
GT domain of LifA from E. coli O127:H6 strain E2348/69 bound to UDP-GlcNAc 
based on homology with TcdA. The catalytic core (grey) is thought to be involved in 
substrate binding and the α-helical/unordered insertions (orange/blue) are thought to 
be involved in target recognition. Purple spheres represent Mn2+ ions (from 
Cassady-Cain et al., 2016). 
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TcdA:UDP-Glc Model of LifA:UDP-
GlcNAc 
(A) (B)  
 
Figure 7.2. The predicted binding sites of the large clostridial toxin TcdA and 
lymphostatin GT domains, illustrating sugar substrate specificity. (A) Model of 
the TcdA binding site in complex with UDP-Glc. Asp285 and Asp287 are shown in 
red. Ile382 and Gln384 of the XNX motif are shown in blue. (B) Model of the LifA 
binding site in complex with UDP-GlcNAc based on homology with TcdA. Asp557 
and Asp559 are shown in red. Lue667 and Gly669 of the XNX motif are shown in blue 
and are predicted to allow for the accommodation of the GlcNAc acetyl group. 
Purple spheres represent Mn2+ ions (from Cassady-Cain et al., 2016). 
 
Cryo-electron microscopy (EM) is another technique that could be used to 
produce three-dimensional models of the recombinant fragments. Cryo-EM uses thin 
sections of molecules frozen at low temperatures on a porous carbon grid, which are 
visualised by EM, and has the advantage over X-ray crystallography of requiring less 
material (reviewed in Murata and Wolf, 2018). This technique is predicted to be 
feasible for lymphostatin, as rLifA appears soluble and monodispersed by negative 
staining and transmission electron microscopy (Cassady-Cain et al., 2016). It is 
difficult to visualise proteins smaller than 50 kDa using standard cryo-EM, with the 
current smallest protein visualised being ~43 kDa (Herzik et al., 2019), which would 
be problematic for studying rF5 (~38 kDa). This could be overcome by fusing rF5 to 
a modular, self-assembling protein scaffold, which can hold an attached protein in 
symmetric and rigidly defined orientations (Liu et al., 2018b). However, given that 
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rF5 appeared to aggregate, this method may not be possible as proteins that naturally 
self-associate prevent the assembly of the scaffold protein (Liu et al., 2018b). 
Cryo-EM has previously been used to visualise pH-dependent conformational 
changes in TcdA (Pruitt et al., 2010), and given that rLifA requires endosome 
acidification for cleavage, a similar experiment could be performed to detect 
pH-dependent structural changes in lymphostatin. 
 Small angle X-ray scattering (SAXS) can also be used to provide lower 
resolution information on the structure of proteins. SAXS measures the intensity of 
X-rays scattered by a solution of particles to provide information on the size, shape 
and molecular weight of a protein of interest (reviewed in Kikhney and Svergun, 
2015). Although SAXS provides less detailed information than X-ray 
crystallography, it can be combined with this technique, as well as nuclear magnetic 
resonance, to provide information on protein flexibility that detailed structural 
measurements do not detect (Schulte et al., 2014; Grishaev et al., 2005). Further, it 
has the advantage that we have successfully used this technique to gain structural 
insights into lymphostatin. SAXS was combined with transmission electron 
microscopy of negatively stained rLifA to estimate the surface envelope and volume 
of the protein (Cassady-Cain et al., 2016) and has also been used to detect 
pH-dependent changes in rLifA and the mutant proteins rLifADTD/AAA and 
rLifAC1480A (Walkinshaw Laboratory, unpublished data). Highly purified rGT and 
rF3, produced by Dr Liz Blackburn, EPPF, have also been subjected to SAXS but the 
results were confounded by the self-association of these fragments (Walkinshaw 
Laboratory, unpublished data). 
 
7.1.2 Investigating the role of functional domains 
 
 Other methods could also be used to study the roles of predicted functional 
domains. Given that the N-terminus of lymphostatin contains the GT and CP 
domains, it was hypothesised that the C-terminus is involved in cell binding and 
uptake. Immunocytochemistry and confocal microscopy using the polyclonal 
anti-LifA antibody against rF3 and rF5 could be used to assess the location of these 
proteins within T cells. However, since these proteins could not be detected in T cell 
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lysates (see Section 3.9), despite being reactive to anti-LifA antibodies in isolation, 
they may not be detectible using this method. It is possible that these proteins are 
incapable of entering cells due to missing amino acids, therefore an alternative would 
be to produce recombinant LifA C-terminus (aa 1621–3223). Another alternative is 
splicing by overlap extension (SOEing) PCR. SOEing PCR uses primers for two 
different genes that overlap, thereby allowing for the creation of fusion proteins 
(Higuchi et al., 1988; Bryksin and Matsumura, 2010). SOEing PCR could be used to 
create a fusion protein of a reporter such as enhanced green fluorescent protein and 
the C-terminal end of LifA. After treating T cells with the purified fusion protein, 
confocal microscopy could then be used to assess the location of the protein. This 
method would not be limited by antibody sensitivity but may be limited by the 
quantity of protein that is taken up by cells. 
 Another method that could be used to study functional domains is the use of 
nested truncations. A number of methods have been developed to create nested 
truncations in various genes but all rely on the same underlying principle (Frischauf 
et al., 1980; Poncz et al., 1982; Henikoff, 1990). A series of truncations could be 
made from the N- or C-terminus of LifA and the resulting proteins could be assessed 
for inhibitory activity to determine which regions of the protein are required for 
activity. However, when producing truncations from the N-terminus, the possibility 
of deleting a signal sequence for protein secretion should be considered. 
Alternatively, a series of in-frame deletions could be created within the coding 
sequence of lifA, for example using restriction and re-ligation (McKnight and 
Kingsbury, 1982), SOEing PCR or by de novo synthesis of the desired lifA 
sequences. It should be noted however, that truncated proteins may not fold properly 
unless the correct boundaries for structure are chosen (Stevens Laboratory, 
unpublished data). 
Alanine scanning mutagenesis could be used for fine-scale mapping of 
residues required for activity and involves the sequential substitution of each amino 
acid in a specific region with Ala residues (Cunningham and Wells, 1989). Since 
alanine scanning mutagenesis cannot be used to investigate the role of Ala residues 
within these regions, serine scanning mutagenesis could potentially be used for these 
particular residues (Pál et al., 2005; Follis et al., 2005). With a protein the size of 
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lymphostatin, such a time- and resource-intensive strategy would be optimally 
focused on predicted catalytic domains or to test structure predictions. 
Error-prone PCR could be used to randomly insert mutations into the lifA 
gene. This is performed using a low-fidelity polymerase, such as Taq, and modified 
PCR conditions, such as increasing the concentration of MgCl2, adding MnCl2 and 
unbalancing the concentrations of dNTPs (Leung et al., 1989; Cadwell and Joyce, 
1992). However, not all nucleotide changes will introduce coding changes and some 
may alter the reading frame, meaning that large numbers of cloned amplicons would 
likely need to be sequenced. Lastly, mutagenesis using transposons such as Tn5, 
which inserts at near-random could be used (Ruvkun and Ausubel, 1981). 
Transposons can also include reporter genes that can provide information regarding 
the location of proteins within the bacterial cell, such as TnphoA or TnlacZ which 
can create translational fusions to alkaline phosphatase or -galactosidase and 
respectively identify domains located outside or inside the cytoplasmic membrane 
(Manoil and Beckwith, 1985; Manoil, 1990). A TnphoA insertion in lifA from EHEC 
E45035 confirmed that at least part of the protein is located outside the bacterial 
cytoplasmic membrane (Nicholls et al., 2000). The main drawback of all of these 
methods is that there is currently no high throughput system for producing and 
screening the large number of mutant proteins that could be made. Lysates of the 
mutant strains could be used in assays of lymphostatin activity, however, lysates are 
known to be less sensitive than recombinant protein for this purpose and biophysical 
experiments could not be performed to ensure the mutant proteins are folded and 
stable. 
 
7.2 Mode of action of lymphostatin on T lymphocytes 
 
 Due to the N-terminal homology between LifA and the LCTs, it was 
hypothesised that LifA may similarly enter cells by receptor-mediated endocytosis, 
undergo a pH-dependent conformational change in the endosome and insert the 
N-terminus through the endosomal membrane prior to CP domain-mediated cleavage 
of the protein and release of the GT domain-containing N-terminus into the 
cytoplasm. In this study, CP domain-mediated cleavage of recombinant lymphostatin 
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was observed in both primary bovine T cells and J774A.1 murine macrophage-like 
cells. The cleavage event was found to produce N- and C-terminal cleavage products 
of ~140 and 225 kDa respectively, but attempts to determine if a co-factor(s) is 
required for cleavage have been unsuccessful (Cassady-Cain et al., 2016). 
Lymphostatin does not self-cleave in isolation, which suggests a co-factor of some 
form is required for this event. Using the inhibitors bafilomycin A1 and chloroquine, 
endosome acidification was also found to be required for rLifA cleavage in T cells, 
consistent with the prediction of a low pH-dependent membrane insertion event akin 
to LCTs. 
 Attempts to identify targets or other interacting partners of lymphostatin were 
less successful. Shotgun mass spectrometry appeared to be limited by the sensitivity 
of the spectrometer, as very few GlcNAcylated proteins were detected, even after 
using a method to enrich GlcNAcylated proteins from T cell lysates. Two possible 
candidate targets were identified from the eluates of protein pull-downs, however, 
follow-up experiments could not confirm that these proteins specifically interacted 
with rLifA. A candidate target approach with the protein kinase Akt revealed that 
pre-incubating T cells with rLifA or live EPEC inhibits Akt1 Ser473 phosphorylation. 
However, this inhibition does not appear to be caused by O-GlcNAcylation of Akt as 
suggested by the laboratory of Professor Brendan Kenny (unpublished observations). 
The LifA/LifA-like-independent inhibition of Akt1 Ser473 phosphorylation by EPEC 
also suggests that the bacteria possess another virulence factor that may target Akt. 
 There are a number of experiments based on previous studies with LCTs that 
could be performed to further the understanding of the mode of action of 
lymphostatin, which are described in Sections 7.2.1–7.2.4. 
 
7.2.1 Mechanism of cell entry 
 
 Lymphostatin is known to be secreted via the LEE-encoded T3SS (Deng et 
al., 2012; Bease, 2015), but this is not necessary for activity as lysates and 
recombinant protein can inhibit mitogen-activated lymphocyte proliferation 
(Klapproth et al., 1995, 1996 and 2000; Malstrom and James, 1998; Stevens et al., 
2002; Bease, 2015; Cassady-Cain et al., 2016 and 2017). This, and the requirement 
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for endosome acidification for rLifA cleavage, suggests that LifA enters cells to 
reach its target rather than targeting a protein on the host cell surface. However, the 
exact mechanism by which LifA is taken up has yet to be identified. LCTs are taken 
up by clathrin-mediated endocytosis (Papatheodorou et al., 2010), but given the lack 
of homology between LifA and LCTs at the C-terminus uptake of LifA by the same 
pathway cannot be predicted with confidence. 
 To determine which endocytic pathway LifA is taken up by, experiments 
could be performed using inhibitors of different pathways. During this study, I 
attempted to carry out proliferation assays in which T cells were treated with 
inhibitors before incubation with buffer/rLifA and ConA stimulation. The following 
inhibitors were used: chlorpromazine, which inhibits clathrin-mediated endocytosis 
by preventing the formation of clathrin coated pits at the plasma membrane (Wang et 
al., 1993); methyl-β-cyclodextrin, which inhibits cholesterol-dependent endocytosis 
by forming soluble inclusion complexes with cholesterol and thus depleting it from 
cell membranes (Vieth et al., 2010; Ohtani et al., 1989; Kilsdonk et al., 1995); and 
cytochalasin D, which inhibits actin polymerisation and induces depolymerisation, 
thereby preventing phagocytosis and macropinocytosis (Casella et al., 1981; Sakr et 
al., 2001). It was hypothesised that ConA-stimulated T cell proliferation would not 
be suppressed if the inhibitors used blocked the uptake of rLifA, however, the 
concentrations of inhibitors used in these experiments proved to be cytotoxic. A 
more effective method for examining the mechanism of cell entry may be to 
pre-incubate T cells with a titration of each inhibitor, similar to the experiments 
performed with bafilomycin A1 and chloroquine. The presence/absence of the 
c. 140 kDa cleavage product at different inhibitor concentrations could then be used 
as an indicator for the effects of each inhibitor on rLifA uptake, before loss of cell 
viability occurs. Other inhibitors could also be tested, such as a combination of PMA 
and filipin, which inhibits caveolae-mediated endocytosis (Smart et al., 1994; 
Schnitzer et al., 1994), and nocodazole, which inhibits microtubule formation 
(Hoebeke et al., 1976; Samson et al., 1979). It should be noted, however, that some 
of these inhibitors have overlapping functions and are not specific to one form of 
endocytosis (reviewed in Ivanov, 2008). This could prove useful in that two 
inhibitors with overlapping functions that block rLifA entry could indicate which 
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mechanism lymphostatin is taken up by. It is unlikely that data exist on the inhibitor 
concentrations required to specifically block uptake pathways in bovine T cells, 
therefore significant pilot work and use of control ligands or pathogens would be 
required. 
 Chondroitin sulphate proteoglycan 4, polio virus receptor-like 3 and frizzled 
proteins have all been identified as receptors for TcdB (Yuan et al., 2015; LaFrance 
et al., 2015; Tao et al., 2016), while lipoprotein receptor-related protein 1 has been 
identified as a receptor for TpeL (Schorch et al., 2014). These LCT receptors were 
identified by various library screening methods, including gene traps and haploid 
genetic screens, which screened for toxin resistance. Gene trapping is a form of 
insertional mutagenesis that uses random integration of a reporter gene with a 
selectable marker throughout the genome of a host cell. This disrupts gene function 
and produces a dominant expression phenotype, allowing the products of disrupted 
genes that would normally interact with a protein of interest to be identified 
(reviewed in Kumari et al., 2018). Haploid genetic screening is a similar method but 
uses haploid cell lines so that the effects of gene disruption are not masked a second 
copy of the gene (reviewed in Elling and Penninger, 2014). It may be possible to use 
such screens to identify the receptor for lymphostatin using Jurkat cells and 
measuring IL-2 secretion by enzyme-linked immunosorbent assay, which has been 




 Little is known about LCT pore formation and translocation through the 
endosomal membrane, but knowledge thus far may be useful for understanding how 
the N-terminus of LifA escapes the endosome and mostly derives from structural 
studies and mutagenesis of particular sequences (Genisyuerek et al., 2011; Zhang et 
al., 2013b; Chen et al., 2016; Chumbler et al., 2016). Computational methods could 
be used to predict regions with particular secondary structures that may be of interest 
to investigate (Zhang et al., 2014; Chen et al., 2016). Zhang et al. (2014) used 
TMHMM v2.0 (Krogh et al., 2001), which uses a hidden Markov model to predict 
amino acid sequences that form transmembrane helices in the translocation domain 
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of TcdB. This programme does not predict EPEC E2348/69 LifA to contain any 
transmembrane helices, but the complimentary probability plot reveals several 
regions of hydrophobicity that are more likely to form these structures than the rest 
of the protein. Similar results are obtained when analysing LCTs, therefore it is likely 
that transmembrane helices are not predicted because LifA and LCTs are not true 
transmembrane proteins. Eight small hydrophobic regions were identified in LifA 
using TMHMM v2.0 at positions 96–113, 1362–1377, 1674–1697, 1901–1927, 
2053–2069, 2330–2353, 2571–2590 and 2957–2971. Five larger distinct peaks were 
identified at positions 1850–1883, 1947–1988, 1988–2038, 2119–2138 and 2235–
2264 (Figure 7.3). Interestingly, the largest of these peaks spans the transmembrane 
domain predicted by Nicholls et al. (2000) and the smaller preceding peak 
encompasses the aminotransferase II motif predicted by Klapproth et al. (2005). The 
overall size of the protein also affects the probability score, as separately analysing 
the region containing the five peaks provides a higher score for each peak. This 
suggests that a region of LifA may be inserted into the endosomal membrane of host 
cells to facilitate translocation of the catalytic N-terminus into the cytoplasm. 
Zhang et al. (2014) mutated amino acids within the hydrophobic regions that 
were highly conserved between LCTs. Amino acids were substituted for either polar 
lysine residues, which would disrupt hydrophobic interactions, or less polar cysteine 
residues. A similar approach could be taken with LifA, however, choosing highly 
conserved amino acids may be problematic as LifA homologues do not exhibit as 
high similarity at the primary sequence level as LCTs. If defective LifA mutants 
were identified using this method, which would likely be performed by screening 
lysates, mutant proteins could be purified and biophysically characterised. Mutant 
proteins that were structurally stable could then be assayed for activity and the ability 
to form pores as described in Section 4.9 (Qa’dan et al., 2000; Barth et al., 2001).  
Amino acids involved in the predicted pH-dependent conformational change 
of LifA could be identified by performing similar experiments to Genisyuerek et al. 
(2011). This study first used nested deletions to identify a region of TcdB that was 
required for pore-forming activity. Two glutamic acid residues located between 
hydrophobic clusters were substituted for lysine residues, which are not neutralised 
upon acidification. These amino acids were chosen because similar residues are 
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required for pore formation by diphtheria toxin (Silverman et al., 1994). Mutant 
TcdB proteins were then assayed for cytotoxicity and pore-forming activity 
(Genisyuerek et al., 2011). Acidic amino acids are found between predicted 
transmembrane helices in EPEC E2348/69 LifA at the following positions: 1886, 
1887, 1898, 1904, 1922, 1930, 1935, 1988, 2040, 2041, 2048, 2055, 2066, 2071, 
2084, 2095, 2101, 2109, 2112, 2117, 2151, 2153, 2168, 2170, 2180, 2184, 2195, 
2207, 2220, 2224, 2227, and 2234. These may warrant investigation in future studies. 
 
Figure 7.3. Probability plot of transmembrane helices as predicted by TMHMM 
v2.0 for EPEC E2348/69 LifA. Five distinct peaks located within the ‘hinge’ 
(aa 1621–2110) and F3 (aa 2111–2900) regions of LifA indicate amino acids with 
higher probabilities of forming transmembrane helices than the rest of the protein. 
Two smaller hydrophobic regions (aa 1901–1927 and 2053–2069) are located 
between these peaks but are barely visible on the plot. The largest peak and the 
preceding smaller peak span the predicted transmembrane domain and 



























 The requirement of cholesterol for pore formation could also be tested as it 
has been for TcdA and B (Giesemann et al., 2006). Methyl-β-cyclodextrin could be 
used to deplete T cell membranes of cholesterol, and since the acid pulse method 
used to detect pore formation (see Section 4.9) allows the protein to translocate 
through the plasma membrane, the potential effects of methyl-β-cyclodextrin on 
endocytosis would be irrelevant. Rescuing pore formation by restoring cholesterol 
levels with water-soluble cholesterol could then be attempted. The biggest limitation 
for studying the translocation of LifA is that any mutant proteins that are made 
cannot be easily tested for effects of the mutation on other predicted functional 
domains. Tryptophan fluorescence assays could be used to confirm UDP-GlcNAc 
binding and directly labelling the protein with a fluorophore could be used to assess 
uptake. However, unlike LCTs, there is currently no in vitro cleavage assay for LifA. 
As such, using T cells or J774A.1 cells to detect the presence of cleavage products 
would be prevented if the mutant protein cannot form a pore in the endosomal 
membrane. 
 
7.2.3 Cleavage of lymphostatin 
 
 Although this study found that lymphostatin was cleaved within T cells and 
J774A.1 cells, autocatalytic cleavage has not been proven as it has with LCTs. 
Although LifA likely requires a co-factor for cleavage, it unclear whether or not said 
co-factor is proteinaceous. It was thought that the apparent shortening of rF1 may be 
the result of autoproteolysis caused by the missing C-terminus acting as a 
conformational change, which triggers cleavage (see Section 3.11). However, the 
shortened form of rF1 was ~150 kDa, which is slightly larger than the N-terminal 
cleavage product detected in cells (c. 140 kDa). If the shortening of rF1 is caused by 
autoproteolysis it is unclear why cleavage would occur at a different site in vitro than 
in cells. Possible evidence for the autocatalytic cleavage of LifA comes from SAXS 
experiments. rLifA was reported to shorten after the buffer was acidified by X-ray 
ionisation, whereas proteins would normally appear larger due to being denatured 
(Walkinshaw Laboratory, unpublished data). However, this may simply be the result 
of pH-induced structural changes that cause the protein to adopt a conformation with 
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a smaller volume. This theory is supported by the fact that rLifA in acidic buffer was 
observed to elute at a later point than normal on a SAXS-SEC column, and the 
protein did not appear to fragment (Walkinshaw Laboratory, unpublished data). 
 The present study only examined the effects of mutating the predicted 
catalytic Cys1480, but the His and Asp residues of the C/H/D catalytic triad have been 
reported to be essential for cleavage in both C58 proteases and LCTs (Shao et al., 
2002; Dai et al., 2008; Egerer et al., 2007; Pruitt et al., 2009). As such, the predicted 
catalytic His1581 and Asp1596 could be substituted for alanine residues by site-directed 
mutagenesis to determine whether these are also required for LifA cleavage and 
activity. Additionally, the cleavage site of LifA could be identified using the same 
method that was used for TcdB (Rupnik et al., 2005). First, a suitable quantity of the 
C-terminal c. 225 kDa cleavage product would need to be generated. This may 
require using J774A.1 cells and potentially immunoprecipitating the cleavage 
products from the cell lysates. Western blot analysis using polyclonal anti-LifA 
antibodies indicates that this should be feasible as rF3 and rF5 were reactive. 
N-terminal sequencing of the c. 225 kDa cleavage product could then be used to 
identify the site of cleavage. Alternatively, MALDI-TOF/TOF analysis could be 
used, as was done to identify the cleavage site of TcdA (Kreimeyer et al., 2011). The 
cleavage site could then be confirmed by substituting the identified residues using 
site-directed mutagenesis. 
 Despite the findings of this study, it may be that cleavage of LifA is not 
strictly necessary for inhibitory activity. CP domain mutants of TcdB still induce 
toxicity in epithelial cell lines but require a longer incubation (Chumbler et al., 2012; 
Li et al., 2013a). It is presumed that the GT domain remains bound to the surface of 
the endosome and is able to interact with Rho GTPases in close proximity. If the GT 
domain of rLifAC1480A is capable of interacting with its target, albeit at a reduced 






7.2.4 Target of glycosylation 
 
 Further work could be done to identify the target(s) of lymphostatin based on 
its impact on signal transduction pathways. It is hypothesised that the target(s) of 
lymphostatin is located between the points where ConA and PMA/ionomycin 
stimulate the T cell signalling cascade. The kinase array experiments performed by 
Dr Robin Cassady-Cain, The Roslin Institute, revealed several proteins other than 
Akt, which exhibited a LifA-dependent inhibition of phosphorylation. These 
included Erk1/2, CREB, p70 S6 kinase and p27. It is therefore possible that LifA 
targets a protein upstream of these in the T cell signalling cascade. Lck is a plausible 
candidate as it activates the main T cell signalling cascade through CD3 ITAMs 
(reviewed in Simeoni, 2017) and Akt through PI3K (von Willebrand et al., 1994). 
There is a potentially complex interplay, however, between T cell signalling through 
the LAT signalosome and the PI3K/Akt pathways. Studies have shown that Akt can 
activate PLCγ1 in COS-7 kidney cells (Wang et al., 2006), and that both Akt and 
ERK can inactivate tuberous sclerosis 2 (TSC2) to promote cell growth and cell 
cycle progression in various cell types, including epithelial, myoblast and bone 
marrow cells (Inoki et al., 2002; Ma et al., 2005; Wang et al., 2009; Miyazaki and 
Takemasa, 2017). This is further complicated by the fact that TSC2, in complex with 
TSC1, regulates Akt phosphorylation by enhancing mTORC2 kinase activity 
(experiments performed using epithelial cells; Huang et al., 2008). However, it is 
unclear whether these findings apply to T cells. Studies targeting candidate proteins 
can be limited by the availability of specific antibodies and the time required to test 
individual proteins. Moreover, only O-GlcNAcylation can be tested for by western 
blotting as antibodies specific to GlcNAc on N-linkages are presently lacking. 
 Several other methods exist that could be used to identify the target(s) of 
lymphostatin. Yeast two-hybrid screening has a variety of forms and is commonly 
used to detect protein-protein interactions (reviewed in Zhu et al., 2016). The 
simplest method was first described by Fields and Song (1989) and uses blue-white 
colour screening to detect interactions between two proteins. The gene encoding 
LifA, or more likely the GT domain owing to size, could be fused to the DNA 
binding domain of the transcription factor GAL4. This could then be screened 
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against a library of human proteins fused to the activation domain of GAL4 (or vice 
versa). If LifA/GT and the putative interacting partner have a genuine interaction, 
and thus bring the GAL4 binding and activation domains into close proximity, a 
GAL1-lacZ fusion gene will be transcribed enabling blue-white screening in the 
presence of a chromogenic substrate of -galactosidase. However, the proteins under 
investigation must be small enough to allow the two domains of GAL4 to come 
within the required distance of each other for activation. The interaction between the 
two proteins must also be able to occur in the yeast nucleus. Using a mammalian cell 
two-hybrid system would allow for experiments to be carried out in a native 
environment (Dang et al., 1991) and using fluorescent reporter fusion proteins would 
allow the proteins to interact outside the nucleus (Zolghadr et al., 2008). 
 Two-hybrid systems are useful for high throughput screening but can result in 
high numbers of false positives (Deane et al., 2002). To confirm any putative 
interactions, co-immunoprecipitation could be used. This would involve treating T 
cells with rLifA then using IP to recover rLifA and any associated interacting 
partner. Western blotting could then be used to confirm the presence of both proteins 
in the IP sample (reviewed in Lin and Lai, 2017). A monoclonal antibody to rLifA 
may be required to improve the specificity of such IPs. An alternative may be to use 
far western blotting, whereby cellular proteins resolved by SDS-PAGE are 
transferred to a PVDF membrane, which is then exposed to rLifA. Bound protein is 
then detected with specific antibody and revealed by an enzyme-conjugated 
secondary antibody. This is not typically as specific as co-IP and can be sensitive to 
denaturants in the gel system. Candidate interacting partners can then be identified 
by mass spectrometry of tryptic fragments of proteins excised from the blot 
(reviewed in Hall, 2015). 
 Co-IP and far western blotting cannot detect transient interactions, however. 
To detect targets of LifA when the interaction may be transient, chemoenzymatic 
labelling could be employed, as it was with NleB to demonstrate transfer of a 
labelled GlcNAc moiety onto cellular targets (Li et al., 2013b). Firstly, genes 
encoding LifA or the GT domain and a tagged variant of the putative target protein 
must be transfected into an immortalised cell line where they can be overexpressed. 
Cells expressing these proteins are then incubated with tetraacylated 
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N-azidoacetylgalactosamine (Ac4GalNAz), which is then converted into 
Ac4GlcNAz via the GlcNAc salvage pathway (Boyce et al., 2011). IP could be used 
against the tag of the target protein, the azide group of which would then be bonded 
to alkyne-linked biotin via a copper catalysed Huisgen 1,3-cycloaddition ‘click 
reaction’ (Nishikaze et al., 2013; Li et al., 2013b). Western blot analysis of the 
reaction product using streptavidin-HRP or antibodies against the target protein’s tag 
could then reveal whether the target protein has been GlcNAzylated. This technique 
could also be performed using native proteins, in which case the ‘click reaction’ 
would be performed using cell lysates. This may require proteins to be resolubilised 
after the reaction (reviewed in Speers and Cravat, 2009), which can then be isolated 
with streptavidin beads. One problem associated with performing this experiment in 
cells is that Ac4GlcNAz can be added to other proteins. This can be alleviated by 
pre-treating cells with tunicamycin, which inhibits N-glycosylation (reviewed in 
Esko et al., 2017), and inhibitors of O-GlcNAc transferase, such as alloxan, L01 or 
5SGlcNHex (reviewed in Trapannone et al., 2016; Liu et al., 2017; Liu et al., 
2018a). Similar to inhibitors of O-GlcNAcase (see Section 5.4), O-GlcNAc 
transferase inhibitors that are analogues of GlcNAc should be tested to ensure that 
they do not bind to and inhibit LifA. Performing the reaction in vitro would also 
prevent the GlcNAzylation of non-target proteins by cellular enzymes. 
 
7.2.5 Cell cycle analysis 
 
 If lymphostatin causes T cells to pause in a particular phase of the cell cycle, 
this could be detected using flow cytometry using DNA-binding fluorescent dyes, 
such as propidium iodide, DAPI or Hoechst 33342 (Krishan, 1975; Belloc et al., 
1994). This allows for the distinction between cells in the G0/G1, S and G2/M phases. 
Since doublets of cells in the G0/G1 phase contain the same quantity of DNA as 
single cells in the G2/M phase, these must be excluded (Wersto et al., 2002). Cells 
may first have to be synchronised to the G0 phase, which can be reversibly achieved 
by serum starvation (Griffin, 1976), although this may not be necessary as is it has 
been reported that peripheral T cells from humans are predominantly in this phase 
(Witkowski and Bryl, 2004). Such methods have previously been used to 
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characterise a number of bacterial toxins and Type III secreted effectors termed 
cyclomodulins (Marchès et al., 2003; reviewed in Taieb et al., 2011). 
 
7.3 Lymphostatin homologues 
 
 There are a number of homologous proteins to lymphostatin in A/E E. coli 
and other bacteria (reviewed in Klapproth, 2010), but few studies have been carried 
out with regards to the function of these proteins. Abu-Median et al. (2006) did not 
observe inhibitory activity against PBMCs with lysates of efa1 and toxB EHEC 
O157:H7 85-170 NalR mutants. However, it has recently been shown that ToxB does 
in fact possess lymphostatin activity against bovine peripheral T cells (Cassady-Cain 
et al., 2017). This is consistent with earlier observations that showed the EHEC 
O157:H7 lysates could inhibit IL-2 production by ConA-stimulated human PBMCs 
in a manner dependent on the c. 92 kb pO157 plasmid that encodes toxB (Klapproth 
et al., 2000). A number of LifA homologues were described in C. trachomatis that 
exhibit cytotoxic activity (Belland et al., 2001). A LifA homologue from C. pecorum 
has recently been shown to inhibit ConA-stimulated T cell proliferation, without 
causing direct cytotoxicity (Stevens Laboratory, unpublished data). Given that 
Chlamydia species are obligate intracellular pathogens, it is unclear how such 
proteins would escape infected cells to target T cells. The extracellular elementary 
bodies of Chlamydia are metabolically active (reviewed in Elwell et al., 2016) but 
are not known to secrete virulence factors. C. pneumonia have been shown to infect 
T cells (Haranaga et al., 2001), although they do not possess any LifA homologues. 
However, if other Chlamydia species are capable of infecting lymphocytes, this may 
allow them to secrete LifA homologues either directly into the host cell cytoplasm 
via the T3SS or into the phagosome, where the protein may then cross the 
membrane. 
 Few studies have so far investigated the role of LifA-like protein from EPEC 
E2348/69 (Cepeda-Molero et al., 2017; see Section 7.4), while the slightly different 
LifA-like protein from EPEC O111:H- strain B171-8 has never been studied. 
However, if data from the Kenny Laboratory is correct, and EPEC does inhibit Akt1 
Ser473 phosphorylation in a LifA-like-dependent manner, this suggests that LifA-like 
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protein may target the same protein(s) as LifA. It would therefore appear that LifA is 
merely one protein in a larger lymphostatin family with some redundancy of 
function. Many of the same experiments used to study LifA could be performed with 
these homologues and/or of particular interest would be whether they use the same 
sugar substrates and have the same target(s). The biggest limitation to studying these 
proteins is likely to be obtaining sufficient quantities of the proteins, as purified 
rToxB and the recombinant C. pecorum homologue were obtained in much lower 
quantities than rLifA (Stevens/Walkinshaw Laboratory, unpublished data). It may be 
possible to obtain larger quantities of protein using an alternative expression system, 
such as Bacillus megaterium, which were used to produce LCTs as they are 
expressed poorly in E. coli (Burger et al., 2003; Yang et al., 2008). Given that the 
LifA-like proteins from EPEC E2348/69 and B171-8 lack the C-terminal 867 and 
668 amino acids of LifA respectively, it would be of interest to determine whether 
these proteins can enter cells in the same way as LifA. If inhibitory activity against T 
cells could not be detected with exogenously applied LifA-like proteins, using the 
acid pulse method (see Section 4.9) may reveal activity, as analysis of these proteins 
with TMHMM v2.0 predicted that they also contain C-terminal transmembrane 
helices. It is also possible that the LifA-like proteins may be directly secreted into 
cells via the T3SS, meaning that phenotypes may only be evident after bacterial 
infection. 
 Perhaps the most peculiar of the LifA homologues is Efa1, as it is unclear 
whether efa1 encodes a functional protein or is merely a pseudogene. Given that a 
DNA vaccine of efa1 has been reported to confer protective immunity against EHEC 
O157:H7 in mice (Riquelme-Neira et al., 2016), this suggests that the protein is 
functional. However, studies using single and double efa1 and toxB mutants of E. 
coli O157:H7 in calves did not reveal a significant role for the proteins in intestinal 
colonisation (Stevens et al., 2004). If both open reading frames z4332 and z4333 are 
transcribed via ribosome frameshifting, then the full-length Efa1 protein would 
include a portion of the LifA GT domain, including the DXD motif. Abu-Median et 
al. (2006) did not attribute inhibitory activity of lysates of EHEC 85-170NalR to 
Efa1, however, we cannot preclude the possibility that it may require Type III 
secretion into host cells for activity. Transfection of the Efa1 protein or the gene 
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encoding it into cells could be used to determine whether this protein possesses 
lymphostatin activity. The dedicated study of lymphostatin homologues may reveal 
insights into how these virulence factors evolved and lead to effective therapies 
against the pathogens that produce them. 
 
7.4 Other potential activities of lymphostatin 
 
 The genes encoding lymphostatin from EPEC E2348/69 (lifA) and EHEC 
factor for adhesion (efa1) from EHEC O111:H- E43035N were described in the same 
year and are almost identical (Klapproth et al., 2000; Nicholls et al., 2000). A 
number of studies have reported that lifA, toxB and efa1 mutant EPEC and EHEC 
strains have reduced adherence to epithelial cells (Nicholls et al., 2000; Tatsuno et 
al., 2001; Stevens et al., 2002 and 2004; Badea et al., 2003; Deacon et al., 2010). 
Immunofluorescence microscopy of EPEC O127:H6 strain JPN15 also reportedly 
detected LifA associated with the perimeter of the bacterial outer membrane (Badea 
et al., 2003). However, the deletion of these genes in some strains has been reported 
to affect the expression and secretion of Type III secreted proteins that are required 
for adherence (Tatsuno et al., 2001; Stevens et al., 2002 and 2004; Deacon et al., 
2010). This suggests that the role of LifA and its homologues in adherence may be 
indirect, at least in some strains. The fact that the effect does not appear to occur at 
the level of transcription (Stevens et al., 2004) leads to the hypothesis that the 
mutations may affect translation of the proteins while docked at T3SS complexes or 
the hierarchy of secretion of T3S proteins (Wang et al., 2008; Mills et al., 2013). 
This suggests that A/E E. coli strains possessing lifA or its homologues may be more 
virulent, as observed with atypical EPEC strains (Afset et al., 2006; Narimatsu et al., 
2010; Slinger et al., 2017). To determine whether the role of LifA in adherence is 
direct, laboratory-adapted strains of E. coli could be mixed with rLifA or buffer and 
applied to epithelial cell lines. A count of the microcolonies would reveal whether 
LifA can enhance bacterial adhesion independently of other effector proteins, unless 
another protein is required to interact with LifA, similar to the intimin-Tir interaction 
(see Section 1.1.3.6). A precedent exists for proteins to bridge an interaction between 
bacteria and host cells in this way, as the Type I secreted 595 kDa SiiE protein from 
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Salmonella associates with both the bacterial surface and glycan moieties on host 
cells (Morgan et al., 2007; Gerlach et al., 2007; Wagner et al., 2014). Alternatively, 
rLifA could be conjugated to fluorescent carboxylate-modified latex beads and cells 
with bound beads could be detected by flow cytometry, as was performed with 
intimin (Gonçalves et al., 2003). 
 Recently, it was reported that LifA and LifA-like protein have an accessory 
role in A/E lesion formation that is masked by other Type III secreted effectors 
(Cepeda-Molero et al., 2017). This function was independent of effects on other 
effectors as the secretion of T3S proteins was normal in strains lacking LifA and 
LifA-like protein. Identifying interacting partners of these proteins from epithelial 
cells may help to elucidate the underlying mechanism of LifA/LifA-like-mediated 
pedestal formation. Other studies also suggest a potential role for LifA in 
non-lymphocyte cells. If observations by the Kenny Laboratory are correct in that 
EPEC inhibit Akt1 Ser473 phosphorylation in a LifA/LifA-like-dependent manner in 
J774A.1 cells (see Section 6.1), this may indicate a role for LifA in modulating a 
plethora of Akt-dependent cellular processes. The extent to which LifA and its 
homologues may modulate innate immune responses in other cell types also merits 
study, given the number of other Type III secreted effectors that target this. 
 
7.5 Concluding remarks 
 
 This study significantly contributes to our understanding of the mode of 
action and molecular biology of lymphostatin, an important virulence factor of A/E 
E. coli. However, while this research has revealed new insights from rLifA-treated 
bovine T lymphocytes in vitro, it does not demonstrate the relevance of lymphocyte 
inhibitory activity during the course of A/E E. coli infection in cattle or other 
animals. Various studies have previously shown that LifA is an important 
colonisation factor (see Section 1.3.4) but none have investigated the effects of LifA 
on the host immune response. One experiment that could be performed to investigate 
the effects of LifA on the adaptive immune response of the host would be to generate 
an E. coli strain that overexpresses a model antigen, such as ovalbumin, in the 
presence or absence of lymphostatin. This may allow the impact of LifA on the 
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induction of ovalbumin-specific antibody or effector cells to be quantified, however, 
disentangling the contribution of LifA to the modulation of host immunity from its 
role in gut colonisation may be challenging. It is possible that this could be overcome 
by repeatedly reapplying the bacteria, or recombinant proteins, directly to an 
accessible site of immune priming in cattle, such as follicle-associated epithelium in 
the terminal rectum. This is a key site of persistence of EHEC O157:H7 in cattle and 
cellular immune responses can be quantified by studying phenotypes of cells from 
lymph nodes draining this site (Corbishley et al., 2014 and 2016). Given that LifA is 
also produced by C. rodentium and RDEC, mouse or rabbit models of infection could 
be used as alternatives. 
 Also worthy of consideration is how lymphostatin reaches its target cells 
given that the frequency that A/E E. coli come into direct contact with lymphocytes 
in vivo may be low (see Section 1.3.3). It may be that LifA is directly injected into 
intraepithelial lymphocytes or is secreted into the extracellular milieu and diffuses to 
reach intraepithelial lymphocytes. Alternatively, LifA may be translocated across the 
epithelial cell layer to gut associated lymphoid tissue or into the bloodstream, where 
it acts on circulating lymphocytes before they reach the site of infection. Future 
research could seek to determine whether LifA production and/or translocation could 
be detected in the gut of infected animals using reporter fusions, as was carried out 
for Salmonella Type III secreted proteins (Geddes et al., 2007). Studies could also 
seek to determine whether LifA might be transported through the blood stream in 
microvesicles, similar to Stx (Ståhl et al., 2015). A ligated intestinal loop model 
previously failed to detect lifA-dependent effects on bovine intraepithelial 
lymphocytes exposed to EHEC in situ (Menge et al., 2004b), however, the model is 
constrained by the relatively short time that the animals were maintained under 
terminal anaesthesia. A model in which loops of gut formed by end-to-end 
anastomoses of ileal segments could be inoculated with strains and the animals then 
recovered to enable longer exposure may be useful (Coombes et al., 2005). Similar 
to experiments with Stx (Kolling and Matthews, 1999), outer membrane vesicles 
from A/E E. coli could also be examined for the presence of LifA protein or nucleic 
acids encoding LifA and homolgous proteins to determine whether this is a possible 
method of lymphostatin delivery. 
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 There have been few vaccine studies with LifA and its homologues and these 
have had mixed results (van Diemen et al., 2007; Riquelme-Neira et al., 2016). 
However, a greater understanding of the molecular basis of lymphostatin activity 
may allow for the creation of novel forms of the protein that act as more potent T and 
B cell antigens as they do not possess inhibitory activity. This follows a similar 
strategy to the development of detoxified variants of E. coli heat labile toxin or 
cholera toxin, which are immunogenic but lack the capacity to cause pathology 
(Holmgren et al., 1993; Douce et al., 1999; Sánchez et al., 2002). Continued studies 
also have the potential to reveal novel aspects of lymphocyte activation, which may 
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Appendix 1: Composition of buffers and reagents 
 
Red blood cell lysis buffer was composed of 1 L dH2O with 100 mM KHCO3, 
1.5 mM NH4Cl and 10 mM EDTA. It was made up to pH 8 using NaOH and HCl 
split into 10 x 100 mL aliquots and autoclaved. 
 
NP-40 lysis buffer was composed of 100 mL dH2O with 250 mM Tris, pH 7.4, 
150 mM NaCl, 2 mM EGTA, 50 mM NaF, 1 mM EDTA, 1 mM Na3VO4 and 1 % 
(v/v) NP-40. One protease inhibitor tablet (Roche) or 100 µL of HaltTM protease 
inhibitor cocktail (Thermo Scientific) was added fresh to 10 mL of lysis buffer 
before use. 
 
To make 300 mL of NZY+ broth, 2 g of NZ amine, 1 g of yeast extract and 1 g of 
NaCl was dissolved in dH2O and made up to pH 7.5 using NaOH and HCl. The 
media was autoclaved then 2.5 mL of sterile 1 M MgCl and 1 M MgSO4 was added 
along with 0.4 % (w/v) glucose. 
 
IMAC buffer A was composed of 500 mL dH2O with 20 mM NaH2PO4, 300 mM 
NaCl, 5 % (v/v) glycerol and 0.1 % (v/v) Tween 20. It was made up to pH 7.6 using 
NaOH and HCl and 1 mM fresh DTT was added before use. It was kept on ice or at 
6 °C when not in use. 
 
IMAC buffer B was composed of 200 mL dH2O with 20 mM NaH2PO4, 300 mM 
NaCl, 5 % (v/v) glycerol, 0.1 % (v/v) Tween 20 and 500 mM imidazole. It was made 
up to pH 7.6 using NaOH and HCl and 1 mM fresh DTT was added before use. It 
was kept on ice or at 6 °C when not in use. 
 
SEC buffer was composed of 1 L dH2O with 10 mM NaH2PO4, 50 mM NaCl, 5 % 
(v/v) glycerol and 0.1 % (v/v) Tween 20. It was made up to pH 7.6 using NaOH and 
HCl and 1 mM fresh DTT was added before use. It was kept on ice or at 6°C when 
not in use. 
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The low salt buffer used for anion exchange chromatography was composed of 1 L 
dH2O with 10 mM Tris or 10 mM NaH2PO4, 50 mM NaCl, 5 % (v/v) glycerol and 
0.05 % (v/v) Tween 20. It was made up to pH 7.6 using NaOH and HCl and 1 mM 
fresh DTT was added before use. It was kept on ice or at 6 °C when not in use. 
 
The high salt buffer used for anion exchange chromatography was composed of 
200mL dH2O with 10 mM Tris or 10 mM NaH2PO4, 1 M NaCl, 5 % (v/v) glycerol 
and 0.05 % (v/v) Tween 20. It was made up to pH 7.6 using NaOH and HCl and 
1 mM fresh DTT was added before use. It was kept on ice or at 6 °C when not in use. 
 
Assay buffer was composed of 200 mL of dH2O with 15 mM NaH2PO4, 150 mM 
NaCl and 5 % (v/v) glycerol. It was made up to pH 7.6 using NaOH and HCl and 
1 mM fresh DTT was added before use. It was kept on ice or at 6 °C when not in use. 
 
CD buffer was composed of 200 mL of dH2O with 15 mM NaH2PO4, 150 mM NaF 
and 5 % (v/v) glycerol. It was made up to pH 7.6 using NaOH and HCl and 1 mM 
fresh DTT was added before use. It was kept on ice or at 6 °C when not in use. 
 
The α-cyano-4-hydoxycinnamic acid matrix was composed of 400 µL dH2O with 
10 mg/mL α-cyano-4-hydoxycinnamic acid, 0.3 % (v/v) trifluoroacetic acid and 
50 % (v/v) acetonitrile. The solution was mixed thoroughly after the addition of each 
reagent then centrifuged at 5000 rpm for 1 minute in a benchtop centrifuge. The 
supernatant was used for spotting with samples on the MALDI plate. 
 
X-Gal staining mix was made from reagents provided in the Beta-Glactosidase 
Staining Kit (Clonetech Laboratories Inc.). It was composed of 10 µL of X-Gal 
Solution, 2 µL of each of Staining Solutions 1, 2 and 3 and 184 µL of 1 x PBS.
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Appendix 2: Nucleotide sequences of the lifA fragment genes 
 


































































































































































































Appendix 3: Peptide map of recombinant LifA fragments 
 




1    MRLPEKVLFP PVTSGLSGQE KQKKPKSITG FQENYQRNIR PIKTASEARL 
51   RFFDKMVSKE NSLEDVVSLG EMIQKEIYGH EQRTFSPVHH TGNWKSSLLH 
101  NALLGLANVY NGLRETEYPN TFNRDGIKST NSFRDNLLTK TRTPRDNFEE 
151  GIKHPEHATI PYDNDNESNK LLKAGKIAGN NNELLMEIKK ESQSDHQIPL 
201  SDKFLKRKKR SPVAEDKVQN SLTPENFVQK ISLSDELKTK YANEIIEIKR 
251  IMGEYNLLPD KNSRNGLKLL QKQADLLKII MEDTSVTENT FKNIEIAITD 
301  IKREYYSHTV DIEKNIHAIW VAGSPPESIS DYIKTFLKTY KEFTYYLWVD 
351  EKAFGAAKFT SVLKQIAFDL ACRTIQQNTP QKNIDFINLY NEIRKKYNNN 
401  PSGQQEYLNK LRELYATYQK ISTPLKHMFN SFFLENMIKL QDNFFNYCIV 
451  KGVTEINDEL RINYLKNVIK LSDDDIGNYQ KTINDNKDRV KKLILDLQKQ 
501  FGENRISIKD VNSLTSLSKS ENNHNYQTEM LLRWNYPAAS DLLRMYILKE 
551  HGGIYTDTDM MPAYSKQVIF KIMMQTNGDN RFLEDLKLRR AISDGVLRYV 
601  NNQNIDEVNY NEISDADKNI IKKILTEISK MPEDSIFTKI NTRIPRDTMP 
651  ILRRYHLWPD GWNIRGLNGF MLSHKGSEVI DAVIAGQNQA YRELRRIRDN 
701  IHSEIYFKQT DELSSLPDTD KIGGILVKKY LSGSLFSKFR QDTIIPEALS 
751  TLQISGPDLI QRKMLQFFRS RGVLGEEFIN ERKLSDKAYI GVYKTTGTGK 
801  YDWLTPESIG VNDVTPADES TWCIGKGRCV DDFLFKDVST LKTENLPELF 
851  LTKIDTDTFF SQWSTKTKKD LQKKIQDLTV RYNELIDSST IDFKNLYEID 
901  QMLHMIMLEM NDDIAKRSLF SLQVQIAEKI RRMTIPVDNI INIYPDLHKK 
951  NDNDLSMSIK GFLASNPHTK INILYSNKTE HNIFIKDLFS FAVMENELRD 
1001 IINNMSKDKT PENWEGRVML QRYLELKMKD HLSLQSSQEA NEFLEISTFI 
1051 YENDFLREKI EAVKNKMNSH ELYFEKIKKE QNTWQDLSTK EQKLQLIKAL 
1101 KEISGNTEKD SHYDRLLDAF FKKHNENIHN KIQRIKDEFK EYSRVAIHNI 
1151 DKVIFKGQTL DRLYHEGYVF SDINTLSRYT LHGLGITGVH TEENLLPAPS 
1201 SSLINILKEH YNEDEISAKL PLAYDYILNK KESSSIPVEI LNKLSELPPH 
1251 ELLTPVLGQS VNPLGMGYSS DNGKITEQVI VSGADGFDNP ISGLIYTYLE 
1301 DLYNIHVRMR EGTLNSQNLR QLLENSVSSC FLTEQSINKL LSEAEKRPYQ 
1351 SLTEIHQHLT GLPTIADATL SLLSVGLPGT GKLLRREQDY GRPPVTAIQD 
1401 STFVLPYNFK GIGFNDNIIS SAPVASSLHF IAEHAKYTLL SWPEFYRHHA 
1451 QRWFEMAKGY GSQNIDFHPQ SLLVTQEGRC MGLALLYLQT EDTAHYSILQ 
1501 ENLMTVSALH QTSNRDKLPL SKDDNSLMTR TYSLIEMLQY QGNKYITNES 
1551 LLHKTAWNQE RITLLFNEKG VKRALISTPN HTLVLQQLED IYRLTDPNFG 




1   MHHHHHHSLT PENFVQKISL SDELKTKYAN EIIEIKRIMG EYNLLPDKNS 
51  RNGLKLLQKQ ADLLKIIMED TSVTENTFKN IEIAITDIKR EYYSHTVDIE 
101 KNIHAIWVAG SPPESISDYI KTFLKTYKEF TYYLWVDEKA FGAAKFTSVL 
151 KQIAFDLACR TIQQNTPQKN IDFINLYNEI RKKYNNNPSG QQEYLNKLRE 
201 LYATYQKIST PLKHMFNSFF LENMIKLQDN FFNYCIVKGV TEINDELRIN 
251 YLKNVIKLSD DDIGNYQKTI NDNKDRVKKL ILDLQKQFGE NRISIKDVNS 
301 LTSLSKSENN HNYQTEMLLR WNYPAASDLL RMYILKEHGG IYTDTDMMPA 
351 YSKQVIFKIM MQTNGDNRFL EDLKLRRAIS DGVLRYVNNQ NIDEVNYNEI 
401 SDADKNIIKK ILTEISKMPE DSIFTKINTR IPRDTMPILR RYHLWPDGWN 
451 IRGLNGFMLS HKGSEVIDAV IAGQNQAYRE LRRIRDNIHS EIYFKQTDEL 
501 SSLPDTDKIG GILVKKYLSG SLFSKFRQDT IIPEALSTLQ ISGPDLIQRK 
551 MLQFFRSRGV LGEEFINERK LSDKAYIGVY KTTGTGKYDW LTPESIGVND 
601 VTPADESTWC IGKGRCVDDF LFKDVSTLKT ENLPELFLTK IDTDTFFSQW 
651 STKTKKDLQK KIQDLTVRYN ELIDSSTIDF KNLYEIDQML HMIMLEMNDD 
701 IAKRSLFSLQ VQISEKIRRM TIPVDNIINI YPDLHKKNDN DLSMSIKGFL 
751 ASNPHTKINI LYSNKTEHNI FIKDLFSFAV MENELRDIIN NMSKDKTPEN 




1   MGDWQIREKV GYANSISPYS SLAHGYANSK WPRTIPKIPS GEYDTIILGY  
51  GHQYQANTEI EYLSNWIVWR EAVPDSTSRH KRPPLEVLNS QCTVIAGERK 
101 TTVLPLRVLS DLTPECTEQA ISLKDYKFIL RGGSGGLAVQ VGGAGYYDID 
151 ANLVAKENTL SFRGLPEEFP LTFDLSKQTQ SVMLKTPDDE VPVMTITQKG 
201 INTLVGTAAG KDRLIGNDKD NTFHTSSGGG TVISGGGNNR YIIPRDLKTP 
251 LTLTLSSNSV SHEIFLPETT LAELKPVAFE LSLIYWAGNN INVQPEDEAK 
301 LNHFAGNFRV HTRDGMTLEA VSRENGIQLA ISLCDVQRWQ AVYPEENNRP 
351 DAILDRLHDM GWSLTPEVRF QGGETQVSYD PLTRQLVYQL QARYSEFQLA 
401 GSRHHTTAVT GTPGSRYIIM KPVTTQILPT QIILAGDNDH PETIDLLEAS 
451 PVLVEGKKDK NSVILTIATI QYSLQLTISG IEESLPETTR VAIQPQDTRL 
501 LGDVLRILPD NGNWVGIFRS GHTPTVNRLE NLMALNQVMT FLPRVSGSAE 
551 QVLCLENLGG VRKKVEGELL SGKLKGAWKA EGEPTVPVNI SDLSIPPYSR 
601 LYLIFEGKNN VLLRSKVHAA PLKITSAGEM QLSERQWQQQ EHIIVKPDNE 
651 APSLILSEFR RFTISSDKTF SLKLMCHQGM VRIDRRSLSV RLFYLREQPG 
701 IGSLRLTFRD FFTEVMDTTD REILEKELRP ILIGDTHRFI NAAYKNHLNI 




1   MPSVVEDAIM TTTVTTDSGE LFPTFHPWYT DDLSGRYKSV PMARKADTLY  
51  HLTPKGDLQI IYQVATKMVN QAMIVSLPNY RHEWEKYNLS ILSEIPQNNN 
101 TVVHSILRVN GPTMQVRTID YRGTDENNPI VSFSDTTFIN GEQMLSYDSH 
151 SSGRVYSREE YMMWELQQRV SEASSARTQD YWLMDAAVRN GEWKITPELL 
201 RHTPGYIRST VSKWSRGWLK TGTILQTPED RNTDVYLTTI QNNVFSRQGG 
251 GYQVYYRIDG MAGADIADNA PGETRCTLRP GTCFEVTSVD ERHYEWNIIY 
301 VTLKTCGWSR NGQSKTPNGD NLFNHHHHHH
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Appendix 4: Nucleotide sequence of the lifAC1480A gene 
 
The sequence contains the polyhistidine tag and stop codon. The substituted 





































































































































































Appendix 5: Electronic files 
 
The attached CD contains the following: 
1. Files with detailed information on the proteins/peptides identified by liquid 
chromatography mass spectrometry (LC-MS). Note that Calpain 7 is referred 
to as CAPN7 in the file ‘LC-MS_rLifA + cells_Uniprot_Cow’. 
2. Files with detailed information on the proteins/peptides identified by shotgun 
mass spectrometry. 
3. A copy of a draft manuscript for publication based on work from Chapter 4. 
4. Word document and PDF copies of this thesis. 
